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Abstract 
Introduction: The coexistence of multiple chronic diseases within an individual, also known as 
multimorbidity, is an ongoing challenge for patients, caregivers and primary health care (PHC) 
providers.  An enhanced understanding of the burden of multimorbidity in Canada is needed.   
 
Objectives: This research had two main objectives.  Objective One aimed to understand the 
prevalence of multimorbidity among adult PHC patients, as well as the patterns of unordered and 
ordered clusters of multiple chronic diseases.   Objective Two aimed to determine the natural 
progression of multimorbidity over time, as well as the patient-, provider- and practice-level 
predictors of progressing into more complex clinical profiles.  
 
Methods:  Data were derived from the Canadian Primary Care Sentinel Surveillance Network 
(CPCSSN) electronic medical record (EMR) database.  For Objective One, descriptive and 
computational analyses were conducted and for Objective Two, multilevel survival analyses 
were conducted to account for clustering.  Patients with at least one encounter recorded in their 
EMR and who were at least 18 years of age at their first encounter were included in the analyses.  
Chronic disease diagnoses were identified using the International Classification of Diseases, 9th 
Revision (ICD-9) and a list of 20 chronic disease categories identified patients with 
multimorbidity.   
 
Results: Overall, 53.3% and 33.1% of adult PHC patients were living with at least two and at 
least three chronic diseases, respectively.  Patients with at least two chronic diseases had a mean 
age of 59.0 years (SD: 17.0), while the majority were female (57.8%) and living in an urban 
iii 
setting (52.2%).  Among female patients with multimorbidity, 6,095 unique combinations and 
14,911 unique permutations were found.  Among male patients with multimorbidity, 4,316 
unique combinations and 9,736 unique permutations were detected.  The multilevel survival 
analysis indicated that several patient-level (patient age, patient sex and total number of chronic 
diseases), provider-level (provider age) and practice-level (EMR type and practice location) 
variables predicted time until subsequent chronic disease diagnosis.   
 
Conclusion: This research explored the prevalence, characteristics, patterns and natural 
progression of multimorbidity over time among a large cohort of adult PHC patients.  When 
carefully assessed, these findings will help to create a more nuanced understanding of the burden 
of multimorbidity.  
 
Keywords 
Multimorbidity, primary health care, electronic medical records, chronic disease, prevalence, 
multilevel survival analysis, epidemiology 
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Chapter 1 
1 Introduction  
The coexistence of multiple chronic diseases within an individual, also known as 
multimorbidity, has been deemed the “norm rather than the exception” in primary health care 
(PHC) by both researchers and health care providers for many years.  Beyond being recognized 
as the “norm”, multimorbidity in fact represents one of the most complex issues in modern 
medicine; an increasingly common issue that requires a more effective clinical approach to 
respond to this complexity.  To contribute towards the knowledge base in the area of 
multimorbidity, as well as to address notable gaps in the existing multimorbidity literature, this 
thesis aimed to achieve three main areas of understanding: 1) to identify the prevalence and 
common characteristics of multimorbidity among adult PHC patients within a pan-Canadian 
database; 2) to determine the patterns (both unordered clusters and ordered clusters) of multiple 
chronic disease occurrence among adult PHC patients with multimorbidity; and 3) to understand 
the natural progression of adult PHC patients as they moved to more complex clinical profiles 
over time, as well as the patient-, provider- and practice-level variables that may predict the time 
until an additional chronic disease diagnosis.  The use of a national, longitudinal, de-identified 
electronic medical record (EMR) database from the Canadian Primary Care Sentinel 
Surveillance Network (CPCSSN) has allowed for this research to be possible.  This exploration 
of a complex issue in health care, using a complex set of electronic medical record data, has 
provided insight that can contribute to the efforts of the international community that is working 
to understand the burden of multimorbidity.   
 
2 
Chapter 2 
2 Literature Review   
This chapter will introduce the three interrelated pillars of this doctoral research: primary 
health care, electronic medical records and multimorbidity.  While each pillar is presented 
separately, the interrelatedness of these concepts creates the basis for this thesis.  
 
2.1 Primary Health Care 
2.1.1 Definition of Primary Health Care 
According to Health Canada, the term “primary health care” refers to an approach to 
health and a spectrum of services that go beyond the traditional health care system (Health 
Canada, 2012).  Primary health care serves a dual function in the broader health care system: 1) 
to direct provision of first-contact services by health care providers such as family physicians 
and nurse practitioners; and 2) to integrate and coordinate patients in need of more specialized 
services such as those provided by specialists or through in-patient hospital care (Health Canada, 
2012; Hutchison et al., 2011; Starfield et al., 2005).  The range and configuration of PHC 
services that are available varies from community to community, but often focusses on the 
prevention and treatment of common diseases and injuries, basic emergency services, referrals 
and coordination with other levels of care, mental health care, health promotion, maternity and 
early-life care, as well as palliative and end-of-life care (Health Canada, 2012).   The concept of 
“primary care” is the element within PHC that focusses on the delivery of these health care 
services to achieve health promotion, illness and injury prevention (both acute and chronic 
illness prevention) and the diagnosis and treatment of illness and injury among populations 
(Health Canada, 2012).  In a similar sense, the World Health Organization (WHO) Alma Ata 
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International Conference in 1978 and reports from the Institute of Medicine (IOM) defined 
primary care as “the provision of integrated, accessible health care services by clinicians who are 
accountable for addressing a large majority of personal health care needs, developing a sustained 
partnership with patients and practicing in the context of family and community” (WHO, 1978; 
IOM, 1978).  As well, this definition of primary care has been used to measure four main 
features of primary care services: 1) first-contact access for each new need; 2) long-term person-
focussed care (not disease-focussed care); 3) comprehensive care for most health needs; and 4) 
coordinated care when it must be sought elsewhere (Starfield et al., 2005; McWhinney and 
Freeman, 2009).  The term “primary health care” is used herein and refers to the definition of all 
aspects of both “primary health care” and “primary care”, as defined above.  Indeed, a strong 
primary health care system is required to address the marked disparities or inequities in health 
across populations and evidence of the substantial influence of a strong patient-centered PHC 
system has been accumulating (Stewart et al., 2014; Kelley et al., 2014; Starfield et al., 2005).   
In Canada, family physicians and nurse practitioners who see patients in a PHC setting 
(e.g., in-office clinic, walk-in clinic or emergency department) provide the first point of contact 
between a patient who is in need of health services and the health care system.  This first-point 
access is distinct from secondary health care services (e.g., medical specialist or in-patient 
hospitalization) in which a referral or admission order is typically first required before receiving 
these specialized services.  The ways in which PHC services are organized and delivered have 
been the focus of much debate.  In fact, numerous studies have emphasized the importance of 
PHC reform, including the Romanow Report published in 2002 (Hutchison et al., 2011; 
Romanow, 2002).  Explained further in the next section, the key feature of PHC reform was the 
fundamental shift from singular PHC providers in their own in-office, unattached clinics to more 
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robust teams of health care providers who work together to deliver multidisciplinary and 
comprehensive services to their patients or clients (Hutchison et al., 2011; Health Council of 
Canada, 2007; Starfield et al., 2005).  This shift occurred based on the increasing evidence that a 
team of professionals working as partners could achieve positive health outcomes, as well as 
improved access to services, more efficient use of resources and higher satisfaction of both 
patients and providers (Health Canada, 2012; Hutchison et al., 2011; Health Council of Canada, 
2007).  In fact, a team-based approach to PHC has become the focus in Canada and helps to 
ensure that each health service is provided by the most appropriate professional, at the most 
appropriate time and in the most appropriate location.   
 
2.1.2 Primary Health Care in Canada 
Canada has thirteen provincial and territorial health care systems that operate separately, 
but are united under the legislative framework of the 1984 Canada Health Act.  In 2010, 71% of 
Canada’s health spending was publicly funded, but the delivery of care was largely private 
(Hutchison et al., 2013).  This means that most providers are independent contractors who are 
then reimbursed by the provincial or territorial governments.  In the early 2000s, despite the 
country’s universal health care coverage, the Canadian PHC system experienced a period of 
lagging behind other high-income countries on many PHC access and quality indicators 
(Blendon et al., 2001; Hutchison et al., 2011).  In an international survey examining PHC quality 
among five high-income countries (Australia, Canada, New Zealand, United Kingdom and 
United States), 61% of Canadian family physicians (the highest among all five participating 
countries) were “very concerned” that their quality of care would decline in the future (Blendon 
et al., 2001).  These findings, combined with a number of federal and provincial reports, led to 
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PHC reform in Canada. Although the goals and objectives of the provinces and territories for 
PHC and its reform differ, common themes included focus on improved access to PHC services; 
better coordination and integration of care; expansion of team-based approaches and 
partnerships; improved quality of care, with an emphasis on patient engagement and self-
management; and the implementation and utilization of electronic records and other health 
information management systems (Hutchison et al., 2011).  Since this transition, several PHC 
reform initiatives have been implemented broadly in one or more jurisdictions to advance the 
quality of care received by PHC patients.  For example, Family Health Teams and Community 
Health Centres serve as the main interprofessional models in Ontario, while Family Medicine 
Groups (Groupes de medicine de famille) are the main delivery models in Québec (Hutchison et 
al., 2011).   
A common criticism of PHC is the degree of “generalism” that this field of medicine 
provides to their patients (McWhinney and Freeman, 2009; Stange and Ferrer, 2009).  This 
criticism is often referred to as the “paradox of primary health care”.  This includes two 
interrelated observations: 1) that PHC providers deliver poor quality of care for specific diseases, 
as compared to specialists; and 2) that PHC is associated with higher value health care for the 
whole person, resulting in better overall health, greater equity, lower health care costs and better 
quality of care for the broader population (Stange and Ferrer, 2009).  Quality of care is 
commonly measured by the application of disease-specific, evidence-based process-of-care 
guidelines, where PHC tends to require a more generalist approach to delivering services.  To 
date, family physicians and (increasingly) nurse practitioners are the principal sources of primary 
medical care in Canada.  As such, the term “primary health care provider” will be used herein 
and refers to both family physicians and nurse practitioners.  In their roles as primary health care 
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providers, these professionals deliver ongoing, accessible care to their patient population and 
build relationships with their patients to enhance the effectiveness of preventive and therapeutic 
interventions over time (Martin et al., 2014; McWhinney and Freeman, 2009; van Weel, 2005).  
Indeed, primary health care has been promoted as the building block of a high-value health care 
system and should be supported to achieve its goals of providing quality care to its patients 
(Stange and Ferrer, 2009; Chan, 2008; Rowan et al., 2007; Starfield et al., 2005).   
A recent study conducted by Stewart and Ryan (2015) provided a Canadian synthesis of 
health care use at the population level.  This study examined health care needs and health care 
use among provincial jurisdictions using the 2007 Canadian Community Health Survey (CCHS).  
This database provided a large sample size of over 100,000 respondents from the ten Canadian 
provinces (territories were excluded due to small sample sizes).  The “ecology of health care” 
was assessed by province, after age-sex standardization per 1,000 individuals for those who were 
15 years of age and older (Stewart and Ryan, 2015).  This study measured visits with family 
physicians, visits with specialist physicians, visits with nurses and hospitalizations, as well as the 
presence of chronic diseases.  In Canada, a total of 243 contacts were reported to a family 
physician per month per 1,000 people (Stewart and Ryan, 2015).  This represented the most 
frequent number of contacts per month, as there were only 70 contacts per month to a specialist 
physician and 8 contacts per month that involved a hospitalization (both per 1,000 people).  
Notable variation was observed from province-to-province.  In fact, monthly contacts with 
family physicians per 1,000 people ranged from as low as 158 contacts in Québec to as high as 
295 contacts in British Columbia (Stewart and Ryan, 2015).  Interestingly, the monthly rate of 
having at least one chronic condition ranged from 524 per 1,000 people in Québec to 638 per 
1,000 people in Nova Scotia, indicating differences in chronic disease occurrence based on 
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geographic location (Stewart and Ryan, 2015).  This study indicates the demand placed on the 
primary health care system at the population-level in Canada.  When these PHC services are 
integrated, interdisciplinary and focused on the evolving health care needs of their patients, this 
system is well positioned to provide the important facets of chronic disease prevention and 
management to the populations they serve over time.  Furthermore, these PHC providers can 
deliver ongoing care to their patients, developing relationships that are beneficial to achieving 
better health outcomes.   
 
2.1.3 Chronic Disease Management in Primary Health Care 
According to the 2014 WHO Global Status Report on Noncommunicable Diseases, 
noncommunicable or chronic diseases are of a long duration and generally demonstrate slow 
progression (WHO, 2014).  These are health issues that require ongoing management over a 
period of years or decades (WHO, 2014).  The definition of “chronicity” proposed by O’Halloran 
et al. (2004) is a disease lasting at least six months, having a documented pattern of recurrence or 
deterioration, as well as an impact on an individual’s quality of life.  Individuals living with 
chronic diseases (and particularly those with multiple chronic diseases) often manage complex 
treatment regimens that can include multiple appointments, multiple medications, regular 
monitoring and adherence to different treatment and management protocols (Moffat and Mercer, 
2015; Onder et al., 2015; Mercer et al., 2014; Smith et al., 2012; Sinnott et al., 2013; Fortin et al., 
2007; Boyd et al., 2005).  For patients who are living with chronic diseases, access to regular and 
effective PHC services can be highly desirable and associated with better health outcomes 
(Smith et al., 2012; Soubhi et al., 2010; Noël et al., 2005; Starfield et al., 2003).  
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In Ontario, almost two-thirds of respondents to the 2014 Commonwealth Fund 
International Health Policy Survey of Older Adults who were living with chronic diseases 
reported that they had easy access to a professional who could help with medical questions 
between visits (Health Quality Ontario, 2015).  Similarly, the 2011 Commonwealth Fund Survey 
of Sicker Adults found that 96% of respondents with a chronic disease had access to a regular 
medical doctor (Health Council of Canada, 2011).  The vast majority (95.1%) of adults aged 40 
years and older in the four western Canadian provinces (British Columbia, Alberta, 
Saskatchewan and Manitoba) indicated they had access to a regular medical doctor (Weaver et 
al., 2014).  Generally, these results indicate that many Canadians with a disease that is of long 
duration and generally slow progression are able to access their PHC provider.  However, there 
is a need to provide a complement of health care professionals in order to achieve the most 
successful health outcomes for these patients (Rudland and Macey, 2013; Smith et al., 2007; 
Hemmelgarn et al., 2007; Noël et al., 2007).  This includes the involvement of health 
professionals like dietitians, pharmacists, social workers, physiotherapists and occupational 
therapists, many of which are now actively recruited into team-based settings.  Even further, 
these teams may involve specialist physicians, such as a psychiatrist or a geriatrician.  This 
increasingly diverse set of professionals will help to address the multidimensional needs of many 
individuals who are living with chronic disease.   
As stated by Barbara Starfield (2011), “Neither morbidity nor multimorbidity is randomly 
distributed in populations.  People and populations differ in their overall vulnerability to illness 
and resistance to threats to their health; some have more than their share of illness and some have 
less”.  To date, a clear and comprehensive understanding of why “people and populations differ 
in their overall vulnerability” and why some chronic diseases tend to cluster together within 
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certain individuals.  Indeed, this life course approach to understanding the occurrence of 
individual chronic diseases, as well as multiple chronic diseases, is a large area of complex and 
longitudinal research.  More specifically, it is unclear how patients accumulate one disease after 
another, as compared to other patients who remain unhindered by disease throughout their 
lifetime (van den Akker et al., 2006).  Extensive research has been conducted examining the 
aetiology of individual chronic diseases (Ben-Shlomo et al., 2016; Non et al., 2014; Kamphuis et 
al., 2013; Braveman and Barclay et al., 2009; Lynch and Smith, 2005; Barker 2004; Kuh et al., 
2004), however, a small subset of studies has examined the aetiology of multiple pathologies or 
general disease susceptibility for multimorbidity, using a life course approach (Wister et al., 
2016; Vos et al., 2015; Pavela and Latham, 2015; Tomasdottir et al., 2015; Tucker-Seeley et al., 
2011).  An article published more than twenty years ago by van den Akker et al. (1996) 
identified the need for causal explanations or description of general susceptibility for disease in 
observed patterns of chronic disease accumulation.  Not only did this publication identify the 
need for a differentiation between comorbidity and multimorbidity, but it signified the need to 
understand the occurrence of multiple diseases in more detail.   
Some patients may be more vulnerable to the co-occurrence of chronic diseases due to 
genetic and immunological factors, the environment in which they live and work, lifestyle 
behaviours and their level of adaptive or coping capacities (van den Akker et al., 1996).  
Individual patient characteristics, such as stressful life events, vulnerability to stress, 
(mal)adaptive approaches to illness and personal locus of control could be influential factors in 
disease accumulation (van den Akker et al., 1996).  Moreover, some chronic diseases may have a 
common aetiology, common predisposing characteristics or a shared pathogenesis.  For example, 
although the aging process can vary from patient-to-patient, the biological ageing of organ 
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systems can lead to increased general vulnerability for disease (van den Akker et al., 1996).  As 
well, some health care providers may be more aggressive in diagnosing, treating and managing 
symptoms presented by their patients, due to personal or contextual influences on clinical care 
behaviours (Vos et al., 2015).  Finally, and particularly with the use of electronic records for 
research, the potential influence of “detection bias” may result in increased chronic disease 
burden.  This detection bias refers to the fact that patients who have already been diagnosed with 
one disease will contact the health care system more often than those who are relatively healthy.  
As such, these patients will likely be examined more frequently and more extensively than their 
healthy counterparts (van den Akker et al., 1996).  Consequently, these patients are more likely 
to be diagnosed with additional diseases, and may be more alert in recognizing or presenting 
with symptoms for examination (van den Akker et al., 1996).  The time elapsing between 
diagnoses indicates an important period to either detect further pathophysiology or to avoid the 
potential for overdiagnosis.  While clinical judgement is intrinsic to family medicine, this 
represents a point of intervention to avoid further disease progression.  Therefore, the 
management of chronic diseases over time and the assessment of variables that may influence the 
accumulation of chronic diseases over time is an important, yet fairly unexamined, area of 
research for those patients living with multiple chronic diseases.  
 
2.2 Electronic Medical Records  
2.2.1 Definition of Electronic Medical Records 
Computer-based technology and the associated digital infrastructure, such as an 
electronic medical record (EMR), can be particularly useful in facilitating the delivery and 
organization of care to patients over time.  An EMR is a computer-based repository of patient 
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information, which is securely stored and readily accessible to authorized users.  These 
electronic records represent an important shift from traditional paper-based records and their 
primary purpose is to support continuous, comprehensive, efficient and high quality health care 
(Manca, 2015; Canada Health Infoway, 2013; Health Council of Canada, 2011; Schoen et al., 
2009; Hayrinen et al., 2008).  Several elements can be documented within an electronic record 
including patient demographics, lifestyle behaviours, presenting complaints or symptoms, past 
medical history, family history, physical examination findings, clinical diagnoses, laboratory 
tests and corresponding results, diagnostic imaging, medication administration, allergies, 
immunizations, referrals, hospital admission and discharge notes (Canada Health Infoway, 2013; 
Tu et al., 2015).   
Health care systems are also increasingly offering patients the ability to access and 
manage their health information through their own personal health record or through companion 
applications such as health-related mobile applications or patient portals (Manca, 2015; Zulman 
et al., 2015b; Goldzweig et al., 2013).  Patient portals, in particular, are designed to give patients 
secure access to health information (such as appointment and laboratory test results) and allow 
secure methods for communication and information sharing between patients and their PHC 
provider (Goldzweig et al., 2013).  In comparison, an EMR is only accessible to an authorized 
health professional or health organization (Canada Health Infoway, 2013).  For example, within 
a single PHC organization, those with access to the EMR system can be family physicians, nurse 
practitioners, nurses, medical trainees (e.g., residents and medical students), administrative staff 
and (in some cases) allied health professionals.   
These EMR software programs can hold thousands of individual patient records, but 
allow each health care provider to enter relevant patient-level data in unique ways (e.g., highly 
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structured or “drop-down” data recording vs. highly unstructured or “free-text” data recording).  
These EMR systems can also be integrated with other software that manages activities such as 
billing and appointment scheduling.  Canada Health Infoway is working towards the goal of one 
electronic medical record system for all Canadians.  However, since health care is organized at 
the provincial and territorial level, each jurisdiction has its own EMR adoption program and 
policies (Tu et al., 2015).  This has had three important consequences: 1) there are multiple 
vendors or companies that develop and sell EMR software programs to health care organizations, 
such as PHC practices and hospitals; 2) there are no consistent or enforced guidelines for 
recording clinical information within these electronic records; and 3) there is not a single 
repository in Canada that automatically collects all of this clinical information.  The United 
Kingdom and its Clinical Practice Research Datalink is an excellent example of a country that 
has recorded health-related data for every person registered with the National Health Service, 
from birth to death, within a singular clinical database (Clinical Practice Research Datalink, 
2016).  The Canadian Primary Care Sentinel Surveillance Network (CPCSSN), which will be 
described further in the next chapter, was established to address this notable gap in the Canadian 
EMR landscape (Birtwhistle and Williamson, 2015; CPCSSN, 2016; Birtwhistle, 2011).   
 
2.2.2 Adoption and Use of Electronic Medical Records in Canada 
A systematic review conducted by Chang and Gupta (2015) indicated that the rates of 
adoption of EMRs in Canada have increased from about 20% of physicians in 2006 to an 
estimated 62% of physicians in 2013.  This study found substantial regional variation in adoption 
rates ranging from 40% of physicians in New Brunswick and Québec to more than 75% of 
physicians in Alberta (Chang and Gupta, 2015; Schoen et al., 2012).  As the use of EMR systems 
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becomes increasingly common in PHC settings throughout Canada, it is important that these 
EMR systems are used as effectively and efficiently as possible to maximize benefits and 
improve quality of care (Terry et al., 2014; Canada Health Infoway, 2013).  A recent study by 
Paré et al. (2015) assessed the EMR use patterns of 331 family physicians in Québec and 
determined that EMR systems “as-used” vary substantially from one family physician to another 
in terms of the system capabilities that are actually mobilized in day-to-day clinical care.  The 
group of family physicians that were most impacted by their EMR system were those who had 
the longest usage experience and consciously made the most use of their system’s capabilities 
(Paré et al., 2015).  However, many EMR adopters use only a fraction of their software’s 
available functions and perceive the enhanced use of EMR systems as a substantial and 
underused opportunity (Paré et al., 2015; Chang and Gupta, 2015).  User-cited benefits of the 
adoption of an EMR system into clinical care include time savings, improved record keeping, 
heightened patient safety and confidence in the retrieved data when EMRs are used efficiently 
(Chang and Gupta, 2015).  In comparison, user-cited barriers to EMR adoption included 
financial and time constraints (particularly for initial adoption of an EMR system), lack of 
knowledgeable support personnel, lack of interoperability with hospital and pharmacy systems 
and lack of integration with other allied health professionals (Chang and Gupta, 2015).   
A recent study conducted by Zulman et al. (2015b) demonstrated that from the 
perspective of patients living with multiple chronic diseases, the presence of an EMR can 
markedly alleviate challenges and create opportunities for enhanced support.  In a similar sense, 
EMR use can support improved interactions and communications among members of the health 
care team, as well as between providers and patients (Canada Health Infoway, 2013).  The 
patient-provider relationship may improve through additional opportunities for patient education 
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(e.g., trending of test results over time), availability of information in real-time to facilitate 
decision-making and options for patients and providers to communicate via secured messaging 
(Manca, 2015; Canada Health Infoway, 2013).  In contrast, the use of EMRs may introduce 
challenges in building rapport between patients and providers, such as the distraction of entering 
information electronically during the encounter or the unsuitable placement of the computer in 
the examination room (Canada Health Infoway, 2013).  To date, a balance between the benefits 
and challenges of EMR use has not been consistently achieved.   
 
2.2.3 Use of Electronic Medical Records in Epidemiological Research  
Structured electronic records provide the potential to access point-of-care data to inform 
clinical practice and to conduct academic research.  With meaningful use, including standard and 
consistent data entry in specific fields, EMR data can provide valuable practice-level information 
(Manca, 2015).  Epidemiological studies and public health assessments that measure population 
morbidity often rely on the development and administration of surveys, which can capture self-
reported morbidity among a sample of the target population of interest.  An alternative approach 
is to utilize information and diagnoses recorded during routine consultations in a clinical setting, 
particularly in a PHC setting.  An advantage of PHC consultation data is that encounter-level 
information is collected longitudinally or at multiple time points.  This information is recorded at 
individual encounters between the patient and their PHC provider when the patient presents for a 
clinical visit.  This is distinct from typical population-level surveys, which are specifically 
designed for a one-time or cyclic administration.   
However, it is important to recognize that these PHC consultations and their 
corresponding medical records do not necessarily reflect the “true” level of morbidity in a 
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population, as many of the symptoms or morbidities (e.g., conditions or diseases) a patient may 
be living with are not brought to the attention of the PHC provider.  As well, a patient may be 
living with a morbidity that remains undetected by the PHC provider.  In a study completed by 
Barber et al. (2010), the estimated population burden of multiple chronic diseases was actually 
very similar between a population-level survey and an electronic medical record and was more 
consistent for diseases with clear diagnostic features, such as diabetes mellitus.  Electronic 
medical records provide data that can reflect the entire care experience and can be analyzed for 
entire populations receiving care (e.g., entire PHC practices and potentially in an ongoing and 
real-time basis).  This source of data can also improve the depth and breadth of information 
available for research based on the longitudinal and patient-level data that are recorded.   
Other sources of data, such as administrative data recorded for billing purposes, can be 
used to capture real-world clinical information from a large population of patients (e.g., even 
whole provinces such as Ontario or Alberta).  These data, which can be held and analyzed by the 
Canadian Institutes for Health Information, can be very valuable for clinical and policy purposes.  
However, these data do not cover the breadth of clinical information from the PHC perspective 
and are limited to patients who appear in the administrative database after receiving adjudicated 
claims (e.g., prescriptions or hospital visits).  In comparison, primary data collection, such as 
surveys, allow researchers the ability to structure data collection to capture specific variables of 
interest.  This is particularly valuable for information that is not typically collected or contained 
within a medical chart or an administrative database, such as patient socioeconomic 
characteristics, experiences of disease or satisfaction with clinical care.  The challenges of 
primary data collection (e.g., surveys) include the time and resources that are required to recruit a 
sufficient number of participants (Belletti et al., 2010).   
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Electronic medical records offer great potential for research, enabling the rapid 
identification of patients in the context of primary health care.  EMRs use a combination of 
structured data and unstructured (or free text) data (CIHI, 2013; Orueta et al., 2012; Terry et al., 
2010).  The balance between these two components varies across different record systems with 
some EMRs consisting primarily of coded data and others are a combination of coded and free 
text fields.  The accuracy of a diagnostic code within an electronic record depends on two steps: 
whether the code accurately reflects the provider’s clinical opinion and whether that diagnosis 
was correct (Coleman et al., 2015; Nicholson et al., 2011).  A valid diagnostic code indicates that 
a provider believes that: 1) a patient has a specific symptom, condition or disease; 2) this clinical 
diagnosis is correct; and 3) this diagnosis code is accurately recorded within the patient’s EMR.  
Occasionally, a code may be entered in error and not corrected (Greiver, 2015; Nicholson et al., 
2011).  Alternatively, a provider may make a diagnosis, but not record it (Tu et al., 2015; 
Weiskopf et al., 2013; Thiru et al., 2003).  The practice of recording diagnostic codes is yet to be 
fully understood and requires further research (Coleman et al., 2015; Orueta et al., 2012).  At 
present, the extent of accurately identified and non-missing cases in an electronic record database 
can be estimated by comparison of prevalence rates obtained from within the database with those 
from external sources, such as administrative datasets or population-based estimates.   
Increasingly, the data contained within EMRs are being used for research purposes.  
Although not collected for research purposes, these records contain rich, longitudinal and 
individual-level data for each patient visiting their PHC provider.  When the quality of these data 
can be ensured, researchers using a PHC EMR database often have access to more robust clinical 
data, when compared with self-reported surveys or administrative data.  For example, 
comprehensive and quality information can be derived from the diagnoses or referral data within 
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an electronic record.  Work is needed to enhance the coding practices of PHC providers, as well 
as the technologies that are used by the PHC community, so that all data recorded in these EMRs 
can be put to better use in clinical and epidemiological research, health services planning and 
health care policy decisions (Terry et al., 2014; Hayrinen et al., 2008; Lobach and Detmer, 2007; 
Thiru et al., 2003). 
 
2.3 Multimorbidity  
2.3.1 Concept of Multimorbidity  
The issue of multimorbidity (that is, multiple chronic diseases occurring within the same 
individual) is among the 21st century’s major emerging health issues and poses a myriad of 
challenges for public health, primary health care and community care (Afshar et al., 2015; 
Mercer et al., 2014; Parekh and Goodman, 2013).  Moving beyond the health challenges and 
economic burden of individual chronic diseases, the emerging prevalence of multimorbidity will 
potentially lead to a substantial increase in demands on our society in the near future (Stewart et 
al., 2013).  The construct of “comorbidity” dates back to 1970, when Alvin Feinstein used the 
term in addressing the functional effects of comorbid conditions on the patient, as well as the 
combined effects of these comorbid conditions on the patient’s clinical profile (Feinstein, 1970).  
Feinstein first defined the term “comorbidity” as “any distinct additional clinical entity that has 
existed or that may occur during the clinical course of a patient who has the index disease under 
study” (Feinstein, 1970).  This definition implies that the index disease under study is of 
principal importance and is the main focus for the health care provider.  Although used 
interchangeably in the past by many authors, there are important distinctions between the terms 
“comorbidity” and “multimorbidity”.  The concept of “multimorbidity” describes the 
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“coexistence of two or more chronic diseases in the same individual”, in which no one disease is 
designated the index disease or primary focus for the health care provider (van den Akker et al., 
1996; Boyd and Fortin, 2011).  This conceptual difference between the terms comorbidity and 
multimorbidity (Boyd and Fortin, 2011) has been adapted in this thesis and can be seen in 
Figure 2.1.  In this adapted figure, the patient becomes ancillary to the co-occurring chronic 
diseases in the concept of comorbidity, as compared to the concept of multimorbidity, which 
facilitates a more holistic and patient-centered approach.  
 
2.3.2 Operationalization of Multimorbidity  
To date, there is no internationally accepted list of chronic diseases that define or capture 
patients with multimorbidity (Almirall and Fortin, 2013; Stewart et al., 2013; Diederichs et al., 
2011).  Researchers must therefore create a list that is suitable for their research purposes and 
corresponding data source.  For this research, a list of twenty chronic disease categories and 
corresponding diagnostic codes were used.  Based on previous international literature that 
examined the burden of multimorbidity among PHC patients using comprehensive national 
electronic health records, this list of twenty chronic diseases was created (Mercer et al., 2014; 
Barnett et al., 2012; Diederichs et al., 2011; George et al., 2006; Bayliss et al., 2005; Byles et al., 
2005; Crabtree et al., 2000; Greenfield et al., 1993; Charlson et al., 1987).  This final list was 
compared with more recently published definitions of multimorbidity (those studies that have 
published the list of individual chronic diseases), to assess consistency in diseases and disease 
categories that were captured.  The comparison among lists is presented in Table 2.1.    
Perhaps one of the reasons for the varying definitions and conceptualizations of 
multimorbidity in the literature is the lack of a clear philosophical understanding of what it 
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means to examine the multidimensional concept of “multimorbidity”.  For example, part of the 
problem in choosing an appropriate measure of multimorbidity is due to the abstract nature of the 
concept of multimorbidity and how it relates to other concepts, such as disease burden and 
patient complexity (Huntley et al., 2012; Valderas et al., 2009).  The methodology used to 
measure multimorbidity is based on the underlying elements of multimorbidity that are important 
for research work (e.g., count numbers of chronic diseases, burden on distinct body systems, 
treatment burden, health system burden).   
The definition of multimorbidity indicates the presence of multiple health issues within 
an individual.  The use of the terms disease, illness or condition are often used interchangeably 
to describe these “health issues” of patients.  The term disease refers to a defined pathological 
process with a characteristic set of signs and symptoms, while the term illness is frequently used 
as a synonym for disease, but in many cases it refers to the patients’ personal experience of their 
disease (McWhinney and Freeman, 2009).  In comparison, the term condition is a broader term 
that includes the concept of disease, as well as other health issues that fall outside of the 
traditional disease model (McWhinney and Freeman, 2009).  For example, health issues like 
obesity or hypertension may be seen as pre-existing conditions and a preceding risk factor to 
subsequent diseases.  Alternatively, they may be seen as their own chronic disease entity.  In a 
recent study examining the various terms that have been used in research to describe multiple 
coexistent diseases, it was noted that the terms disease and condition were overwhelmingly used 
in the definition of multimorbidity and seem to be more appropriate for describing the 
coexistence of multiple health issues in a patient, particularly when no one disease has been 
identified as the index disease (Almirall and Fortin, 2013).  Therefore, the term disease was used 
herein.  
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Figure 2.1 Conceptual diagram of the terms comorbidity and multimorbidity (adapted 
from Boyd and Fortin, 2010) 
 
 
2.3.3 Measurement of Multimorbidity  
Similar to its multiple definitions, multimorbidity can be measured in several different 
ways.  Measures of multimorbidity broadly fall into two types: simple counts of diseases in 
individuals (with variation in the disease types included in this count) and indices to assess 
morbidity burden that differentially weight disease to account for burden of illness or number of 
body systems that are affected.   Many commonly used indices were originally developed and 
validated among elderly or specialized patient populations or hospital-based populations 
(Brilleman and Salisbury, 2013; Huntley et al., 2012).  To date, research has assessed the 
prevalence of multimorbidity by comparing between multiple measures (Harrison et al., 2014; 
Brilleman and Salisbury, 2013; Huntley et al., 2012; Diederichs et al., 2011; Valderas et al., 
2009; Fortin et al., 2005).   
A study that examined the predictive validity of 17 different measures (including simple 
disease counts, Adjusted Clinical Groups, Charlson Index of Comorbidity and Cumulative 
Illness Rating Scale) of multimorbidity and their relationship with related outcomes (e.g., health 
care utilization, health care costs, mortality and quality of life) found that simple counts of 
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disease performed almost as well as complex measures in predicting important outcomes in 
patients (Huntley et al., 2012).  While the choice of measure of multimorbidity is primarily based 
on the suitability of the measure for the data available, this systematic review indicated that the 
most common approach to measuring multimorbidity is the use of simple disease counts 
(Huntley et al., 2012).  However, it remains challenging to compare findings between studies 
examining the burden of multimorbidity, as different authors have utilized different lists of 
diseases in their measure of multimorbidity.  Also hindering the comparability between studies is 
the fact that many publications do not include details about which diseases were included in the 
multimorbidity list and the criteria for inclusion (Diederichs et al., 2011).  Similarly, most studies 
are based on counting of chronic diseases; however a definition of “chronicity” is rarely 
explicitly stated. This can again lead to varying lists of multiple chronic diseases.  
While the simple count of chronic diseases tends to be the most common approach to 
examine the burden of multimorbidity, other commonly used indices to measure the burden of 
multimorbidity have included the Charlson Index of Comorbidity (Charlson et al., 1987), the 
Cumulative Illness Rating Scale (Miller et al., 1992), or indices that are applied to evaluate 
quality of outcomes and resource utilization, such as the Johns Hopkins University Adjusted 
Clinical Groups Case-Mix System (Salisbury et al., 2011).  While these measures have been 
applied in previous research examining multimorbidity burden, they are more complex and were 
originally created for different purposes than estimating multimorbidity prevalence (e.g., risk of 
mortality or health care cost).  Therefore, the simple count of chronic diseases may indeed be the 
useful approach to determining the prevalence of multimorbidity in a population.  It may be 
anticipated that more complex measures of multimorbidity (e.g., the Charlson Index of 
Comorbidity, Cumulative Illness Rating Scale or Adjusted Clinical Group System) that 
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differentially weight diseases, would be more effective at predicting outcomes related to 
multimorbidity as compared to simple counts that weigh all diseases equally.  However, some 
studies have concluded that simple measures, such as counts of chronic diseases, are almost as 
effective at predicting health care utilization and quality of life as more sophisticated 
measurements (Huntley et al., 2012).  In fact, these approaches to measuring multimorbidity are 
more ideal as they are less costly (e.g., no registration or purchasing fee required) and can be 
more easily applied to secondary data sources (e.g., electronic records or administrative data).   
To date, clear and comprehensive criteria for the selection of individual chronic diseases, 
which qualify for multimorbidity are still lacking.  As a result, there is no clear agreement or 
consensus on the number and type of diseases to be included in multimorbidity research.  In fact, 
existing definitions are characterized by their large degree of heterogeneity, considering as little 
as four diagnoses (stroke, coronary heart disease, hypertension and diabetes) by McGee et al. 
(1996) to as many as 185 diagnoses by Kadam et al. (2007).  This often leads to incomparable 
prevalence levels across studies and a lack of a “gold standard” measure for multimorbidity.  In a 
systematic review by Diederichs et al. (2011), researchers found that almost 60% of studies did 
not specify the criteria for selecting the list of diseases included in the multimorbidity measure.  
In these publications, a list of diseases was presented without any further explanation or 
justification for the list selected (Diederichs et al., 2011).  Overall, the mean number of diseases 
that were considered in 39 multimorbidity indices was 18.5 diseases (median of 14 diseases).  
Interestingly, the range of the number of diseases was in fact rather small, with 87.2% of the 
indices including between 6 and 25 chronic diseases (Diederichs et al., 2011).  When criteria 
were given, the most frequently used selection criterion was found to be those diseases that were 
“highly prevalent” in the population of interest (Diederichs et al., 2011).  This systematic review 
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concluded that future multimorbidity indices should include and measure at least 11 diagnoses, 
particularly for studies that rely on ICD-10 diagnoses (Diederichs et al., 2011).  It also 
highlighted the heterogeneity of existing indices and the need for a new, established instrument 
to assess multimorbidity.   
Likewise, a systematic review conducted by Fortin et al. (2012) suggested that 
investigators designing future studies to assess the prevalence of multimorbidity should include 
at least 12 frequent chronic diseases and should attempt to report results for the two main 
definitions of multimorbidity: at least two and at least three chronic diseases.  This more uniform 
operationalization and presentation of multimorbidity will assist in creating more comparable 
estimates of multimorbidity prevalence in the literature.  Indeed, the comparable estimation of 
the burden of multimorbidity is important to fully characterizing this global health issue.   
Valid comparisons of the prevalence rates of multimorbidity also require a rigorous 
methodological approach, with specific criteria made explicit in academic publications (Stewart 
et al., 2013; Schellevis, 2013; Fortin et al., 2012).  According to Stewart et al. (2013), the criteria 
for comparability of multimorbidity studies include commonality in: 1) the definition of 
multimorbidity; 2) the definition of chronicity; 3) the level at which chronic diseases are defined 
(e.g., transient ischemic heart attack or cerebrovascular disease; split or lumped); 4) the list of 
chronic diseases that will be considered; and 5) the study population and data source being used 
(e.g., administrative, clinical or survey data).  Ultimately, there is a need to establish an approach 
to measuring multimorbidity that balances both comprehensiveness (e.g., including all important 
diseases) and efficiency (e.g., particularly for use in large secondary databases) when measuring 
the burden of multimorbidity.  
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2.3.4 Prevalence of Multimorbidity in Community Populations  
Managing chronic disease is a daily reality for at least one third of Canadians, with this 
proportion increasing as the Canadian population ages and risk factors continue to rise 
(Broemeling et al., 2008).  These chronic diseases impact the health and wellbeing of individuals 
and represent a significant health system and economic burden.  In their analyses of the 2005 
Canadian Community Health Survey (CCHS Cycle 3.1), Broemeling et al. (2008) demonstrated 
that multimorbidity was a common experience as more than one-half of adults over the age of 65 
years reported having at least two of seven chronic diseases (arthritis, cancer, chronic obstructive 
pulmonary disease, diabetes, heart disease, high blood pressure and mood disorders).  This study 
also found that among the almost 9 million Canadian respondents (over the age of 12 years), 
approximately 33% had at least two of seven chronic diseases (Broemeling et al., 2008).  
Individuals living with chronic disease also use health care services (e.g., visits to a PHC 
provider) more often than individuals without chronic disease and the intensity of service use 
increases as the number of chronic disease diagnoses increases (Broemeling et al., 2008).   
A systematic review conducted by Fortin et al. (2012) examined previously published 
prevalence estimates of multimorbidity in both general populations and primary health care 
populations from more than ten different countries, including Canada, the United States, the 
United Kingdom, the Netherlands and Australia.  This review found that the prevalence of 
multimorbidity, defined as at least two diseases, ranged between less than 10% to as high as 70% 
in general population studies, stratified by age (Fortin et al., 2012), indicating wide variation.  
In the United States, the National Health Interview Survey conducted in 2010 found that 
among respondents who were over the age of 18 years, 26% had at least two of ten chronic 
diseases and rates significantly increased among women and with advancing age (Ward and 
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Schiller, 2013).  A study conducted by Barber et al. (2010) in the United Kingdom found similar 
rates of multimorbidity (defined as at least two of a possible seven chronic diseases) among more 
than 5,000 respondents aged 50 years of age and older who replied to a self-reported postal 
health survey (36.2%) and whose electronic medical record was also reviewed (32.3%).  A study 
conducted in Spain by Violán et al. (2013) also found comparable prevalence levels of 
multimorbidity (defined as at least two of a possible 27 chronic diseases) among more than 
15,000 respondents aged 15 years of age and older who responded to a self-reported national 
survey (Health Survey for Catalonia) and whose electronic medical record was reviewed for 
clinical chronic disease diagnoses (77.4% and 67.7%, respectively).  Although conducted outside 
of Canada, this work indicates that there is reasonable agreement between prevalence estimates 
of multimorbidity derived from data sources that access general populations and primary health 
care populations. 
 
2.3.5 Prevalence of Multimorbidity in Clinical Populations  
Among primary health care populations, the prevalence of multimorbidity (defined as at 
least two diseases, ever diagnosed in the health record) has been calculated as high as 98.5% 
among patients aged 65 years or older (Fortin et al., 2012).  In studies that included patients of 
all ages, an S-shaped curve was observed for the association between increasing patient age and 
the prevalence of multimorbidity.  More specifically, multimorbidity prevalence was 
approximately 20% or lower before the age of 40 years, then increased dramatically between 40 
and 70 years and finally plateaued around the age of 70 years (Fortin et al., 2012).  Barnett et al. 
(2012) utilized a national EMR dataset in Scotland, which holds records for almost two million 
patients from 314 medical practices, representing about one-third of the entire Scottish 
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population.  Among all patients, the prevalence of multimorbidity (defined as at least two of a 
possible forty chronic diseases) was found to be 23.2%, and the association between increasing 
patient age and prevalence showed the same S-shaped curve (Barnett et al., 2012).  However, 
there was a notable excess of multimorbidity among those living in economically deprived areas.  
In fact, young and middle-aged adult patients living in economically deprived areas (measured 
using a deprivation score) had the same prevalence of multimorbidity 10 to 15 years earlier, as 
compared to adult patients living in the most affluent areas (Barnett et al., 2012).   This echoed 
previous work that found that the most deprived people spend twice as many years in poor health 
before they die than those who live in affluent settings (Mercer et al., 2007).    
A study conducted by Brett et al. (2013) estimated patterns and prevalence of 
multimorbidity across the entire age spectrum of patients attending two large metropolitan 
practices in Western Australia during a six-month period.  Data were extracted from the medical 
records of 7,247 patients at the two practices and the Cumulative Illness Rating Scale was used 
to categorize 42 conditions into 14 domains.  This study found that multimorbidity was present 
among 52% of patients examined.  The prevalence of multimorbidity was 20.6% among patients 
younger than 25 years, 43.7% among patients aged 25 to 44 years, 75.5% among patients aged 
45 to 64 years, 74.6% among patients aged 65 to 74 years and 92.0% among patients aged 75 
years and older.  These findings demonstrate the challenge and ultimate limitations of the single-
disease framework by which most health care, medical research and medical education is 
structured.  In fact, research demonstrates that the clinical care to manage multiple individual 
diseases can become duplicative, costly and inefficient.  As well, this becomes burdensome and 
unsafe for patients because of poor coordination and integration of care and management plans.  
Better understanding of the epidemiology of multimorbidity, as well as a patient-centered 
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perspective to delivering this care, is necessary to develop proactive interventions to prevent or 
reduce the burden and to properly align health care services with patient need (Wang and Lo, 
2016; Schattner et al., 2015; Green, 2013; Shippee et al., 2012; Soubhi et al., 2010).  Until these 
changes are achieved, a significant burden will be felt by many key stakeholders: the patients and 
caregivers, the health care providers and the health care system.  
 
2.3.6 Burden of Multimorbidity on Health Care System 
Multimorbidity has been linked with adverse health outcomes including more frequent 
and longer hospitalizations (Gruneir et al., 2014; Agborsangaya et al., 2013; Gijsen et al., 2001; 
Librero et al., 1999), reduced functional status (Ryan et al., 2015; Vogeli et al., 2007; Bayliss et 
al., 2004), polypharmacy, (Smith et al., 2007; Boyd et al., 2005; Tinetti et al., 2004), 
compromised care and patient safety (Panagioti et al., 2015; Zulman et al., 2013; Vogeli et al., 
2007; Gijsen et al., 2001), reduced quality of life (Agborsangaya et al., 2013; Boyd and Fortin, 
2010; Fortin et al., 2007; Fortin et al., 2006), higher health care costs (Salisbury et al., 2011; 
Hartmann et al., 2011; Vogeli et al., 2007; Rapoport et al., 2004) and higher mortality (St. John 
et al., 2014; Gijsen et al., 2001).  Studies have projected that the number of Americans living 
with chronic disease will increase from 125 million in 2000 to 164 million (or nearly 50% of the 
population) in 2030 (Anderson and Horvath, 2004).  An estimated 78% of the total health care 
resources in the United States are devoted to individuals with chronic disease (Anderson and 
Horvath, 2004).   
In a study conducted by Charlson et al. (2008), electronic medical records were used to 
construct a model that identified the demographic and clinical features (e.g., age, sex, multiple 
morbidities and medications) that were predictive of total yearly costs to the healthcare system.  
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Data were obtained for almost 6,000 patients over a one-year period and indicated a mean annual 
per patient health system cost of $2,655 (Charlson et al., 2008).  In this predictive model, 
individuals with higher levels of morbidity (more disease diagnoses) incurred exponentially 
higher annual costs, ranging from $4,317 among patients with two morbidities to $13,326 among 
patients with seven or more morbidities (Charlson et al., 2008).  More importantly, these 
predictive models help to identify those patients who are at high risk of costly and ineffective 
care.  In fact, a study conducted by Alonso-Morán et al. (2015) found that predictive risk models 
for negative health outcomes (e.g., hospitalization, readmission, cost) were most accurate when 
measures of multimorbidity were included.  This review indicated the impact of multimorbidity 
on adverse and repeated health care utilization (Alonso-Morán et al., 2015).    
 
2.3.7 Burden of Multimorbidity on Primary Health Care Providers 
As identified by the United States Department of Health and Human Services Initiative 
on Multiple Chronic Conditions, there is a need to catalyze change within the context of how 
chronic diseases are addressed, from an approach focussed on individual diseases to one that 
uses a multiple chronic disease approach.  In fact, this report states that this process of evolution 
and refocus will require a “culture change, or paradigm shift” for PHC providers (United States 
Department of Health and Human Services, 2010).  In a qualitative interview among 25 primary 
health care providers (15 physicians and 10 nurses) in the United Kingdom, providers identified 
tensions between delivering care to meet quality targets and fulfilling the patient’s needs and 
these tensions were exacerbated with the presence of multimorbidity (Bower et al., 2011).  Other 
challenges included the need for patients to coordinate and navigate their own health care path 
(through the health care system and with multiple appointments and providers); the difficulties of 
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self-management support for multiple diseases; and understanding the relationship between 
physical and mental health (Bower et al., 2011).   
Clinical practice guidelines have been developed to guide clinical management decisions 
for patients and improve quality of health care delivery.  However, adherence to current single 
morbidity-focused, single disciplinary guidelines may result in undesirable effects for those with 
multimorbidity, such as adverse interactions from polypharmacy and conflicting management 
strategies (Blozik et al., 2013; Boyd et al., 2005).  Although clinical practice guidelines are not 
intended to replace the diagnostic, therapeutic and patient-centered priorities of the patient-
provider encounter, providing health care in compliance with the current practice guidelines 
might in fact result in worse outcomes and increased cost for a growing population of complex 
(and even vulnerable) patients.   
Boyd and colleagues (2005) illustrated the limitations of clinical practice guidelines by 
aggregating recommendations from relevant clinical guidelines for a hypothetical (yet typical) 
case of a 79-year-old woman with five common chronic diseases: chronic obstructive pulmonary 
disease, diabetes mellitus, osteoporosis, hypertension and osteoarthritis.  This analysis found that 
most clinical practice guidelines did not modify or discuss the applicability of their 
recommendations for patients living with multimorbidity.  If the relevant clinical practice 
guidelines were followed, this hypothetical patient would be prescribed 12 medications, 19 doses 
per day, which would cost her US$4,877 per year (assuming no prescription drug coverage).  
This patient would also have a complicated and often conflicting, list of 14 non-pharmacological 
activities, including weight bearing exercise and energy conservation (Boyd et al., 2005).  
Furthermore, none of the five clinical practice guidelines were patient- or family-centered as they 
did not discuss the burden of comprehensive treatment on the patients or caregivers.  This review 
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provides evidence that current clinical practice guidelines do not provide an appropriate, 
evidence-based foundation for assessing quality of care in patients with multiple chronic 
diseases.  In the Canadian context, Fortin et al. (2011) appraised 16 Canadian guidelines and 
assessed their relevance for patients with multimorbidity.  This study found that although 56.2% 
of individual chronic disease guidelines addressed treatment for patients with multiple chronic 
diseases, three guidelines addressed specific recommendations for patients with two co-occurring 
diseases and only one addressed more than two concurrent diseases (Fortin et al., 2011).  Indeed, 
it is widely recognized that current clinical practice guidelines provide little guidance for PHC 
providers on how to appropriately care for patients with multimorbidity (Tinetti et al., 2014; 
Blozik et al., 2013; Hughes et al., 2013; Guthrie et al., 2012; Tinetti et al., 2004).  Furthermore, 
there is a need for PHC providers to form an ongoing and collaborative partnership with patients 
and their families to prioritize care efforts.   
 
2.3.8 Burden of Multimorbidity on Patients and Caregivers  
The full physical and psychological impact of multimorbidity can be highly dependent on 
the specific disease combinations within a patient, the severity of the coexisting conditions, the 
patient’s age and their ability to effectively cope with multiple chronic diseases (Duguay et al., 
2014; Smith and O’Dowd, 2007).  Consequential impact is also felt by the family members and 
informal caregivers of those affected by multimorbidity.  Interestingly, while support may be 
available in the community for single diseases (e.g., through the Heart and Stroke Foundation or 
the Canadian Diabetes Association), it is less likely to be available for those with multimorbidity 
(Smith and O’Dowd, 2007).  There continues to be a lack of investigation into the longitudinality 
of multimorbidity, in which patients experiencing multimorbidity are followed over time to 
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understand their progression into more complex clinical profiles and how their associated needs 
evolve (Noël et al., 2005).  As a result, complex patients are forced to depend on a health care 
system and societal resources that have been traditionally designed to serve only single diseases 
(Guthrie et al., 2012; Tinetti et al., 2012; Upshur et al., 2008).  Moreover, there is often a 
mismatch between the needs and priorities as defined by patients and their caregivers and those 
priorities of their health care providers (Gill et al., 2014).  As such, patients with multimorbidity 
are most in need of shared decision-making and enhanced communication with their providers.  
Individuals living with multimorbidity face many challenges, including managing 
polypharmacy (Hughes et al., 2013; Blozik et al., 2013; Taylor et al., 2010; Noël et al., 2005; 
Boyd et al., 2005; Townsend et al., 2003; Bayliss et al., 2003), increased risk of drug interactions 
(Moffat and Mercer, 2015; Cheraghi-Sohi et al., 2013; Boyd and Fortin, 2010; Boyd et al., 
2005), dealing with barriers to self-care and self-management (Kenning et al., 2015; Liddy et al., 
2014; Morris et al., 2011; Bayliss et al., 2007; Boyd et al., 2005; Bayliss et al., 2003) and 
difficulties in coordinating health care services (Zulman et al., 2015; Gill et al., 2014; Gustafsson 
et al., 2013; Hartmann et al., 2011; Noël et al., 2005).  Because of these challenges, research has 
confirmed that individuals living with multimorbidity place higher demands on the system and 
have poorer health outcomes.  Multimorbidity can also impact an individual’s overall quality of 
life (Agborsangaya et al., 2013; Boyd and Fortin, 2010; Fortin et al., 2007; Fortin et al., 2006).  
In a cross-sectional questionnaire (Health Related Quality Council of Alberta 2010 Patient 
Experience Survey) of almost 5,000 adult respondents in the province of Alberta, multimorbidity 
was associated with reduction in the health-related quality of life (HRQOL), which is a self-
reported multi-attribute health utility instrument for describing and valuing health states 
(Agborsangaya et al., 2013).  Moreover, a study conducted by Fortin et al. (2007) has detected 
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significant impacts on HRQOL among patients with multimorbidity, and even specific 
synergistic negative effects of co-occurring diseases (e.g., cluster of respiratory and cardiac 
morbidity).  Overall, both quantitative and qualitative research demonstrates that those living 
with multimorbidity experience considerable pressure from the management of their chronic 
diseases and the maintenance of all other activities of daily life.   
 
2.3.9 Natural History and Progression of Multimorbidity  
Previous research has noted that examining how multimorbidity develops over time, as 
well as understanding causal mechanisms, is an important area for progress in our understanding 
(Boyd and Fortin, 2010; Valderas et al., 2009).  The lack of prospective studies that examine the 
changing burden of multimorbidity over time has been highlighted in the literature (Strauss et al., 
2014; France et al., 2012; Mercer et al., 2011).  There is increasing recognition that clinicians 
must move away from the single disease management approach for patients with multiple 
chronic diseases and use an integrated treatment or management plan for these patients.  
However, greater insight is required to provide the evidence for these treatment and management 
plans.  Research that identifies clusters of the most prevalent chronic diseases and investigates 
the nuanced patterns or natural history of multimorbidity could indicate areas in which evidence-
based information can integrate clinical practice guidelines for multimorbidity.  The study of the 
amount of time elapsing between chronic disease diagnoses may provide important points of 
focus for prevention.  More specifically, identifying those patients who are considered to be most 
“at risk” of developing a subsequent chronic disease can allow both clinicians and researchers to 
focus on this cohort of patients and to create resources to potentially avoid the next occurrence of 
chronic disease.  To date, this has not been achieved in the multimorbidity literature.   
33 
2.3.10 Clusters and Patterns of Multimorbidity  
When analyzing the impacts of multimorbidity, previous literature has focused on the 
descriptive counting of individual diseases or the simple link between co-occurring pairs of 
diseases.  However, the analysis of cumulative interactions and non-random associations 
between chronic disease diagnoses can lead to a deeper understanding of the multidimensional 
burden and impacts of multimorbidity (Sinnige et al., 2015; Vos et al., 2014; Garin et al., 2014; 
Prados-Torres et al., 2014; Prados-Torres et al., 2012).  A retrospective study using an 
exploratory factor analysis and EMR data from 275,682 adult patients in Spain and found that 
five patterns of multimorbidity could be detected (Prados-Torres et al., 2012).  These five 
patterns were: cardio-metabolic (e.g., diabetes, hypertension and heart disease); psychiatric-
substance abuse (e.g., psychosis and neurosis); mechanical-obesity-thyroidal (e.g., low back 
pain, varicose veins of lower extremities and osteoporosis); psychogeriatric (e.g., dementia and 
Parkinson’s disease); and depressive (e.g., depression and insomnia).  In the systematic review 
conducted by Prados-Torres et al. (2014), 97 patterns composed of two or more diseases were 
detected and the three most prevalent combinations of chronic diseases were classified as: 
cardiovascular and metabolic diseases; mental health problems; and musculoskeletal disorders.  
In comparison, a systematic review conducted by Sinnige et al. (2015) found that among older 
adult populations, depression was the disease that was most commonly clustered with other 
disease diagnoses and was specifically paired with eight other diseases (hypertension, arthritis, 
diabetes mellitus, asthma or chronic obstructive pulmonary disease, stroke, cancer, heart failure 
and heart disease).  This work is beginning to uncover the previously unexplored complexities of 
multiple chronic diseases within an individual.  A comparable set of multimorbidity patterns, 
identified in the Canadian primary health care context, has yet to be established.  This research 
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will work to address this gap in order to create a deeper understanding of the complexity of 
multimorbidity in Canada.  
As demonstrated, the epidemiology of multimorbidity has been examined in international 
literature and a recent editorial concluded that although new descriptive epidemiological studies 
will likely show similar trends as seen in past multimorbidity literature (despite variations in 
methodology), future work should focus on statistical clustering of chronic diseases and the 
development of prevalence rates of multimorbidity over time (Schellevis, 2013).  Studies 
examining the (statistical) clustering of diseases, showing higher prevalence rates of 
combinations of chronic diseases than can be expected by chance (observed vs. expected rates), 
may provide clues for further exploration of etiological factors.  Moreover, the study of living 
with multimorbidity must take a life course view, examining the development of multiple 
chronic diseases over time.  Such studies may provide clues for preventing or delaying the 
occurrence of subsequent chronic diseases, as well as support health care planning and program 
development to address patient needs (Schellevis, 2013; France et al., 2012; Mercer et al., 2011).   
 
2.4 Summary 
The current literature has indicated the importance of creating a more nuanced 
understanding of multimorbidity, the critical role of primary health care and the emerging 
benefits of using EMR data for epidemiological research.  As such, this research will use a large 
national EMR data source to determine the burden of multimorbidity among adult PHC patients 
across Canada.  The intent of this doctoral research is to add to the growing international 
multimorbidity literature, as well as to contribute a perspective to improving the care and well-
being for this increasing and complex patient population.  
35 
Table 2.1 Comparison of multimorbidity chronic disease lists from publications in multimorbidity literature and the current list 
of twenty chronic disease categories 
Chronic Disease 
Category 
Pefoyo 
et al., 
2015 
Roberts 
et al., 
2015 
Tonelli 
et al., 
 2015 
St. Sauver 
et al., 
2015 
Zulman 
et al., 
2015 
Fortin 
et al.,  
2014 
Rocca  
et al., 
 2014 
Strauss 
et al., 
2014 
Ornstein 
et al., 
2013 
Agborsangaya 
et al., 2012 
Hypertension ++ - ++ ++ ++ ++ ++ ++ ++ + 
Obesity - - - - - ++ - ++ ++ + 
Diabetes ++ + ++ ++ ++ ++ ++ ++ ++ + 
Chronic Obstructive 
Pulmonary Disease or 
Asthma 
++ + ++ ++ ++ ++ ++ ++ ++ + 
Hyperlipidemia + - - ++ - ++ ++ - ++ + 
Cancer ++ + ++ ++ ++ ++ ++ - - + 
Cardiovascular Disease ++ + ++ ++ ++ ++ ++ ++ ++ + 
Heart Failure ++ - ++ ++ ++ ++ ++ ++ ++ + 
Anxiety or Depression + + + ++ + ++ + - ++ + 
Osteoarthritis or 
Rheumatoid Arthritis 
++ + + ++ + ++ + ++ ++ + 
Stroke or Transient 
Ischemic Attack 
++ + ++ ++ ++ ++ ++ - ++ + 
Thyroid Problem - - + - ++ ++ - ++ - - 
Kidney Disease or 
Failure 
++ - ++ ++ ++ ++ ++ ++ ++ + 
Osteoporosis ++ - - ++ ++ ++ ++ ++ ++ - 
Dementia ++ + ++ - - ++ ++ ++ ++ - 
Musculoskeletal Problem - - + - ++ ++ - + - + 
Stomach Problem - - ++ - + - - - ++ + 
Colon Problem - - ++ - + - - - - - 
Liver Disease - - ++ ++ ++ - + - ++ - 
Urinary Problem - - - - ++ - - - - - 
Note: ++ indicates that the definition, diagnosis codes and/or disease categories were the same or almost similar; + indicates that the definition, diagnosis codes 
and/or disease categories were somewhat similar; - indicates that no comparable definition, diagnosis codes or disease categories were identified 
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Table 2.1 Comparison of multimorbidity chronic disease lists from publications in multimorbidity literature and the current list 
of twenty chronic disease categories, Continued 
Chronic Disease Category 
Barnett 
et al., 
2012 
Muggah 
et al., 
2012 
Prados-Torres  
et al., 
2012 
Rizza  
et al., 
2012 
van Oostrom 
et al., 
2012 
Diederichs  
et al., 
2011 
Broemeling  
et al.,  
2008 
George  
et al.,  
2006 
Bayliss  
et al.,  
2005 
Byles  
et al.,  
2005 
Hypertension ++ ++ ++ ++ - ++ ++ - ++ ++ 
Obesity - - ++ ++ - - - - + - 
Diabetes ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 
Chronic Obstructive 
Pulmonary Disease or 
Asthma 
++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 
Hyperlipidemia - - ++ - - - - - ++ - 
Cancer ++ - ++ ++ ++ ++ ++ + ++ ++ 
Cardiovascular Disease ++ ++ ++ ++ ++ ++ ++ ++ ++ + 
Heart Failure ++ ++ ++ ++ ++ - - + ++ ++ 
Anxiety or Depression ++ - ++ ++ ++ ++ + - ++ ++ 
Osteoarthritis or 
Rheumatoid Arthritis 
++ - + ++ ++ ++ + - ++ ++ 
Stroke or Transient 
Ischemic Attack 
++ ++ - ++ ++ ++ - - ++ ++ 
Thyroid Problem ++ - ++ ++ - - - - ++ - 
Kidney Disease or Failure ++ ++ ++ + - ++ - + - + 
Osteoporosis - - ++ ++ ++ ++ - - ++ - 
Dementia ++ - ++ ++ ++ ++ - ++ - - 
Musculoskeletal Problem + - ++ ++ ++ - - - + + 
Stomach Problem ++ - ++ ++ - - - + ++ - 
Colon Problem ++ - ++ ++ + - - - ++ + 
Liver Disease ++ - ++ ++ - - - - - ++ 
Urinary Problem + - - ++ - - - + - - 
Note: ++ indicates that the definition, diagnosis codes and/or disease categories were the same or almost similar; + indicates that the definition, diagnosis codes 
and/or disease categories were somewhat similar; - indicates that no comparable definition, diagnosis codes or disease categories were identified 
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Chapter 3 
3 Research Objectives  
The objectives of this doctoral research are two-fold.  Objective One is to understand the 
prevalence and characteristics of adult (at least 18 years of age) primary health care patients within 
the CPCSSN database who are living with multimorbidity as of September 30, 2013.  This 
objective will also determine the clusters of multiple chronic diseases that tend to occur most 
frequently together among patients with multimorbidity.  Objective Two will build on this initial 
understanding to provide more robust information on the natural history or progression of 
multimorbidity among adult PHC patients over time.  Both objectives will contribute to the 
understanding of multimorbidity in PHC using the national and longitudinal electronic medical 
record database from the Canadian Primary Care Sentinel Surveillance Network.   
 
3.1 Objective One 
The first objective has three key research questions (included below), which will measure 
the point prevalence, characteristics and clusters of multimorbidity among adult PHC patients.  
More specifically, this objective will determine the prevalence (and corresponding 95% 
confidence intervals) of multimorbidity, defined as at least two chronic diseases and at least three 
chronic diseases occurring in the same individual.  The characteristics of patients living with 
multimorbidity will also be reported.  These characteristics will be compared to those 
characteristics found in the scientific literature.  Previous research has indicated that many patients 
living with multimorbidity are more likely to be older, female and live in a rural or low 
socioeconomic setting (Barnett et al., 2012; Salisbury et al., 2011; Harrison et al., 2013; Britt et 
al., 2008; Uijen et al., 2008; Fortin et al., 2005; van den Akker et al., 1998).   
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Objective One Research Questions: 
1a) What is the point prevalence of multimorbidity among adult PHC patients within 
the CPCSSN database as of September 30, 2013?  
1b)  How does this prevalence compare to those prevalence estimates reported in the 
scientific literature?  
 
2a)  What are the common characteristics of adult PHC patients with multimorbidity 
within the CPCSSN database?  
2b)  How do these characteristics compare to those reported in the scientific literature?  
 
3a)  Among adult PHC patients with multimorbidity, what are the most frequent 
combinations (that is, unordered clusters) of multiple chronic diseases?  
3b) Among adult PHC patients with multimorbidity, what are the most frequent 
permutations (that is, ordered clusters) of multiple chronic diseases?  
 
3.2 Objective Two  
The second objective has three research questions (included below), which will examine 
the natural history and changing burden of multimorbidity over time among adult PHC patients.  
This objective will examine the time-to-event patterns of multiple chronic disease diagnoses, 
among a cohort of adult patients.  More specifically, the amount of time elapsing (in days) between 
multiple chronic disease diagnoses will be determined using a multilevel recurrent event survival 
analysis.  In order to account for clustering of events at the patient-, provider- and practice-level, 
the multilevel survival analysis will assess the variance contributed by each level.  Research has 
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suggested that chronic diseases involving related body systems will lead to a quicker accumulation 
of related chronic disease diagnoses, beyond the effect of increasing age (Strauss et al., 2014).  
However, previous research has not indicated the extent to which patient-, provider- and practice-
level factors will impact the subsequent rate of chronic disease accumulation.   
 
Objective Two Research Questions: 
1) Among adult PHC patients with at least one chronic disease, what is the mean time 
elapsing until next chronic disease diagnosis?  
 
2) Does the mean time until next chronic disease decrease as the number of chronic 
disease diagnoses increase?  
 
3)  What are the patient-, provider- and practice-level variables that predict the mean 
time until next chronic disease diagnosis?  
 
 
 
 
 
 
Chapter 4 
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4 Methodology  
This chapter will describe the key elements of this doctoral research: the main data 
source, relevant database variables, database management techniques, study design and statistical 
analyses for Objective One and Objective Two.  
 
4.1 Canadian Primary Care Sentinel Surveillance Network Database  
Data were derived from the Canadian Primary Care Sentinel Surveillance Network 
(CPCSSN) database located in Kingston, Ontario (CPCSSN, 2016; Birtwhistle, 2011).  This 
network was initially funded in 2008 by the Public Health Agency of Canada (PHAC) to develop 
a national repository of primary health care information derived from EMRs (Queenan et al., 
2016; Birtwhistle, 2011; Birtwhistle et al., 2009).  This information was intended to be a 
resource for monitoring chronic disease in Canada, as well as for PHC-oriented research.  
CPCSSN’s vision is to collect these point-of-care data and facilitate clinical and epidemiological 
research to understand the health of Canadians from the PHC perspective (CPCSSN, 2016).  
CPCSSN also strives to build a stronger national knowledge base on chronic disease 
management, in order to improve the quality of PHC delivery for millions of Canadians 
(CPCSSN, 2016).   
CPCSSN is a growing entity with ongoing recruitment of practice-based research 
networks: PHC sites (nested within networks), PHC providers (nested within sites), PHC patients 
(nested within providers) and health care encounters (nested within patients).  This multilevel 
structure of the CPCSSN data is presented in Appendix A.  While this database does not include 
all PHC patients across Canada, these data represent the largest source of patient-level PHC data 
that are available in Canada.  For CPCSSN, database recruitment begins at the network level 
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(e.g., in a specific geographic area like London, Ontario or Halifax, Nova Scotia), followed by 
the recruitment of PHC sites and providers in the network’s geographic area.  CPCSSN has 
attempted to achieve representativeness in their network locations (e.g., recruitment has recently 
begun in the Northwest Territories), as well as representative patient and provider characteristics.   
The participation of PHC sites and providers is not random, but instead relies on a number of 
related factors: self-selection of sites and providers that utilize EMR systems and are interested 
in participating in CPCSSN; providers who are willing to contribute their patients’ EMR data; 
logistics of data extraction and geographic location of the sites (e.g., limiting potential 
participation of rural and remote sites); and financial remuneration to participating providers, 
which can impact initial recruitment and sustainability of participating networks.  To date, the 
CPCSSN database includes PHC sites from inner-city, urban, suburban, small town and rural 
settings and is continuously looking to expand its coverage and representativeness (Queenan et 
al., 2016; Godwin et al., 2015).   
A recent study determined the level of representativeness of both patient and provider 
characteristics in the CPCSSN database, as compared to the broader Canadian population.  
Queenan et al. (2016) identified that CPCSSN patients were slightly older than the age reported 
by the 2011 Canadian Census (mean age of CPCSSN patients was 3.5 years older than the mean 
age calculated from the 2011 Canadian Census), but followed the same patterns of sex 
distribution (slightly larger proportion of females in both populations) and residential location 
(majority of patients and respondents were living in an urban setting).  The provincial-level 
comparison indicated a lack of representation from Québec and British Columbia within the 
CPCSSN database (Queenan et al., 2016).  This was likely due to the health legislative 
requirements in Québec that has slowed recruitment and because the network located in British 
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Columbia is relatively new and still recruiting providers and patients (Queenan et al., 2016).  
Likewise, the PHC providers in the CPCSSN database had similar characteristics as those 
reported in the 2013 National Physician Survey (NPS).  Among both populations, similar 
distributions were seen among provider age, provider sex and whether the providers practiced in 
a rural or urban location (Queenan et al., 2016).  However, this study identified a larger 
proportion of academic primary health care centres participating in the CPCSSN database, as 
compared to those reported in the 2013 NPS (Queenan et al., 2016).  The representation of the 
CPCSSN data will continue to improve as the number of sites, providers and patients increase.  
Each participating CPCSSN site and provider was recruited after transitioning from 
paper-based to electronic-based health records.  As such, each site had a pre-adopted EMR 
software type (e.g., Wolf or Nightingale).  As well, each site varied in when the EMR was 
adopted and implemented (e.g., when the transition took place) and the extent to which the EMR 
system is used in daily clinical care.  For example, some sites may rely heavily on their EMR 
software for scheduling appointments and ordering referrals, but may not enter complete or 
consistent diagnostic information during patient encounters (Coleman et al., 2015; Orueta et al., 
2012; Lau et al., 2012; Hayrinen et al., 2008).  Other sites may achieve a higher level of 
“meaningful use”, in which their EMR system is used regularly as an important tool for disease 
prevention and ongoing disease management (Manca 2015; Terry et al., 2014; Blumenthal et al., 
2010; Thiru et al., 2003).  In these sites, the providers actively engage with their EMR software 
for each patient encounter.  These patterns of meaningful use can vary from site to site and from 
provider to provider.  Throughout this thesis, the term “software” will refer to the EMR software 
program (e.g., Nightingale or Wolf) used by a PHC provider, whereas the term “record” will 
refer to the individual patient-level data.  
43 
Every three months, de-identified data are extracted from the participating sites’ EMR 
software by the regional CPCSSN data managers (individuals who are skilled in information 
technology).  These extracted data are then cleaned, coded and transformed into a common data 
format that is compiled into the secure CPCSSN database.  The exact details of these data 
extraction processes vary slightly from network to network (e.g., some extractions are conducted 
remotely, while others require in-person and manual extraction).  However, each network's data 
extraction process, specifically the de-identification, storage and utilization of these EMR data, 
has been approved by their respective university research ethics boards and by the Health Canada 
Research Ethics Board (CPCSSN, 2016).   
One element of this ethics approval is that all participating CPCSSN sites must post 
informational posters and distribute brochures about CPCSSN to their patients, in order to give 
individual patients an opportunity to learn about this database and to opt-out (or opt-in, as is the 
case in the network based in Québec) of contributing their personal health information to the 
CPCSSN database.  If a patient decides to opt-out, this decision is recorded in their EMR and 
these patients do not have their health information extracted.  At the CPCSSN central data 
repository in Kingston, Ontario, a variety of organizational, physical and technological 
safeguards are implemented to ensure that the privacy of patients is protected.  These safeguards 
are also important to ensure that all collection, retention and use or disclosure of data complies 
with current privacy legislation and the 2010 Tri-Council Policy Statement, Ethical Conduct of 
Research Involving Humans (CPCSSN, 2016).  Personal information (of both patients and 
providers) is removed from the data prior to being extracted from the EMR and further de-
identification (e.g., removal of names from free text notes) is conducted by the data managers 
after data collection and before compiling the data into the CPCSSN database.  
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The longitudinal, clinical data held within the CPCSSN database are not only available 
for academic research and policy purposes, but participating PHC providers can elect to receive 
quarterly reports on their patient population and how their site characteristics (e.g., number of 
patients who smoke or who have diabetes, performance of preventive measures for patients) 
compare to other PHC sites in their region and across the country.  This information can provide 
valuable insight into the characteristics of a provider’s patient population, their clinical care 
activities and their data input behaviours.  The intent of this feedback is to improve both patient 
care and the quality of data entered into EMRs. 
As of June 2016, more than 1,500,000 de-identified electronic patient records have been 
collected from more than 1,000 PHC providers (referred to as “sentinels” by CPCSSN) across 
Canada (CPCSSN, 2016).  During the data extraction period for this thesis work (known as the 
Q3-2013 extract), a total of 600,565 de-identified electronic patient records were collected from 
475 PHC providers in ten regional networks.  These ten regional networks are located in seven 
Canadian provinces: British Columbia, Alberta (two networks), Manitoba, Ontario (three 
networks), Québec, Nova Scotia and Newfoundland and Labrador.  The characteristics of these 
ten participating networks (e.g., geographical location, number of sites, number providers, 
number of patients, number of recorded encounters, type of EMR systems and time since EMR 
adoption) at the time of data extraction are described in Table 4.1.   
The CPCSSN data elements used for this research contain information on practice 
characteristics (e.g., geographical location); provider characteristics (e.g., provider birth year and 
provider sex); patient characteristics (e.g., patient birth year, patient sex and residential forward 
sortation area); and in-office encounters (e.g., encounter date, billing diagnoses codes and 
encounter diagnoses codes).  The majority (approximately 95%) of the disease diagnosis codes 
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within the CPCSSN database at the time of data extraction were recorded using the International 
Classification of Disease, 9th Revision (ICD-9) system.  As such, this coding system will be used 
to detect chronic disease diagnoses for both Objective One and Objective Two.  
These CPCSSN data contain patient-level, point-of-care information on disease 
management and morbidity over time until the date of data extraction.  While this information is 
not principally collected for research purposes, the CPCSSN database represents the only known 
pan-Canadian PHC EMR database.  To obtain these secondary data, approval was obtained from 
CPCSSN Research Committee in September 2013 (Project ID: 2013DEL04).  The Letter of 
Permission to access the CPCSSN database is provided in Appendix B.  Ethical approval has 
also been obtained from the Research Ethics Board at Western University and the Approval 
Notice (File Number: 104705) is presented in Appendix C.   
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Table 4.1 Characteristics of ten practice-based research networks participating in CPCSSN as of Q3-2013 data extract* 
Network ID Province or Region Number of Sites 
Start of 
EMR 
EMR Software 
Number of 
Providers 
Number of 
Patients 
Number of 
Encounters 
1 Southern Alberta 7 2001 Med Access, Wolf 60 55,053 1,204,548 
2 Northern Alberta 5 2002 Med Access, Wolf 35 25,901 449,525 
3 Southwestern Ontario 6 2005 Accuro, Healthscreen 21 19,029 516,523 
4 Central Ontario 21 2006 
Nightingale, Practice 
Solutions, Xwave 
81 140,791 1,610,614 
5 Eastern Ontario 9 2010 Bell, Nightingale, Oscar 102 151,531 2,641,669 
6 Québec 1 2012 DaVinci 25 8,942 212,694 
7 
Newfoundland and 
Labrador 
9 2005 Nightingale, Wolf 53 47,860 896,053 
8 Manitoba 3 2004 Jonoke 30 47,362 1,244,319 
9 Nova Scotia 19 2006 Nightingale 53 86,359 1,093,733 
10 British Columbia 2 2002 Wolf 15 17,737 343,087 
Total  82   475 600,565 10,212,765 
* All networks had the same data extraction date of September 30, 2013
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4.2 CPCSSN Data Procedures 
After ethical approval and CPCSSN permission was received, a copy of the database (as 
of the Q3-2013 extraction date) was transferred via an encrypted and password-protected 
Microsoft Access database to a password-protected device at Western University.  These 
Microsoft Access files were then imported into the Stata SE 14.1 software to conduct 
management, cleaning and statistical analyses of the data.   
 
4.2.1 CPCSSN Database Management 
The data dictionary of relevant CPCSSN variables is included in Appendix D.  This 
codebook outlines the variable names and the general process of entry into the EMR by the PHC 
provider (e.g., family physician, nurse practitioner, nurse, medical resident or medical student).  
New variables that were created for purposes of Objective One and Objective Two are also 
included in the codebook and highlighted using italics.  These new variables are described in a 
similar manner to the original CPCSSN variables.  
 
4.2.2 CPCSSN Data Cleaning  
Once the data were received, all of the data tables and key variables of interest were 
examined and explored.  This “diagnostic exploration” uncovered the nuances of the data, 
particularly the data entry patterns that were evident among networks, sites and providers.  All 
included variables (both original and new) were checked for range and consistency; 
consequently, potential outliers and implausible values were identified.  For continuous 
variables, respective means, medians, range of values and standard deviations were calculated.  
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For categorical variables, data distribution between categories was explored graphically and 
statistically.  The frequency and patterns of missingness were also assessed for each variable.   
 
4.3 CPCSSN Data Elements 
4.3.1 Primary Health Care Practice Characteristics  
Each CPCSSN network has been assigned a unique Network ID, which is an auto-
incrementing value in which a unique number is generated when a new record is inserted into the 
EMR table.  The participating PHC practices (referred to as “sites” by CPCSSN, and these two 
terms will be used interchangeably in this thesis) within each network were then assigned a 
unique, auto-incrementing Site ID.  While the network names and geographic locations (e.g., 
city, province or territory) are provided in the CPCSSN database and displayed on the CPCSSN 
website (CPCSSN, 2016), specific Site ID information remains unavailable for researchers.  
Instead, the geographic location of each site is recorded using the site’s forward sortation area 
(first three characters of the site location’s postal code).  Finally, details of each site’s EMR 
software are recorded, including the name of the EMR software and the date the EMR software 
was started within the practice.  Therefore, the length of use and EMR software details for each 
site can be explored.  Each PHC provider (referred to as “sentinels” by CPCSSN, and these two 
terms will be used interchangeably in this thesis) is nested within each Site ID and Network ID, 
and their characteristics are described further in the next section.   
 
4.3.2 Primary Health Care Provider Characteristics  
Within the CPCSSN database, both family physicians and nurse practitioners have been 
recruited as eligible PHC providers or sentinels.  These are providers who: 1) are located at an 
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academic or community site; 2) practice generalized or primary health care; and 3) utilize an 
EMR system in their clinical work.  After recruitment and consent to participate in the CPCSSN 
database, each provider is then assigned a unique, auto-incrementing Provider ID.  Similar to 
Site ID, the majority of Provider ID information remains de-identified for researchers.  Instead, 
only the provider’s birth year and sex is recorded.  Each patient and their health care encounters 
are nested within each Provider ID, and these variables are described further in the next sections.   
 
4.3.3 Primary Health Care Patient Characteristics  
Patients who seek care from the participating CPCSSN providers (and who have not 
refused to contribute their health data) are assigned a Patient ID, which is a unique, auto-
incrementing identifier for each patient in the database.  Both patient birth year and patient sex 
are recorded, as well as corresponding health information.  As stated earlier, if a patient has 
decided to opt-out of any data extraction period, the patient and their respective health 
information are removed from subsequent data analyses.  Unfortunately, details of the patient’s 
socioeconomic characteristics, such as patient occupation, level of education, housing status, 
language and ethnicity are incomplete and of poor quality in the CPCSSN database.  This may be 
because these fields within the EMR that are completed inconsistently, if at all, by the PHC 
providers or more complete information is contained in another area of the EMR software not 
extracted by the CPCSSN data managers (e.g., within clinical notes or patient profile).  Examples 
of data entries for these characteristics can be found in Appendix E.  Due to missingness and 
inconsistency, these socioeconomic variables were not a reliable source of information for use in 
data analyses.  However, the patient residential forward sortation area (FSA) has been recorded 
for a larger proportion of patients and was used to identify whether a patient lived in a rural or 
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urban setting and their median household income.  This identification was done via a link with 
Canada Post and Statistics Canada data and will be described further in the next two sections.  
 
Residential Location and Forward Sortation Areas  
The typical form of the Canadian postal code system is “ANA NAN”, where each “A” 
represents an alphabetic character and each “N” represents a numeric character (Statistics 
Canada, 2015).  The first three characters of the postal code identify the FSA (Statistics Canada, 
2015), which can be used to classify individuals into rural or urban residence.  The first character 
of the FSA (first alphabetic character) represents a province or territory, or a major region within 
a province, as can be seen in Appendix F.  The second character of the FSA (numeric character) 
identifies whether the postal code is for a “rural” or “urban” area.  For this character, a zero (0) 
indicates a rural area, while any other digit between 1 through 9 represents a comparatively 
urban area.  As defined by Canada Post, “rural” residence refers to individuals living outside 
centres with a population of 1,000 and outside areas with 400 persons per square kilometre 
(Statistics Canada, 2015).  In comparison, “urban” residence refers to individuals living within 
population centres of 1,000 or more (Statistics Canada, 2015).  The third character of the FSA 
(second alphabetic character) narrows down the area of coverage and boundaries of each region.  
The last three characters of the postal code (“NAN”) identify routes known as local delivery 
units for mail delivery.  For the purposes of this research, the CPCSSN database collects 
residential FSA data for participating patients.  The second character of each patient’s FSA was 
used to categorize patients into rural (second character = 0) or urban (second character ≠ 0) 
residence.  
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Median Household Income and Forward Sortation Areas  
In addition to linking with Canada Post data, the patient FSA data were linked with 
household income data from the National Household Survey (2011) conducted by Statistics 
Canada.  Access to Statistics Canada data is covered through the Data Liberation Initiative 
licence from Western University, which is a partnership between post-secondary institutions and 
Statistics Canada for improving access to Canadian data resources (Western University, 2016).  
Source data were derived from the Income Statistics Division of Statistics Canada (CANSIM 
Table 202-0701), which collected information on market, total and after-tax income by economic 
family type and income quintiles as of 2011.  As such, annual household income was determined 
before tax (total) and in Canadian dollars as of 2011 (Statistics Canada, 2016).  More 
specifically, household income was recorded for economic families (defined as two or more 
persons who live in the same dwelling and are related to each other by blood, marriage, common 
law or adoption), as well as unattached individuals (defined as a person living either alone or 
with unrelated roommates), as of 2011 (Statistics Canada, 2016).  The median annual household 
income measure was used, instead of the mean annual household income, to account for a non-
symmetrical distribution.  This median value helps to provide a better description of the central 
tendency of the income data distribution.   
 
4.3.4 Primary Health Care Encounter Characteristics  
Each time a participating CPCSSN patient visits or seeks care from their CPCSSN PHC 
provider, an encounter is recorded and assigned a unique, auto-incrementing Encounter ID.  As 
well, an associated Encounter Date (for Encounter Diagnosis information) or Service Date (for 
Billing Diagnosis information) is recorded to indicate the date on which the encounter occurred.  
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The details of the encounter are then documented in the EMR (again, the level of detail recorded 
or documented within an EMR varies by site, provider and encounter).  A number of 
characteristics, specifically linked to the encounter, can be entered into the EMR by the provider.  
For example, a provider has the ability to record relevant diagnostic codes, medication 
information and specialist referrals that are made during the encounter.  These data can also be 
entered into various parts of a patient’s electronic record, as each EMR software has its own 
individualized structure for clinical data input.  This flexibility in data entry creates a need to 
identify and extract from, all relevant areas of the EMR software program and the CPCSSN 
database.  Variability in EMR data entry requires adaptability from the researcher and the 
approach used to identify the main source of diagnostic information is described in Section 4.6.   
 
4.4 Identifying Sample of CPCSSN Patients  
As of the Q3-2013 data extraction, the complete CPCSSN database consisted of 600,565 
patients from 475 providers within ten regional networks.  For both objectives, the inclusion 
criteria required that eligible patients have at least one in-office encounter recorded in their EMR 
and were at least 18 years of age as of their first encounter date (calculated using the patient’s 
birth year and first recorded encounter date).  Patients who had a missing or implausible (e.g., 
entry of “0”) Patient ID or birth year were excluded from the patient sample.  A patient inclusion 
flowchart is included in Figure 4.1.  After applying the inclusion and exclusion criteria, the final 
sample consisted of 367,743 eligible adult patients (at least 18 years of age at first encounter 
date) who had at least one in-office encounter with their primary health care provider.   
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4.5 Identifying Patients with Multimorbidity  
As described in the Literature Review Chapter, there is currently no gold standard list for 
measuring multimorbidity.  Therefore, a list of twenty chronic disease categories and 
corresponding ICD-9 diagnostic codes was created and used in this research to identify eligible 
adult patients with multimorbidity.  This list was created by a supervisory committee member 
and an internationally recognized expert in multimorbidity research (Dr. Martin Fortin) as part of 
a nationally funded research project.  This project is co-led by Dr. Moira Stewart (Distinguished 
University Professor, Western University, Ontario) and Dr. Martin Fortin (Professor, Université 
de Sherbrooke, Québec) and is entitled “Patient-Centered Innovations for Persons with 
Multimorbidity” or “PACE in MM” (PACE in MM, 2014).  It is funded by the Canadian 
Institutes of Health Research (CIHR) as a five-year signature initiative in community-based 
primary health care (CBPHC), which supports innovative approaches to improve the delivery of 
appropriate and high-quality primary health care to Canadians.  The final list is composed of 
chronic disease categories that are particularly relevant among clinical and general populations in 
Canada.  For example, the ICD-9 codes of 278 and 278.01, as well as a body mass index (BMI) 
of thirty or greater, were used to capture patients with Obesity.  The abbreviated list of chronic 
disease categories and their corresponding ICD-9 codes is found in Table 4.2, while a more 
detailed list is available in Appendix G.  
To date, the performance of the list of chronic disease categories has been assessed using 
a combination of criterion validity (through chart reviews), construct validity (through quality of 
life), as well as through test-retest reliability and inter-rater reliability.  This work has not yet 
been published, but was conducted by Maude Richards who is a Master of Science student at the 
Université de Sherbrooke in Québec.  This study recruited 245 patients from the Family 
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Medicine Group in Chicoutimi, Québec.  After comparing the measurement of multimorbidity 
with a chart review, this list of categories for multimorbidity had an overall sensitivity of 84.6% 
(95% CI: 77.0 – 90.9) and specificity of 84.3% (95% CI: 76.4 – 90.4).  Ms. Richard’s work also 
found a moderate correlation between the measure of multimorbidity and quality of life (-0.5).  
In terms of the reliability, there was fair agreement in the test-retest reliability (Cohen’s Kappa 
coefficient of 0.64) and inter-rater reliability (Cohen’s Kappa coefficient of 0.79).  Overall, this 
research has demonstrated a fairly strong performance of this measure of multimorbidity, when 
compared to the gold standard of chart review.  For the research described herein, it was used as 
a marker for multimorbidity among adult PHC patients within the CPCSSN database.  
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Figure 4.1 Patient inclusion flowchart to create the final sample of adult patients with at least 
one in-office encounter recorded during the data extraction period  
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Table 4.2 List of twenty chronic disease categories and abbreviated ICD-9 disease codes*  
Chronic Disease Category ICD-9 Codes 
Hypertension 401-405, 401, 401.1, 401.9, 405, 405.01, 405.09, 405.1, 405.11, 405.19, 405.9, 405.91, 
405.99 
Obesity 278, 278.01, BMI ≥ 30 
Diabetes 250, 250.01, 250.02, 250.03, 250.1, 250.11, 250.12, 250.13, 250.2, 250.21, 250.22, 250.23, 
250.3, 250.31, 250.32, 250.33, 250.4, 250.41, 250.42, 250.43, 250.5, 250.51, 250.52, 
250.53, 250.6, 250.61, 250.62, 250.63, 250.7, 250.71, 250.72, 250.73, 250.8, 250.81, 
250.82, 250.83, 250.9, 250.91, 250.92, 250.93 
Chronic Obstructive 
Pulmonary Disease or 
Asthma 
491, 491.1, 491.2, 491.21, 491.22, 491.8, 491.9, 492, 492.8, 493, 493.01, 493.02, 493.1, 
493.11, 493.12, 493.2, 493.21, 493.22, 493.8, 493.81, 493.82, 493.9, 493.91, 493.92, 496 
Hyperlipidemia 272, 272.1, 272.2, 272.3, 272.4 
Cancer  140-239, 140-149, 150-159, 160-165, 170-176, 179-189, 190-199, 200-209 
Cardiovascular Disease 412, 413, 413.1, 413.2, 440-449, 427, 427.3, 427.31, 417.32 
Heart Failure 428, 394, 394.1, 394.2, 395, 395.1, 395.2, 395.9 
Anxiety or Depression 296, 296.2, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.3, 296.31, 296.32, 296.33, 
296.34, 296.35, 296.36, 300, 300.01, 300.02, 300.09 
Osteoarthritis or 
Rheumatoid Arthritis 
714, 714.1, 714.2, 714.3, 715, 715.1, 715.2, 715.3, 715.8, 715.9 
Stroke or Transient 
Ischemic Attack 
434, 434.01, 434.1, 434.11, 433.9, 434.9, 434.91, 435, 435.1, 435.2, 435.3, 435.8, 435.9 
Thyroid Problem 240-246, 240, 241, 242, 243, 244, 245, 246 
Kidney Disease or Failure 585, 585.1, 585.2, 585.3, 585.4, 585.5, 585.6, 585.9 
Osteoporosis 733, 733.01, 733.02, 733.03, 733.09 
Dementia 290, 290.1, 290.11, 290.12, 290.13, 290.2, 290.21, 290.3, 290.4, 294, 294.1, 294.2 
Musculoskeletal Problem 723, 723.1, 724, 724.1, 724.2, 724.3, 724.4, 724.5, 725, 726, 726.1, 726.2, 726.3, 726.31, 
726.32, 726.33, 726.39, 726.4, 726.5, 726.6, 726.61, 726.62, 726.63, 726.64, 726.65, 
726.69, 726.7, 726.71, 726.72, 726.73, 726.79, 726.9, 726.91, 727, 727.01, 727.03, 727.04, 
727.05, 727.06, 727.09, 727.2, 727.3, 729, 729.1, 729.2, 729.4, 729.5 
Stomach Problem 530, 530.81, 531, 531.4, 531.41, 531.5, 531.51, 531.6, 531.61, 531.7, 531.71, 531.9, 531.91 
Colon Problem 555, 555.1, 555.2, 555.9, 556, 556.4, 556.5, 556.6, 556.8, 556.9, 564, 564.1 
Liver Disease 571, 571.1, 571.2, 571.3, 571.4, 571.41, 571.42, 571.49, 571.5, 571.6, 571.8, 571.9 
Urinary Problem 593, 593.3, 593.4, 593.5, 593.7, 593.71, 593.72, 593.73, 593.8, 593.82, 593.89, 593.9, 595, 
595.1, 595.2, 595.9, 597, 597.8, 597.81, 597.82, 600, 601, 601.1, 601.3, 601.8, 601.9, 602, 
602.1, 602.2, 602.3, 602.8, 602.9 
* Reproduced with permission from co-Principal Investigator of PACE in MM CBPHC Team (Dr. Martin Fortin) 
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4.6 Identifying Source of Chronic Disease Diagnoses  
There are two areas of the CPCSSN database where diagnostic codes for each patient are 
stored based on how the information was originally entered into the EMR.  These are the Billing 
Diagnosis and Encounter Diagnosis tables.  After exploration of the raw data, it was clear that 
the patterns of data entry for diagnostic information varied among sites and providers.  There 
was not a consistent source of diagnostic information for all patients between these two tables, 
and diagnostic data had to be explored on a patient-by-patient basis.  To overcome this 
variability, the mean number of Billing Diagnosis codes and Encounter Diagnosis codes 
(including both acute and chronic diagnoses) per encounter was calculated for each patient.  
More specifically, the total number of Billing Diagnoses codes and the total number of 
Encounter Diagnoses codes recorded for a patient in their EMR was divided by the total number 
of encounters recorded for a patient.  This produced the mean number of Billing Diagnosis codes 
per encounter and the mean number of Encounter Diagnosis codes per encounter, respectively.  
From this calculation, the higher mean number of diagnoses codes was identified as the main 
source of chronic disease diagnoses for that individual patient.  For patients with the same mean 
number of Billing Diagnosis codes per encounter and Encounter Diagnosis codes per encounter, 
the Encounter Diagnosis codes were selected as these codes were deemed more closely tied to 
the encounter itself and were recorded beyond purposes of billing.  The number of eligible adult 
patients with a higher mean of Billing Diagnosis codes per encounter was 245,365 (66.7%), 
while 110,608 (30.1%) patients had a higher mean of Encounter Diagnosis codes per encounter.  
A total of 11,770 (3.2%) patients had the same mean number of Billing Diagnosis and Encounter 
Diagnosis codes per encounter.  Consequently, Encounter Diagnosis codes were used for 
122,378 (33.3%) patients.  This approach aimed to capture the maximum amount of clinical 
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information available on a patient-by-patient basis.  This produced a final prevalence estimate of 
53.3%.  
A three-part sensitivity analyses was conducted to detect potential differences in 
prevalence of multimorbidity using either the Billing Diagnoses codes only, the Encounter 
Diagnoses codes only or a combination of the two diagnostic sources.  The results from these 
three sensitivity analyses are presented in Table 4.3, as well as the results from the original 
analysis.  When all Billing Diagnosis codes were used to detect patients with multiple chronic 
diseases, the prevalence of multimorbidity was found to be 56.7%.  When all Encounter 
Diagnosis codes were used to detect patients with multiple chronic diseases, the prevalence of 
multimorbidity was found to be 54.1%.  For the third part of the sensitivity analysis, Billing 
Diagnosis codes were used for the 11,770 patients with an equal mean of Billing Diagnosis and 
Encounter Diagnosis codes per encounter.  Consequently, Billing Diagnosis codes were used for 
257,135 (69.9%) and the resulting prevalence of multimorbidity was found to be 57.2%.  After 
conducting these analyses, the original analysis (reported in the Results Chapter) was deemed to 
provide the most conservative estimate of multimorbidity among adult PHC patients in Canada.   
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Table 4.3 Prevalence of multimorbidity (defined as patients with two or more chronic 
diseases), stratified by source of diagnostic code information 
Original Analysis Prevalence of Multimorbidity 
Highest Mean of Billing and Encounter Diagnosis Codes Selected and 
Encounter Diagnosis Codes Selected for Patients with Equal Mean 
53.3% 
Sensitivity Analyses 
Prevalence of Multimorbidity  
(% Change from Original Analysis)  
All Billing Diagnosis Codes Selected for All Patients 56.7% (+3.4) 
All Encounter Diagnosis Codes Selected for All Patients 54.1% (+0.8) 
Highest Mean of Billing and Encounter Diagnosis Codes Selected and 
Billing Diagnosis Codes Selected for Patients with Equal Mean 
57.2% (+3.9) 
 
4.7 Objective One 
4.7.1 Patient Sample 
The first objective measured the point prevalence, characteristics and clusters of 
multimorbidity among adult PHC patients in Canada.  The patient sample, or population at-risk 
of multimorbidity occurrence, was composed of participating CPCSSN patients with at least one 
in-office encounter recorded in their EMR and who were at least 18 years of age as of their first 
encounter date.  As described in a previous section, this final sample consisted of 367,743 adult 
patients.  While the clinical data for these patients were recorded prospectively as the patients 
consulted their PHC provider over time, the CPCSSN database created a retrospective or historic 
cohort.  The prevalence estimates of individual chronic diseases and multimorbidity were 
calculated as of September 30, 2013.   
 
4.7.2 Study Design 
The first objective used a retrospective or historic observational cohort study design.  
Prevalence estimates and corresponding 95% confidence intervals were calculated using the 
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Stata SE 14.1 software (StataCorp., 2015).  Prevalence estimates were stratified according to 
relevant patient-, provider- and practice-level predictors: patient age, patient sex, residential 
location, provider age, provider sex, EMR software type, practice location and CPCSSN 
Network.  Both crude and stratified prevalence estimates of multimorbidity were reported.  To 
identify the most frequently occurring clusters of chronic diseases accumulated by patients over 
time, the frequency and type of unordered and ordered clusters (also known as combinations and 
permutations, respectively) of chronic disease diagnoses were computed using customized Java 
programming and the Stata SE 14.1 software (StataCorp., 2015), which are described in more 
detail in Section 4.7.3.3.  
 
4.7.3 Data Analyses  
4.7.3.1 Research Question 1 – Prevalence of Multimorbidity  
Prevalence estimates were calculated using two approaches, corresponding to the 
prevalence estimates that are commonly reported within the multimorbidity literature.  This 
means that prevalence estimates of patients with at least two or at least three chronic diseases 
were calculated, as well as the prevalence level of patients with zero, one, two, three, four and 
five or more chronic diseases.  Prevalence estimates and corresponding 95% confidence 
intervals, were calculated using the proportion procedure in the Stata SE 14.1 software 
(StataCorp., 2015).  For all calculations, the denominator consisted of all adult patients (N = 
367,743) in the final sample.  These estimates were stratified by patient-level (age, sex, 
residential location, median household income and total number of chronic diseases), provider-
level (age and sex) and practice-level (EMR software type, practice location and CPCSSN 
Network) variables to investigate distinct patterns of multimorbidity.  
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Patient age was calculated (in years) as of 2013, using the patient’s recorded birth year.  
Age categories were then created to group patients into five categories: 18 – 34 years; 35 – 44 
years; 45 – 64 years; 65 – 84 years; and 85 years or older.  This calculation is separate from that 
used in the inclusion criteria, which used the date of the patient’s first in-office encounter and the 
patient’s birth year.  Patient sex was recorded as a binary variable, female or male.  As described 
earlier, residential location and median household income were determined using each patient’s 
residential FSA.  The total number of chronic diseases was summed (ranging from zero to 
twenty) for each patient as of September 30, 2013.  Provider age was calculated (in years) as of 
2013, using the provider’s recorded birth year and categorized into three groups: 25 – 44 years; 
45 – 64 years; and 65 years or older.  Provider sex was recorded as a binary variable, female or 
male.  Each practice’s EMR type was categorized based on the EMR software name (e.g., 
Nightingale or Oscar).  Similar to patient residential location, practice location was defined by 
the practice’s recorded FSA.  Finally, practices were categorized according to their associated 
CPCSSN Network (e.g., Network 1 or Network 2).   
To compare prevalence estimates of multimorbidity with the existing international 
literature on multimorbidity, a review of the literature was conducted and relevant articles that 
reported prevalence of multimorbidity (defined as two or more chronic diseases and three or 
more chronic diseases) were selected.  For this review, both the Medline and Embase electronic 
databases were searched for the reference period starting on January 1, 1990 and ending on April 
25, 2016.  As the term “multimorbidity” does not have an established Medical Subject Heading 
(MeSH) Term, the term “multimorbidity” was searched as a keyword (in all fields) and the term 
“comorbidity” was searched as a MeSH Term.  The “epidemiology” and “prevalence” of 
multimorbidity estimates were incorporated into the search as keywords and MeSH Terms.  
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Similarly, the terms “characteristics”, “adult” and “humans” were all included to narrow the 
literature search.  Details of the main search terms used in this review are included in Table 4.4.  
The final selection of published literature was identified from the titles derived from this search, 
as well as through the review of references from included literature.  The key methodological 
elements (e.g., country of origin, study design, sample size, age range, sample recruitment, data 
source, diagnostic coding system and number of diseases considered) and corresponding 
prevalence estimates from relevant research articles were compiled into a summary table and 
presented in the Results Chapter.  Separate tables were created for those studies that defined 
multimorbidity as at least two chronic diseases and those studies that defined multimorbidity as 
at least three chronic diseases.  The methodological elements and prevalence estimates from the 
current study were also incorporated into these tables for qualitative comparison.    
 
Table 4.4 Details of search terms to identify prevalence and characteristics of adults with 
multimorbidity in the published literature 
("comorbidity"[MeSH Terms] OR "comorbidity"[All Fields] OR "co-morbidity"[All Fields] OR 
"multimorbidity"[All Fields] OR “multi-morbidity”[All Fields])  
AND ("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR 
"prevalence"[MeSH Terms])  
AND (“characteristics”[All Fields]) 
AND ("adult"[MeSH Terms] OR "adult"[All Fields])  
AND ("1990/01/01"[PDAT] : "2016/04/25"[PDAT]) 
AND ("humans"[MeSH Terms])  
 
 
 
63 
4.7.3.2 Research Question 2 – Characteristics of Adult PHC Patients with Multimorbidity 
The characteristics of adult patients with multimorbidity were examined and compared 
with the published multimorbidity literature.  More specifically, the distribution of patient age, 
patient sex, residential location, median household income and total number of chronic diseases 
were explored for all adult patients with multimorbidity, defined as at least two chronic diseases 
and at least three chronic diseases.  The distribution of provider-level (provider age and provider 
sex) and practice-level (EMR software type, practice location and CPCSSN Network) were also 
explored for both definitions of multimorbidity.   
In order to compare these patient characteristics with the existing multimorbidity 
literature, a review of the literature was conducted and relevant articles that reported 
characteristics of individuals with multimorbidity were selected.  Similar to the previous search 
for multimorbidity literature, this review included both Medline and Embase electronic databases 
that were searched for the reference period of January 1, 1990 to April 25, 2016.  Details of the 
main search terms used in this review are included in Table 4.4.  The final selection of published 
literature was identified from the titles derived from this search, as well as through the review of 
references from included literature.  While it would be ideal to compare all patient-level 
characteristics from the current research with those in the multimorbidity literature, there is a 
lack of consistent reporting of characteristics of individuals living with multimorbidity (e.g., 
residential location or level of household income).  Instead, the most consistently reported 
characteristics in studies were in fact mean age and sex distribution.  As such, these two 
characteristics were used as a starting point in the qualitative comparison between the current 
research and the published multimorbidity literature.  These characteristics, as well as the key 
methodological elements (e.g., country of origin, study design, sample size, age range, sample 
64 
recruitment, data source, diagnostic coding system and number of diseases considered), from 
relevant articles were compiled into a summary table and presented in the Results Chapter.  Once 
again, separate tables were created for those studies that defined multimorbidity as at least two 
chronic diseases and those studies that defined multimorbidity as at least three chronic diseases.  
The methodological elements and characteristics of patients with multimorbidity from the 
current study were also incorporated into this table for comparison.    
 
4.7.3.3 Research Question 3 – Most Frequent Clusters of Multiple Chronic Diseases  
The prevalence estimates of individual chronic disease diagnoses among patients with 
multimorbidity were calculated, stratified by patient age category and patient sex.  Where 
possible, the prevalence levels of individual chronic diseases were compared to the national 
prevalence estimates from the 2013 Canadian Community Health Survey.  Clusters of multiple 
chronic diseases were then examined, accounting for both combinations (unordered clusters) and 
permutations (ordered clusters).  The frequency of unique clusters was determined in Objective 
One, whereas the time elapsing between diagnoses was analyzed in Objective Two (to be 
described in an upcoming section).  A customized computational cluster analysis program was 
created in Java in collaboration with Dr. Michael Bauer (Professor, Department of Computer 
Science) at Western University.  This computational program allowed for the identification and 
sorting of the more than 18,000 unique combinations (unordered clusters) and 55,000 unique 
permutations (ordered clusters) possible from our list of twenty chronic diseases.  Further 
information about this computational cluster analysis program (both its availability and 
instruction for use) is provided within the Multimorbidity Cluster Analysis Toolkit, which is 
included in Appendix H.  This document is also provided when the computational program is 
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accessed by external researchers who are interested in exploring unordered and ordered clusters 
of diseases in their own data.   
In order to run properly, this computational cluster analysis program requires a basic data 
input file (in .txt format) that contains the unique Patient IDs, as well as the diagnostic codes 
received by each patient by the end of the observation period.  From there, the analysis program 
detects and sorts all disease combinations and permutations into mutually exclusive groups.  As 
such, two sets of output are created from the raw data: 1) frequency and type of all unique 
combinations (unordered clusters); and 2) frequency and type of all unique permutations 
(ordered clusters).  For this research, the data input files were stratified by patient age category 
and patient sex to provide more specific output information.  For example, the most frequently 
occurring combinations were explored among all female patients with multimorbidity, as well as 
those female patients in each of the five age categories.  Likewise, the most frequently occurring 
permutations were explored among all female patients with multimorbidity, as well as those 
female patients in each of the five age categories.  Similar output files were created for all male 
patients with multimorbidity, as well as those male patients in each of the five age categories.  
Finally, these results were further stratified by the total number of chronic disease diagnoses to 
create mutually exclusive groups (e.g., female patients aged 18 to 34 years with exactly two 
chronic diseases or male patients aged 45 to 64 years with exactly four chronic diseases).   
To create the output files for the frequency and type of combinations, the computational 
analysis program detected all patients (within the input data file) with the exact same number and 
type of chronic disease diagnoses, regardless of the order in which these diagnoses occurred.  For 
example, all patients who were diagnosed with Hypertension, Obesity and Musculoskeletal 
Problem at the end of the observation period were detected and categorized into the same 
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combination cluster.  To create the output data files for the frequency and type of permutations, 
the computational analysis program detected all patients with the exact same number, type and 
sequence of chronic disease diagnoses.  For example, all patients who were diagnosed with 
Obesity, then Hypertension and then Musculoskeletal Problem were detected and categorized 
into one permutation cluster.  However, all patients who were diagnosed with Musculoskeletal 
Problem, then Hypertension and then Obesity were categorized into another permutation cluster.  
In addition to reporting the frequency of the most frequently occurring cluster in each age-sex 
multimorbidity subgroup (e.g., female patients aged 18 to 34 years or male patients aged 45 to 64 
years), the proportion of patients living with this cluster from the subgroups was calculated.  
 
4.8 Objective Two  
4.8.1 Patient Sample  
The second objective examined the natural history and the changing burden of 
multimorbidity over time among adult PHC patients.  The sample consisted of patients with at 
least one in-office encounter recorded in their EMR and who were at least 18 years of age as of 
their first encounter date.  For this objective, patients with one or more chronic disease diagnoses 
were included in order to assess both the onset and progression of multimorbidity over time.  
This created a final sample of 286,998 adult patients.  All patients were followed over time to 
calculate the time elapsing (in days) between chronic disease diagnoses (regardless of disease 
type).  These patients were observed prospectively from one chronic disease diagnosis until a 
subsequent chronic disease diagnosis or the end of the observation period, which was September 
30, 2013.  The beginning of the observation period occurred when a patient was diagnosed with 
their first chronic disease, which is depicted in Figure 4.2.   
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4.8.2 Study Design  
The second objective used a prospective cohort study design.  To determine time elapsing 
between chronic diseases, the corresponding encounter date for each chronic disease diagnosis 
was determined, as described in a previous section and Appendix I.  These dates were ordered 
chronologically and the time difference (in days) between each diagnosis date was calculated.  
Patients were stratified into subgroups to examine both “Time Until Multimorbidity” and “Time 
Until Advancing Multimorbidity”.  To examine “Time Until Multimorbidity”, the time elapsing 
between a patient’s first chronic disease diagnosis and their second chronic disease diagnosis 
was calculated.  As such, this was calculated for the first patient subgroup shown in Figure 4.2.  
The “Time Until Advancing Multimorbidity” was assessed for the remaining patient subgroups.  
In these analyses, the observation period  for the second patient subgroup began on the date of a 
patient’s second chronic disease diagnosis; the observation for the third patient subgroup began 
on the date of a patient’s third chronic disease diagnosis; the observation period for the fourth 
patient subgroup began on the date of a patient’s fourth chronic disease diagnosis; and the 
observation period for the fifth patient subgroup began on the date of a patient’s fifth chronic 
disease diagnosis.  As seen in Figure 4.2, the end of the observation period was when a patient 
was diagnosed with a subsequent chronic disease diagnoses (referred to as the “event” in the 
survival analysis) or as of September 30, 2013 if the patient did not receive another chronic 
disease diagnosis (referred to as “right censoring” in the survival analysis).   
If more than one chronic disease diagnosis was documented for a patient on the same 
date (likely within the same encounter), the time elapsing between chronic disease diagnoses was 
calculated to be zero days.  For example, if a patient was diagnosed with Hypertension, Diabetes 
and Depression or Anxiety at the same encounter, the time elapsing between all three diagnoses 
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was equal to zero days.  However, these data points did not necessarily depict a clear transition 
from one chronic disease state to another.  More specifically, there were three possible reasons of 
the zero days elapsing between chronic disease diagnoses: 1) the patient was diagnosed with two 
or more chronic diseases after a series of tests and clinical observations (therefore accurate 
diagnoses of multiple chronic diseases occurred at the same encounter); 2) the patient was new to 
the PHC practice and the provider was updating the patient’s EMR with their current health 
status information (therefore inputting multiple chronic disease diagnoses at the same 
encounter); or 3) data entry error into the patient’s EMR (that is, the second and third diagnoses 
were entered by mistake at the same encounter).  The second and third potential reason for zero 
days elapsing between diagnoses would indicate an artefact in the EMR data, which cannot be 
clearly differentiated from the first reason.  Instead, the first reason is of interest for this research.  
Exploration of the data was conducted to determine the proportion of patients with at 
least one chronic disease who had at least one data point of zero days elapsing between 
subsequent chronic disease diagnoses.  While these data points (where time = 0) were maintained 
in the complete dataset and contributed to the overall prevalence estimates of multimorbidity, 
they were dropped from the computational cluster analysis previously described in Objective 
One and the longitudinal analysis in Objective Two.  This was done to ensure that the analysis 
described a “true” transition from one chronic disease state to the next.  The distribution of time 
elapsing between incident chronic disease diagnoses are displayed in Figure 4.3 and Figure 4.4 
and those patients with at least one data point of zero days were removed from the cluster and 
time-to-event analyses.  In total, 65,828 female patients had at least one data point of zero days 
elapsing between chronic disease diagnoses, whereas 52,144 male patients had at least one data 
point of zero days elapsing between chronic disease diagnoses.  The approach of case-wise 
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deletion of these patients was selected due to the large sample size, but more importantly, 
because the sequence between the chronic disease diagnoses could not be reasonably assessed if 
the pattern between two or more chronic disease diagnoses was not clear.  However, sensitivity 
analyses were conducted by including these excluded data points and similar patterns were seen 
in both the cluster and longitudinal analyses (described further in the Results Chapter).  
70 
Figure 4.2 Depiction of time elapsing (in days) between chronic disease diagnoses, as well as the corresponding start and end of 
observation periods, among separate subgroups of patients with at least one chronic disease diagnosis  
 
Legend:  
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Figure 4.3 Distribution of time elapsing until subsequent chronic disease diagnoses among 
female patients with multimorbidity 
 
Figure 4.4 Distribution of time elapsing until subsequent chronic disease diagnoses among 
male patients with multimorbidity 
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4.8.3 Data Analyses  
4.8.3.1 Research Question 1 – Time Until Multimorbidity 
Descriptive statistics were used to examine the time (in days) that elapsed between 
chronic disease diagnoses.  The time elapsing between the first (or index) and second chronic 
disease diagnosis was designated as the “Time Until Multimorbidity”, indicating the onset of 
multimorbidity (defined as two or more chronic diseases).  The time elapsing between the 
subsequent chronic disease diagnoses was defined as the “Time Until Advancing 
Multimorbidity”.  As seen in Figure 4.5, the “Time Until Multimorbidity” observation period 
began when a patient received their first chronic disease diagnosis (T1) and ended on the date the 
patient received their second chronic disease diagnosis (T2).  Likewise, the “Time Until 
Advancing Multimorbidity” observation period began when a patient received their second 
chronic disease diagnosis (T2) and ended on the date the patient received their third chronic 
disease diagnosis (T3).  The time elapsing was calculated using the summarize procedure in the 
Stata SE 14.1 software (StataCorp., 2015) and was assessed by patient age category and between 
females and males.  As seen in Figure 4.6, “Time Until Multimorbidity” was stratified by index 
chronic disease type in order to explore whether variations in time elapsing until subsequent 
chronic disease diagnoses varied by a patient’s index chronic disease.  For example, the “Time 
Until Multimorbidity” was reported among patients who were first diagnosed with Hypertension, 
as compared to those patients who were first diagnosed with Cancer or Cardiovascular Disease.  
As described in Section 4.8.2, the data points where time elapsing between diagnoses was equal 
to zero days were dropped from this analysis.  This was done to ensure this described a “true” 
transition from one chronic disease state to the next.  A sensitivity analyses was conducted to 
examine the impact of excluding these data points (described further in the Results Chapter). 
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Figure 4.5 Time elapsing (in days) between first and second chronic disease diagnoses, as well as second and third chronic 
disease diagnoses, among adult patients with at least one chronic disease diagnoses 
 
Legend:  
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Figure 4.6 Time elapsing (in days) until subsequent chronic disease diagnoses, stratified by index chronic disease type among 
adult patients with at least one chronic disease diagnoses  
 
Legend: 
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4.8.3.2 Research Question 2 – Time Until Advancing Multimorbidity 
The approach described in the previous section was replicated for Research Question 2, 
in which the mean time (in days) until subsequent chronic disease was explored among all 
patients with at least two chronic disease diagnoses.  As such, the “Time Until Advancing 
Multimorbidity” was assessed in more detail.  The mean time (in days) elapsing between the 
penultimate and final chronic disease diagnosis was stratified among patients living with at least 
two, at least three, at least four and at least five chronic diseases.  These non-mutually exclusive 
patient subgroups (except those patients with at least five chronic diseases) are presented in 
Figure 4.2 and indicate the start and end of the observation period for each subgroup.  This 
analysis was conducted to determine whether the mean time until subsequent chronic disease 
decreases when the number of chronic disease diagnoses increases.  In each analyses, the time 
elapsing was calculated using the summarize procedure in the Stata SE 14.1 software 
(StataCorp., 2015) and was assessed among patient age categories and between females and 
males.  As described in Section 4.8.2, the data points where time elapsing between diagnoses 
was equal to zero days were dropped from this analysis.  This was done to ensure that this 
analysis described a “true” transition from one chronic disease state to the next.  A sensitivity 
analyses was conducted to examine the impact of excluding these data points (described further 
in the Results Chapter). 
 
4.8.3.3 Research Question 3 – Predicting Time Until Subsequent Chronic Disease  
The time elapsing between multiple chronic disease diagnoses was further examined in 
Research Question 3.  To observe patient progression into a more complex clinical profile, a 
multilevel survival analysis was conducted using the Stata SE 14.1 software (StataCorp., 2015).  
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Survival analysis, or time-to-event analysis, has historically been used in epidemiological 
research to observe health-related events in patients.  A multilevel survival analysis was used to 
adjust for patient-, provider- and practice-level predictors and the data analyses plan followed the 
recommended sequential process (Hosmer et al., 2008; Hosmer and Lemeshow, 2000).  This 
technique allowed for staggered entry dates of patients into the study period, as well as a non-
normal distribution in the time-to-event data.  These non-normal data violate the normality 
assumption of most commonly used statistical approaches, such as a multiple regression model.   
A multilevel, mixed-effects parametric survival model was fit using the mestreg 
command in the Stata SE 14.1 software (StataCorp., 2015), which can be used with single- or 
multiple-record survival data.  As patients were nested within PHC providers and providers were 
nested within PHC practices, observations from the same cluster may have been correlated and 
may have shared common cluster-level random effects.  As such, a random effects model was 
used to account for this intra-cluster correlation.  An ordered, recurrent event (also known as 
multivariate or multi-failure) analysis was conducted because two or more events (also referred 
to as “failures”) may have occurred within one patient and the first chronic disease diagnosis 
must have occurred before the second chronic disease diagnoses event could occur.  As a result, 
failure times were further correlated within PHC patients, which violated the independence of 
failure times assumption required in traditional survival analysis and these dependencies between 
failure times were accounted for using a variance-corrected model.   
The event of interest was the point at which a patient received their subsequent chronic 
disease diagnosis (regardless of the disease type).  Once again, an ordered, recurrent event 
analysis was conducted, in which patients were included more than once in the analysis if they 
had more than two chronic disease diagnoses before the end of the observation period.  For all 
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analyses, the level of significance was set to 0.05.  Consequently, this longitudinal analysis 
utilized all relevant data (that is, including information for all patients diagnosed with more than 
two chronic disease diagnoses).  Right censoring occurred when a patient did not have another 
event of interest during the observation period either because: 1) the observation period was not 
long enough (that is, the patient would have received a subsequent chronic disease diagnosis 
after September 30, 2013); or 2) the patient simply would never have the event of interest (that 
is, the patient would not have been diagnosed with another chronic disease diagnosis after 
September 30, 2013).  The basic or reference structure of the survival analysis model is included 
below:    
 
h(t) = h0(t) exp(B1X1 + B2X2 + … BkXk) 
 where  h(t) = hazard rate at time t  
h0(t) = hazard for a patient with value of 0 for all independent variables (baseline 
hazard function)  
Bi = regression coefficient for independent variable Xi 
Xi = independent variable  
 
As previously described in Section 4.8.2, the data points where time elapsing between 
diagnoses was equal to zero were dropped from this multilevel survival analysis.  This was done 
to ensure that the final results described the predictors that were relevant in the time elapsing 
until a true transition from one chronic disease state to the next.  A sensitivity analyses was 
conducted to examine the impact of excluding these data points and a similar pattern of findings 
were found between the two approaches (described further in the Results Chapter). 
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4.8.3.4 Conceptual Model for Multilevel Variables  
The multilevel predictors that were included in the multilevel survival analysis are 
presented in Figure 4.7.  This conceptual model was developed for the purposes of this research 
and has not been published previously.  Instead, the identification of these relevant independent 
variables was informed by the existing multimorbidity literature, as well as those variables that 
were available within the CPCSSN EMR database.  For example, the patient-level variables 
listed in Figure 4.7 have been reported previously to be associated with the occurrence of 
multimorbidity (Barnett et al., 2012; Salisbury et al., 2011; Harrison et al., 2013; Britt et al., 
2008; Uijen et al., 2008; Fortin et al., 2005; van den Akker et al., 1998).  Beyond the field of 
multimorbidity, however, research has demonstrated patient-, provider- and practice-level non-
clinical influences on clinical decision-making and diagnostic behaviour (Hajjaj et al., 2010).   
While most clinical decisions are based on “traditional” clinical criteria, they are also 
influenced by a wide range of non-clinical factors.  At the patient-level, these influences can 
include a patient’s personal characteristics, such as age (Bond et al., 2003; Little et al., 1999; 
Haug and Ory, 1987), sex (Bertakis, 2009; Verbruggei and Steiner, 1981; Bernstein and Kane, 
1981), culture (Waldman et al., 2009) and faith (Silvestri et al., 2003); socioeconomic status 
(Bernheim et al., 2008; Dunlop et al., 2000); attitudes and behaviours (Steinmetz and Tabenkin, 
2001; Jackson and Kroenke, 1999); concerns and worries about their health (Petursson, 2005; 
Escher et al., 2004); and influences of a patient’s family members or friends (Franz et al., 2007).  
At the provider-level, these influences can include a physician’s personal characteristics, such as 
age (McKinlay et al., 2002), sex (Bertakis, 2009; Tracy et al., 2005; Franks and Bertakis, 2003; 
Bertakis et al., 2003; Bensing et al., 1993), culture (Modi et al., 2007) and faith (Modi et al., 
2007); time constraints and workload (Hajjaj et al., 2010); demands from the patients or their 
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caregivers (Franz et al., 2007; Petursson, 2005; Escher et al., 2004); and whether the physician 
prefers to use an “interventionist” or “wait and see” approach (Hajjaj et al., 2010; Forrest et al., 
2006).  Finally, practice-level influences can include characteristics of the practice organization, 
such as practice size and type (McKinlay et al., 1996); management policies or culture within the 
practice (Schumock et al., 2004; Prosser and Walley, 2003); geographic location of the practice 
and availability of health resources (Iverson et al., 2005; McKinlay et al., 1996).  Consequently, 
the patient-, provider- and practice-level domains were considered to be relevant layers to 
capture and explore in this time-to-event analysis.   
The variables that comprise the conceptual model for this thesis are those variables that 
were deemed to be relevant in predicting the time until subsequent chronic disease diagnoses.  
More specifically, these variables were informed by the existing multimorbidity literature and 
the variables that were available within the CPCSSN EMR database were highlighted and 
selected for use in the multivariable analysis.  The final patient-level variables included: Age 
(continuous), Sex (binary), Residential Location (binary), Median Household Income 
(continuous) and Total Number of Chronic Diseases (discrete).  The final provider-level 
variables included: Age (continuous) and Sex (binary).  The final practice-level variables 
included: Practice Location (binary) and EMR Type (categorical).  These independent variables 
were first explored in the univariate and bivariate analyses (described further in the next 
sections) and were used to predict the dependent variable of interest, which was the time until 
subsequent chronic disease diagnosis.   
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Figure 4.7 Conceptual model depicting the patient-, provider- and practice-level variables 
used to predict mean time until subsequent chronic disease diagnosis  
 
* Variable available within CPCSSN EMR database 
 
4.8.3.5 Univariate Analyses  
All independent variables were explored using individual univariate analyses that 
summarized the patterns and distribution for both continuous and categorical variables.  For the 
continuous variables (patient age, median household income, total number of chronic diseases 
and provider age), the mean, median, range of values and standard deviations were reported.  For 
the binary and categorical variables (patient sex, residential location, provider sex, EMR type 
and practice location), the distribution among categories were calculated.  The continuous 
dependent variable (time until subsequent chronic disease) was also explored.  The 
characteristics of all independent variables, as well as the main dependent variable, are presented 
in Table 4.5.  
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Table 4.5 Characteristics of all variables included in Objective Two analyses  
Independent Variable Variable Characteristics 
Patient-Level 
Age Continuous, Measured in Years 
Sex Binary, Female or Male 
Residential Location Binary, Rural or Urban 
Median Household Income Continuous, Measured in Canadian Dollars 
Total Number of Chronic Diseases Count, Range from 0 to 20 
Provider-Level 
Age Continuous, Measured in Years 
Sex Binary, Female or Male 
Practice-Level 
EMR Type Categorical, Based on EMR Software Name 
Practice Location Binary, Rural or Urban 
Dependent Variable  
Time Until Subsequent Chronic Disease  Continuous, Measured in Days 
 
4.8.3.6 Bivariate Analyses 
All independent variables were explored using bivariate analyses to determine the joint 
distribution between each independent variable and the continuous dependent variable.  The 
dependent variable was non-normally distributed.  As a result, non-parametric tests were 
conducted to explore relationships between variables.  A Spearman correlation was conducted 
for all continuous independent variables using the spearman command in the Stata SE 14.1 
software (StataCorp., 2015), whereas a Wilcoxon-Mann-Whitney test was conducted using the 
ranksum command for all binary independent variables.  For the remaining categorical 
independent variables, a Kruskal Wallis test was conducted using the kwallis command in the 
Stata SE 14.1 software (StataCorp., 2015).   
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4.8.3.7 Creation and Interpretation of Final Survival Analysis Model 
Due to sufficient sample size (ratio of 9 independent variables to 286,998 patients), all 
independent variables remained in the final survival analysis.  To date, published multimorbidity 
literature has not explored potential interaction among variables that may predict the occurrence 
of multimorbidity.  While included interaction terms can also be theory-driven, the eventual 
interpretation of these interaction terms must be carefully considered.  Among the independent 
variables included in the final analysis, the potential interaction between patient age and patient 
sex and the joint influence on the mean time until subsequent chronic disease diagnoses was 
considered to be the only interpretable interaction.  Consequently, this interaction term was 
included in the final analysis.  The final survival analysis model demonstrated the time elapsing 
among recurrent events (that is, multiple chronic disease diagnoses) and all predictor variables at 
the patient-, provider- and practice-level were included in the final model.  Both crude and 
adjusted hazard rates were calculated.  The hazard rate described the probability that a patient 
would experience the event of interest during time, t, at-risk.   
 
4.9 Summary  
In summary, this research utilized a national, longitudinal EMR database to examine the 
prevalence, patterns and progression of multimorbidity among adult PHC patients within the 
CPCSSN database.  The point prevalence, patient characteristics and most frequently occurring 
unordered and ordered clusters of multimorbidity were assessed in Objective One.  The 
progressing burden of multimorbidity was assessed in Objective Two, which analyzed the 
amount of time elapsing between chronic disease diagnoses and potential patient-, provider- and 
practice-level predictors of this progression were explored.  A summary of the similarities and 
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differences between the methodological approaches used for these two distinct, yet interrelated, 
objectives is presented in Table 4.6. 
 
Table 4.6 Summary of methodological elements for Objective One and Objective Two 
Methodological 
Element 
Objective One Objective Two 
Final Patient Sample 
Patients with at least one in-office encounter recorded in their EMR and who are at 
least 18 years of age as of their first encounter date 
Chronic Disease 
Diagnoses 
All twenty chronic disease categories presented in Table 4.2 
Study Design 
Retrospective or historic observational 
cohort 
(retrospectively analyzed data) 
Multilevel mixed-effects recurrent event 
survival analysis 
(prospectively analyzed data) 
Eligible Patients 
All patients from final sample 
(N = 367,743) 
All patients from final sample with at 
least one chronic disease diagnosis 
(n = 286,998) 
Patient Groups 
Mutually exclusive groups (patients with 
only two, only three, only four and five or 
more chronic diseases) 
Non-mutually exclusive group (patients 
with one or more chronic diseases) 
Start of Observation 
Period 
Date of “first occurrence” chronic disease diagnosis 
End of Observation 
Period 
September 30, 2013 
Next chronic disease diagnosis or 
September 30, 2013 (if no event) 
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Chapter 5 
5 Results  
5.1 Objective One  
The results for Objective One present the overall patient sample characteristics, as well as 
the prevalence patterns, patient characteristics, individual chronic disease distribution and the 
most frequently occurring clusters among patients with multimorbidity.  
 
5.1.1 Overall Patient Sample Characteristics  
Following the inclusion and exclusion criteria, a total of 367,743 patients had at least one 
in-office encounter recorded in their electronic record and were at least 18 years of age as of 
their first encounter date.  The characteristics of this final sample of adult PHC patients are 
presented in Table 5.1.  The mean number of chronic diseases and the prevalence of 
multimorbidity (defined as two or more chronic diseases) for all adult PHC patients are also 
presented in Table 5.1.  The mean age of these patients was 52.3 years (SD: 18.3 years), with a 
range between 18 and 114 years.  Approximately 73.7% of the patients included in this sample 
were under the age of 65 years and 36.6% of patients were between the ages of 45 and 64 years. 
The majority (58.0%) of patients were female and were living in an urban setting (56.3%), 
according to the first three letters of their residential postal code.  While only thirty patients in 
the sample were missing data on whether they were female or male, 27.4% of patients did not 
have a suitable FSA recorded in their electronic record; therefore, whether they lived in a rural or 
urban setting could not be determined.  After linking with the Statistics Canada data, the adult 
patient sample had a median household income of $60,310 per year, ranging from as low as 
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$22,457 to $181,454 per year.  Once again, 27.4% of patients could not be linked with the 
income data as they did not have a suitable FSA recorded within their EMR.   
 
Table 5.1 Patient-level variables for all eligible adult PHC patients (N = 367,743) 
  Patient Characteristics  
Patient-Level Variable 
n (%) 
of Patients 
Mean Number of  
Chronic Diseases (SD) 
Prevalence (95% CI) of 
Multimorbidity** 
Age (Years) 
Mean (SD) 52.3 Years (18.3 Years) 
Range (Minimum – Maximum)  18 Years – 114 Years 
18 – 34 74,539 (20.3%) 0.9 (1.1) 23.4% (23.1% – 23.7%) 
35 – 44 61,783 (16.8%) 1.4 (1.3) 38.6% (38.2% – 39.0%) 
45 – 64 134,550 (36.6%) 2.1 (1.7) 59.1% (58.9% – 59.4%) 
65 – 84 77,816 (21.2%) 3.2 (2.0) 78.0% (77.7% – 78.3%) 
≥ 85 19,055 (5.2%) 3.2 (2.2) 74.8% (74.2% – 75.4%)  
Sex 
Female 213,402 (58.0%) 2.0 (1.8) 53.0% (52.8% – 53.3%) 
Male 154,311 (42.0%) 2.0 (1.8) 53.5% (53.3% – 53.8%) 
Missing 30 (0.0%) 1.1 (1.5) 23.3% (11.4% – 41.8%) 
Residential Location  
Rural  59,740 (16.3%) 2.1 (2.0) 54.6% (54.2% – 55.0%) 
Urban  207,192 (56.3%) 1.9 (1.9) 49.3% (49.1% – 49.5%) 
Missing 100,811 (27.4%) 2.2 (1.6) 60.6% (60.3% – 60.9%) 
Median Household Income (Canadian Dollars)  
Median (IQR) $60,130 ($12,497) 
Range (Minimum – Maximum)  $22,457 – $181,454 
Missing 100,811 (27.4%) 2.2 (1.6) 60.4% (60.1% – 60.7%) 
* SD = Standard deviation, CI = Confidence interval, IQR = Interquartile range 
** Multimorbidity defined as patients with two or more chronic diseases 
 
The demographic characteristics of the PHC providers for the final sample of adult 
patients are presented in Table 5.2.  The mean number of chronic diseases and the prevalence of 
multimorbidity, stratified by provider-level variables, for all adult patients are also presented in 
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Table 5.2.  As demographic data for providers are not commonly recorded in the EMR, missing 
data existed for both provider variables.  The PHC providers for these patients had a mean age of 
50.5 years (SD: 10.4 years) as of September 30, 2013 and a large proportion of these providers 
were between the ages of 45 and 64 years.  For patients with a mean of 2.0 chronic diseases, their 
PHC providers were over the age of 65 years.  In comparison, those patients with a mean of 1.7 
chronic diseases had a PHC provider who was between the ages of 25 and 44 years.  For patients 
with a mean of 1.9 chronic diseases, their PHC providers were female.  For those patients with 
the highest mean number of chronic diseases, their PHC providers were missing information on 
their age (these patients had a mean of 2.2 chronic diseases) or whether they were female or male 
(these patients had a mean of 2.3 chronic diseases).   
 
Table 5.2 Provider-level variables for all eligible adult PHC patients (N = 367,743) 
Provider-Level Variable n (%) of Patients 
Mean Number of 
Chronic Diseases (SD) 
Prevalence (95% CI) of 
Multimorbidity** 
Age (Years) 
Mean (SD) 50.5 Years (10.4 Years) 
Range (Minimum – Maximum) 27 Years – 72 Years 
25 – 44 52,383 (14.2%) 1.7 (1.8) 42.7% (42.3% – 43.2%) 
45 – 64  101,864 (27.7%) 1.8 (1.8) 49.0% (48.7% – 49.3%) 
≥ 65 15,077 (4.1%) 2.0 (1.9) 51.3% (50.5% – 52.1%) 
Missing 198,419 (54.0%) 2.2 (1.8) 58.4% (58.2% – 58.6%) 
Sex 
Female 116,039 (31.6%) 1.9 (1.9) 42.8% (42.5% – 43.1%) 
Male 92,319 (25.1%) 1.6 (1.7) 50.3% (50.0% – 50.6%) 
Missing 159,385 (43.3%) 2.3 (1.7) 61.5% (61.2% – 61.7%) 
* SD = Standard deviation, CI = Confidence interval 
** Multimorbidity defined as patients with two or more chronic diseases 
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The characteristics of the PHC practices for the final sample of adult patients are 
presented in Table 5.3.  The mean number of chronic diseases and the prevalence of 
multimorbidity among all adult PHC patients, stratified by practice-level variables, can also be 
seen in Table 5.3.  For 28.0% of adult patients, their PHC practices were using the Nightingale 
EMR software.  The majority of patients received care from urban PHC practices, according to 
the first three letters of the practices’ postal code.  The largest proportion of patients belonged to 
Network 4 (21.7%) and Network 5 (23.3%), which were located in Central Ontario and Eastern 
Ontario, respectively.  While all adult PHC patients were allocated to one of the ten CPCSSN 
Networks, missing data were present for both the EMR software type and PHC practice location 
variables.  For patients with a mean of 2.5 chronic diseases, their PHC practice was using the 
Jonoke EMR software, while those patients with a mean of 0.9 chronic diseases were based at a 
PHC practice that was using the DaVinci EMR software.  Those patients who received care at a 
rural PHC practice had an average of 2.2 chronic diseases, while those patients who received 
care at an urban PHC practice had an average of 1.9 chronic diseases.  For those patients with a 
higher mean number of chronic diseases, their PHC practices were missing information on their 
EMR software (these patients had a mean of 2.4 chronic diseases) or whether the practices were 
rural or urban (these patients had a mean of 2.3 chronic diseases).  The range of the mean 
number of chronic diseases and the prevalence of multimorbidity were also explored among 
CPCSSN Network locations.  The crude prevalence of multimorbidity, defined as two or more 
chronic diseases, is presented geographically among all ten regional networks and can be seen in 
Figure 5.1.  
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Table 5.3 Practice-level variables for all eligible adult PHC patients (N = 367,743) 
Practice-Level Variable n (%) of Patients 
Mean Number of 
Chronic Diseases (SD) 
Prevalence (95% CI) of 
Multimorbidity** 
EMR Type 
Accuro 36,480 (9.9%) 1.7 (1.8) 43.9% (43.4% – 44.4%) 
Bell 27,178 (7.4%) 2.2 (1.9) 57.4% (56.8% – 58.0%) 
DaVinci 1,431 (0.4%) 0.9 (1.0) 26.3% (24.1% – 28.6%) 
Jonoke 20,862 (5.7%) 2.5 (2.1) 62.1% (61.4% – 62.7%) 
Med Access 12,548 (3.4%) 2.1 (2.2) 51.3% (50.4% – 52.2%) 
Nightingale 103,031 (28.0%) 1.9 (1.8) 49.5% (49.2% – 49.8%) 
Oscar 16,537 (4.5%) 1.4 (1.5) 37.5% (36.8% – 38.3%) 
Practice Solutions 20,095 (5.5%) 1.6 (1.5) 43.4% (42.7% – 44.1%) 
Wolf 38,056 (10.4%) 2.0 (2.1) 49.2% (48.7% – 49.7%) 
Xwave 821 (0.2%) 2.4 (1.8) 64.3% (61.0% – 67.5%) 
Missing 90,704 (24.7%) 2.4 (1.5) 65.4% (65.0% – 65.7%) 
Practice Location 
Rural  35,390 (9.6%) 2.2 (2.0) 55.0% (54.5% – 55.5%) 
Urban  233,744 (63.6%) 1.9 (1.9) 48.4% (48.2% – 48.6%) 
Missing 98,609 (26.8%) 2.3 (1.5) 64.1% (63.8% – 64.4%) 
CPCSSN Network 
1 38,031 (10.3%) 2.2 (1.9) 55.4% (54.9% – 55.9%) 
2 19,253 (5.2%) 2.3 (2.1) 57.6% (56.9% – 58.3%) 
3 6,954 (1.9%) 2.8 (2.1) 69.0% (67.9% – 70.1%) 
4 79,941 (21.7%) 1.8 (1.6) 48.5% (48.2% – 48.9%) 
5 85,834 (23.3%) 2.0 (1.7) 55.9% (55.6% – 56.2%) 
6 2,507 (0.7%) 1.2 (0.9) 32.5% (30.7% – 34.3%) 
7 36,391 (9.9%) 1.9 (1.9) 47.3% (46.8% – 47.8%) 
8 31,741 (8.6%) 2.5 (1.9) 64.2% (63.7% – 64.7%) 
9 53,624 (14.6%) 1.9 (1.7) 51.6% (51.2% – 52.0%) 
10 13,467 (3.7%) 1.8 (2.0) 44.9% (44.1% – 45.8%) 
* SD = Standard deviation, CI = Confidence interval 
** Multimorbidity defined as patients with two or more chronic diseases 
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Figure 5.1 Crude prevalence estimates of multimorbidity (defined as two or more chronic 
diseases) among all ten regional networks of the CPCSSN database  
 
 
5.1.2 Objective One, Research Question 1 – Prevalence of Multimorbidity 
The patient-level variables, stratified by the total number of chronic diseases, among all 
adult patients are presented in Table 5.4.  While the largest proportion (24.8%, 95% CI: 24.6 – 
24.9) of adult patients were living with one chronic disease diagnosis, 22.0% (95% CI: 21.8 – 
22.1) of adult patients had no chronic disease diagnoses and 20.1% (95% CI: 20.0 – 20.2) of 
adult patients had been diagnosed with two chronic diseases as of September 30, 2013.  A total 
of 14.0% (95% CI: 13.9 – 14.1) of these patients were living with three chronic disease 
diagnoses; 8.9% (95% CI: 8.8 – 9.0) were living with four chronic diseases; and 10.2% (95% CI: 
10.1 – 10.3) had been diagnosed with five or more chronic disease diagnoses.  Among our final 
adult patient sample, the prevalence of multimorbidity defined as patients with two or more 
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chronic diseases was 53.3% (95% CI: 53.1% – 53.4%), whereas the prevalence of 
multimorbidity defined as patients with three or more chronic diseases was 33.1% (95% CI: 33.0 
– 33.3).  These results can be found in Table 5.5.  
As seen in Table 5.4, an increasing mean age of patients was observed as the total 
number of chronic disease diagnoses increased.  For example, the mean age of patients with no 
chronic disease diagnoses was 41.8 years (SD: 16.1 years) and the mean of age of patients with 
five or more chronic diseases diagnoses was 68.4 years (SD: 14.1 years), indicating an increase 
of 26.6 years on average between these two groups of patients.  The proportion of female and 
male patients did not change notably as the number of chronic diseases increased, in that the 
majority of patients in all six categories were female (representing from 56.6% to 60.7% of the 
patient sample).  The largest proportion of patients living in a rural setting was seen in the five or 
more chronic disease category (21.2% of those living with five or more chronic diseases), while 
the largest proportion of patients living in an urban setting was seen in the category of patients 
with no chronic disease diagnoses (73.9% of those living without any chronic disease diagnoses).  
The median household income was fairly consistent among the six categories of patients, and did 
not produce a clear trend between the categories. 
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Table 5.4 Patient-level variables, stratified by total number of chronic diseases, among final adult patient sample (N = 367,743) 
 Total Number of Chronic Diseases 
Patient-Level Variable Zero One Two Three Four Five or More 
Number of Patients 80,745 91,160 73,974 51,608 32,866 37,390 
Prevalence (95% CI) 22.0 (21.8 – 22.1) 24.8 (24.6 – 24.9) 20.1 (20.0 – 20.2) 14.0 (13.9 – 14.1) 8.9 (8.8 – 9.0) 10.2 (10.1 – 10.3) 
Age (Years) 
Mean (SD)   41.8 (16.1) 47.3 (17.0) 53.1 (16.9) 58.4 (16.3) 62.9 (15.3) 68.4 (14.1) 
Range (Minimum – Maximum)  18 – 114  18 – 111 18 – 114  18 – 108 20 – 114  20 – 114 
Sex (% of Patients) 
Female 59.8 56.9 56.6 57.4 57.9 60.7 
Male 40.2 43.1 43.4 42.6 42.1 39.3 
Residential Location (% of Patients) 
Rural  18.6 13.3 14.0 16.3 18.1 21.2 
Urban  73.9 49.8 50.2 52.0 53.8 54.9 
Missing 7.5 36.9 35.8 31.7 28.1 23.9 
Median Household Income (Canadian Dollars)  
Median (IQR) 59,980 (13,867) 60,310 (12,497) 60,952 (12,497) 61,130 (12,497) 60,480 (12,497) 61,221 (12,953) 
Range (Minimum – Maximum)  22,457 – 181,454 23,370 – 181,454 22,457 – 181,454 23,972 – 181,454 23,972 – 181,454 22,457 – 181,454 
Missing (% of Patients) 7.8 37.1 36.0 31.8 28.3 24.0 
* SD = Standard deviation, CI = Confidence interval, IQR = Interquartile range   
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The proportion of patients living with multimorbidity, stratified by patient-level variables 
and the two definitions of multimorbidity, are presented in Table 5.5.  For patients with two or 
more chronic diseases, 40.6% of patients were between the age of 45 and 64 years and 57.8% 
were female.  The majority of these patients were living in an urban setting (52.2%) and the 
median of the median household income was $60,952 per year (Canadian dollars).  In fact, these 
patients were living with a mean of 3.3 chronic diseases, ranging from two to fourteen chronic 
disease diagnoses.  For patients with three or more chronic disease, 39.6% of patients were 
between the age of 45 and 64 years and 58.5% were female.  The majority of these patients were 
living in an urban setting (53.4%) and the median of the median household income was $61,175 
per year (Canadian dollars).  Similar to the group of patients with two or more chronic diseases, 
the group of patients with three or more chronic diseases were living with a mean of 4.2 chronic 
diseases, ranging from three to fourteen chronic disease diagnoses.  These results will be 
discussed further in the next section, which will compare the characteristics of patients with 
multimorbidity in this research with those that have been reported in the published 
multimorbidity literature.   
The demographic characteristics of the PHC providers for patients stratified by the two 
definitions of multimorbidity are seen in Table 5.6.  Once again, as demographic data for 
providers are not commonly recorded in the EMR, missing data existed for both provider 
variables.  However, for both definitions of multimorbidity, the PHC providers of these patients 
were a mean age of about 51.0 years and tended to be between 45 and 64 years.  However, 
contrast was observed based on whether the PHC provider was female or male: about 30.0% of 
patients with two or more chronic diseases were being cared for by a male provider, while about 
31.0% of patients with three or more chronic diseases were being cared for by a female provider.   
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Table 5.5 Prevalence of multimorbidity, defined as two or more and three or more chronic 
diseases, and corresponding patient-level characteristics for Objective One 
Patient-Level Variable 
Two or More Chronic Diseases  
(n = 195,838)  
Three or More Chronic Diseases  
(n = 121,864)  
Prevalence (95% CI) 53.3% (53.1% – 53.4%) 33.1% (33.0% – 33.3%)  
Age (Years) 
Mean (SD) 59.0 Years (17.0 Years) 62.7 Years (15.9 Years) 
Range (Minimum – Maximum)  18 Years – 114 Years 18 Years – 114 Years 
Age Category, n (%) of Patients   
18 – 34 17,466 (8.9%) 6,119 (5.0%) 
35 – 44 23,855 (12.2%) 10,719 (8.8%) 
45 – 64 79,571 (40.6%) 48,254 (39.6%) 
65 – 84 60,696 (31.0%) 45,961 (37.7%) 
≥ 85 14,250 (7.3%) 10,811 (8.9%) 
Sex, n (%) of Patients 
Female 113,209 (57.8%) 71,319 (58.5%) 
Male 82,629 (42.2%) 50,545 (41.5%) 
Residential Location, n (%) of Patients 
Rural  32,607 (16.7%) 22,274 (18.3%) 
Urban  102,151 (52.2%) 65,026 (53.4%) 
Missing 61,080 (31.2%) 34,564 (28.4%) 
Median Household Income (Canadian Dollars)  
Median (IQR) $60,952 ($12,497) $61,175 ($12,497) 
Range (Minimum – Maximum)  $22,457 – $181,454 $22,457 – $181,454 
Missing, n (%) of Patients 61,263 (31.3%) 34,662 (28.4%) 
Total Number of Chronic Diseases 
Mean (SD) 3.3 (1.5) 4.2 (1.4) 
Range (Minimum – Maximum)  2 – 14  3 – 14  
* SD = Standard deviation, CI = Confidence interval, IQR = Interquartile range 
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Table 5.6 Prevalence of multimorbidity, defined as two or more and three or more chronic 
diseases, and corresponding provider-level characteristics for Objective One 
Provider-Level Variable 
Two or More Chronic Diseases 
(n = 195,838) 
Three or More Chronic Diseases 
(n = 121,864) 
Age (Years) 
Mean (SD) 51.2 Years (10.2 Years) 51.5 Years (10.1 Years) 
Range (Minimum – Maximum)  27 Years – 72 Years 27 Years – 72 Years 
Age Category, n (%) of Patients   
25 – 44 22,402 (11.4%) 13,589 (11.2%) 
45 – 64  49,871 (25.5%) 31,158 (25.6%) 
≥ 65 7,730 (4.0%) 5,152 (4.2%) 
Missing 115,835 (59.2%) 71,965 (59.1%) 
Sex, n (%) of Patients 
Female 39,517 (20.2%) 23,738 (31.1%) 
Male 58,364 (29.8%) 37,931 (19.5%) 
Missing 97,957 (50.0%) 60,195 (49.4%) 
* SD = Standard deviation, CI = Confidence interval 
 
The characteristics of the PHC practices for patients stratified by the two definitions of 
multimorbidity are seen in Table 5.7.  For both definitions of multimorbidity, the PHC practices 
of these patients tended to use the Nightingale EMR software (26.0% and 26.5%, respectively) 
and the majority were based in an urban setting (57.8% and 59.2%, respectively).  Almost one 
quarter of those patients with two or more chronic diseases and three or more chronic diseases 
were from Network 5 (24.5% and 23.5%, respectively).   
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Table 5.7 Prevalence of multimorbidity, defined as two or more and three or more chronic 
diseases, and corresponding practice-level characteristics for Objective One 
Practice- Level Variable 
Two or More Chronic Diseases 
(n = 195,838) 
Three or More Chronic Diseases 
(n = 121,864) 
EMR Type, n (%) of Patients 
Accuro 16,001 (8.2%) 10,115 (8.3%) 
Bell 15,601 (8.0%) 10,467 (8.6%) 
DaVinci 376 (0.2%) 109 (0.1%) 
Jonoke 12,953 (6.6%) 9,407 (7.7%) 
Med Access 6,437 (3.3%) 4,553 (3.7%) 
Nightingale 50,998 (26.0%) 32,287 (26.5%) 
Oscar 6,208 (3.2%) 3,192 (2.6%) 
Practice Solutions 8,723 (4.5%) 4,738 (3.9%) 
Wolf 18,732 (9.6%) 12,949 (10.6%) 
Xwave 528 (0.3%) 355 (0.3%) 
Missing 59,281 (30.3%) 33,692 (27.7%) 
Practice Location, n (%) of Patients 
Rural  19,471 (9.9%) 13,744 (11.3%) 
Urban  113,120 (57.8%) 72,085 (59.2%) 
Missing 63,247 (32.3%) 36,035 (29.6%) 
CPCSSN Network, n (%) of Patients 
1 21,060 (10.8%) 13,743 (11.3%) 
2 11,081 (5.7%) 7,507 (6.2%) 
3 4,801 (2.5%) 3,430 (2.8%) 
4 38,797 (19.8%) 21,946 (18.0%) 
5 47,986 (24.5%) 28,612 (23.5%) 
6 814 (0.4%) 181 (0.2%) 
7 17,218 (8.8%) 11,136 (9.1%) 
8 20,374 (10.4%) 13,831 (11.4%) 
9 27,656 (14.1%) 17,555 (14.4%) 
10 6,051 (3.1%) 3,923 (3.2%) 
* SD = Standard deviation, CI = Confidence interval 
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To place the prevalence of multimorbidity found in this research within the context of the 
prevalence estimates reported in the existing multimorbidity literature, a review of the literature 
was conducted.  A summary of the methodological characteristics, as well as the reported 
prevalence of multimorbidity, are presented in Table 5.8 (for the definition of two or more 
chronic diseases) and Table 5.9 (for the definition of three or more chronic diseases).  The 
methodological characteristics and prevalence estimates from this research were also included 
and separated between the two definitions of multimorbidity.  A total of 23 studies that defined 
multimorbidity as two or more chronic diseases, as well as 15 studies that defined 
multimorbidity as three or more chronic diseases, were included in the prevalence comparison.  
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Table 5.8 Key methodological elements and prevalence estimates from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research  
Citation Country of 
Origin 
Study Design Sample 
Size 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Nicholson et 
al., 2016 
Canada Retrospective 
cohort 
367,743 ≥ 18 Adult PHC 
patients 
CPCSSN EMR 
database 
ICD-9 20 53.3%** 
Pefoyo et al., 
2015 
Canada Retrospective 
cohort 
10,336,297 ≥ 18 All residents of 
Ontario 
Administrative 
claims data 
ICD-9; 
ICD-10 
16 30.2%** 
Roberts et al., 
2015 
Canada Cross-
sectional 
105,416 ≥ 20 General adult 
population in 
Canada 
2011/2012 
Canadian 
Community Health 
Survey 
Self-report 9 12.9% 
Stewart et al., 
2013 
Canada Retrospective 
cohort 
2,998 ≥ 18 Adult PHC 
patients 
Deliver Primary 
Health Care 
Information EMR 
database 
ICPC-2-R 98 34.0% 
Agborsangaya 
et al., 2012 
Canada Cross-
sectional 
5,010 ≥ 18 General adult 
population in 
Alberta 
2010 Patient 
Experience Survey 
Self-report 14 18.8%** 
Muggah et al., 
2012 
Canada Cross-
sectional 
28,450,000 ≥ 20 All residents of 
Ontario 
Administrative 
claims data 
ICD-9 9 15.9%** 
Fortin et al., 
2005 
Canada Cross-
sectional 
980 ≥ 18 Adult PHC 
patients from 
consecutive 
encounters 
Health charts 
review 
Count; 
CIRS 
14 89.3%** 
 
* CIRS = Cumulative Illness Rating Scale; CPCSSN = Canadian Primary Care Sentinel Surveillance Network; EMR = Electronic medical record; ICD-9 = 
International Classification of Disease, 9th Revision; ICD-10 = International Classification of Disease, 10th Revision; ICPC-2-R = International Classification of 
Primary Care, 2nd Edition, Revised; MM = Multimorbidity; PHC = Primary health care 
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** Prevalence estimate extracted and calculated by author 
Table 5.8 Key methodological elements and prevalence estimates from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research, Continued 
Citation Country of 
Origin 
Study Design Sample 
Size 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Harrison et al., 
2014 
Australia Prospective 
cohort 
8,707 ≥ 20 Randomly 
selected PHC 
patients 
Health charts 
review 
ICD-10 20 43.7% 
Taylor et al., 
2010 
Australia Cross-
sectional 
6,411 ≥ 20 Randomly 
selected adults 
Northwest 
Adelaide Health 
Study 
Self-report 7 17.1% 
Wang et al., 
2015 
China Cross-
sectional 
21,435 18 – 79 Community-
dwelling adults 
Questionnaire and 
interview 
Self-
report; 
ICD-10 
18 24.7% 
Chung et al., 
2015 
Hong Kong Cross-
sectional 
25,780 ≥ 15 General adult 
population 
Hong Kong 
Thematic 
Household Survey 
Self-
report; 
ICD-10 
46 12.5% 
Pati et al., 
2015 
India Cross-
sectional 
1,649 ≥ 18 Adult patients 
from PHC 
facilities 
Multimorbidity 
Assessment 
Protocol Survey 
Self-report 22 28.3% 
van Oostrom 
et al., 2012 
The 
Netherlands 
Retrospective 
cohort 
173,958 ≥ 15 PHC patients Network of 
General Practice 
EMR database 
ICPC 29 12.9% 
 
* CIRS = Cumulative Illness Rating Scale; EMR = Electronic medical record; ICD-10 = International Classification of Disease, 10th Revision; ICPC = 
International Classification of Primary Care; ICPC-2 = International Classification of Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health 
care 
** Prevalence estimate extracted and calculated by author 
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Table 5.8 Key methodological elements and prevalence estimates from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research, Continued 
Citation Country of 
Origin 
Study Design Sample 
Size 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System 
Number of 
Diseases 
Considered 
MM 
Prevalence 
van den 
Akker et al., 
1998 
The 
Netherlands 
Cross-
sectional 
47,140 ≥ 20 Adult PHC 
patients 
RegistratieNet 
Huisartspraktijken 
EMR database 
ICPC 335 35.4%** 
Prazeres et 
al., 2015 
Portugal Cross-
sectional 
1,993 ≥ 18 Adult PHC 
patients 
Questionnaire ICPC-2 147 72.7% 
Jovic et al., 
2016 
Serbia Cross-
sectional 
13,103 ≥ 20 Community-
dwelling adults 
2013 National 
Health Survey 
Self-report 12 26.8% 
Orueta et al., 
2014 
Spain Cross-
sectional 
1,923,156 ≥ 18 Adult PHC 
patients 
Population 
Stratification 
Programme EMR 
database 
ICD-9-CM; 
ACG  
40 23.6% 
Prados-Torres 
et al., 2012 
Spain Retrospective 
cohort 
275,682 ≥ 15 PHC patients Spanish National 
Health System EMR 
database 
ICPC; ICD-9-
CM; ACG 
114 36.8%** 
Rizza et al., 
2012 
Switzerland Retrospective 
cohort 
66,212 ≥ 20 Adult PHC 
patients 
Swiss Family 
Medicine ICPC 
Research using 
EMR database 
ICPC-2 147 14.5% 
 
* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision, 
Clinical Modification; ICPC= International Classification of Primary Care; ICPC-2 = International Classification of Primary Care, 2nd Edition; MM = 
Multimorbidity; PHC = Primary health care 
100 
 
** Prevalence estimate extracted and calculated by author 
Table 5.8 Key methodological elements and prevalence estimates from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research, Continued 
Citation Country 
of Origin 
Study Design Sample 
Size 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Barnett et 
al., 2012 
United 
Kingdom 
Cross-
sectional 
1,751,841 All ages All PHC patients National EMR 
database 
Read 
codes 
40 23.2% 
Salisbury et 
al., 2011 
United 
Kingdom 
Retrospective 
cohort 
99,997 ≥ 18 Randomly selected 
adult PHC patients 
General Practice 
Research Datalink 
ACG 114 58.0% 
Rocca et al., 
2014 
United 
States 
Cross-
sectional 
100,833 ≥ 20 Adult PHC patients Rochester 
Epidemiology 
Project EMR 
database 
ICD-9 20 22.6%** 
Ornstein et 
al., 2013 
United 
States 
Cross-
sectional 
667,379 ≥ 18 Adult PHC patients Practice-Based 
Research Network 
EMR database 
ICD-9-CM 24 45.3% 
Ward et al., 
2013 
United 
States 
Cross-
sectional 
27,157 ≥ 18 Randomly selected 
community-
dwelling adults 
2010 National 
Health Survey 
Self-report 10 26.0% 
 
* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICD-9 = International Classification of Disease, 9th Revision; ICD-9-
CM = International Classification of Disease, 9th Revision, Clinical Modification; MM = Multimorbidity; PHC = Primary health care 
** Prevalence estimate extracted and calculated by author 
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Table 5.9 Key methodological elements and prevalence estimates from multimorbidity literature (defined as three or more 
chronic diseases), as compared to elements and prevalence from current research 
Citation Country of 
Origin 
Study Design Sample 
Size 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Nicholson et 
al., 2016 
Canada Retrospective 
cohort 
367,743 ≥ 18 Adult PHC 
patients 
CPCSSN EMR 
database 
ICD-9 20 33.1%** 
Pefoyo et al., 
2015 
Canada Retrospective 
cohort 
10,336,297 ≥ 18 All residents of 
Ontario 
Administrative 
claims data 
ICD-9; 
ICD-10 
16 13.6%** 
Roberts et al., 
2015 
Canada Cross-sectional 105,416 ≥ 20 General adult 
population in 
Canada 
2011/2012 
Canadian 
Community Health 
Survey 
Self-report 9 3.9% 
Agborsangaya 
et al., 2012 
Canada Cross-sectional 5,010 ≥ 18 General adult 
population in 
Alberta 
2010 Patient 
Experience Survey 
Self-report 14 11.1%** 
Muggah et al., 
2012 
Canada Cross-sectional 28,450,000 ≥ 20 All residents of 
Ontario 
Administrative 
claims data 
ICD-9 9 5.6% 
Fortin et al., 
2005 
Canada Cross-sectional 980 ≥ 18 Adult PHC patients 
from consecutive 
encounters 
Health charts 
review 
Count; 
CIRS 
14 75.6%** 
Harrison et al., 
2014 
Australia Prospective 
cohort 
8,707 ≥ 20 Randomly selected 
PHC patients 
Health charts 
review 
ICD-10 20 27.4% 
 
* CIRS = Cumulative Illness Rating Scale; CPCSSN = Canadian Primary Care Sentinel Surveillance Network; EMR = Electronic medical record; ICD-9 = 
International Classification of Disease, 9th Revision; ICD-10 = International Classification of Disease, 10th Revision; ICPC-2 = International Classification of 
Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health care 
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** Prevalence estimate extracted and calculated by author 
Table 5.9 Key methodological elements and prevalence estimates from multimorbidity literature (defined as three or more 
chronic diseases), as compared to elements and prevalence from current research, Continued  
Citation Country of 
Origin 
Study Design Sample 
Size 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Taylor et al., 
2010 
Australia Cross-
sectional 
6,411 ≥ 20 Randomly selected 
community-
dwelling adults 
Northwest 
Adelaide Health 
Study 
Self-report 7 5.3%** 
Wang et al., 
2015 
China Cross-
sectional 
21,435 18 – 79 Community-
dwelling adults 
Questionnaire and 
interview 
Self-report; 
ICD-10 
18 12.0% 
Chung et al., 
2015 
Hong Kong Cross-
sectional 
25,780 ≥ 15 General adult 
population 
Hong Kong 
Thematic 
Household Survey 
Self-report; 
ICD-10 
46 5.4%** 
Prazeres et al., 
2015 
Portugal Cross-
sectional 
1,993 ≥ 18 Adult PHC 
patients 
Questionnaire of 
PHC patients 
ICPC-2 147 57.2% 
Jovic et al., 
2016 
Serbia Cross-
sectional 
13,103 ≥ 20 Community-
dwelling adults 
2013 National 
Health Survey 
Self-report 12 14.3%** 
Prados-Torres 
et al., 2012 
Spain Retrospective 
cohort 
275,682 ≥ 15 PHC patients Spanish National 
Health System 
EMR database 
ICPC; ICD-
9-CM; ACG 
114 20.2%** 
 
* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision, 
Clinical Modification; ICD-10 = International Classification of Disease, 10th Revision; ICPC= International Classification of Primary Care; MM = 
Multimorbidity; PHC = Primary health care 
** Prevalence estimate extracted and calculated by author 
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Table 5.9 Key methodological elements and prevalence estimates from multimorbidity literature (defined as three or more 
chronic diseases), as compared to elements and prevalence from current research, Continued  
Citation Country of 
Origin 
Study Design Sample 
Size 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Rizza et al., 
2012 
Switzerland Retrospective 
cohort 
66,212 ≥ 20 Adult PHC 
patients 
Swiss Family 
Medicine ICPC 
Research using 
EMR database 
ICPC-2 147 7.3% 
Zulman et al., 
2015 
United 
States 
Retrospective 
cohort 
5,233,994 All 
ages 
United States 
military veterans 
Veterans Affairs 
health care system 
database 
AHRQ 
Chronic 
Condition 
Indicator 
33 28.5% 
Ornstein et al., 
2013 
United 
States 
Cross-
sectional 
667,379 ≥ 18 Adult PHC 
patients 
Practice-Based 
Research Network 
EMR database 
ICD-9-CM 24 30.4% 
 
* AHRQ = Agency for Health Care Research and Quality; EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision, 
Clinical Modification; ICPC-2 = International Classification of Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health care
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5.1.3 Objective One, Research Question 2 – Characteristics of Adult PHC Patients with 
Multimorbidity  
The proportion of patients living with multimorbidity, stratified by patient-level variables 
and the two definitions of multimorbidity, are presented in Table 5.5.  Among patients with two 
or more chronic diseases, 40.6% were between the ages of 45 and 64 years.  When age categories 
were grouped together, almost two-thirds (61.7%) of patients living with two or more chronic 
diseases were under the age of 65 years.  The majority of these patients were female (57.8%) and 
lived in an urban setting (52.2%), while the median of the median household income was 
approximately $60,950 per year (Canadian dollars).  While all patients were living with at least 
two chronic diseases, these patients in fact had a mean of 3.3 chronic disease diagnoses (SD: 1.5) 
and the total number of diagnosed chronic diseases ranged from 2 to as many as 14 diagnoses.  
Similar characteristics were seen among patients with three or more chronic diseases.  
For example, the mean age of these patients was 62.7 years (SD: 15.9 years) and the largest 
proportion (39.6%) of patients were between the ages of 45 and 64 years.  Once again, the 
majority of patients were female (58.5%) and living in an urban setting (53.4%), while the 
median of the median household income was approximately $61,175 per year (Canadian dollars).  
Similar to those patients living with two or more chronic diseases, while all patients within this 
definition of multimorbidity were living with three or more chronic diseases, these patients in 
fact had a mean of 4.2 chronic disease diagnoses (SD: 1.4), indicating a slightly higher burden of 
chronic diseases than required within the definition itself.    
To place the characteristics of those with multimorbidity found in this research within the 
context of the characteristics reported in the existing multimorbidity literature, a review of the 
literature was conducted.  A summary of the methodological characteristics, as well as the 
105 
 
characteristic category with the highest prevalence of multimorbidity, are presented in Table 
5.10 (for the definition of two or more chronic diseases) and Table 5.11 (for the definition of 
three or more chronic diseases).  Due to the heterogeneity of methodology and reporting in the 
multimorbidity literature, the main patient characteristics that were possible to consistently 
compare with the existing literature were the prevalence estimates stratified by age and sex 
category.  A total of 21 studies that defined multimorbidity as two or more chronic diseases, as 
well as 8 studies that defined multimorbidity as three or more chronic diseases, were included in 
the characteristic comparison.  
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research 
Citation 
 
Country 
of Origin 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System* 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Age Group (Years) 
with Highest 
Prevalence 
Sex Category 
with Highest 
Prevalence 
Nicholson et 
al., 2016 
Canada ≥ 18 Adult PHC 
patients 
CPCSSN 
EMR 
database 
ICD-9 20 53.3%** 18 – 34 
35 – 44 
45 – 64: 40.6%** 
65 – 84  
≥ 85 
Female: 
57.8%** 
Pefoyo et al., 
2015 
Canada ≥ 18 All residents 
of Ontario 
Administrative 
claims data 
ICD-9; 
ICD-10 
16 30.2%** 18 – 44 
45 – 64 
65 – 74 
75 – 89 
≥ 90: 83.2% 
Not Reported 
Roberts et al., 
2015 
Canada ≥ 20 General adult 
population in 
Canada 
2011/2012 
Canadian 
Community 
Health Survey 
Self-report 9 12.9% 20 – 34  
35 – 49 
50 – 64 
≥ 65: 31.3% 
Female: 
15.1% 
Stewart et al., 
2013 
Canada ≥ 18 Adult PHC 
patients 
Deliver 
Primary Health 
Care 
Information 
EMR database 
ICPC-2-R 98 34.0% 18 – 34  
45 – 64  
≥ 65: 55.8%** 
Male: 40.4%** 
* CPCSSN = Canadian Primary Care Sentinel Surveillance Network; EMR = Electronic medical record; ICD-9 = International Classification of Disease, 9th 
Revision; ICD-10 = International Classification of Disease, 10th Revision; ICPC-2-R = International Classification of Primary Care, 2nd Edition Revised; MM = 
Multimorbidity; PHC = Primary health care 
** Prevalence estimate extracted and calculated by author 
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research, Continued 
Citation Country 
of Origin 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System* 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Age Group (Years) 
with Highest 
Prevalence 
Sex 
Category 
with Highest 
Prevalence 
Agborsangaya 
et al., 2012 
Canada ≥ 18 General adult 
population in 
Alberta 
2010 Patient 
Experience 
Survey 
Self-report 14 18.8%** 18 – 24 
25 – 44 
45 – 64  
≥ 65: 35.8% 
Female: 
20.6% 
Fortin et al., 
2005 
Canada ≥ 18 Adult patients 
from 
consecutive 
encounters 
Health charts 
review 
Count; 
CIRS 
14 89.3%** 18 – 44  
45 – 64  
≥ 65: 98.6%** 
Male:  
89.4%** 
Harrison et al., 
2014 
Australia ≥ 20 Randomly 
selected PHC 
patients 
Health charts 
review 
ICD-10 20 43.7% 20 – 29 
30 – 39 
40 – 49 
50 – 59 
60 – 69 
70 – 79 
80 – 89 
≥ 90: 93.2% 
Not Reported 
Taylor et al., 
2010 
Australia ≥ 20 Randomly 
selected adults 
Northwest 
Adelaide 
Health Study 
Self-report 7 17.1% 20 – 39 
40 – 59 
≥ 60: 57.9% 
Not Reported 
* CIRS = Cumulative Illness Rating Scale; ICD-10 = International Classification of Disease, 10th Revision; MM = Multimorbidity; PHC = Primary health care 
** Prevalence estimate extracted and calculated by author 
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research, Continued 
Citation Country  
of Origin 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System* 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Age Group (Years) 
with Highest 
Prevalence 
Sex Category 
with Highest 
Prevalence 
Wang et al., 
2015 
China 18 – 
79 
Community-
dwelling 
adults 
Questionnaire and 
interview 
Self-
report; 
ICD-10 
18 24.7% 18 – 44 
45 – 59 
60 – 79: 51.2% 
Female: 
29.6% 
Pati et al., 
2015 
India ≥ 18 Adult 
patients from 
PHC 
facilities 
Multimorbidity 
Assessment 
Protocol Survey 
Self-report 22 28.3% 18 – 29 
30 – 39 
40 – 49 
50 – 59 
60 – 69 
≥ 70: 44.4% 
Female: 
32.5% 
van 
Oostrom et 
al., 2012 
The 
Netherlands 
≥ 15 PHC patients Network of 
General Practice 
EMR database 
ICPC 29 12.9% 15 – 24 
25 – 54 
55 – 64 
65 – 74 
≥ 75: 59.2% 
Female: 
15.0% 
van den 
Akker et 
al., 1998 
The 
Netherlands 
≥ 20 Adult PHC 
patients 
RegistratieNet 
Huisartspraktijken 
EMR database 
ICPC 335 35.4%** 20 – 39 
40 – 59 
60 – 79 
≥ 80: 78.2%** 
Female: 
37.9%** 
* EMR = Electronic medical record; ICD-10 = International Classification of Disease, 10th Revision; ICPC = International Classification of Primary Care; MM = 
Multimorbidity; PHC = Primary health care 
** Prevalence estimate extracted and calculated by author 
 
109 
 
Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research, Continued 
Citation Country 
of 
Origin 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System* 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Age Group (Years) 
with Highest 
Prevalence 
Sex Category 
with Highest 
Prevalence 
Prazeres 
et al., 
2015 
Portugal ≥ 18 Adult PHC 
patients 
Questionnaire ICPC-2 147 72.7% 18 – 34  
35 – 49 
50 – 64 
≥ 65: 92.6% 
Male: 75.9% 
Jovic et 
al., 2016 
Serbia ≥ 20 Community-
dwelling 
adults 
2013 National 
Health Survey 
Self-report 12 26.8% 20 – 44 
45 – 64 
≥ 65: 57.4%** 
Not Reported 
Orueta et 
al., 2014 
Spain ≥ 18 Adult PHC 
patients 
Population 
Stratification 
Programme 
EMR database 
ICD-9-CM; 
ACG  
40 23.6%** 18 – 34 
35 – 44 
45 – 54 
55 – 64 
65 – 69 
70 – 74 
75 – 79 
80 – 84: 76.4% 
≥ 85 
Female: 25.9% 
Prados-
Torres et 
al., 2012 
Spain ≥ 15 PHC patients Spanish 
National Health 
System EMR 
database 
ICPC; ICD-
9-CM; ACG 
114 36.8%** 15 – 44 
45 – 64 
≥ 65: 67.5%** 
Female: 40.1% 
* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision, 
Clinical Modification; ICPC = International Classification of Primary Care; ICPC-2 = International Classification of Primary Care, 2nd Edition; MM = 
Multimorbidity; PHC = Primary health care  
** Prevalence estimate extracted and calculated by author 
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research, Continued 
Citation Country  
of Origin 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System* 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Age Group (Years) 
with Highest 
Prevalence 
Sex Category 
with Highest 
Prevalence 
Rizza et al., 
2012 
Switzerland ≥ 20 Adult PHC 
patients 
Swiss Family 
Medicine ICPC 
Research using 
EMR database 
ICPC-2 147 14.5% 20 – 29 
30 – 39 
40 – 49 
50 – 59 
60 – 69 
70 – 79 
≥ 80: 37.7% 
Male: 14.8% 
Barnett et 
al., 2012 
United 
Kingdom 
All 
ages 
All PHC patients National EMR 
database 
Read 
codes 
40 23.2% 0 – 24 
25 – 44 
45 – 64 
65 – 84 
≥ 85: 81.5% 
Female: 
26.2% 
Salisbury et 
al., 2011 
United 
Kingdom 
≥ 18 Randomly 
selected adult 
PHC patients 
General Practice 
Research 
Datalink 
ACG 114 58.0% 18 – 24 
25 – 34 
35 – 44 
 45 – 54 
55 – 64 
65 – 74 
≥ 75: 64.0%** 
Not Reported 
* ACG = Adjusted Clinical Groups Case-Mix System; EMR = Electronic medical record; ICPC = International Classification of Primary Care; ICPC-2 = 
International Classification of Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health care  
** Prevalence estimate extracted and calculated by author 
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Table 5.10 Key methodological elements and sample characteristics from multimorbidity literature (defined as two or more 
chronic diseases), as compared to elements and prevalence from current research, Continued 
Citation Country 
of Origin 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System* 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Age Group (Years) 
with Highest 
Prevalence 
Sex Category 
with Highest 
Prevalence 
Rocca et al., 
2014 
United 
States 
≥ 20 Adult PHC 
patients 
Rochester 
Epidemiology 
Project EMR 
database 
ICD-9 20 22.6%** 20 – 39 
40 – 49 
50 – 59 
60 – 69 
70 – 79 
≥ 80: 87.9% 
Female: 
23.4% 
Ornstein et 
al., 2013 
United 
States 
≥ 18 Adult PHC 
patients 
Practice-Based 
Research 
Network EMR 
database 
ICD-9-CM 24 45.3% 18 – 34 
35 – 44 
45 – 54 
55 – 64 
65 – 74 
75 – 85: 81.0% 
≥ 85 
Not Reported 
Ward et al., 
2013 
United 
States 
≥ 18 Randomly 
selected 
community-
dwelling adults 
2010 National 
Health Survey 
Self-report 10 26.0% 18 – 44 
45 – 64 
≥ 65, Female: 
61.9%** 
Female, ≥ 65 
Years: 
61.9%** 
* EMR = Electronic medical record; ICD-9 = International Classification of Disease, 9th Revision; ICD-9-CM = International Classification of Disease, 9th 
Revision, Clinical Modification; MM = Multimorbidity; PHC = Primary health care 
** Prevalence estimate extracted and calculated by author 
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Table 5.11 Key methodological elements and sample characteristics from multimorbidity literature (defined as three or more 
chronic diseases), as compared to elements and prevalence from current research 
Citation Country 
of Origin 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System* 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Age Group (Years) 
with Highest 
Prevalence 
Sex Category 
with Highest 
Prevalence 
Nicholson et 
al., 2016 
Canada ≥ 18 Adult PHC 
patients 
CPCSSN EMR 
database 
ICD-9 20 33.1%** 18 – 34 
35 – 44 
45 – 64: 39.6%** 
65 – 84  
≥ 85 
Female: 
58.5%** 
Pefoyo et al., 
2015 
Canada ≥ 18 All residents 
of Ontario 
Administrative 
claims data 
ICD-9; 
ICD-10 
16 13.6%** 18 – 44 
45 – 64 
65 – 74 
75 – 89 
≥ 90: 66.0%** 
Not Reported 
Roberts et 
al., 2015 
Canada ≥ 20 General adult 
population in 
Canada 
2011/2012 
Canadian 
Community 
Health Survey 
Self-report 9 3.9% 20 – 34  
35 – 49 
50 – 64 
≥ 65: 11.3% 
Female: 
4.5% 
Fortin et al., 
2005 
Canada ≥ 18 Adult PHC 
patients from 
consecutive 
encounters 
Health charts 
review 
Count; 
CIRS 
14 75.6%** 18 – 44  
45 – 64  
≥ 65: 95.4%** 
Female: 
77.4%** 
* CIRS = Cumulative Illness Rating Scale; CPCSSN = Canadian Primary Care Sentinel Surveillance Network; EMR = Electronic medical record; ICD-9 = 
International Classification of Disease, 9th Revision; ICD-10 = International Classification of Disease, 10th Revision; MM = Multimorbidity; PHC = Primary 
health care 
** Prevalence estimate extracted and calculated by author 
 
113 
 
Table 5.11 Key methodological elements and sample characteristics from multimorbidity literature (defined as three or more 
chronic diseases), as compared to elements and prevalence from current research, Continued  
Citation Country  
of Origin 
Age 
Range 
Sample 
Recruitment 
Data 
Source 
Diagnostic 
Coding 
System* 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Age Group 
(Years) with 
Highest 
Prevalence 
Sex 
Category 
with Highest 
Prevalence 
Harrison et 
al., 2014 
Australia ≥ 20 Randomly 
selected PHC 
patients 
Health 
charts 
review 
ICD-10 20 27.4% 20 – 29 
30 – 39 
40 – 49 
50 – 59 
60 – 69 
70 – 79 
80 – 89: 81.8% 
≥ 90 
Not Reported 
Taylor et al., 
2010 
Australia ≥ 20 Randomly 
selected adults 
Northwest 
Adelaide 
Health 
Study 
Self-report 7 5.3%** 20 – 39 
40 – 59 
≥ 60: 14.5% 
Not Reported 
Prazeres et 
al., 2015 
Portugal ≥ 18 Adult PHC 
patients 
Questionnair
e of PHC 
patients 
ICPC-2 147 57.2% 18 – 34 
35 – 49 
50 – 64 
≥ 65: 82.7% 
Male: 61.6% 
Rizza et al., 
2012 
Switzerland ≥ 20 Adult PHC 
patients 
Swiss 
Family 
Medicine 
ICPC 
Research 
using EMR 
database 
ICPC-2 147 7.3% 20 – 29 
30 – 39 
40 – 49 
50 – 59 
60 – 69 
70 – 79 
≥ 80: 22.7% 
Male: 7.6% 
* ICD-10 = International Classification of Disease, 10th Revision; ICPC = International Classification of Primary Care; ICPC-2 = International Classification of 
Primary Care, 2nd Edition; MM = Multimorbidity; PHC = Primary health care 
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Table 5.11 Key methodological elements and sample characteristics from multimorbidity literature (defined as three or more 
chronic diseases), as compared to elements and prevalence from current research, Continued  
Citation Country  
of Origin 
Age 
Range 
Sample 
Recruitment 
Data Source Diagnostic 
Coding 
System* 
Number of 
Diseases 
Considered 
MM 
Prevalence 
Age Group 
with Highest 
Prevalence 
Sex Category 
with Highest 
Prevalence 
Ornstein et 
al., 2013 
United 
States 
≥ 18 Adult PHC 
patients 
Practice-Based 
Research Network 
EMR database 
ICD-9-CM 24 30.4% 18 – 34 
35 – 44 
45 – 54 
55 – 64 
65 – 74 
75 – 85 
≥ 85: 69.0% 
Not Reported 
* EMR = Electronic medical record; ICD-9-CM = International Classification of Disease, 9th Revision, Clinical Modification; MM = Multimorbidity; PHC = 
Primary health care 
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5.1.4 Objective One, Research Question 3 – Most Frequent Clusters of Multiple Chronic 
Diseases  
 In addition to presenting the most frequently occurring combinations (that is, unordered 
clusters) and permutations (that is, ordered clusters) among all adult patients with multimorbidity 
(stratified by both patient age and patient sex), the prevalence of the twenty individual chronic 
disease diagnoses (included within the measure of multimorbidity) will first be presented.   
 
Prevalence of Individual Chronic Diseases 
 The prevalence of individual chronic disease diagnoses among all adult patients, as well 
as patients with multimorbidity, is displayed in Table 5.12 and includes the prevalence of all 
twenty chronic disease diagnoses.  Among all three patient groups (that is: 1) all adult patients; 
2) patients with two or more chronic diseases; and 3) patients with three or more chronic 
diseases), the most prevalent chronic disease diagnosis was Obesity, ranging from a prevalence 
of 24.6% (95% CI: 24.5 – 24.8) among all adult patients to a prevalence of 30.2% (95% CI: 30.0 
– 30.4) among patients with two or more chronic diseases.  Once again for all three patient 
groups, the second most prevalent chronic disease diagnosis was Hypertension, ranging from a 
prevalence of 10.5% (95% CI: 10.4 – 10.6) among all adult patients to a prevalence of 18.9% 
(95% CI: 18.6 – 19.1) among patients with three or more chronic diseases.  The third most 
prevalent chronic disease among all three patient groups was the diagnosis for Musculoskeletal 
Problem, which ranged from a prevalence of 8.9% (95% CI: 8.8 – 9.0) among all adult patients 
to a prevalence of 10.2% (95% CI: 10.1 – 10.4) among patients with two or more chronic 
diseases.  The least prevalent chronic disease diagnoses among all three patient groups were 
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Stroke or Transient Ischemic Attack, Kidney Disease or Failure and Liver Disease.  Each of 
these chronic diseases had a prevalence of about 0.1% within each patient group.  
 The prevalence of individual chronic disease diagnoses among all patients with 
multimorbidity, defined as two or more chronic diseases and stratified by patient age and patient 
sex, are presented in Figure 5.2 to Figure 5.7.  When compared, these six Figures indicate a 
changing distribution of prevalent chronic disease diagnoses as patients age, regardless of patient 
sex.  Among all female patients with multimorbidity (n = 113,209), the most prevalent chronic 
disease diagnoses were Obesity (28.4%, 95% CI: 28.1 – 28.7); Hypertension (16.0%, 95% CI: 
15.7 – 16.2); Anxiety or Depression (10.5%, 95% CI: 10.4 – 10.7); Musculoskeletal Problem 
(10.3%, 95% CI: 10.2 – 10.5); and Cancer (5.8%, 95% CI: 5.6 – 5.9).  Among all male patients 
with multimorbidity (n = 82,622), the most prevalent chronic disease diagnoses were Obesity 
(32.7%, 95% CI: 32.4 – 33.0); Hypertension (16.7%, 95% CI: 16.5 – 17.0); Musculoskeletal 
Problem (10.1, 95% CI: 9.9 – 10.3); Diabetes (7.4%, 95% CI: 7.2 – 7.6); and Anxiety or 
Depression (6.4%, 95% CI: 6.3 – 6.6).  
Among both female and male patients aged 18 to 34 years, the most prevalent chronic 
diseases were Obesity, Anxiety or Depression and Musculoskeletal Problem.  For young female 
patients, the prevalence of Obesity was 32.7% (95% CI: 31.8 – 33.5); of Anxiety or Depression 
was 19.8% (95% CI: 19.1 – 20.6); and of Musculoskeletal Problem was 12.6% (95% CI: 12.0 – 
13.2).  For young male patients, the prevalence of Obesity was 33.1% (95% CI: 32.5 – 34.9); of 
Anxiety or Depression was 16.8% (95% CI: 15.9 – 17.8); and of Musculoskeletal Problem was 
16.7% (95% CI: 15.8 – 17.7).  Interestingly, these three chronic disease diagnoses remained the 
most prevalent among both female and male patients aged 35 to 44 years.  However, in this age 
group, the overall prevalence of these diseases decreased as the frequency of other chronic 
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diseases increased (except for Obesity, which had a rise in prevalence).  The prevalence of 
Obesity was 34.1% (95% CI: 33.3 – 34.9) and 36.4% (95% CI: 35.4 – 37.4) for female and male 
patients aged 35 to 44 years, respectively.  Among female patients, the prevalence of Anxiety or 
Depression was 17.1% (95% CI: 16.5 – 17.7) and the prevalence of Musculoskeletal Problem 
was 13.3% (95% CI: 12.8 – 13.9).  For male patients of the same age, the prevalence of Anxiety 
or Depression was 12.4% (95% CI: 11.7 – 13.1) and the prevalence of Musculoskeletal Problem 
was 16.3% (95% CI: 15.6 – 17.1).  Among female patients aged 45 to 64 years, the most 
prevalent chronic diseases were Obesity (31.3%, 95% CI: 30.9 – 31.7); Hypertension (12.8%, 
95% CI: 12.5 – 13.1); and Musculoskeletal Problem (12.4%, 95% CI: 12.0 – 12.7).  This was 
followed closely by Anxiety or Depression, which had a prevalence of 11.3% (95% CI: 11.0 – 
11.6).  Among male patients aged 45 to 64 years, the most prevalent chronic diseases were also 
Obesity (36.3%, 95% CI: 35.8 – 36.8); Hypertension (15.4%, 95% CI: 15.1 – 15.8); and 
Musculoskeletal Problem (11.6%, 95% CI: 11.3 – 12.0).   
Female and male patients who were between the ages of 65 and 84 years were most likely 
to be living with Obesity, Hypertension and Diabetes.  For female patients, the prevalence of 
Obesity was 24.6% (95% CI: 24.1 – 25.1); of Hypertension was 24.9% (95% CI: 24.4 – 25.3); 
and of Diabetes was 7.4% (95% CI: 7.2 – 7.7).  For male patients, the prevalence of Obesity was 
29.5% (95% CI: 29.0 – 30.1); of Hypertension was 22.2% (95% CI: 21.7 – 22.7); and of 
Diabetes was 10.9% (95% CI: 10.5 – 11.2).  With the exception of the prominent diagnoses of 
Obesity and Hypertension, prevalence estimates were more evenly distributed among a number 
of other chronic diseases, such as Musculoskeletal Problem, Hyperlipidemia, Cancer and 
Cardiovascular Disease.  Likewise, those patients who were 85 years of age and older were most 
likely to be living with Obesity and Hypertension.  However, the most prevalent chronic disease 
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in this age group was Hypertension with a prevalence of 33.9% (95% CI: 32.9 – 34.9) and 26.9% 
(95% CI: 25.8 – 28.2) among female and male patients, respectively.  While the next prevalent 
chronic disease diagnosis was Obesity, the prevalence estimates were again more evenly 
distributed among a number of other chronic diseases, such as Cardiovascular Disease, Diabetes, 
Cancer and Osteoarthritis or Rheumatoid Arthritis.   
Prevalence estimates of individual chronic diseases within the CPCSSN EMR database 
were also compared with the 2013 Canadian Community Health Survey (CCHS), which can be 
seen in Appendix J.  These prevalence estimates were stratified by patient age and patient sex.  
Before comparison, it was important to consider the marked differences in the methodology 
between these prevalence estimates.  For example, the 2013 CCHS data were derived from a 
cross-sectional survey of community-dwelling respondents and data were collected directly from 
survey respondents via self-report.  In comparison, the CPCSSN EMR data were derived from 
longitudinal clinical patient records that were recorded prospectively by PHC providers.  Despite 
these key methodological differences, the national estimates of relevant chronic diseases were 
compared.  Overall, Diabetes and Hypertension were the most comparable categories of diseases 
between the CCHS and CPCSSN EMR data.  This was because of the most concise overlap 
between the definitions of both diseases.  For example, the term “High Blood Pressure”, which 
was used in the CCHS survey is commonly interchanged with the more clinical term of 
“Hypertension”.  However, there may have been considerable disparities between a respondent’s 
interpretation of “Heart Disease” in the CCHS survey and whether their definition corresponded 
to the diagnoses for “Cardiovascular Disease” in the CPCSSN EMR data.  This is supported by a 
study conducted by Muggah et al. (2013), which examined the accuracy of self-reported diseases 
from the 2005 CCHS and confirmed that the highest agreement between the self-reported 
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chronic diseases and administrative data (specifically within the province of Ontario) were for 
Diabetes and Hypertension (Kappa range: 0.66 – 0.80).  This was followed by a moderate level 
of agreement for Myocardial Infarction and Asthma, while the remaining self-reported chronic 
diseases (Stroke, Congestive Heart Failure and Chronic Obstructive Pulmonary Disease) showed 
a poor level of agreement (Muggah et al., 2013).   
The prevalence estimates of Diabetes between the CCHS and the CPCSSN EMR data 
were within 10% throughout the age categories.  The prevalence of Hypertension was 
comparable for individuals aged 18 to 34 years and 35 to 44 years in the two datasets, however, 
this prevalence was drastically lower in the CPCSSN EMR data (approximately 20% difference 
in prevalence) among individuals who were 45 years and older.  For both categories, the 
CPCSSN EMR data reported a lower prevalence level as compared to the 2013 CCHS data.  
While these differences in prevalence estimates are notable, it is not clear whether these 
prevalence estimates were artefacts of the methodological differences between the survey and 
EMR data, or whether these differences demonstrate the true prevalence of chronic disease 
within these two study populations.  
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Table 5.12 Prevalence of individual chronic disease diagnoses among all adult patients and 
those with multimorbidity, defined as two or more and three or more chronic diseases  
 Prevalence (95% CI)  
Chronic Disease 
Category 
All Adult Patients  
(N = 367,743) 
Among Patients with Two or 
More Chronic Diseases  
(n = 195,838) 
Among Patients with Three 
or More Chronic Diseases  
(n = 121,864) 
Obesity 24.6 (24.5 – 24.8) 30.2 (30.0 – 30.4) 27.5 (27.3 – 27.8) 
Hypertension 10.5 (10.4 – 10.6) 16.3 (16.1 – 16.5) 18.9 (18.6 – 19.1) 
Musculoskeletal Problem 8.9 (8.8 – 9.0) 10.2 (10.1 – 10.4) 9.5 (9.4 – 9.7) 
Anxiety or Depression 8.1 (8.0 – 8.2) 8.8 (8.7 – 8.9) 7.5 (7.4 – 7.7) 
Cancer  4.8 (4.7 – 4.9) 5.1 (5.0 – 5.2) 4.6 (4.5 – 4.7) 
Diabetes 3.7 (3.6 – 3.8) 5.9 (5.8 – 6.0) 7.0 (6.8 – 7.1) 
Chronic Obstructive 
Pulmonary Disease or Asthma 
3.1 (3.0 – 3.2) 3.9 (3.8 – 4.0) 3.7 (3.6 – 3.8) 
Hyperlipidemia 3.1 (3.0 – 3.1) 4.4 (4.4 – 4.5) 4.9 (4.8 – 5.0) 
Osteoarthritis or Rheumatoid 
Arthritis 
2.3 (2.3 – 2.4) 3.3 (3.3 – 3.4) 3.9 (3.8 – 4.0) 
Thyroid Problem 2.1 (2.1 – 2.2) 2.9 (2.8 – 3.0) 3.0 (2.9 – 3.1) 
Cardiovascular Disease 1.9 (1.8 – 1.9) 2.8 (2.7 – 2.8) 3.2 (3.1 – 3.3) 
Urinary Problem 1.6 (1.6 – 1.6) 2.0 (1.9 – 2.1) 2.0 (1.9 – 2.1) 
Colon Problem 1.0 (1.0 – 1.1) 1.2 (1.2 – 1.3) 1.2 (1.1 – 1.2) 
Stomach Problem 0.9 (0.8 – 0.9) 1.1 (1.1 – 1.2) 1.2 (1.1 – 1.2) 
Osteoporosis 0.5 (0.4 – 0.5) 0.7 (0.6 – 0.7) 0.8 (0.7 – 0.8) 
Dementia 0.5 (0.4 – 0.5) 0.5 (0.4 – 0.5) 0.4 (0.4 – 0.4) 
Heart Failure 0.2 (0.2 – 0.2) 0.3 (0.3 – 0.3) 0.3 (0.3 – 0.4) 
Kidney Disease or Failure 0.1 (0.1 – 0.1) 0.1 (0.1 – 0.1) 0.1 (0.1 – 0.2) 
Liver Disease 0.1 (0.1 – 0.1) 0.1 (0.1 – 0.1) 0.1 (0.1 – 0.1) 
Stroke or Transient Ischemic 
Attack 
0.1 (0.1 – 0.1) 0.1 (0.1 – 0.2) 0.2 (0.1 – 0.2) 
* CI = Confidence interval
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Figure 5.2 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, all ages 
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Figure 5.3 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged 18 – 34 years
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Figure 5.4 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged 35 – 44 years 
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Figure 5.5 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged 45 – 64 years
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Figure 5.6 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged 65 – 84 years 
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Figure 5.7 Type of chronic disease diagnoses among patients with multimorbidity, stratified by patient sex, aged ≥ 85 years 
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Most Frequent Combinations of Multimorbidity 
Total Number of Combinations 
 Following the computational cluster analysis, the total number of combinations among 
patients with multimorbidity are presented in Table 5.13.  After stratifying the results by patient 
age, patient sex and total number of chronic diseases, a large number of combinations were 
detected in each group.  As described in Section 4.8.2, only those patients with at least one 
chronic disease and with at least one day elapsing between chronic disease diagnoses were 
included in this analysis.  A combination is an unordered cluster of multiple chronic diseases 
where the sequence in which the chronic disease diagnoses occurred is not assessed.  Essentially, 
these are co-occurring chronic diseases.  The specific sequence in which the chronic disease 
diagnoses occurred is explored in the Total Number of Permutations section.  Overall, a total of 
6,095 combinations were found among female patients of all ages with multimorbidity (n = 
47,381) and a total of 4,316 combinations were found among male patients of all ages with 
multimorbidity (n = 30,478).  While these results may indicate a mean of 7.8 female patients and 
7.1 male patients who had the same combination of multiple chronic diseases, the spread of 
patients across combination type was not normally distributed.   
Among patients aged 18 to 34 years (n = 8,189 patients), there were 645 combinations 
found among females and 379 combinations among males.  For those patients aged 35 to 44 
years (n = 10,330 patients), 964 and 589 combinations were detected among females and males, 
respectively.  Among patients aged 45 to 64 years (n = 30,798 patients), the number of patients 
and number of combinations approximately tripled as compared to the previous age group.  For 
female and male patients, 2,769 combinations and 1,863 combinations were detected, 
respectively.  Among both females and males, the largest numbers of combinations were 
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detected among patients aged 65 to 84 years (n = 22,471 patients).  For female patients aged 65 
to 84 years, there were 3,765 combinations detected and among males, there were 2,780 
combinations detected.  For female patients aged 85 years and older, a total of 1,804 
combinations were identified and among male patients aged 85 years and older, a total of 1,241 
combinations were identified.  While the total number of combinations decreased among patients 
aged 85 years and older (n = 6,071 patients), these combinations represented increasingly unique 
clusters.   
As seen in Table 5.13, for both female and male patients, the total number of 
combinations stratified by age category does not add up to the total number of combinations 
among all ages.  For example, male patients of all ages could be grouped into the same 
combination, which would reduce the amount of potential combinations occurring among males 
of all patients.  In contrast, more combinations were observed when stratified by patient age 
category due to the categorization by patient age and combination type.  Therefore, there were a 
total of only 6,095 combinations and 4,316 combinations detected among female and male 
patients, respectively.  Finally, to assess the differences that occurred when excluding cases in 
which the time elapsing between diagnoses was zero days, the same computational analysis was 
conducted for all patients and for all data points (that is, even when time elapsing between 
chronic disease diagnoses was equal to zero).  These results are included in Appendix K to 
Appendix V.  While there were differences in the total number of combinations found among 
the stratified groups, a large number of combinations (as well as similar patterns of combination 
types among females and males, stratified by patient age category) were detected among all 
patients with multimorbidity.   
 
129 
 
Table 5.13 Total number of combinations, stratified by patient age category and patient 
sex, among patients with multimorbidity  
Patient Sex Patient Age Category n Total Number of Combinations* 
Females All Ages 47,381 6,095 
18 – 34 Years 5,565 645 
35 – 44 Years 6,747 964 
45 – 64 Years 18,426 2,769 
65 – 84 Years 12,819 3,765 
≥ 85 Years 3,824 1,804 
Males All Ages 30,478 4,316 
18 – 34 Years 2,624 379 
35 – 44 Years 3,583 589 
45 – 64 Years 12,372 1,863 
65 – 84 Years 9,652 2,780 
≥ 85 Years 2,247 1,241 
* The total number of combinations, stratified by age category among female and male patients, will not add to the 
total number of combinations among female and male patients of all ages 
 
Most Frequently Occurring Combinations Among Female Patients  
The most frequently occurring combinations were explored according to patient age and 
total number of chronic diseases among female patients.  These results include only those 
chronic diseases that had at least one-day elapsing between the associated dates of diagnoses.  
Among adult female patients of all ages (n = 47,381 patients), the most common combination of 
chronic diseases was Anxiety or Depression and Musculoskeletal Problem (1,694 patients).  This 
meant that 1,694 female patients were either diagnosed first with Anxiety or Depression and then 
Musculoskeletal Problem, or first Musculoskeletal Problem and then Anxiety or Depression.  
This was followed by a combination of Anxiety or Depression and Obesity (1,179 patients) and 
Musculoskeletal Problem and Obesity (1,132 patients).  Among patients with three chronic 
diseases, the most common combination was Anxiety or Depression, Musculoskeletal Problem 
130 
 
and Obesity (675 patients).  For patients with four chronic disease diagnoses, the most frequently 
occurring combination was Anxiety or Depression, Cancer, Musculoskeletal Problem and 
Obesity (180 patients).  Lastly, for female patients living with five or more chronic diseases, the 
most frequently occurring combination was present in 58 patients and was a cluster of Anxiety or 
Depression, Hypertension, Musculoskeletal Problem, Obesity and Osteoarthritis or Rheumatoid 
Arthritis.  These results are presented in Table 5.14.  
Among the youngest group of female patients aged 18 to 34 years (n = 5,565 patients), 
the most commonly occurring combination was again Anxiety or Depression and 
Musculoskeletal Problem (443 patients).  Likewise, this was followed by a combination of 
Anxiety or Depression and Obesity (397 patients) and Musculoskeletal Problem and Obesity 
(253 patients).  Among those patients with three chronic diseases, the most frequently occurring 
combination was Anxiety or Depression, Musculoskeletal Problem and Obesity among 157 
patients.  For female patients with four chronic disease diagnoses, the most common 
combinations were Anxiety or Depression, Cancer, Musculoskeletal Problem and Obesity (36 
patients) and Anxiety or Depression, Chronic Obstructive Pulmonary Disease or Asthma, 
Musculoskeletal Problem and Obesity (28 patients).  For female patients aged 18 to 34 years who 
were living with five or more chronic diseases, the most common combination was a diagnosis 
of Anxiety or Depression, Cancer, Chronic Obstructive Pulmonary Disease or Asthma, 
Musculoskeletal Problem and Obesity (8 patients).  These results are presented in Table 5.15.   
Among female patients aged 35 to 44 years (n = 6,747 patients), the most commonly 
occurring combination was again Anxiety or Depression and Musculoskeletal Problem (497 
patients).  This was followed by a combination of Anxiety or Depression and Obesity (333 
patients) and Musculoskeletal Problem and Obesity (330 patients).  Among those female patients 
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with three chronic diseases, the most frequently occurring combinations were Anxiety or 
Depression, Musculoskeletal Problem and Obesity (203 patients) and Anxiety or Depression, 
Cancer and Musculoskeletal Problem (115 patients).  For patients with four chronic disease 
diagnoses, the most common combination was Anxiety or Depression, Cancer, Musculoskeletal 
Problem and Obesity among 50 patients.  Lastly, for female patients aged 35 to 44 years who 
were living with five or more chronic diseases, the most common combination was a diagnosis 
of Anxiety or Depression, Cancer, Musculoskeletal Problem, Obesity and Thyroid Problem, 
which was present among 13 female patients.  These results are presented in Table 5.16.   
For female patients aged 45 to 64 years (n = 18,426 patients), the most commonly 
occurring combination was Anxiety or Depression and Musculoskeletal Problem (674 patients).  
This was followed by a combination of Musculoskeletal Problem and Obesity (472 patients) and 
Cancer and Musculoskeletal Problem (404 patients).  Among those female patients with three 
chronic diseases, the most frequently occurring combinations were Anxiety or Depression, 
Musculoskeletal Problem and Obesity (291 patients) and Hypertension, Musculoskeletal 
Problem and Obesity (205 patients).  For patients with four chronic disease diagnoses, the most 
common combination was Anxiety or Depression, Hypertension, Musculoskeletal Problem and 
Obesity, which was present among 88 patients.  For female patients aged 45 to 64 years who 
were living with five or more chronic diseases, the most common combination was a diagnosis 
of Anxiety or Depression, Cancer, Hypertension, Musculoskeletal Problem and Obesity (28 
patients).  These results are presented in Table 5.17.   
Among female patients aged 65 to 84 years (n = 12,819 patients), the most commonly 
occurring combination was Hypertension and Obesity (323 patients).  This was followed by the 
combinations of Hyperlipidemia and Hypertension (158 patients) and Cancer and Hypertension 
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(147 patients).  Among those female patients with three chronic diseases, the most frequently 
occurring combinations were Diabetes, Hypertension and Obesity (129 patients) and 
Hypertension, Musculoskeletal Problem and Obesity (100 patients).  For patients with four 
chronic disease diagnoses, the most common combination was Hypertension, Musculoskeletal 
Problem, Obesity and Osteoarthritis or Rheumatoid Arthritis (73 patients).  For female patients 
aged 65 to 84 years who were living with five or more chronic diseases, the most common 
combination was a diagnosis of Hyperlipidemia, Hypertension, Musculoskeletal Problem, 
Obesity and Osteoarthritis or Rheumatoid Arthritis, which was present among 32 patients.  These 
results are presented in Table 5.18.   
Finally, among female patients aged 85 years and older (n = 3,824 patients), the most 
commonly occurring combination was Dementia and Hypertension (76 patients).  This was 
followed by the combinations of Cardiovascular Disease and Hypertension (69 patients) and 
Hypertension and Obesity (63 patients).  Among those older female patients with three chronic 
diseases, the most frequently occurring combinations were Hypertension, Obesity and 
Osteoarthritis or Rheumatoid Arthritis (31 patients) and Hypertension, Musculoskeletal Problem 
and Obesity (26 patients).  For female patients with four chronic disease diagnoses, the most 
common combination was Hypertension, Musculoskeletal Problem, Obesity and Osteoarthritis or 
Rheumatoid Arthritis (17 patients).  For female patients aged 85 years and older who were living 
with five or more chronic diseases, the most common combination was a diagnosis of 
Cardiovascular Disease, Hypertension, Musculoskeletal Problem, Obesity and Osteoarthritis or 
Rheumatoid Arthritis, which was present among only 8 patients.  These results are presented in 
Table 5.19.   
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It is important to note that all unique combinations found among female patients 
constituted mutually exclusive groups.  This was because the results were stratified by the total 
number of chronic diseases.  For example, among all female patients, the 675 patients with 
Anxiety or Depression, Musculoskeletal Problem and Obesity (three chronic diseases) or the 180 
female patients with Anxiety or Depression, Cancer, Musculoskeletal Problem and Obesity (four 
chronic diseases) are not subsets of the 1,694 female patients with only Anxiety or Depression 
and Musculoskeletal Problem or the 1,179 female patients with Anxiety or Depression and 
Obesity (two chronic diseases).  This ensured that all clusters represented unique, unordered 
clinical profiles among female patients with multimorbidity.   
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Table 5.14 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
all eligible female patients with multimorbidity (n = 47,381) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female 
Patients, All Ages 
2 
(n = 19,168) 
Anxiety or Depression & Musculoskeletal Problem 1,694 3.6 
Anxiety or Depression & Obesity 1,179 2.5 
Musculoskeletal Problem & Obesity 1,132 2.4 
Hypertension & Obesity 850 1.8 
Anxiety or Depression & Cancer 834 1.8 
3 
(n = 12,631) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 675 1.4 
Hypertension & Musculoskeletal Problem & Obesity 374 0.8 
Anxiety or Depression & Cancer & Musculoskeletal Problem 365 0.8 
Anxiety or Depression & Musculoskeletal Problem & Obesity 286 0.6 
Anxiety or Depression & Hypertension & Obesity 264 0.6 
4 
(n = 7,494) 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 180 0.4 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 176 0.4 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 140 0.3 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity 
111 0.2 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
106 0.2 
≥ 5 
(n = 8,088) 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
58 0.1 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 52 0.1 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
49 0.1 
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity 49 0.1 
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
44 0.1 
* Combinations listed in alphabetical order  
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Table 5.15 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 18 – 34 years with multimorbidity (n = 5,565) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female Patients, 
18 – 34 Years 
2 
(n = 3,478) 
Anxiety or Depression & Musculoskeletal Problem 443 8.0 
Anxiety or Depression & Obesity 397 7.1 
Musculoskeletal Problem & Obesity 253 4.5 
Anxiety or Depression & Cancer 243 4.4 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma 166 3.0 
3 
(n = 1,387) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 157 2.8 
Anxiety or Depression & Cancer & Obesity 67 1.2 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem 
61 1.1 
Anxiety or Depression & Cancer & Musculoskeletal Problem 59 1.1 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Obesity 55 1.0 
4 
(n = 501) 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 36 0.6 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity 
28 0.5 
Anxiety or Depression & Colon Problem & Musculoskeletal Problem & Obesity 18 0.3 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Thyroid Problem 15 0.3 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Urinary Problem 15 0.3 
≥ 5 
(n = 199) 
Anxiety or Depression & Cancer & Chronic Obstructive Pulmonary Disease or Asthma & 
Musculoskeletal Problem & Obesity 
8 0.1 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity & Urinary Problem 
6 0.1 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Thyroid Problem 5 0.1 
Anxiety or Depression & Cancer & Colon Problem & Musculoskeletal Problem & Obesity 5 0.1 
Results Supressed (<5 Patients)   
* Combinations listed in alphabetical order  
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Table 5.16 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 35 – 44 years with multimorbidity (n = 6,747) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number of 
Patients 
% of Female Patients, 
35 – 44 Years 
2 
(n = 3,624) 
Anxiety or Depression & Musculoskeletal Problem 497 7.4 
Anxiety or Depression & Obesity 333 4.9 
Musculoskeletal Problem & Obesity 330 4.9 
Anxiety or Depression & Cancer 206 3.1 
Cancer & Musculoskeletal Problem 180 2.7 
3 
(n = 1,859) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 203 3.0 
Anxiety or Depression & Cancer & Musculoskeletal Problem 115 1.7 
Cancer & Musculoskeletal Problem & Obesity 76 1.1 
Anxiety or Depression & Cancer & Obesity 70 1.0 
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem & Obesity 51 0.8 
4 
(n = 792) 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 50 0.7 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 38 0.6 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity 
31 0.5 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Thyroid Problem 30 0.4 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Urinary Problem 22 0.3 
≥ 5  
(n = 472) 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Thyroid Problem 13 0.2 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Hypertension & 
Musculoskeletal Problem & Obesity 
11 0.2 
Anxiety or Depression & Cancer & Colon Problem & Musculoskeletal Problem & Obesity 9 0.1 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity & Thyroid Problem 
8 0.1 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Stomach Problem 8 0.1 
* Combinations listed in alphabetical order  
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Table 5.17 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 45 – 64 years with multimorbidity (n = 18,426) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female Patients, 
45 – 64 Years 
2 
(n = 7,516) 
Anxiety or Depression & Musculoskeletal Problem 674 3.7 
Musculoskeletal Problem & Obesity 472 2.6 
Cancer & Musculoskeletal Problem 404 2.2 
Anxiety or Depression & Obesity 404 2.2 
Hypertension & Obesity 345 1.9 
3 
(n = 5,171) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 291 1.6 
Hypertension & Musculoskeletal Problem & Obesity 205 1.1 
Anxiety or Depression & Cancer & Musculoskeletal Problem 162 0.9 
Cancer & Musculoskeletal Problem & Obesity 132 0.7 
Anxiety or Depression & Hypertension & Obesity 131 0.7 
4 
(n = 2,981) 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 88 0.5 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 84 0.5 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
68 0.4 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 66 0.4 
Anxiety or Depression & Hyperlipidemia & Musculoskeletal Problem & Obesity 54 0.3 
≥ 5  
(n = 2,758) 
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity 28 0.2 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 27 0.1 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
24 0.1 
Anxiety or Depression & Diabetes & Hypertension & Musculoskeletal Problem & Obesity 22 0.1 
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
20 0.1 
* Combinations listed in alphabetical order  
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Table 5.18 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 65 – 84 years with multimorbidity (n = 12,819) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female Patients, 
65 – 84 Years 
2 
(n = 3,467) 
Hypertension & Obesity 323 2.5 
Hyperlipidemia & Hypertension 158 1.2 
Cancer & Hypertension 147 1.1 
Hypertension & Musculoskeletal Problem 141 1.1 
Hypertension & Osteoarthritis or Rheumatoid Arthritis 123 1.0 
3 
(n = 3,257) 
Diabetes & Hypertension & Obesity 129 1.0 
Hypertension & Musculoskeletal Problem & Obesity 100 0.8 
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 97 0.8 
Hyperlipidemia & Hypertension & Obesity 95 0.7 
Cancer & Hypertension & Obesity 81 0.6 
4 
(n = 2,527) 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 73 0.6 
Diabetes & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 39 0.3 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity 39 0.3 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 35 0.3 
Anxiety or Depression & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 33 0.3 
≥ 5  
(n = 3,568) 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
32 0.2 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
28 0.2 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
24 0.2 
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
21 0.2 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 20 0.2 
* Combinations listed in alphabetical order  
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Table 5.19 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 85 years and older with multimorbidity (n = 3,824) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female Patients,  
≥ 85 Years 
2 
(n = 1,083) 
Dementia & Hypertension 76 2.0 
Cardiovascular Disease & Hypertension 69 1.8 
Hypertension & Obesity 63 1.6 
Hypertension & Osteoarthritis or Rheumatoid Arthritis 54 1.4 
Hypertension & Musculoskeletal Problem 49 1.3 
3 
(n = 957) 
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 31 0.8 
Hypertension & Musculoskeletal Problem & Obesity 26 0.7 
Cardiovascular Disease & Hypertension & Musculoskeletal Problem 21 0.5 
Hypertension & Musculoskeletal Problem & Osteoarthritis or Rheumatoid Arthritis 19 0.5 
Cancer & Hypertension & Obesity 19 0.5 
4 
(n = 693) 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 17 0.4 
Anxiety or Depression & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 14 0.4 
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Osteoarthritis or 
Rheumatoid Arthritis 
11 0.3 
Cancer & Hypertension & Musculoskeletal Problem & Obesity 11 0.3 
Cardiovascular Disease & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 9 0.2 
≥ 5  
(n = 1,091) 
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis 
or Rheumatoid Arthritis 
8 0.2 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis 
or Rheumatoid Arthritis 
7 0.2 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis & 
Osteoporosis 
6 0.2 
Anxiety or Depression & Cardiovascular Disease & Hypertension & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
6 0.2 
Dementia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
5 0.1 
* Combinations listed in alphabetical order 
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Most Frequently Occurring Combinations Among Male Patients 
The most frequently occurring combinations were explored according to patient age and 
total number of chronic diseases among male patients.  These results include only those chronic 
diseases that had at least one-day elapsing between the associated dates of diagnoses.  Among 
adult male patients of all ages (n = 30,478 patients), the most common combination of chronic 
diseases was Musculoskeletal Problem and Obesity (1,073 patients).  This meant that 1,073 male 
patients were either diagnosed with Musculoskeletal Problem and then Obesity, or first with 
Obesity and then Musculoskeletal Problem.  This was followed by a combination of 
Hypertension and Obesity (895 patients) and Anxiety or Depression and Musculoskeletal 
Problem (882 patients).  Among male patients with three chronic diseases, the most common 
combination was Hypertension, Musculoskeletal Problem and Obesity (364 patients).  For 
patients with four chronic disease diagnoses, the most frequently occurring combination was 
Hyperlipidemia, Hypertension, Musculoskeletal Problem and Obesity (153 patients).  Lastly, for 
male patients living with five or more chronic diseases, the most frequently occurring 
combination was present in 66 patients and consisted of Diabetes, Hyperlipidemia, Hypertension, 
Musculoskeletal Problem and Obesity.  These results are presented in Table 5.20.   
Among the youngest group of male patients aged 18 to 34 years (n = 2,624 patients), the 
most commonly occurring combination was Anxiety or Depression and Musculoskeletal 
Problem (313 patients), which was similar to the most common combination among female 
patients aged 18 to 34 years.  This was followed by a combination of Musculoskeletal Problem 
and Obesity (219 patients).  Among those patients with three chronic diseases, the most 
frequently occurring combination was Anxiety or Depression, Musculoskeletal Problem and 
Obesity among 69 patients (again, similar to the findings among females aged 18 to 34 years).  
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For male patients with four chronic disease diagnoses, the most common combinations were 
Anxiety or Depression, Chronic Obstructive Pulmonary Disease or Asthma, Musculoskeletal 
Problem and Obesity, which was present among 8 patients.  For male patients aged 18 to 34 
years who were living with five or more chronic diseases, the combinations that were detected 
were only present in fewer than five patients indicating increasingly unique clinical profiles in 
these young, yet complex male patients.  These results are presented in Table 5.21.   
Among male patients aged 35 to 44 years (n = 3,583 patients), the most commonly 
occurring combination was Musculoskeletal Problem and Obesity (299 patients).  This was 
followed by a combination of Anxiety or Depression and Musculoskeletal Problem (263 
patients) and Anxiety or Depression and Obesity (175 patients).  Among those male patients with 
three chronic diseases, the most frequently occurring combinations were Anxiety or Depression, 
Musculoskeletal Problem and Obesity (99 patients) and Cancer, Musculoskeletal Problem and 
Obesity (50 patients).  For patients with four chronic disease diagnoses, the most common 
combination was Anxiety or Depression, Cancer, Musculoskeletal Problem and Obesity among 
16 patients.  Lastly, for male patients aged 35 to 44 years who were living with five or more 
chronic diseases, the combinations that were detected were only present among fewer than five 
patients, once again indicating unique clinical profiles among male patients aged 35 to 44 years 
with five or more chronic diseases.  These results are presented in Table 5.22.   
For male patients aged 45 to 64 years (n = 12,372 patients), the most commonly 
occurring combinations were Musculoskeletal Problem and Obesity (483 patients) and 
Hypertension and Obesity (441 patients).  Among those male patients with three chronic 
diseases, the most frequently occurring combinations were Hypertension, Musculoskeletal 
Problem and Obesity (201 patients) and Hyperlipidemia, Hypertension and Obesity (193 
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patients).  For patients with four chronic disease diagnoses, the most common combination was 
Hyperlipidemia, Hypertension, Musculoskeletal Problem and Obesity, which was present among 
100 patients.  For male patients aged 45 to 64 years who were living with five or more chronic 
diseases, the most common combination was a diagnosis of Diabetes, Hyperlipidemia, 
Hypertension, Musculoskeletal Problem and Obesity (34 patients).  These results are presented in 
Table 5.23.   
Among male patients aged 65 to 84 years (n = 9,652 patients), the most commonly 
occurring combination was Hypertension and Obesity (280 patients).  This was followed by the 
combinations of Diabetes and Obesity (176 patients) and Hyperlipidemia and Hypertension (124 
patients).  Among those male patients with three chronic diseases, the most frequently occurring 
combinations were Diabetes, Hypertension and Obesity (147 patients) and Hyperlipidemia, 
Hypertension and Obesity (106 patients).  For patients with four chronic disease diagnoses, the 
most common combination was Diabetes, Hyperlipidemia, Hypertension and Obesity (52 
patients).  For male patients aged 65 to 84 years who were living with five or more chronic 
diseases, the most common combination was a diagnosis of Diabetes, Hyperlipidemia, 
Hypertension, Musculoskeletal Problem and Obesity, which was present among 28 patients.  
These results are presented in Table 5.24.   
Finally, among male patients aged 85 years and older (n = 2,247 patients), the most 
commonly occurring combination was Cancer and Hypertension (42 patients).  This was 
followed by the combinations of Hypertension and Obesity (41 patients) and Cardiovascular 
Disease and Hypertension (36 patients).  Among those older male patients with three chronic 
diseases, the most frequently occurring combinations were Diabetes, Hypertension and Obesity 
(29 patients) and Cardiovascular Disease, Hypertension and Obesity (19 patients).  For male 
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patients with four chronic disease diagnoses, the most common combination was Hypertension, 
Musculoskeletal Problem, Obesity and Osteoarthritis or Rheumatoid Arthritis (13 patients).  For 
male patients aged 85 years and older who were living with five or more chronic diseases, the 
most common combinations were among less than five male patients, indicating an elderly and 
uniquely complex set of patients.   These results are presented in Table 5.25.   
Once again, it is important to note that all unique combinations found among male 
patients constituted mutually exclusive groups.  For example, among all male patients, the 364 
patients with Hypertension, Musculoskeletal Problem and Obesity (three chronic diseases) or the 
Hyperlipidemia, Hypertension, Musculoskeletal Problem and Obesity (four chronic diseases) are 
not subsets of the 1,073 patients with only Musculoskeletal Problem and Obesity (two chronic 
diseases).  This ensured that all clusters represented unique, unordered clinical profiles among 
male patients with multimorbidity.   
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Table 5.20 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
all eligible male patients with multimorbidity (n = 30,478) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
All Ages 
2 
(n = 12,557) 
Musculoskeletal Problem & Obesity 1,073 3.5 
Hypertension & Obesity 895 2.9 
Anxiety or Depression & Musculoskeletal Problem 882 2.9 
Anxiety or Depression & Obesity 622 2.0 
Diabetes & Obesity 467 1.5 
3 
(n = 8,158) 
Hypertension & Musculoskeletal Problem & Obesity 364 1.2 
Diabetes & Hypertension & Obesity 343 1.1 
Anxiety or Depression & Musculoskeletal Problem & Obesity 340 1.1 
Hyperlipidemia & Hypertension & Obesity 326 1.1 
Hyperlipidemia & Musculoskeletal Problem & Obesity 238 0.8 
4 
(n = 4,190) 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 153 0.5 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity 120 0.4 
Diabetes & Hyperlipidemia & Hypertension & Obesity 101 0.3 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 92 0.3 
Cancer & Hypertension & Musculoskeletal Problem & Obesity 91 0.3 
≥ 5  
(n = 4,853) 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 66 0.2 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 41 0.1 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
39 0.1 
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 39 0.1 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
38 0.1 
* Combinations listed in alphabetical order  
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Table 5.21 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 18 – 34 years with multimorbidity (n = 2,624) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
18 – 34 Years 
2 
(n = 1,878) 
Anxiety or Depression & Musculoskeletal Problem 313 11.9 
Musculoskeletal Problem & Obesity 219 8.3 
Anxiety or Depression & Obesity 189 7.2 
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem 88 3.4 
Cancer & Musculoskeletal Problem 80 3.0 
3 
(n = 573) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 69 2.6 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem 
35 1.3 
Cancer & Musculoskeletal Problem & Obesity 31 1.2 
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem & Obesity 26 1.0 
Anxiety or Depression & Cancer & Musculoskeletal Problem 22 0.8 
4 
(n = 135) 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity 
8 0.3 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 6 0.2 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
5 0.2 
Anxiety or Depression & Colon Problem & Musculoskeletal Problem & Obesity 5 0.2 
Cancer & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem & 
Obesity 
5 0.2 
≥ 5  
(n = 38) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Combinations listed in alphabetical order  
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Table 5.22 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 35 – 44 years with multimorbidity (n = 3,583) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
35 – 44 Years 
2 
(n = 2,139) 
Musculoskeletal Problem & Obesity 299 8.3 
Anxiety or Depression & Musculoskeletal Problem 263 7.3 
Anxiety or Depression & Obesity 175 4.9 
Hypertension & Obesity 103 2.9 
Cancer & Musculoskeletal Problem 77 2.1 
3 
(n = 945) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 99 2.8 
Cancer & Musculoskeletal Problem & Obesity 50 1.4 
Hypertension & Musculoskeletal Problem & Obesity 41 1.1 
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem & Obesity 32 0.9 
Anxiety or Depression & Hypertension & Obesity 31 0.9 
4 
(n = 352) 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 16 0.4 
Anxiety or Depression & Hyperlipidemia & Musculoskeletal Problem & Obesity 12 0.3 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 11 0.3 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity 
11 0.3 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Stomach Problem 10 0.3 
≥ 5  
(n = 147) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Combinations listed in alphabetical order  
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Table 5.23 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 45 – 64 years with multimorbidity (n = 12,372) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
45 – 64 Years 
2 
(n = 5,237) 
Musculoskeletal Problem & Obesity 483 3.9 
Hypertension & Obesity 441 3.6 
Anxiety or Depression & Musculoskeletal Problem 268 2.2 
Hyperlipidemia & Musculoskeletal Problem 247 2.0 
Hypertension & Musculoskeletal Problem 243 2.0 
3 
(n = 3,644) 
Hypertension & Musculoskeletal Problem & Obesity 201 1.6 
Hyperlipidemia & Hypertension & Obesity 193 1.6 
Hyperlipidemia & Musculoskeletal Problem & Obesity 173 1.4 
Anxiety or Depression & Musculoskeletal Problem & Obesity 154 1.2 
Diabetes & Hypertension & Obesity 147 1.2 
4 
(n = 1,992) 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 100 0.8 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity 65 0.5 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 51 0.4 
Cancer & Hypertension & Musculoskeletal Problem & Obesity 40 0.3 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 39 0.3 
≥ 5  
(n = 1,499) 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 34 0.3 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 24 0.2 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
16 0.1 
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 14 0.1 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
13 0.1 
* Combinations listed in alphabetical order  
 
 
148 
 
Table 5.24 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 65 – 84 years with multimorbidity (n = 9,652) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
65 – 84 Years 
2 
(n = 2,696) 
Hypertension & Obesity 280 2.9 
Diabetes & Obesity 176 1.8 
Hyperlipidemia & Hypertension 124 1.3 
Cancer & Hypertension 115 1.2 
Diabetes & Hypertension 113 1.2 
3 
(n = 2,460) 
Diabetes & Hypertension & Obesity 147 1.5 
Hyperlipidemia & Hypertension & Obesity 106 1.1 
Hypertension & Musculoskeletal Problem & Obesity 95 1.0 
Cancer & Hypertension & Obesity 81 0.8 
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 80 0.8 
4 
(n = 1,995) 
Diabetes & Hyperlipidemia & Hypertension & Obesity 52 0.5 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity 48 0.5 
Cardiovascular Disease & Diabetes & Hypertension & Obesity 41 0.4 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 40 0.4 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 38 0.4 
≥ 5  
(n = 2,501) 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 28 0.3 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
23 0.2 
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 23 0.2 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
22 0.2 
Diabetes & Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity 16 0.2 
* Combinations listed in alphabetical order  
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Table 5.25 Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 85 years and older with multimorbidity (n = 2,247) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
≥ 85 Years 
2 
(n = 607) 
Cancer & Hypertension 42 1.9 
Hypertension & Obesity 41 1.8 
Cardiovascular Disease & Hypertension 36 1.6 
Diabetes & Hypertension 26 1.2 
Hypertension & Osteoarthritis or Rheumatoid Arthritis 20 0.9 
3 
(n = 536) 
Diabetes & Hypertension & Obesity 29 1.3 
Cardiovascular Disease & Hypertension & Obesity 19 0.8 
Hypertension & Musculoskeletal Problem & Obesity 12 0.5 
Cancer & Hypertension & Obesity 10 0.4 
Cancer & Cardiovascular Disease & Hypertension 10 0.4 
4 
(n = 436) 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 13 0.6 
Cancer & Hypertension & Musculoskeletal Problem & Obesity 7 0.3 
Cardiovascular Disease & Diabetes & Hypertension & Obesity 7 0.3 
Cardiovascular Disease & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 6 0.3 
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity 6 0.3 
≥ 5  
(n = 668) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Combinations listed in alphabetical order 
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Most Frequent Permutations of Multimorbidity 
Total Number of Permutations 
 The total numbers of permutations among patients with multimorbidity are presented in 
Table 5.26.  After stratifying the results by patient age, patient sex and total number of chronic 
diseases, a large number of permutations were detected in each group.  As described in Section 
4.8.2, only those patients with at least one chronic disease and with at least one day elapsing 
between chronic disease diagnoses were included in this analysis.  A permutation is an ordered 
cluster of multiple chronic diseases where the specific sequence in which the chronic disease 
diagnoses occurred is assessed.  These are not simply co-occurring chronic diseases, but instead 
indicate a sequence of events over time.  Overall, a total of 14,911 permutations were found 
among female patients of all ages with multimorbidity (n = 47,381) and a total of 9,736 
permutations were found among male patients of all ages with multimorbidity (n = 30,478).  
While these results may indicate a mean of 3.2 female patients and 3.1 male patients who had the 
same permutation of multiple chronic diseases, the spread of patients across permutation type 
was not normally distributed.  
Among patients aged 18 to 34 years, there were 1,288 permutations found among females 
and approximately half the number (610) of permutations found among males.  A more 
comparative number of permutations were detected among females and males who were 35 to 44 
years of age, with 1,917 and 1,026 permutations identified, respectively.  For patients aged 45 to 
64 years, there were 6,351 permutations found among females and 4,076 permutations found 
among males.  Similar to the total number of combinations, the largest number of permutations 
were detected among patients aged 65 to 84 years; 7,019 permutations were found among 
females and 5,149 permutations were found among males.  For female and male patients aged 85 
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years and older, a total of 2,532 permutations and 1,633 permutations were identified, 
respectively.  While the total number of permutations decreased among patients aged 85 years 
and older, these permutations represented increasingly unique clusters.   
As seen in Table 5.26, for both female and male patients, the total number of 
permutations stratified by age category does not add up to the total number of permutations 
among all ages.  For example, male patients of all ages could be grouped into the same 
permutation, which would reduce the amount of potential permutations occurring among males 
of all patients.  In contrast, more permutations were observed when stratified by patient age 
category due to the categorization by patient age and permutation type.  Therefore, there were a 
total of only 14,911 permutations and 9,736 permutations detected among female and male 
patients, respectively.  Finally, to assess the differences that occurred when excluding cases in 
which the time elapsing between diagnoses was zero days, the same computational analysis was 
conducted for all patients and for all data points (that is, even when time elapsing between 
chronic disease diagnoses was equal to zero).  These results are included in Appendix W to 
Appendix AH.  While there were differences in the total number of permutations found among 
the stratified groups, a large number of permutations (as well as similar patterns of permutation 
types among females and males, stratified by patient age category) were detected among all 
patients with multimorbidity.   
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Table 5.26 Total number of permutations, stratified by patient age and patient sex, among 
patients with multimorbidity  
Patient Sex Patient Age Category n Total Number of Permutations* 
Females All Ages 47,381 14,911 
18 – 34 Years 5,565 1,288 
35 – 44 Years 6,747 1,917 
45 – 64 Years 18,426 6,351 
65 – 84 Years 12,819 7,019 
≥ 85 Years 3,824 2,532 
Males All Ages 30,478 9,736 
18 – 34 Years 2,624 610 
35 – 44 Years 3,583 1,026 
45 – 64 Years 12,372 4,076 
65 – 84 Years 9,652 5,149 
≥ 85 Years 2,247 1,633 
* The total number of permutations, stratified by age category among female and male patients, will not add to the 
total number of permutations among female and male patients of all ages 
 
Most Frequently Occurring Permutations Among Female Patients 
 The most frequently occurring permutations were explored according to patient age and 
total number of chronic diseases among female patients.  These results include only those 
chronic diseases that had at least one day elapsing between the associated dates of diagnoses.  
Among adult female patients of all ages (n = 47,381 patients), the most common permutation of 
chronic diseases was Anxiety or Depression, and then Obesity (1,160 patients).  This meant that 
1,160 female patients were first diagnosed with Anxiety or Depression and then with Obesity.  
This was followed by a permutation of Musculoskeletal Problem, and then Obesity (1,094 
patients) and Anxiety or Depression, and then Musculoskeletal Problem (909 patients).  Among 
patients with three chronic diseases, the most common permutation was Anxiety or Depression, 
then Obesity, and then Musculoskeletal Problem (177 patients).  For patients with four chronic 
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disease diagnoses, the most frequently occurring permutation was Hypertension, then Obesity, 
then Musculoskeletal Problem, and then Anxiety or Depression (24 patients).  Lastly, for female 
patients living with five or more chronic diseases, the most frequently occurring permutations 
were only present among fewer than five patients.  These results are presented in Table 5.27.  
Among the youngest group of female patients aged 18 to 34 years (n = 5,565 patients), 
the most commonly occurring permutation was again Anxiety or Depression, and then Obesity 
(388 patients).  Likewise, the next two commonly occurring permutations were Anxiety or 
Depression, and then Musculoskeletal Problem (249 patients) and Musculoskeletal Problem, and 
then Obesity (245 patients).  Among those female patients with three chronic diseases, the most 
frequently occurring permutation was Musculoskeletal Problem, then Obesity, and then Anxiety 
or Depression (41 patients).  For female patients with four chronic disease diagnoses, the most 
common permutation was the diagnoses of Thyroid Problem, then Anxiety or Depression, then 
Obesity, and then Musculoskeletal Problem, which was present among 5 patients.  For female 
patients aged 18 to 34 years who were living with five or more chronic diseases, the 
permutations that were detected were only present among fewer than five patients.  These results 
are presented in Table 5.28.   
Among female patients aged 35 to 44 years (n = 6,747 patients), the most commonly 
occurring permutation was again Anxiety or Depression, and then Obesity (327 patients).  This 
was followed by the permutations of Musculoskeletal Problem, and then Obesity (318 patients) 
and Anxiety or Depression, and then Musculoskeletal Problem (256 patients).  Among those 
female patients with three chronic diseases, the most frequently occurring permutation was 
Anxiety or Depression, then Musculoskeletal Problem, and then Obesity (57 patients).  For 
patients with four chronic disease diagnoses, the most common permutation was Anxiety or 
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Depression, then Musculoskeletal Problem, then Obesity, and then Cancer, which was present in 
10 patients.  Lastly, for female patients aged 35 to 44 years who were living with five or more 
chronic diseases, the most common permutations were once again present in fewer than five 
patients.  These results are presented in Table 5.29.   
For female patients aged 45 to 64 years (n = 18,426 patients), the most commonly 
occurring permutation was Musculoskeletal Problem, and then Obesity (456 patients).  This was 
followed by a permutation of Anxiety or Depression, and then Obesity (400 patients) and 
Anxiety or Depression, and then Musculoskeletal Problem (365 patients).  Among those female 
patients with three chronic diseases, the most frequently occurring permutation was 
Hypertension, then Obesity, and then Musculoskeletal Problem, which was present among 87 
patients.  For patients with four chronic disease diagnoses, the most common permutation was 
Hypertension, then Obesity, then Musculoskeletal Problem, and then Anxiety or Depression (14 
patients).  Similar to the previous age groups, for female patients aged 45 to 64 years who were 
living with five or more chronic diseases, the most frequent permutations were present among 
less than five patients.  These results are presented in Table 5.30.   
Among female patients aged 65 to 84 years (n = 12,819 patients), the most commonly 
occurring permutation was Hypertension, and then Obesity (322 patients).  This was followed by 
the permutation of Hypertension, and then Musculoskeletal Problem (102 patients) and 
Hypertension, and then Hyperlipidemia (98 patients).  Among those female patients with three 
chronic diseases, the most frequently occurring permutations were Hypertension, then Obesity, 
and then Hyperlipidemia (48 patients) and Hypertension, then Obesity, and then Musculoskeletal 
Problem (46 patients).  For patients with four chronic disease diagnoses, the most common 
permutation was Hypertension, then Obesity, then Musculoskeletal Problem, and then 
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Osteoarthritis or Rheumatoid Arthritis, which occurred in 9 patients.  For female patients aged 65 
to 84 years who were also living with five or more chronic diseases, the most frequent 
permutations were present in fewer than five patients.  These results are presented in Table 5.31.   
Finally, among female patients aged 85 years and older (n = 3,824 patients), the most 
commonly occurring permutation was Hypertension, and then Obesity (62 patients).  This was 
followed by the permutations of Hypertension, and then Dementia (53 patients) and 
Hypertension, and then Cardiovascular Disease (44 patients).  Among those older female patients 
with three chronic diseases, the most frequently occurring permutations were Hypertension, then 
Obesity, and then Osteoarthritis or Rheumatoid Arthritis (15 patients) and Hypertension, then 
Obesity, and then Cancer (14 patients).  For female patients aged 85 years and older who were 
living with four and five or more chronic diseases, the most frequent permutations were present 
among less than five female patients.  These results are presented in Table 5.32.   
All unique permutations found among female patients constituted mutually exclusive 
groups as the results were stratified by the total number of chronic diseases.  For example, 
among all female patients, the 177 female patients who were diagnosed with Anxiety or 
Depression, then Obesity, and then Musculoskeletal Problem (three chronic diseases) were not a 
subset of the 1,160 female patients with only Anxiety or Depression, and then Obesity (two 
chronic diseases) or the 1,094 female patients with only Musculoskeletal Problem, and then 
Obesity (two chronic diseases).  This ensured that all clusters represented unique, ordered 
clinical profiles among female patients with multimorbidity.  Likewise, patients diagnosed first 
with Obesity, and then with Anxiety or Depression represent a distinct clinical profile from those 
patients who were diagnosed first with Anxiety or Depression, and then with Obesity.  This 
ensured that all clusters were unique, ordered clinical profiles of multimorbidity. 
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Table 5.27 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
all eligible female patients with multimorbidity (n = 47,381) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female 
Patients, All Ages 
2 
(n = 19,168) 
Anxiety or Depression >> Obesity 1,160 2.4 
Musculoskeletal Problem >> Obesity 1,094 2.3 
Anxiety or Depression >> Musculoskeletal Problem 909 1.9 
Hypertension >> Obesity 836 1.8 
Musculoskeletal Problem >> Anxiety or Depression 785 1.7 
3 
(n = 12,631) 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 177 0.4 
Musculoskeletal Problem >> Obesity >> Anxiety or Depression 176 0.4 
Anxiety or Depression >> Musculoskeletal Problem >> Obesity 161 0.3 
Hypertension >> Obesity >> Musculoskeletal Problem 159 0.3 
Musculoskeletal Problem >> Anxiety or Depression >> Obesity 149 0.3 
4 
(n = 7,494) 
Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression 24 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis 18 0.0 
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia 18 0.0 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 18 0.0 
Anxiety or Depression >> Musculoskeletal Problem >> Obesity >> Cancer 18 0.0 
≥ 5  
(n = 8,088) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Table 5.28 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 18 – 34 years with multimorbidity (n = 5,565) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female Patients, 
18 – 34 Years 
2 
(n = 3,478) 
Anxiety or Depression >> Obesity 388 7.0 
Anxiety or Depression >> Musculoskeletal Problem 249 4.5 
Musculoskeletal Problem >> Obesity 245 4.4 
Musculoskeletal Problem >> Anxiety or Depression 194 3.5 
Anxiety or Depression >> Cancer 131 2.4 
3 
(n = 1,387) 
Musculoskeletal Problem >> Obesity >> Anxiety or Depression 41 0.7 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 41 0.7 
Musculoskeletal Problem >> Anxiety or Depression >> Obesity 37 0.7 
Anxiety or Depression >> Musculoskeletal Problem >> Obesity 35 0.6 
Anxiety or Depression >> Obesity >> Cancer 22 0.4 
4 
(n = 501) 
Thyroid Problem >> Anxiety or Depression >> Obesity >> Musculoskeletal Problem 5 0.1 
Results Supressed (<5 Patients) 
  
  
  
  
≥ 5  
(n = 199) 
  
  
  
  
  
* Permutations listed in sequential order 
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Table 5.29 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 35 – 44 years with multimorbidity (n = 6,747) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female Patients, 
35 – 44 Years 
2 
(n = 3,624) 
Anxiety or Depression >> Obesity 327 4.8 
Musculoskeletal Problem >> Obesity 318 4.7 
Anxiety or Depression >> Musculoskeletal Problem 256 3.8 
Musculoskeletal Problem >> Anxiety or Depression 241 3.6 
Cancer >> Obesity 161 2.4 
3 
(n = 1,859) 
Anxiety or Depression >> Musculoskeletal Problem >> Obesity 57 0.8 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 51 0.8 
Musculoskeletal Problem >> Obesity >> Anxiety or Depression 48 0.7 
Musculoskeletal Problem >> Anxiety or Depression >> Obesity 43 0.6 
Anxiety or Depression >> Obesity >> Cancer 25 0.4 
4 
(n = 792) 
Anxiety or Depression >> Musculoskeletal Problem >> Obesity >> Cancer 10 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression 6 0.1 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem >> Cancer 6 0.1 
Anxiety or Depression >> Obesity >> Cancer >> Musculoskeletal Problem 6 0.1 
Musculoskeletal Problem >> Obesity >> Anxiety or Depression >> Cancer 5 0.1 
≥ 5  
(n = 472) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Table 5.30 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 45 – 64 years with multimorbidity (n = 18,426) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female Patients, 
45 – 64 Years 
2 
(n = 7,516) 
Musculoskeletal Problem >> Obesity 456 2.5 
Anxiety or Depression >> Obesity 400 2.2 
Anxiety or Depression >> Musculoskeletal Problem 365 2.0 
Hypertension >> Obesity 340 1.8 
Musculoskeletal Problem >> Anxiety or Depression 309 1.7 
3 
(n = 5,171) 
Hypertension >> Obesity >> Musculoskeletal Problem 87 0.5 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 80 0.4 
Musculoskeletal Problem >> Obesity >> Anxiety or Depression 78 0.4 
Anxiety or Depression >> Musculoskeletal Problem >> Obesity 65 0.4 
Musculoskeletal Problem >> Anxiety or Depression >> Obesity 63 0.3 
4 
(n = 2,981) 
Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression 14 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia 10 0.1 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 10 0.1 
Musculoskeletal Problem >> Obesity >> Hypertension >> Anxiety or Depression 9 0.0 
Musculoskeletal Problem >> Obesity >> Osteoarthritis or Rheumatoid Arthritis >> Anxiety or 
Depression 
9 0.0 
≥ 5  
(n = 2,758) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Table 5.31 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 65 – 84 years with multimorbidity (n = 12,819) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female Patients, 
65 – 84 Years 
2 
(n = 3,467) 
Hypertension >> Obesity 322 2.5 
Hypertension >> Musculoskeletal Problem 102 0.8 
Hypertension >> Hyperlipidemia 98 0.8 
Hypertension >> Cancer 97 0.8 
Diabetes >> Obesity 97 0.8 
3 
(n = 3,257) 
Hypertension >> Obesity >> Hyperlipidemia 48 0.4 
Hypertension >> Obesity >> Musculoskeletal Problem 46 0.4 
Diabetes >> Obesity >> Hypertension 42 0.3 
Hypertension >> Obesity >> Cancer 38 0.3 
Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis 34 0.3 
4 
(n = 2,527) 
Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis 9 0.1 
Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis >> Musculoskeletal Problem 8 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia 8 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Cancer 7 0.1 
Hypertension >> Obesity >> Hyperlipidemia >> Osteoarthritis or Rheumatoid Arthritis 7 0.1 
≥ 5  
(n = 3,568) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Table 5.32 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible female patients aged 85 years and older with multimorbidity (n = 3,824) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female 
Patients, ≥ 85 Years 
2 
(n = 1,083) 
Hypertension >> Obesity 62 1.6 
Hypertension >> Dementia 53 1.4 
Hypertension >> Cardiovascular Disease 44 1.2 
Hypertension >> Cancer 37 1.0 
Hypertension >> Osteoarthritis or Rheumatoid Arthritis 33 0.9 
3 
(n = 957) 
Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis 15 0.4 
Hypertension >> Obesity >> Cancer 14 0.4 
Hypertension >> Obesity >> Musculoskeletal Problem 12 0.3 
Hypertension >> Osteoarthritis or Rheumatoid Arthritis >> Obesity 9 0.2 
Hypertension >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis 8 0.2 
4 
(n = 693) 
Results Supressed (<5 Patients) 
  
  
  
  
  
≥ 5  
(n = 1,091) 
  
  
  
  
  
* Permutations listed in sequential order 
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Most Frequently Occurring Permutations Among Male Patients  
The most frequently occurring permutations were explored according to patient age and 
total number of chronic diseases among male patients.  These results include only those chronic 
diseases that had at least one day elapsing between the associated dates of diagnoses.  Among 
adult male patients of all ages (n = 30,478 patients), the most common permutation of chronic 
diseases was Musculoskeletal Problem, and then Obesity (1,051 patients).  This meant that 1,051 
male patients were first diagnosed with Musculoskeletal Problem, and then Obesity and with that 
specific sequence.  This was followed by a permutation of Hypertension, and then Obesity (880 
patients) and Anxiety or Depression, and then Obesity (618 patients).  Among patients with three 
chronic diseases, the most common permutation was Hypertension, then Obesity, and then 
Hyperlipidemia (162 patients).  For patients with four chronic disease diagnoses, the most 
frequently occurring permutation was Hypertension, then Obesity, then Hyperlipidemia, and then 
Musculoskeletal Problem (19 patients).  Lastly, for male patients living with five or more chronic 
diseases, the common permutations were present among less than five male patients.  These 
results are presented in Table 5.33.  
Among the youngest group of male patients aged 18 to 34 years (n = 2,624 patients), the 
most commonly occurring permutation was again Musculoskeletal Problem, and then Obesity, 
which was present among 216 patients.  The next two commonly occurring permutations were 
Anxiety or Depression, and then Obesity (187 patients) and Anxiety or Depression, and then 
Musculoskeletal Problem (161 patients).  Among those male patients with three chronic diseases, 
the most frequently occurring permutation was Anxiety or Depression, then Obesity, and then 
Musculoskeletal Problem (22 patients).  For male patients aged 18 to 34 years who were living 
with four and five or more chronic diseases, the most common permutations were detected in 
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fewer than five patients, indicating increasingly unique clinical profiles in these young, yet 
complex male patients.  These results are presented in Table 5.34.   
Among male patients aged 35 to 44 years (n = 3,583 patients), the most commonly 
occurring permutation was Musculoskeletal Problem, and then Obesity (291 patients).  This was 
followed by the permutation of Anxiety or Depression, and then Obesity (174 patients) and 
Musculoskeletal Problem, and then Anxiety or Depression (135 patients).  Among those male 
patients with three chronic diseases, the most frequently occurring permutation was Anxiety or 
Depression, then Obesity, and then Musculoskeletal Problem (31 patients).  Lastly, for male 
patients aged 35 to 44 years who were living with four and five or more chronic diseases, the 
permutations that were detected were only present among less than five patients.  These results 
are presented in Table 5.35.   
For male patients aged 45 to 64 years (n = 12,372 patients), the most commonly 
occurring permutation was Musculoskeletal Problem, and then Obesity (473 patients).  This was 
followed by a permutation of Hypertension, and then Obesity (432 patients) and Anxiety or 
Depression, and then Obesity (228 patients).  Among those male patients with three chronic 
diseases, the most frequently occurring permutation was Hypertension, then Obesity, and then 
Hyperlipidemia, which occurred among 94 patients.  For these middle-aged male patients with 
four chronic disease diagnoses, the most common permutations were Hypertension, then 
Obesity, then Hyperlipidemia, and then Musculoskeletal Problem (10 patients) and 
Musculoskeletal Problem, then Obesity, then Hypertension, and then Hyperlipidemia (10 
patients).  For male patients aged 45 to 64 years who were living with five or more chronic 
diseases, the most frequent permutations were detected in less than five patients and these results 
were supressed.  These results are presented in Table 5.36.   
164 
 
Among male patients aged 65 to 84 years (n = 9,652 patients), the most commonly 
occurring permutation was Hypertension, and then Obesity (278 patients).  This was followed by 
the permutation of Diabetes, and then Obesity (175 patients) and Hypertension, and then 
Hyperlipidemia (79 patients).  Among those male patients with three chronic diseases, the most 
frequently occurring permutations were Diabetes, then Obesity, and then Hypertension (56 
patients) and Hypertension, then Obesity, and then Musculoskeletal Problem (55 patients).  For 
patients with four chronic disease diagnoses, the most common permutations were Hypertension, 
then Obesity, then Musculoskeletal Problem, and then Cancer, which occurred among 9 male 
patients.  For male patients aged 65 to 84 years who were living with five or more chronic 
diseases, there were a number of permutations that were present among groups of fewer than five 
male patients.  These results are presented in Table 5.37.   
Finally, among male patients aged 85 years and older (n = 2,247 patients), the most 
commonly occurring permutation was Hypertension, and then Obesity (41 patients).  This was 
followed by the permutations of Hypertension, and then Cancer (30 patients) and Hypertension, 
and then Cardiovascular Disease (22 patients).  Among those older male patients with three 
chronic diseases, the most frequently occurring permutations were Diabetes, then Obesity, and 
then Hypertension (12 patients) and Hypertension, then Obesity, and then Musculoskeletal 
Problem (9 patients).  For male patients aged 85 years and older who were living with four and 
five or more chronic diseases, the most common permutations occurred among fewer than five 
patients.  These results are presented in Table 5.38.   
Similar to the combination analysis, all unique permutations found among male patients 
constituted mutually exclusive groups as the results were stratified by the total number of chronic 
diseases a patient had by the end of the observation period.  For example, among male patients of 
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all ages, the 162 patients who were diagnosed with Hypertension, then Obesity, and then 
Hyperlipidemia (three chronic diseases) or the 132 patients who were diagnosed with 
Hypertension, then Obesity, and then Musculoskeletal Problem (three chronic diseases) were not 
a subset of the 880 patients who were diagnosed first with Hypertension, and then with Obesity.  
Likewise, patients diagnosed first with Obesity, and then with Hypertension represent a distinct 
clinical profile from those patients who were diagnosed first with Hypertension, and then with 
Obesity.  This ensured that all clusters represented unique, ordered clinical profiles among male 
patients with multimorbidity. 
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Table 5.33 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
all eligible male patients with multimorbidity (n = 30,478) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male 
Patients, All Ages 
2 
(n = 12,557) 
Musculoskeletal Problem >> Obesity 1,051 3.4 
Hypertension >> Obesity 880 2.9 
Anxiety or Depression >> Obesity 618 2.0 
Diabetes >> Obesity 458 1.5 
Musculoskeletal Problem >> Anxiety or Depression 451 1.5 
3 
(n = 8,158) 
Hypertension >> Obesity >> Hyperlipidemia 162 0.5 
Hypertension >> Obesity >> Musculoskeletal Problem 132 0.4 
Diabetes >> Obesity >> Hypertension 110 0.4 
Musculoskeletal Problem >> Obesity >> Hypertension 103 0.3 
Hypertension >> Obesity >> Diabetes 97 0.3 
4 
(n = 4,190) 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 19 0.1 
Diabetes >> Obesity >> Musculoskeletal Problem >> Hypertension 15 0.0 
Hypertension >> Obesity >> Musculoskeletal Problem >> Cancer 14 0.0 
Hypertension >> Obesity >> Hyperlipidemia >> Diabetes 14 0.0 
Hypertension >> Obesity >> Diabetes >> Musculoskeletal Problem 13 0.0 
≥ 5  
(n = 4,853) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Table 5.34 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 18 – 34 years with multimorbidity (n = 2,624) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients, 
18 – 34 Years 
2 
(n = 1,878) 
Musculoskeletal Problem >> Obesity 216 8.2 
Anxiety or Depression >> Obesity 187 7.1 
Anxiety or Depression >> Musculoskeletal Problem 161 6.1 
Musculoskeletal Problem >> Anxiety or Depression 152 5.8 
Chronic Obstructive Pulmonary Disease or Asthma >> Obesity 62 2.4 
3 
(n = 573) 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 22 0.8 
Anxiety or Depression >> Musculoskeletal Problem >> Obesity 17 0.6 
Musculoskeletal Problem >> Anxiety or Depression >> Obesity 16 0.6 
Musculoskeletal Problem >> Obesity >> Anxiety or Depression 14 0.5 
Chronic Obstructive Pulmonary Disease or Asthma >> Musculoskeletal Problem >> Anxiety or Depression 11 0.4 
4 
(n = 135) 
Results Supressed (<5 Patients) 
  
  
  
  
  
≥ 5  
(n = 38) 
  
  
  
  
  
* Permutations listed in sequential order 
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Table 5.35 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 35 – 44 years with multimorbidity (n = 3,583) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients, 
35 – 44 Years 
2 
(n = 2,139) 
Musculoskeletal Problem >> Obesity 291 8.1 
Anxiety or Depression >> Obesity 174 4.9 
Musculoskeletal Problem >> Anxiety or Depression 135 3.8 
Anxiety or Depression >> Musculoskeletal Problem 128 3.6 
Hypertension >> Obesity 99 2.8 
3 
(n = 945) 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 31 0.9 
Musculoskeletal Problem >> Obesity >> Anxiety or Depression 27 0.8 
Musculoskeletal Problem >> Anxiety or Depression >> Obesity 24 0.7 
Musculoskeletal Problem >> Obesity >> Cancer 21 0.6 
Musculoskeletal Problem >> Obesity >> Hypertension 17 0.5 
4 
(n = 352) 
Results Supressed (<5 Patients) 
  
  
  
  
  
≥ 5  
(n = 147) 
  
  
  
  
  
* Permutations listed in sequential order 
169 
 
Table 5.36 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 45 – 64 years with multimorbidity (n = 12,372) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients, 
45 – 64 Years 
2 
(n = 5,237) 
Musculoskeletal Problem >> Obesity 473 3.8 
Hypertension >> Obesity 432 3.5 
Anxiety or Depression >> Obesity 228 1.8 
Diabetes >> Obesity 201 1.6 
Hyperlipidemia >> Obesity 184 1.5 
3 
(n = 3,644) 
Hypertension >> Obesity >> Hyperlipidemia 94 0.8 
Musculoskeletal Problem >> Obesity >> Hyperlipidemia 69 0.6 
Musculoskeletal Problem >> Obesity >> Hypertension 67 0.5 
Hypertension >> Obesity >> Musculoskeletal Problem 58 0.5 
Hypertension >> Obesity >> Diabetes 52 0.4 
4 
(n = 1,992) 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 10 0.1 
Musculoskeletal Problem >> Obesity >> Hypertension >> Hyperlipidemia 10 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia 8 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Diabetes 7 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression 7 0.1 
≥ 5  
(n = 1,499) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Table 5.37 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 65 – 84 years with multimorbidity (n = 9,652) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients, 
65 – 84 Years 
2 
(n = 2,696) 
Hypertension >> Obesity 278 2.9 
Diabetes >> Obesity 175 1.8 
Hypertension >> Hyperlipidemia 79 0.8 
Hypertension >> Cancer 78 0.8 
Cardiovascular Disease >> Obesity 67 0.7 
3 
(n = 2,460) 
Diabetes >> Obesity >> Hypertension 56 0.6 
Hypertension >> Obesity >> Musculoskeletal Problem 55 0.6 
Hypertension >> Obesity >> Hyperlipidemia 54 0.6 
Hypertension >> Obesity >> Cancer 37 0.4 
Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis 36 0.4 
4 
(n = 1,995) 
Hypertension >> Obesity >> Musculoskeletal Problem >> Cancer 9 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis 8 0.1 
Hypertension >> Obesity >> Hyperlipidemia >> Urinary Problem 8 0.1 
Hypertension >> Diabetes >> Hyperlipidemia >> Obesity 8 0.1 
Diabetes >> Obesity >> Hypertension >> Musculoskeletal Problem 8 0.1 
≥ 5  
(n = 2,501) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Table 5.38 Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
eligible male patients aged 85 years and older with multimorbidity (n = 2,247) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients, 
≥ 85 Years 
2 
(n = 607) 
Hypertension >> Obesity 41 1.8 
Hypertension >> Cancer 30 1.3 
Hypertension >> Cardiovascular Disease 22 1.0 
Diabetes >> Obesity 17 0.8 
Hypertension >> Osteoarthritis or Rheumatoid Arthritis 14 0.6 
3 
(n = 536) 
Diabetes >> Obesity >> Hypertension 12 0.5 
Hypertension >> Obesity >> Musculoskeletal Problem 9 0.4 
Hypertension >> Obesity >> Cancer 8 0.4 
Diabetes >> Hypertension >> Obesity 8 0.4 
Hypertension >> Obesity >> Dementia 7 0.3 
4 
(n = 436) 
Results Supressed (<5 Patients) 
  
  
  
  
  
≥ 5  
(n = 668) 
  
  
  
  
  
* Permutations listed in sequential order 
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5.2 Objective Two 
The results for Objective Two describe the time elapsing between chronic disease 
diagnoses among patients with at least one chronic disease.  These results will describe the mean 
time until subsequent chronic disease diagnosis, an assessment of whether this mean time 
decreases as the number of chronic disease diagnoses increases, and whether other factors (e.g., 
patient age, patient sex, patient residential location, patient median household income, total 
number of chronic diseases, provider age, provider sex, practice EMR type and practice location) 
influence the mean time until subsequent chronic disease diagnosis.   
 
5.2.1 Patient Sample Characteristics  
The characteristics of patients with one or more chronic disease diagnoses (n = 286,998 
patients) and two or more chronic disease diagnoses (n = 195,838 patients) are presented in 
Table 5.39 to Table 5.41.  For Research Question 1 and Research Question 3, the sample was 
derived from all adult patients with at least one chronic disease diagnoses as of September 30, 
2013.  However, for Research Question 2, the sample was focused on those adult patients with at 
least two chronic disease diagnoses.  As described previously in the Methodology Chapter, all 
analyses for Objective Two were conducted using those chronic diseases (or data points) that had 
at least one day elapsing between diagnoses.   
Overall, the patients with one or more chronic diseases were a mean age of 55.3 years 
(SD: 17.8 years), with a range from 18 to 114 years.  The majority of patients were female 
(57.5%) and were between the ages of 45 and 64 years (39.2%).  Slightly more than half of these 
patients (51.4%) were living in an urban setting and the median of the median household income 
was found to be $60,310 per year (Canadian dollars), ranging from as low as $22,457 to as much 
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as $181,454 per year.  Approximately one-third of patients did not have data recorded for their 
residential postal code, and therefore their median household income could not be determined.  
The mean number of chronic diseases these patients were living with was 2.6 (SD: 1.6) with a 
range from those patients living with one chronic disease to fourteen chronic diseases.  These 
characteristics can be seen in Table 5.39.   
 The characteristics of patients with two or more chronic diseases were previously 
presented for Objective One and are presented again in Table 5.39.  These patients had a mean 
age of 59.0 years (SD: 17.0 years), with a range between 18 and 114 years.  The majority of 
patients were female (57.8%) and were between 45 and 64 years of age (40.6%).  Approximately 
52% of these patients were living in an urban setting and the median of the median household 
income was found to be $60,952 per year (Canadian dollars).  Once again, approximately one-
third of patients did not have data recorded for their residential postal code, and therefore their 
median household income could not be determined.  The mean number of chronic diseases these 
patients were living with was 3.3 (SD: 1.5) with a range from those patients living with two 
chronic diseases to fourteen chronic diseases.   
 The demographic characteristics of the PHC providers who were caring for these two 
patient groups are presented in Table 5.40.  For patients with one or more chronic diseases, 
about one-quarter (25.3%) were being cared for by PHC providers who were aged 45 to 64 years.  
These PHC providers had a mean age of 50.8 years (SD: 10.3 years).  About 28.9% of patients 
with one or more chronic diseases were being cared for by male PHC providers.  For patients 
with two or more chronic diseases, about 25.5% were being cared for by PHC providers who 
were aged 45 to 64 years, these PHC providers had a mean age of 51.2 years (SD: 10.2 years) 
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and about 29.8% of patients with two or more chronic diseases were being cared for by male 
PHC providers.   
 
Table 5.39 Patient-level characteristics of the two groups of adult patients (those with one 
or more and two or more chronic diseases) for Objective Two  
Patient-Level Variable 
Patients with One or More 
Chronic Diseases  
(n = 286,998) 
Patients with Two or More  
Chronic Diseases  
(n = 195,838)  
Age (Years), n (%) 
Mean (SD) 55.3 Years (17.8 Years) 59.0 Years (17.0 Years) 
Range (Minimum – Maximum)  18 Years – 114 Years 18 Years – 114 Years 
18 – 34 41,980 (14.6%) 17,466 (8.9%) 
35 – 44 43,450 (15.1%) 23,855 (12.2%) 
45 – 64 112,354 (39.2%) 79,571 (40.6%) 
65 – 84 71,808 (25.0%) 60,696 (31.0%) 
≥ 85 17,406 (6.1%) 14,250 (7.3%) 
Sex, n (%) 
Female 165,111 (57.5%) 113,209 (57.8%) 
Male 121,870 (42.5%) 82,622 (42.2%) 
Residential Location, n (%) 
Rural  44,741 (15.6%) 32,607 (16.7%) 
Urban  147,501 (51.4%) 102,151 (52.2%) 
Missing 94,756 (33.0%) 61,080 (31.2%) 
Median Household Income (Canadian Dollars) 
Median (IQR) $60,310 ($$12,497) $60,952 ($12,497) 
Range (Minimum – Maximum)  $22,457 – $181,454 $22,457 – $181,454 
Missing (%) 95,092 (33.1%) 61,263 (31.3%) 
Total Number of Chronic Diseases 
Mean (SD) 2.6 (1.6) 3.3 (1.5) 
Range (Minimum – Maximum)  1 – 14 2 – 14  
* SD = Standard deviation, CI = Confidence interval, IQR = Interquartile range 
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Table 5.40 Characteristics of PHC providers caring for the two groups of adult patients 
(those with one or more and two or more chronic diseases) for Objective Two  
Provider-Level Variable 
Patients with One or More  
Chronic Diseases 
(n = 286,998) 
Patients with Two or More 
Chronic Diseases 
(n = 195,838) 
Age (Years), n (%) 
Mean (SD) 50.8 Years (10.3 Years) 51.2 Years (10.2 Years) 
Range (Minimum – Maximum)  27 Years – 72 Years 27 Years – 72 Years 
25 – 44 35,020 (12.2%) 22,402 (11.4%) 
45 – 64  72,662 (25.3%) 49,871 (25.5%) 
≥ 65  10,681 (3.7%) 7,730 (4.0%) 
Missing 168,635 (58.8%) 115,835 (59.2%) 
Sex, n (%) 
Female 61,082 (21.3%) 39,517 (20.2%) 
Male 83,017 (28.9%) 58,364 (29.8%) 
Missing 142,899 (49.8%) 97,957 (50.0%) 
* SD = Standard deviation, CI = Confidence interval 
 
The characteristics of the PHC practices where these two patient groups were cared for 
are presented in Table 5.41.  Among adult patients with one or more chronic diseases, 25.6% 
came from PHC practices that were using the Nightingale EMR software.  This was followed by 
clinical data recorded using the Wolf (9.0%), Accuro (8.5%) and Bell (7.4%) EMR software 
programs.  The majority of these patients (57.2%) received care from urban PHC practices, 
according to the first three letters of the practices’ postal code.  The largest proportion of patients 
belonged to Network 4 (21.4%) and Network 5 (24.4%), which were located in Central Ontario 
and Eastern Ontario, respectively.  While all adult PHC patients were allocated to one of the ten 
CPCSSN Networks, approximately one-third of patients were missing data for both the EMR 
software type and practice location variables.   
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Table 5.41 Characteristics of PHC practices caring for the two groups of adult patients 
(those with one or more and two or more chronic diseases) for Objective Two  
Practice-Level Variable 
Patients with One or More 
Chronic Diseases 
(n = 286,998) 
Patients with Two or More  
Chronic Diseases 
(n = 195,838) 
EMR Type, n (%) 
Accuro 24,324 (8.5%) 16,001 (8.2%) 
Bell 21,247 (7.4%) 15,601 (8.0%) 
DaVinci 824 (0.3%) 376 (0.2%) 
Jonoke 16,399 (5.7%) 12,953 (6.6%) 
Med Access 8,676 (3.0%) 6,437 (3.3%) 
Nightingale 73,328 (25.6%) 50,998 (26.0%) 
Oscar 11,177 (3.9%) 6,208 (3.2%) 
Practice Solutions 14,111 (4.9%) 8,723 (4.5%) 
Wolf 25,713 (9.0%) 18,732 (9.6%) 
Xwave 680 (0.2%) 528 (0.3%) 
Missing 90,519 (31.5%) 59,281 (30.3%) 
Practice Location, n (%) 
Rural  26,450 (9.2%) 19,471 (9.9%) 
Urban  164,048 (57.2%) 113,120 (57.8%) 
Missing 96,500 (33.6%) 63,247 (32.3%) 
CPCSSN Network, n (%) 
1 30,128 (10.5%) 21,060 (10.8%) 
2 15,344 (5.4%) 11,081 (5.7%) 
3 5,897 (2.1%) 4,801 (2.5%) 
4 61,403 (21.4%) 38,797 (19.8%) 
5 70,098 (24.4%) 47,986 (24.5%) 
6 1,900 (0.7%) 814 (0.4%) 
7 25,883 (9.0%) 17,218 (8.8%) 
8 27,278 (9.5%) 20,374 (10.4%) 
9 40,003 (13.9%) 27,656 (14.1%) 
10 9,064 (3.2%) 6,051 (3.1%) 
* SD = Standard deviation, CI = Confidence interval 
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5.2.2 Objective Two, Research Question 1 – Time Until Multimorbidity   
 To address Research Question 1, the median and mean time until the second chronic 
disease diagnoses were explored for all adult patients with at least one chronic disease as of 
September 30, 2013.  As described previously in the Methodology Chapter, this included only 
those chronic diseases in which at least one day elapsed between diagnoses.  As such, the data 
points that reported zero days elapsing between diagnoses were removed.  A descriptive analysis 
was conducted to determine the time elapsing (in days) between the first (X1) and second (X2) 
chronic diseases.  This time from morbidity to multimorbidity or “Time Until Multimorbidity” is 
presented in Table 5.42 and has been stratified by patient age and patient sex.   
These results indicate that the time elapsing until the onset of multimorbidity decreased 
between the youngest and oldest age groups: a decrease of 200 days among female patients and a 
decrease of 150 days among male patients.  For example, among female patients aged 18 to 34 
years, the median time elapsing between the first and second chronic disease diagnoses was 
301.7 days, as compared to a median time of 97.4 days among female patients aged 85 years and 
older.  Similarly, among male patients aged 18 to 34 years, the median time until the onset of 
multimorbidity was 249.0 days, while among male patients aged 85 years and older the median 
time was only 93.0 days.  For patients aged 35 to 44 years, the median time elapsing until the 
second chronic disease diagnosis was 308.3 days among females and 244.0 days among males.  
For patients aged 45 to 64 years, the median time elapsing between the first and second chronic 
disease diagnoses was 224.3 days among females and 149.8 days among males.  Finally, among 
patients aged 65 to 84 years, the median time elapsing until the second chronic disease was 114.6 
days among females and 83.0 days among males.  Interestingly, the median time elapsing until 
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multimorbidity was 10 days shorter among males aged 65 to 84 years, as compared to males 
aged 85 years and older.   
 The “Time Until Multimorbidity” was also explored by the first or index chronic disease 
type, and these results were stratified by patient age and patient sex.  Table 5.43 presents the 
index chronic disease types that led to the quickest and slowest accumulation of the next chronic 
disease.  For patients aged 18 to 34 years, both female and male patients progressed most quickly 
to the second chronic disease when they were first diagnosed with Diabetes (median of 131.0 
days and 30.8 days, respectively).  In comparison, female patients aged 35 to 44 years progressed 
most quickly to the next chronic disease when they were first diagnosed with Stroke or Transient 
Ischemic Attack (median of 79.3 days) and male patients aged 35 to 44 years progressed quickly 
when they first experienced Heart Failure (median of 69.6 days).  Progression to the second 
chronic disease occurred the quickest after first being diagnosed with Diabetes for female 
patients aged 45 to 64 years (median of 50.1 days), 65 to 84 years (median of 39.5 days) and 85 
years and older (median of 46.5 days).  A similar quick progression was seen among male 
patients aged 45 to 64 years and 65 to 84 years who were first diagnosed with Diabetes (median 
of 44.4 days and 32.0 days, respectively).  Finally, among male patients aged 85 years and older, 
the quickest accumulation occurred for those patients who were first diagnosed with Stroke or 
Transient Ischemic Attack (median of 18.5 days).  
The index chronic disease types that led to the slowest accumulation of the second 
chronic disease diagnosis was also explored in Table 5.43.  For patients aged 18 to 34 years, the 
longest median time until multimorbidity was observed among female patients who were first 
diagnosed with Osteoporosis (median time of 921.4 days) and male patients who were first 
diagnosed with Stroke or Transient Ischemic Attack (median of 1,993.1 days).  For patients aged 
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35 to 44 years, the slowest accumulation to the second chronic disease was seen among female 
patients who were first diagnosed with Heart Failure (median time of 935.0 days) and male 
patients who were first diagnosed with Liver Disease (median of 627.0 days).  Among patients 
aged 45 to 64 years, both female and male patients had the longest median time until 
multimorbidity when they were first diagnosed with Dementia (median time of 603.3 days and 
369.0 days, respectively).  Progression to the second chronic disease occurred the slowest after 
first being diagnosed with Kidney Disease or Failure for female patients aged 65 to 84 years and 
85 years and older (median time of 680.4 days and 449.7 days, respectively).  Male patients aged 
65 to 74 years experienced the longest time until multimorbidity when they were first diagnosed 
with Dementia (266.0 days).  Male patients aged 85 years and older had the longest median time 
(260.5 days) until the second chronic disease after first being diagnosed with Osteoporosis.   
To assess the differences that occur when excluding data points in which the time 
elapsing between diagnoses was zero days, the same analysis was conducted for all patients and 
for all data points (that is, when time elapsing between chronic disease diagnoses was equal to 
zero days).  These results are included in Appendix AI.  After including these data points, the 
same patterns of time elapsing until multimorbidity were observed, while the median and mean 
time elapsing between chronic disease diagnoses were notably lower as compared to the 
estimates presented in Table 5.42.  For example, within the sensitivity analysis, male patients 
aged 18 to 34 years had a median time of only 87.0 days (mean of 424.1 days) until the second 
chronic disease, as compared a median time of 249.0 days (mean of 534.1 days) in the original 
analysis.  A similar pattern was observed for all remaining patient categories, indicating the 
impact of removing those data points where the time elapsing between diagnoses was equal to 
zero days.  
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Table 5.42 Time (in days) until subsequent chronic disease diagnosis, stratified by patient age category (years), patient sex and 
total number of chronic diseases 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
T1  T2 
(n = 238,237) 
301.7 
537.1 
(635.4) 
308.3 
569.7 
(688.9) 
224. 3 
521.6 
(707.0) 
114.6 
407.2 
(677.4) 
97.4  
366.4 
(638.6) 
249.0 
534.1 
(692.1) 
244.0 
525.2 
(694.2) 
149.8 
473.5 
(695.4) 
83.0 
387.9 
(682.3) 
93.0 
363.4 
(646.7) 
T2  T3 
(n = 141,684) 
377.9 
561.1 
(598.8) 
396.0 
606.0 
(667.1) 
342.0 
562.3 
(667.1) 
238.5 
466.6 
(617.6) 
202.4 
398.1 
(519.3) 
364.8 
565.7 
(667.3) 
365.0  
577.2 
(680.7) 
321.0  
544.0  
(661.3) 
239.0  
473.8 
(649.3) 
211.0  
406.0 
(542.0) 
T3  T4 
(n = 82,373) 
343.2 
488.8 
(486.7) 
357.0  
522.4 
(533.4) 
304.1 
473.0 
(506.7) 
248.0 
408.6 
(460.3) 
238.1 
398.9 
(453.1) 
340.0 
524.2 
(556.2) 
326.9 
508.2 
(547.6) 
311.0  
484.3 
(530.1) 
252.0 
421.8 
(490.7) 
236.5 
389.0 
(443.6) 
T4  T5 
(n = 44,255) 
292.0 
439.1 
(462.6) 
360.0 
514.0 
(516.2) 
294.0 
454.7 
(485.3) 
260.0  
402.1 
(435.4) 
245.9  
392.4 
(427.2) 
349.2  
458.8 
(430.0) 
301.4  
489.4 
(529.1) 
320.0  
469.9 
(487.3) 
278.0  
424.1 
(466.2) 
251.4  
406.1 
(462.6) 
T5  T6 
(n = 22,035) 
283.0 
395.5 
(388.5) 
358.1 
496.7 
(477.7) 
289.8 
433.9 
(451.3) 
266.7  
398.6  
(424.6) 
274.5 
417.5 
(445.4) 
276.9 
441.4 
(492.3) 
316.5 
461.2 
(472.4) 
301.0 
451.8 
(485.5) 
275.1  
417.2 
(444.8) 
259.7 
398.4 
(446.5) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red 
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Table 5.43 Time (in days) until multimorbidity, stratified by patient age category (years), patient sex and index chronic disease 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
Hypertension  T2 184.8 
448.2 
(591.1) 
193.0 
442.6 
(583.2) 
102.0 
368.8 
(616.2) 
68.8 
304.5 
(582.9) 
70.0 
278.8 
(551.4) 
127.1 
474.8 
(709.8) 
76.7 
386.4 
(635.0) 
57.8 
348.4 
(607.8) 
44.0 
286.2 
(582.9) 
62.6 
292.6 
(581.7) 
Obesity  T2 165.0 
280.4 
(371.1) 
169.0 
383.9 
(499.5) 
132.5 
370.8 
(536.9) 
50.6 
274.8 
(479.4) 
133.6 
184.3 
(203.9) 
268.8 
571.6 
(791.3) 
163.5 
437.7 
(669.1) 
175.7 
410.2 
(540.9) 
123.3 
182.2 
(235.3) 
Results 
Suppresse
d 
Diabetes  T2 131.0 
437.8 
(677.8) 
196.5 
488.4 
(694.8) 
50.1 
321.3 
(574.5) 
39.5 
316.8 
(653.5) 
46.5 
327.8 
(639.6) 
30.8 
284.6 
(551.8) 
75.0 
362.9 
(608.0) 
44.4 
319.6 
(580.8) 
32.0 
258.6 
(542.2) 
59.1 
306.5 
(610.2) 
Chronic Obstructive Pulmonary 
Disease or Asthma  T2 
216.5 
433.1 
(566.3) 
286.0 
526.5 
(646.8) 
219.9 
496.5 
(732.1) 
153.2 
410.6 
(650.0) 
91.7 
415.4 
(692.3) 
154.7 
390.0 
(558.6) 
218.1 
474.6 
(631.6) 
193.5 
500.0 
(742.8) 
130.1 
475.7 
(809.4) 
109.3 
309.2 
(517.4) 
Hyperlipidemia  T2 238.6 
580.6 
(766.0) 
209.6 
483.6 
(614.6) 
178.6 
459.3 
(675.2) 
103.1 
344.0 
(540.3) 
47.3 
254.8 
(526.4) 
126.1 
372.5 
(559.9) 
150.0 
414.0 
(577.1) 
99.0 
404.7 
(629.7) 
62.6 
325.6 
(573.0) 
88.0 
280.9 
(427.6) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red for each patient category
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Table 5.43 Time (in days) until multimorbidity, stratified by patient age category (years), patient sex and index chronic 
disease, Continued 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
Cancer  T2 321.5 
525.5  
(617.8) 
350.8 
601.8 
(689.6) 
311.9 
579.5 
(724.5) 
168.6 
484.3 
(761.1) 
107.0 
389.9 
(630.1) 
217.5 
509.6 
(692.2) 
238.0 
528.0 
(691.9) 
183.4 
496.9 
(693.8) 
100.5 
446.6 
(731.2) 
103.7 
423.9 
(749.3) 
Cardiovascular Disease  T2 429.5 
613.3 
(672.2) 
336.5 
635.9 
(722.5) 
354.6 
642.2 
(757.0) 
175.0 
492.3 
(715.3) 
139.7 
449.0 
(725.4) 
275.7 
579.6 
(759.7) 
398.0 
546.9 
(607.6) 
239.5 
591.8 
(778.3) 
111.9 
492.4 
(813.4) 
83.5 
391.7 
(675.4) 
Heart Failure  T2 201.5 
298.1 
(363.2) 
935.0 
820.7 
(306.8) 
259.0 
581.0 
(982.8) 
65.0 
391.0 
(672.8) 
152.0 
372.6 
(565.4) 
141.9 
561.3 
(1,010.2) 
69.6 
140.5 
(201.3) 
116.6 
524.8 
(842.2) 
189.0 
433.9 
(636.2) 
87.6 
332.1 
(542.7) 
Anxiety or Depression  T2 278.4 
534.6 
(640.9) 
281.3 
548.8 
(675.5) 
240.0 
540.7 
(692.0) 
174.3 
476.7 
(746.1) 
118.9 
446.2 
(777.5) 
237.7 
518.4 
(662.0) 
244.0 
533.5 
(713.4) 
167.6 
481.0 
(684.1) 
134.1 
507.0 
(757.4) 
207.7 
520.7 
(690.3) 
Osteoarthritis or Rheumatoid 
Arthritis  T2 
249.3 
523.3 
(612.2) 
428.0 
618.5 
(684.4) 
328.6 
640.4 
(785.7) 
219.6 
555.9 
(798.2) 
201.6 
569.0 
(775.7) 
349.4 
667.6 
(799.0) 
305.5 
616.4 
(767.7) 
301.4 
634.7 
(799.4) 
199.7 
600.7 
(875.7) 
254.6 
571.6 
(831.2) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red for each patient category
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Table 5.43 Time (in days) until multimorbidity, stratified by patient age category (years), patient sex and index chronic 
disease, Continued 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
Stroke or Transient Ischemic 
Attack  T2 
Results 
Supressed 
79.3 
155.4 
(219.4) 
220.5 
764.8 
(949.8) 
347.4 
784.9 
(931.4) 
399.5 
662.5 
(842.5) 
1,993.1 
1,569.4 
(1,406.2) 
Results 
Supressed 
153.4 
421.0 
(555.5) 
124.8 
371.0 
(544.5) 
18.5 
291.4 
(689.2) 
Thyroid Problem  T2 218.8 
448.6 
(580.3) 
189.0 
448.2 
(611.6) 
154.0 
438.8 
(644.3) 
96.5 
349.1 
(604.2) 
71.0 
344.5 
(671.5) 
153.5 
392.9 
(636.7) 
110.4 
353.3 
(616.7) 
104.8 
440.6 
(701.5) 
153.6 
382.7 
(524.4) 
81.0 
429.6 
(739.6) 
Kidney Disease or Failure  T2 325.0 
325.0 
(321.5) 
263.0 
464.3 
(552.0) 
134.6 
230.2 
(243.1) 
680.4 
1,049.3 
(1,182.4) 
449.7 
860.7 
(1,039.57) 
31.8 
73.4 
(106.9) 
157.5 
143.4 
(95.7) 
239.6 
683.2 
(893.1) 
97.5 
595.5 
(934.2) 
20.2 
154.9 
(308.1) 
Osteoporosis  T2 921.4 
1,041.3 
(901.2) 
354.0 
590.4 
(660.6) 
258.2 
508.5 
(641.3) 
151.4 
392.3 
(524.2) 
100.0 
313.8 
(495.5) 
55.9 
119.5 
(165.3) 
274.2 
274.2 
(383.6) 
187.3 
388.1 
(502.2) 
96.3 
288.7 
(404.9) 
260.5 
361.4 
(364.2) 
Dementia  T2 669.7 
757.6 
(454.0) 
143.4 
406.6 
(777.2) 
503.3 
681.5 
(835.6) 
125.3 
497.8 
(806.4) 
128.0 
371.9 
(585.5) 
1,002.0 
888.9 
(683.0) 
574.0 
769.7 
(650.4) 
369.0 
633.6 
(734.7) 
266.0 
528.1 
(675.8) 
115.8 
346.7 
(579.0) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red for each patient category 
** Results were supressed when < 5 patients were included in the category 
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Table 5.43 Time (in days) until multimorbidity, stratified by patient age category (years), patient sex and index chronic 
disease, Continued 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
Musculoskeletal Problem  T2 378.3 
609.7 
(676.0) 
371.8 
652.1 
(739.6) 
312.0 
602.3 
(748.8) 
208.6 
504.6 
(724.3) 
165.6 
458.0 
(680.9) 
354.2 
631.2 
(753.2) 
337.9 
612.7 
(736.5) 
274.3 
580.6 
(755.8) 
189.0 
514.0 
(752.6) 
146.0 
477.2 
(735.9) 
Stomach Problem  T2 294.0 
467.8 
(497.0) 
275.0 
542.9 
(690.5) 
326.7 
539.5 
(655.4) 
185.2 
432.7 
(629.5) 
111.3 
226.7 
(319.2) 
263.3 
536.6 
(656.6) 
298.0 
559.6 
(700.7) 
278.6 
534.8 
(694.1) 
205.3 
488.4 
(749.2) 
160.6 
353.7 
(529.5) 
Colon Problem  T2 371.0 
575.8 
(629.3) 
287.5 
542.8 
(708.3) 
229.5 
511.2 
(657.9) 
211.5 
496.9 
(712.7) 
119.0 
287.1 
(450.8) 
298.5 
527.9 
(636.1) 
255.0 
453.4 
(537.0) 
195.4 
475.5 
(667.5) 
206.0 
472.0 
(649.2) 
221.0 
478.5 
(633.9) 
Liver Disease  T2 573.9 
523.5 
(423.5) 
175.5 
175.5 
(73.8) 
135.0 
349.0 
(531.2) 
223.1 
506.9 
(646.1) 
367.7 
367.7 
(519.4) 
681.7 
807.8 
(600.1) 
627.0 
956.5 
(966.8) 
239.1 
472.4 
(620.2) 
46.1 
333.0 
(550.0) 
Results 
Supressed 
Urinary Problem  T2 430.6 
638.3 
(657.5) 
494.0 
722.5 
(772.7) 
439.3 
713.1 
(814.6) 
286.4 
600.2 
(834.5) 
122.5 
407.2 
(680.4) 
364.2 
637.8 
(750.6) 
334.7 
602.9 
(751.2) 
254.1 
582.3 
(754.3) 
122.3 
466.8 
(746.8) 
123.0 
342.9 
(633.0) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red for each patient category 
** Results were supressed when < 5 patients were included in the category
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5.2.3 Objective Two, Research Question 2 – Time Until Advancing Multimorbidity   
To address Research Question 2, the “Time Until Advancing Multimorbidity” was 
assessed by determining the median and mean time until subsequent chronic disease diagnoses 
after the second chronic disease (as seen in Table 5.42).  This was conducted for adult patients 
with at least two chronic diseases as of September 30, 2013 and only those chronic diseases with 
at least one-day elapsing between diagnoses were included in the analysis.  The results presented 
in Table 5.42 were stratified by both patient age and patient sex.  These results indicate that 
generally, the time elapsing until advancing multimorbidity was indeed the slowest from the 
second to third chronic disease diagnoses.  For example, among patients aged 18 to 34 years, the 
median time from the second to third chronic disease was 377.9 days for females and 364.8 days 
for males.  For female patients aged 35 to 44 years and 45 to 64 years, the median time until the 
third chronic disease diagnoses was 396.0 days and 342.0 days, respectively.  For male patients 
aged 35 to 44 years and 45 to 64 years, the median time until the third chronic disease diagnoses 
was 365.0 days and 321.0 days, respectively.  Interestingly, for female and male patients aged 65 
to 84 years and over 85 years, the longest time until the subsequent chronic disease was observed 
from the fifth to sixth diagnoses.  More specifically, for females, the median time until the sixth 
chronic disease diagnoses was 266.7 days and 274.5 days among patients aged 65 to 84 years 
and 85 years and older, respectively.  For males, the median time until the sixth chronic disease 
diagnoses was 279.1 days and 259.7 days among patients aged 65 to 84 years and 85 years and 
older, respectively.  These results demonstrate that the time until advancing multimorbidity is the 
slowest from the second to third chronic disease among female and male patients aged 18 to 64 
years, whereas the longest time was observed from the fifth to sixth chronic disease among 
female and male patients aged 65 years and older.   
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Similar to Research Question 1, in order to assess the differences that occurred when 
excluding data points in which the time elapsing between diagnoses was zero days, the same 
analysis was conducted for all patients and for all data points (that is, when time elapsing 
between chronic disease diagnoses was equal to zero days).  These results are included in 
Appendix AI.  While the same patterns were observed within this sensitivity analyses, the 
median and mean time elapsing between chronic disease diagnoses was again notably lower as 
compared to the estimates presented in Table 5.42.  However, the data points that were equal to 
zero days did not have as much of an impact on the median and mean time elapsing between 
diagnoses when examining the time until advancing multimorbidity (that is, among patients with 
more than two chronic diseases), as compared to the time elapsing until multimorbidity (that is, 
among patients transitioning from the first to second chronic disease).  Nonetheless, the time 
elapsing between chronic diseases diagnoses still decreased within the sensitivity analysis.  For 
example, among male patients aged 18 to 34 years, the median time until the third chronic 
disease was 340.7 days (mean of 577.1 days) when data points that were equal to zero days were 
included in the analysis.  This estimate was only slightly lower than the median time elapsing 
until the third chronic disease in the original analysis, which was 364.8 days (mean of 565.7 
days).  As well, among female patients aged 85 years and older, the median time until the third 
chronic disease diagnoses was only 5.2 days (mean of 224.4 days) when data points that were 
equal to zero days were maintained in the analyses, as compared to a median time of 97.4 days 
(mean of 366.4 days) when these data points were removed from the analysis.   
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5.2.4 Objective Two, Research Question 3 – Examining Patient-, Provider- and Practice-
Level Predictors of Time Until Subsequent Chronic Disease 
To address Research Question 3, univariate and bivariate analyses were first conducted 
for both continuous and categorical predictors, and the results from these analyses are presented 
in Table 5.44.  This was conducted for adult PHC patients with at least one chronic disease as of 
September 30, 2013 and only those chronic diseases with at least one-day elapsing between 
diagnoses were included in the analysis.  As described in the Methodology Chapter, a total of 
nine predictors were included in the multilevel, recurrent event survival analysis.  Among the 
patient-level predictors, all five independent variables were statistically significantly related to 
the dependent variable (p-value < 0.001).  Similarly, among the provider- and practice-level 
predictors, all four independent variables were statistically significantly related to the dependent 
variable of time until subsequent chronic disease diagnosis (p-value < 0.001).  Consequently, a 
statistically significant correlation between each of the nine independent variables and the 
continuous dependent variable (that is, time until subsequent chronic disease) was observed.  
These graphs indicate that the majority of time elapsing until subsequent chronic disease was 
under 5.5 years (or 2,000 days) for both female and male patient groups.  This broad pattern was 
observed among both female and male patients, regardless of patient age category.  The 
unadjusted Kaplan–Meier failure curves for female and male patients can also be seen in Figure 
5.8 and Figure 5.9, and displays the event rate among those patients with one or more chronic 
disease diagnoses and stratified by patient age category. 
The results from the multilevel, recurrent event survival analysis are presented in Table 
5.45 and demonstrate the relationship between each independent variable and dependent 
variable, controlling for all other variables in the final model.  This table also presents the 
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variance contributed by clustering of events at the provider- and practice-level.  After conducting 
the bivariate analyses, each of the nine predictor variables were independently entered into the 
basic survival analysis model.  Following this initial assessment, all nine predictor variables were 
included in the multilevel, recurrent event survival analysis among patients with at least one 
chronic disease diagnosis.  Among the patient-level variables, patient age, patient sex, median 
household income and the total number of chronic diseases were all significantly related to time 
until subsequent chronic disease, after controlling for all other variables in the model (p-value < 
0.05).  While patient sex and total number of chronic diseases demonstrated more notable effect 
sizes, the effects of patient age, residential location and median household income were 
negligible, despite being found statistically significant.  From the hazard ratios reported in the 
adjusted model, female patients experienced a 19% decrease in the rate until the next chronic 
disease diagnosis, as compared to male patients and controlling for all other variables in the 
model (p-value < 0.001).  Similarly, as the number of chronic diseases increased by one unit, and 
with all other variables held constant, there was a 33% increase in the rate until the next chronic 
disease diagnosis (p-value < 0.001).   
Among the provider-level variables, provider age and provider sex were both found to be 
statistically significant (p-value < 0.05).  While the increasing age of a PHC provider created 
only a 2% decrease in the rate until the next chronic disease (p-value < 0.001), the patients who 
received care from a female PHC provider experienced an 8% decrease in the rate until their next 
chronic disease diagnosis (p-value < 0.05).   
Finally, among the practice-level variables, both the EMR type and the location of the 
PHC practice were found to have a statistically significant relationship with the outcome, holding 
all other variables in the model constant.  More specifically, adult patients who were receiving 
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care from an urban-based PHC practices experienced a 26% decrease in the rate until their 
subsequent chronic disease diagnosis (p-value < 0.001).  Multiple EMR software types were also 
significantly related to the outcome of interest, and as compared to the Accuro EMR software 
(reference category).  For example, those patients who were receiving care from a PHC practice 
that utilized the Bell EMR software type had a 46% increase in rate until the subsequent chronic 
disease, as compared to those patients receiving care from a PHC practice that utilized the 
Accuro EMR software (p-value < 0.001).  Likewise, those patients who were receiving care from 
a PHC practice that used the Oscar EMR software had a 62% increase in the rate until 
subsequent chronic disease diagnosis, as compared to the Accuro EMR software and holding all 
other variables in the model constant (p-value < 0.001).  Those patients who received care from a 
PHC practice using the Practice Solutions and Wolf EMR software programs experienced a 
decreased rate until their next chronic disease diagnosis.  For example, those patients whose data 
were recorded using the Practice Solutions EMR software had a 57% decrease in the rate until 
their next chronic disease diagnosis (p-value < 0.001), whereas those patients whose data were 
recorded using the Wolf EMR software had a 27% decrease in the rate until their next chronic 
disease diagnosis (p-value < 0.001).  Both of these hazard ratios were calculated as compared to 
the Accuro EMR software and holding all other variables in the final model constant.  As 
highlighted further in the Discussion Chapter, these results could potentially be due to coding 
artefacts within the EMR data based or due to true differences in the accumulation of multiple 
chronic diseases among the patients within the sample.   
When examining the potential for an interaction between patient age and patient sex, the 
interaction term was found to be statistically significant (p-value < 0.001), but the hazard ratio 
indicated a negligible effect size on the dependent variable and was not interpreted any further.  
190 
The multilevel survival analysis also determined the variance contributed by clustering of events 
at each level, that is within PHC providers and within PHC practices.  In the results presented in 
Table 5.45, almost 10.0% of variance was contributed by provider-level clustering.  There was 
no notable variance contributed by the practice-level clustering (0.18%).  The associated 
likelihood ratio test was statistically significant (p-value < 0.001) indicating the suitability of a 
multilevel survival analysis.  An exploration of the multilevel, single event survival analysis, 
stratified by the total number of chronic diseases, was also conducted and the results are 
presented in Appendix AJ.  These additional analyses produced similar results when the 
multilevel survival analyses was conducted for recurrent or single events.   
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Table 5.44 Results of univariate and bivariate analyses between independent variables and 
dependent variable (time until subsequent chronic disease diagnosis) among adult patients 
with one or more chronic diseases (n = 238,237)  
Independent Variable Univariate Analysis Bivariate Analysis (p-value) 
Patient-Level   
Age (Years) 
Mean (SD) 54.5 Years (17.7 Years) 
<0.001 Median (IQR) 54.0 Years (26.0 Years) 
Range (Minimum – Maximum) 18 Years – 114 Years 
Sex, n (%) 
Female 137,587 (57.8%) 
<0.001 
Male 100,650 (42.2%) 
Residential Location, n (%) 
Rural  37,424 (15.7%) 
<0.001 Urban  112,072 (47.0%) 
Missing 88,741 (37.3%) 
Median Household Income (Canadian Dollars)  
Median (IQR) $61,221 ($12,497) <0.001 
Range (Minimum – Maximum)  $22,457 – $181,454  
Total Number of Chronic Diseases 
Mean (SD) 2.5 (1.6) 
<0.001 Median (IQR) 2.0 (2.0) 
Range (Minimum – Maximum)  1 – 13 
* SD = Standard deviation, IQR = Interquartile range 
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Table 5.44 Results of univariate and bivariate analyses between independent variables and 
dependent variable (time until subsequent chronic disease diagnosis) among adult patients 
with one or more chronic diseases (n = 238,237), Continued 
Independent Variable Univariate Analysis Bivariate Analysis (p-value) 
Provider-Level   
Age (Years) 
Mean (SD) 50.7 Years (10.3 Years) 
<0.001 Median 50.0 Years 
Range (Minimum – Maximum)  27 Years – 72 Years 
Sex, n (%) 
Female 63,494 (26.7%) 
<0.001 Male 45,231 (19.0%) 
Missing 129,512 (54.4%) 
Practice-Level Variable 
EMR Type, n (%) 
Accuro 20,318 (8.5%) 
<0.001 
Bell 18,952 (8.0%) 
DaVinci 678 (0.3%) 
Jonoke 13,572 (5.7%) 
Med Access 6,583 (2.8%) 
Nightingale 53,319 (22.4%) 
Oscar 9,624 (4.0%) 
Practice Solutions 9,446 (4.0%) 
Wolf 19,118 (8.0%) 
Xwave 597 (0.3%) 
Missing 86,030 (36.1%) 
Practice Location, n (%) 
Rural  22,692 (9.5%) 
<0.001 Urban  124,682 (52.3%) 
Missing 90,863 (38.1%) 
* SD = Standard deviation
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Figure 5.8 Kaplan-Meier curves indicating time (in days) until subsequent chronic disease 
diagnosis (event) among female patients, stratified by patient age category 
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Figure 5.9 Kaplan-Meier curves indicating time (in days) until subsequent chronic disease 
diagnosis (event) among male patients, stratified by patient age category 
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Table 5.45 Results of multilevel, recurrent event survival analyses for time until subsequent chronic disease diagnosis among 
adult patients with one or more chronic diseases (n = 238,237)  
Independent Variable Hazard Ratio (95% CI) * p-value  
Patient-Level 
Age 1.002 (1.001 – 1.003) <0.001 
Sex (Female) 0.81 (0.78 – 0.85) <0.001 
Residential Location (Urban) 0.99 (0.97 – 1.01) 0.410 
Median Household Income 1.000001 (1.00 – 1.000001) 0.018 
Total Number of Chronic Diseases 1.33 (1.33 – 1.34) <0.001 
Provider-Level 
Age 0.98 (0.98 – 0.99) <0.001 
Sex (Female) 0.92 (0.85 – 0.99) 0.029 
Practice-Level 
EMR Type   
Accuro Reference 
Bell 1.46 (1.23 – 1.72) <0.001 
DaVinci 0.98 (0.90 – 1.08) 0.067 
Jonoke 1.08 (0.96 – 1.14)  0.093 
Med Access 0.87 (0.74 – 1.01) 0.083 
Nightingale 0.95 (0.85 – 1.06) 0.332 
Oscar 1.62 (1.40 – 1.88) <0.001 
Practice Solutions 0.43 (0.37 – 0.50) <0.001 
Wolf 0.73 (0.64 – 0.84) <0.001 
Xwave 1.98 (0.82 – 4.73) 0.127 
Practice Location (Urban) 0.74 (0.67 – 0.83) <0.001 
Interaction Term 
Patient Age & Patient Sex 1.002 (1.001 – 1.002) <0.001 
% Variance (95% CI) Contributed by Each Level 
Within Provider 9.51 (95% CI: 6.99 – 12.41) 
Within Site 0.18 (95% CI: 0.00 – 0.20) 
*CI = Confidence interval; Extra decimal places added where necessary
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Chapter 6 
6 Discussion 
This chapter will highlight the key results presented in the previous chapter with further 
discussion and interpretation.  This discussion will be supplemented by a highlight of this 
research work’s strengths, limitations and implications within the broader clinical, policy and 
research contexts.   
 
6.1 Summary of Key Findings from Objective One 
6.1.1 Prevalence and Characteristics of Patients with Multimorbidity 
Overall, this research identified that about one in two adult PHC patients (or 53.3%) 
within the CPCSSN database were living with two or more chronic diseases as of September 30, 
2013.  About one in three adult PHC patients (or 33.1%) within the CPCSSN database were 
living with three or more chronic diseases as of September 30, 2013.  These estimates were 
compared to literature where a similar definition of multimorbidity was used, as well as those 
studies that were conducted in a Canadian context and a PHC context.   
Among those studies that were conducted in Canada, the prevalence of individuals with 
two or more chronic diseases ranged from as low as 12.9% in a general adult population sample 
(Roberts et al., 2015), to as high as 89.3% in an adult PHC patient sample (Fortin et al., 2005).  
While the sample size of the study conducted by Roberts et al. (2015) was almost ten times 
smaller than the sample size of the study conducted by Fortin et al. (2005), the prevalence of 
multimorbidity was considerably lower as this was a health survey of the general adult 
population in Canada and the measurement of multimorbidity only included nine, self-reported 
diseases.  In comparison, the study conducted by Fortin et al. (2005) collected data from 
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consecutive visits of adult PHC patients and any diagnosed conditions were included in the 
multimorbidity measurement.  This study represented the collection of data from adults who 
were seeking care from their health care provider and a full health record review was conducted 
for each consenting patient.  While this study provided the first Canadian prevalence estimate for 
multimorbidity in the adult population, the prevalence of multimorbidity was found to be notably 
higher than the prevalence estimate detected in the current study.  Although both studies aimed 
to capture the occurrence of multiple “chronic” health problems within a patient, the lists of 
chronic diseases used in the two studies differed.  A study conducted by Stewart et al. (2013) 
took place in a Canadian setting and reported the most comparable prevalence estimate of 
multimorbidity in the literature.  This study included almost 3,000 adult PHC patients whose data 
were collected in the Deliver Primary Health Care Information (DELPHI) database (also a 
regional network of the CPCSSN database).  Using a list of 98 chronic disease categories from 
the International Classification of Primary Care (ICPC) system, this study found a prevalence of 
34.0% adult PHC patients living with two or more chronic diseases.  This prevalence estimate 
was still approximately 20% lower than the estimate reported in the current study (53.3%), but 
this may have been due to the variation in the definition of multimorbidity or the process of 
identification of chronic disease diagnoses within the EMR data between the two studies.   
The prevalence of individuals with three or more chronic diseases, within a Canadian 
setting, ranged from as low as 3.9% among a general adult population (Roberts et al., 2015) to as 
high as 75.6% among an adult PHC sample (Fortin et al., 2005).  Once again, the study 
conducted by Roberts et al. (2015) utilized self-reported data from just over 100,000 adults in the 
Canadian Community Health Survey.  This definition of multimorbidity included only nine 
chronic diseases, and respondents were asked whether or not they had received a diagnosis for 
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any of the diseases in the past.  The study conducted by Fortin et al. (2005) found a high 
prevalence of adult PHC patients diagnosed with any condition and who had three or more 
chronic diseases, using a similar methodology to identifying patients with two or more chronic 
disease diagnoses.  The Canadian study conducted by Pefoyo et al. (2015) reported the most 
comparable prevalence estimate of multimorbidity in the literature.  This study utilized a large 
population-based cohort and an administrative database from the province of Ontario.  With a list 
of sixteen chronic disease categories in the measurement of multimorbidity, this study reported a 
prevalence estimate of 13.6% of residents who were living with three or more chronic diseases.  
Again, this prevalence estimate was still approximately 20% lower than the estimate reported in 
the current study (33.1%), but this may have been because the study by Pefoyo et al. (2015) used 
a population-level approach, as compared to examining individuals specifically seeking care 
from a PHC provider.   
When compared to the international literature within the context of primary health care, 
the prevalence estimate of adult patients living with two or more chronic diseases was most 
comparable with three recently published studies: a sample of randomly selected PHC patients in 
a retrospective cohort study in the United Kingdom, which reported a prevalence of 58.0% 
among almost 100,000 adult patients over 182 PHC practices (Salisbury et al., 2011); a cross-
sectional sample of adult PHC patients in the United States, which reported a prevalence of 
45.3%  using a list of 24 chronic diseases within their definition of multimorbidity (Ornstein et 
al., 2013); and a sample of randomly selected PHC patients within a prospective cohort study in 
Australia, which reported a prevalence of 43.7% using health charts to capture multimorbidity 
(Harrison et al., 2014).  The prevalence of PHC adults with three or more chronic diseases was 
most comparable with two recently published studies.  As previously described, the study by 
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Harrison et al. (2014) included a prospective sample of adult PHC patients and detected a 
prevalence estimate of 27.4% of patients with three or more chronic diseases, which was 
comparable to the prevalence estimate detected in the current study (33.1%).  A retrospective 
study by Prados-Torres et al. (2012) in Spain among more than 275,000 patients and including 
chronic diseases with at least a 1% prevalence level in the population, reported that 20.2% of 
their patients were living with three or more chronic diseases.  Similar to the high prevalence 
estimates detected by Fortin et al. (2005), a study conducted in Portugal by Prazeres et al. (2015) 
detected a notably higher prevalence of adult PHC patients living with two or more and three or 
more chronic diseases (72.7% and 57.2%, respectively).  This study investigated a large list of 
147 chronic health problems and included clinical data that were collected from three data 
sources for each patient: provider knowledge of a patient’s history, patient self-reported 
information and medical records.  The high prevalence estimates detected by Fortin et al. (2005) 
and Prazeres et al. (2015) may be due to the wide breadth of information that was collected for 
each patient included in the sample.  As a result, these studies may demonstrate the influence of 
the data collection approach on the eventual estimates of multimorbidity.   
Among our sample of patients with two or more chronic diseases, the mean age was 59.0 
years (SD: 17.0) and 57.8% were female.  Slightly more than half of these patients were living in 
an urban setting (52.2%) and the median of the median household income was about $60,950 per 
year (Canadian dollars).  Similar characteristics were observed for patients with three or more 
chronic diseases: the mean age of these patients was 62.7 years (SD: 15.9), the majority were 
female (58.5%), the majority were living in an urban setting (53.4%) and the median of their 
median of household incomes was $61,175 per year (Canadian dollars).  The descriptive analysis 
indicated that the mean age of patients increased as the number of chronic diseases diagnosed 
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also increased.  In fact, the mean age difference between those patients with no chronic disease 
diagnoses and five or more chronic disease diagnoses was 26.6 years.  The association between 
multimorbidity and whether a patient is older or female has been consistently reported in the 
existing literature (Harrison et al., 2013; Barnett et al., 2012; Salisbury et al., 2011; Britt et al., 
2008; Uijen et al., 2008; Fortin et al., 2005; van den Akker et al., 1998).  However, while the 
prevalence of multimorbidity increased as patient age increased, the largest proportion of 
patients living with multimorbidity was between the ages of 45 to 64 years (about 25.0% of adult 
PHC patients) and the majority of patients with multimorbidity were under the age of 65 years.  
More specifically, 61.7% of patients with two or more chronic diseases were under the age of 65 
years, while 53.4% of patients with three or more chronic diseases were under the age of 65 
years.  This finding is consistent with previous literature that has highlighted the growing burden 
of multimorbidity among younger cohorts of individuals.  Indeed, multimorbidity is no longer an 
issue of the oldest patients and it must be appropriately managed among younger and younger 
patients (Barnett et al., 2012; Taylor et al., 2010; Mercer et al., 2009).   
The highest prevalence of multimorbidity was also explored amongst the most commonly 
reported demographic characteristics: age and sex.  This study found that the highest prevalence 
of multimorbidity (defined as two or more chronic diseases) was among those patients aged 45 to 
64 years (40.6%) and those patients who were female (57.8%).  Much of the published 
multimorbidity research conducted in the Canadian and international context has reported the 
highest prevalence among those who are 65 years of age and older (Jovic et al., 2016; Pefoyo et 
al., 2015; Pati et al., 2015; Prazeres et al., 2015; Roberts et al., 2015; Wang et al., 2015; Harrison 
et al., 2014; Orueta et al., 2014; Rocca et al., 2014; Ornstein et al., 2013; Stewart et al., 2013; 
Ward et al., 2013; Agborsangaya et al., 2012; Barnett et al., 2012; Prados-Torres et al., 2012; 
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Rizza et al., 2012; van Oostrom et al., 2012; Salisbury et al., 2011; Fortin et al., 2005; van den 
Akker et al., 1998).  The published multimorbidity research is still demonstrating split findings 
in whether the prevalence of multimorbidity is more notable among female or male individuals, 
but the majority of studies seem to indicate a slightly higher prevalence among females (Roberts 
et al., 2015; Wang et al., 2015; Pati et al., 2015; Orueta et al., 2014; Barnett et al., 2012; Prados-
Torres et al., 2012; van Oostrom et al., 2012; van den Akker et al., 1998).  An exception was 
observed in Portugal, in which the study conducted by Prazeres et al. (2015) found that male 
patients had the highest prevalence of two or more chronic diseases (75.9%), as compared to 
female patients.   
Comparing the demographic characteristics with the literature that defined 
multimorbidity as three or more chronic diseases is more difficult because these studies report 
patient characteristics in less detail.  While the current study found that the prevalence of three or 
more chronic diseases was highest among those patients who were 45 to 64 years and who were 
female (39.6% and 58.5%, respectively), the majority of the literature found the highest 
prevalence of three or more chronic diseases among the oldest age group of patients (e.g., those 
patients who are aged 65 and older or 85 years and older).  The literature also showed mixed 
findings in that some studies reported females with the higher prevalence of three or more 
chronic diseases, ranging from 4.5% by Roberts et al. (2015) to 77.4% by Fortin et al. (2005).  
However, two additional studies reported that males experienced the highest prevalence of three 
or more chronic diseases, ranging from 7.6% by Rizza et al. (2012) to 61.6% by Prazeres et al. 
(2015).  These inconsistent findings indicate a need to further explore and understand the 
characteristics of those patients who are living with advancing multimorbidity, as well as more 
comprehensive reporting of research findings (Stewart et al., 2013).  
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Overall, the estimates of multimorbidity detected within the current study fall on the 
higher end of the prevalence spectrum (e.g., ranging from 0% to 100% prevalence), as compared 
to the estimates that have been reported to date.  The characteristics of those adult patients who 
were living with multimorbidity (regardless of definition) were somewhat comparable with the 
existing literature, but again, notable variation was observed in the distinct patterns of 
characteristics.  These differences may be a result of interrelated causes.  For example, these 
differences may indicate true and distinct differences between populations, in that perhaps the 
burden of multimorbidity is higher in Portugal than in Canada.  However, these differences also 
may be due to methodological differences in data collection, sample recruitment and inclusion 
criteria for disease within the multimorbidity definition.  For example, the lack of comparable 
findings between population-level surveys and clinical chart reviews may be an artefact of the 
data collection approach.  Or, these potential causes may be interrelated and more convoluted.  
As such, comparisons between studies should be made cautiously as long as these differences in 
research methodology continue to prevail.  
 
6.1.2 Most Frequently Occurring Clusters of Multimorbidity  
Before examining the discrete clusters of multiple chronic diseases, the prevalence of 
individual chronic diseases, stratified by patient age and patient sex, were explored.  This 
analysis detected a changing distribution of individual chronic diseases as patient age increased.  
For example, those patients who were between the ages of 18 and 34 years had the highest 
prevalence of diagnoses for Obesity, Anxiety or Depression and Musculoskeletal Problem.  
Among patients aged between 65 and 84 years, the most prevalent individual chronic diseases 
were Hypertension and Obesity.  Those patients who were 85 years of age and older had the 
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highest prevalence of diagnoses for Hypertension, followed by diagnoses of Obesity, Diabetes 
and Cardiovascular Disease.  The changing prevalence of individual chronic diseases by patient 
age group may be reflecting the changing characteristics of an aging patient.  For example, PHC 
providers may be more sensitive or attuned to the mental health challenges experienced by young 
adults, creating a higher prevalence of diagnoses for Anxiety or Depression in this age group, 
particularly due to increased media and policy attention for this important issue.  Or perhaps 
those young patients who are experiencing Anxiety or Depression or a Musculoskeletal Problem 
require a diagnosis and a clinical note if work or school absences are required (e.g., missing an 
examination due to chronic anxiety or requiring time off work due to chronic back pain).  While 
those patients who were aged 85 years and older were most likely to be diagnosed with 
Hypertension and Obesity, the prevalence of the remaining chronic diseases was much more 
evenly distributed.  This pattern was observed for both female and male patients and may 
indicate that older patients who are living with multiple chronic diseases are more likely to live 
with a wide range of chronic diseases or those chronic diseases that have a less direct link with 
mortality.  As will be confirmed shortly, these older patients also represent increasingly complex 
clinical profiles and are managing more unique clusters of multiple chronic disease diagnoses.   
A high prevalence of obesity was found in a Canadian study using the Health Quality 
Council of Alberta 2012 Patient Experience Survey that found an obesity prevalence of 28.1% 
(Agborsangaya et al., 2013).  However, a study conducted in the United States by Ornstein et al. 
(2013) among 148 practices with more than 650,000 adult patients found a prevalence of obesity 
of 11.9% using only ICD-9-CM codes.  A study conducted in Sweden by Rizza et al. (2012) 
using the ICPC-2 classification system found a very small prevalence of obesity, that of less than 
3.0% among adult PHC patients.  Likewise, a study conducted in Germany by Schafer et al. 
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(2012) found a small prevalence of diagnosed obesity of 4.8% among adult PHC patients.  
Hypertension is a consistently measured and highly prevalent chronic disease, particularly 
among those with at least one chronic disease or older populations.  Likewise, psychological 
chronic diseases (including anxiety and depression) were prominent in many of the 
multimorbidity studies.  The study conducted by Prazeres et al. (2015) found a staggeringly high 
prevalence of both hypertension and depressive disorder within their sample of patients.  The 
prevalence of hypertension among female and male patients with multimorbidity was about 
94.0%, whereas the prevalence of depressive disorder among female patients with 
multimorbidity was as high as 88.4% (Prazeres et al., 2015).  In comparison, the study conducted 
in Australia determined the prevalence of psychological or mental and behavioural disorders 
ranged from 22.2% to 21.9% among adult PHC patients using the ICPC-2 and ICD-10 
classification systems, respectively (Harrison et al., 2014).  Although anxiety was not measured, 
the studies conducted by Roberts et al. (2015) and Ornstein et al. (2013) reported a prevalence of 
depression ranging from 11.2% among community-dwelling adults in Canada to almost 20.0% 
among care-seeking adults in the United States.  Finally, a high prevalence of chronic 
musculoskeletal problems (e.g., chronic low back pain) were also reported in the multimorbidity 
literature.  A study conducted in Australia found a prevalence of 26.3% and 26.0% among adult 
PHC patients, as measured using the ICPC-2 and ICD-10 classification systems, respectively 
(Harrison et al., 2014).  A higher prevalence was detected in sample of adult PHC patients in 
Germany, in which at least 50.0% of the sample were living with chronic pain impacting 
function (Schafer et al., 2012).  Overall, the most prevalent individual chronic diseases were 
Obesity, Hypertension, Musculoskeletal Problem and Anxiety or Depression, which 
demonstrated consistency with the multimorbidity literature.   
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The computational cluster analysis that was conducted using the Multimorbidity Cluster 
Analysis Tool detected many unique combinations and permutations, and indicated that patients 
with multimorbidity represent increasingly complex clinical profiles.  A similar computational 
cluster analysis has not been published in the multimorbidity literature to date.  Instead, varying 
techniques to identify co-occurring clusters of multiple chronic diseases have been reported, 
including exploratory factor analysis, cluster analysis and latent class growth analysis (Prados-
Torres et al., 2014; Violán et al., 2014; Garin et al., 2014; Strauss et al., 2014; van Oostrom et 
al., 2014; Ornstein et al., 2013; Prados-Torres et al., 2012; Newcomer et al., 2011; Schafer et al., 
2010; Cornell et al., 2007).  In the current study, approximately 5,000 unique combinations were 
detected for female and male patients living with multimorbidity, while almost 10,000 and 
15,000 unique permutations were found for female and male patients living with multimorbidity, 
respectively.  Due to these large numbers of mutually exclusive clusters, this analysis indicates 
that the top twenty most frequently occurring combinations and permutations among all female 
and male patients represented only about 20.0% of adult patients with multimorbidity.  This 
means that even the most frequently occurring clusters represent a comparatively small 
proportion of adult patients with multimorbidity.   
Among female patients of all ages, the most frequently occurring combinations were 
Anxiety or Depression and Musculoskeletal Problem (1,694 or 3.6% of all female patients); 
Anxiety or Depression and Obesity (1,179 or 2.5% of all female patients); and Musculoskeletal 
Problem and Obesity (1,132 or 2.4% of all female patients).  These three commonly occurring 
combinations remained the most common among female patients aged 18 to 34 years and 35 to 
44 years.  For female patients aged 45 to 64 years, the most common combination was Anxiety 
or Depression and Musculoskeletal Problem (674 or 3.7% of female patients aged 45 to 64 years.  
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The diagnosis of Hypertension was frequent in the top combinations among female patients aged 
65 years and older and the most common combinations were Hypertension and Obesity (323 or 
2.5% of female patients aged 65 to 84 years) and Dementia and Hypertension (76 or 2.0% of 
female patients aged 85 years and older).  Similar to the common combinations among female 
patients of all ages, the most common permutations were Anxiety or Depression then Obesity 
(1,160 or 2.4% of all female patients); Musculoskeletal Problem then Obesity (1,094 or 2.3% of 
all female patients); and Anxiety or Depression then Musculoskeletal Problem (909 or 1.9% of 
all female patients).  These three commonly occurring permutations remained the most common 
among female patients aged 18 to 34 years, 35 to 44 years and 45 to 64 years.  A shift occurred 
among female patients aged 65 years and older, in which the permutation of Hypertension then 
Obesity became the most commonly occurring permutation among patients aged 65 to 84 years 
(322 or 2.5% of female patients aged 65 to 84 years) and 85 years and older (62 or 1.6% of 
female patients aged 85 years and older).   
Among male patients of all ages, the most frequently occurring combinations were 
Hypertension and Obesity (3,866 or 4.7% of all male patients); Musculoskeletal Problem and 
Obesity (3,580 or 4.3% of all male patients); and Anxiety or Depression and Obesity (2,431 or 
2.9% of all male patients).  These three commonly occurring combinations were persistent 
among male patients aged 18 to 34 years, 35 to 44 years and 45 to 64 years.  For male patients 
aged 65 years and older, the diagnosis of Obesity was present in the most common combinations 
and the most frequent combination was Hypertension and Obesity (1,092 or 4.0% of male 
patients aged 65 to 84 years).  Similar to the common combinations among all male patients, the 
most common permutations were Obesity then Hypertension (2,201 or 2.7% of all male 
patients); Obesity then Musculoskeletal Problem (2,138 or 2.6% of all male patients); and 
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Hypertension then Obesity (1,665 or 2.0% of all male patients).  For all age groups of male 
patients, Obesity was involved in the most frequent permutations.  Among male patients aged 18 
to 34 years, the most common permutation was Obesity then Anxiety or Depression (437 or 
7.3% of male patients aged 18 to 34 years); for male patients aged 35 to 44 years, the most 
common permutation was Obesity then Musculoskeletal Problem (532 or 5.8% of male patients 
aged 35 to 44 years); and for patients aged 45 years and older, the most common permutation 
was Obesity then Hypertension (1,167 or 3.3% of male patients aged 45 to 64 years; 584 or 2.1% 
of male patients aged 65 to 84 years; and 68 or 1.3% of male patients aged 85 years and older.  
While to our knowledge, no published literature to date has examined the sequence of 
multiple chronic disease diagnoses, a recent systematic review of the clusters or patterns of 
multimorbidity identified three most prevalent patterns: cardiovascular and metabolic disorders, 
mental health problems and musculoskeletal disorders (Prados-Torres et al., 2014).  The 
cardiovascular and metabolic disorder pattern described by Prados-Torres et al. (2014) was 
composed of diseases that are consistent with what is commonly known as the metabolic 
syndrome, such as hyperlipidemia, hypertension, heart disease, diabetes and obesity.  The second 
group of patterns included at least one mental health problem, such as depression and anxiety, 
which co-occurred with thyroid disease, pain, asthma and obesity.  The third group of patterns 
included at least one musculoskeletal problem, such as back or neck pain (Prados-Torres et al., 
2014).  Another systematic review of patterns of multimorbidity in primary health care found 
similar commonly occurring patterns in that cardiovascular and metabolic disorders, mental 
health disorders and musculoskeletal pain were the most frequent patterns among females and 
males (Newcomer et al., 2011).  Finally, a systematic review conducted by Sinnige et al. (2015) 
found that among older adult populations, depression was the disease that most commonly 
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clustered with other disease diagnoses and was specifically paired with eight other diseases 
(hypertension, arthritis, diabetes mellitus, asthma or chronic obstructive pulmonary disease, 
stroke, cancer, heart failure and heart disease).   
The patterns found in the above systematic reviews were also detected in the current 
study of adult PHC patients.  While the three chronic disease categories of Obesity, 
Musculoskeletal Problem and Anxiety or Depression were the most prevalent individual chronic 
diseases in our sample of adult patients, these diagnoses indicated an interesting clustering with 
less prevalent chronic diseases (e.g., Dementia, Cancer).  Distinct patterns were also seen based 
on whether these chronic disease categories occurred in a combination (no specific sequence) or 
a permutation (specific sequence).  For example, for female patients who were 85 years and 
older, one of the most commonly occurring combination was that of Dementia and Hypertension 
(76 or 2.0% of female patients aged 85 years and older).  However, if the specific sequence of 
chronic disease diagnoses mattered, the more commonly occurring combination was actually 
Hypertension then Obesity (62 or 1.6% of female patients aged 85 years and older).   
Importantly, the aim of this computational cluster analysis was not to determine a causal 
link between disease diagnoses.  While the temporality of diagnoses was accounted for in the 
permutation or ordered cluster analysis, this does not necessarily indicate a pathophysiological 
link between one chronic disease diagnosis and the following chronic disease diagnoses.  Indeed, 
a robust life course approach would be necessary to determine substantial causal links between 
multiple chronic disease occurrence (Wister et al., 2016; Pavela and Latham, 2015; van den 
Akker et al., 2015; Vos et al., 2015; Strauss et al., 2014).  This approach, combined with the 
information provided from objective cluster analysis, could be used to inform single-disease, 
basic science research to investigate the biology of co-occurring diseases and potentially 
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exploring pathophysiological pathways to these clustered diseases.  For example, a study 
conducted by Lappenschaar et al. (2013) determined that among individuals with both 
hyperlipidemia and hypertension at baseline, the probability of having coexisting ischemic heart 
disease and heart failure was greater than the product of their individual rates.  The conclusion 
that hyperlipidemia and hypertension interact synergistically to effect risk of ischemic heart 
disease and heart failure is important for guiding combined prevention efforts, such as population 
interventions to reduce fast-food intake (Prados-Torres et al., 2014).   
From the current study, the synergistic relationship between Hypertension and Obesity, 
as well as the potentially synergistic effects of lifestyle behaviours between Musculoskeletal 
Problem and Obesity, could be explored in more detail.  Even further, these relationships could 
be explored among less concordant diseases, such as the co-occurrence of Hypertension and 
Cancer or the specific sequence of patients who were first diagnosed with Anxiety or Depression 
and then a Musculoskeletal Problem.  While these clusters demonstrate less obvious 
pathophysiological pathways, clinical insight might help to inform why these patterns co-exist.  
Moving beyond these investigations to more broad implications, the results from the cluster 
analysis could be used to suggest new (physiological, clinical or behavioural) interaction 
hypotheses that could be used in the design and implementation of more pragmatic and 
personalized intervention or prevention programs for patient with multimorbidity.  Making these 
interventions more personalized to the unique clusters of patients with multimorbidity will also 
make them more actionable.   
However, these findings should be used cautiously to inform clinical care or intervention 
programs.  While this information may be used to inform more creative approaches to clinical 
care and pragmatic interventions, these quantitative results importantly lack the voice and 
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perspective of the individuals who are living with multimorbidity.  Using a large population-
based database, this research provides empirical evidence of the increasingly unique clinical 
profiles among adult PHC patients with multimorbidity.  While the patients could be grouped 
into the same clusters (based on sequence of diagnosis or not), these clusters do not completely 
capture or depict the same experience among all patients.  Instead, it is crucial to recognize the 
individuality of each patient who has been diagnosed with and is now managing multimorbidity, 
as well as their changing needs over time (Gill et al., 2014; Noël et al., 2007; Fortin et al., 2007; 
Noël et al., 2005).   
Ultimately, this research further supports the need for a patient-centered approach to 
delivering comprehensive and effective care for this important patient population.  Although 
several models of patient-centeredness have been suggested, essential components of a patient-
centered consultation for patients with multimorbidity was presented by Stewart and Fortin in the 
“ABC of Multimorbidity” textbook (Mercer et al., 2014).  These four components are 
interrelated and are meant to be guides for the patient-provider relationship.  Over time, the 
provider will weave back and forth between the four components: exploring diseases and illness 
experience; understanding the whole person; finding common ground; and enhancing the patient-
provider relationship.  Stewart and Fortin state that the main justification for a patient-centered 
approach, particularly for those with multimorbidity, is that this is the “moral imperative” or the 
“right approach to take”.  Moreover, this approach can alleviate common pitfalls encountered 
with complex patients and enable the PHC provider to deliver more comprehensive, effective, 
continuous and responsive health care to their patients over time.  
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6.2 Summary of Key Findings from Objective Two  
6.2.1 Time Until Multimorbidity 
In exploring the “Time Until Multimorbidity”, that is the accumulation of a second 
chronic disease diagnosis, patterns of the shortest and longest amount of time elapsing between 
diagnoses were stratified by patient age and patient sex.  Among all male patients, the quickest 
accumulation of a subsequent chronic disease occurred between the first and second chronic 
disease, regardless of age group.  For example, the median time until the second chronic disease 
ranged from 249.0 days among male patients aged 18 to 34 years to only 93.0 days among male 
patients aged 85 years and older.  In fact, the fastest median time until the second chronic disease 
diagnosis occurred among male patients aged 65 to 84 years.  In comparison, all female patients 
who were 35 years and older and living with at least one chronic disease received their second 
chronic disease the quickest, as compared to diagnoses that occurred after the second chronic 
disease.  The median time until the second chronic disease ranged from 308.3 days among 
female patients aged 35 to 44 years to only 97.4 days among female patients aged 85 years and 
older.  The exception to this pattern was female patients aged 18 to 34 years, who experienced 
the quickest median time (283.0 days) until the subsequent chronic disease diagnosis between the 
fifth and sixth chronic disease.   
The “Time Until Multimorbidity” was also explored when stratified by patient age, 
patient sex and index chronic disease type.  This descriptive analysis indicated that among 
female and male patients, the quickest accumulation until the second chronic disease occurred 
most often when the index chronic disease type was Diabetes.  For example, the median time 
elapsing between the diagnosis of Diabetes until the second chronic disease for female patients 
aged 18 to 34 years was 131.0 days.  Those female patients aged 65 to 84 years who were first 
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diagnosed with Diabetes received their second chronic disease diagnosis in a median time of 
46.5 days.  Likewise, among male patients aged 18 to 34 years who were first diagnosed with 
Diabetes, the second chronic disease diagnosis was made in only 30.8 days.  Among male 
patients aged 65 to 84 years, those patients who were first diagnosed with Diabetes were 
diagnosed with their second chronic disease in a median time of 32.0 days.  Further exploration 
of the data (to potentially describe the very short time elapsing after a diagnosis of Diabetes) 
showed that the large majority of patients (regardless of patient age and patient sex) who were 
first diagnosed with Diabetes were subsequently diagnosed with either Hypertension or Obesity 
following their Diabetes diagnosis.  This may indicate the pathophysiological link between 
diagnoses, but again, the causal associations between chronic diseases were not explored in this 
current research.   
The longest median time until second chronic disease diagnosis did not demonstrate a 
clear pattern.  For example, among patients aged 18 to 34 years, the longest median time until the 
second chronic disease elapsed when female patients were first diagnosed with Osteoporosis 
(921.4 days) and when male patients were first diagnosed with Stroke or Transient Ischemic 
Attack (1,993.1 days).  Those female and male patients aged 45 to 64 years who were first 
diagnosed with Dementia experienced the longest time until their second chronic disease with a 
median time of 503.3 days and 369.0 days, respectively.  Finally, among female and male 
patients who were 85 years and older, the longest median time until their second chronic disease 
occurred when these patients were first diagnosed with Kidney Disease or Failure (449.7 days) 
and Osteoporosis (260.5 days), respectively.  Further exploration of the data also did not show 
consistent patterns in subsequent chronic disease type for these index chronic disease diagnoses.   
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6.2.2 Time Until Advancing Multimorbidity 
The “Time Until Advancing Multimorbidity” exploration, that is the accumulation of 
more than two chronic diseases, indicated two distinct patterns.  First, among both female and 
male patients who were younger than 65 years of age, the longest median time elapsed between 
their second and third diagnoses (as compared to all other diagnoses and regardless of disease 
type).  Second, among both female and male patients who were 65 years of age and older, the 
longest median time elapsed between their fifth and sixth diagnoses (as compared to all other 
diagnoses and regardless of disease type).  It could be hypothesized that patients accumulate 
subsequent chronic diseases quicker as the number of chronic disease diagnoses increases, due to 
an increased exposure to health care services (and therefore higher potential to receive a new 
diagnosis) and an increased potential susceptibility to further pathology (Fabbri et al., 2015; Hsu, 
2015; Vos et al., 2015; Strauss et al., 2014; van den Akker et al., 2006).  This in fact was not 
observed in our sample of adult patients with multimorbidity.  Two studies that examined the 
trajectory of multimorbidity determined specific groups of low risk of multimorbidity, specific 
risk of a cluster and risk of multiple clusters of chronic diseases (Hsu, 2015; Strauss et al., 2014).   
More specifically, Strauss et al. (2014) detected five groups of individuals who 
represented different trajectories: those who had no recorded chronic diseases (40.0% of 
sample); those who developed their first chronic disease in a 3-year observation period (10.0% of 
sample); those who progressed into multimorbidity (37.0% of sample); those with advancing 
multimorbidity (12.0% of sample); and those patients who started with multimorbidity and 
further developed more chronic diseases during the observation period (1.0% of sample).  A 
study conducted by Hsu (2015) used a group-based trajectories approach to identify four 
trajectory groups of multimorbidity: low risk (55.5% of sample); cardiovascular disease risk only 
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(15.6% of sample); gastrointestinal disease and lung disease risk (20.2% of sample); and 
multiple risks (8.7% of sample).  These two studies indicate a differentiation between the onset 
of multimorbidity and the progression of multimorbidity, which was was also detected in the 
current study.  More specifically, the potential or risk for a subsequent chronic disease diagnosis 
(after existing morbidity) changes over time.  However, this study explored risk using the 
measurement of time (that is, the time-to-event risk that will be presented in the next section).  In 
fact, comparing methodologies in this broad life course approach to multimorbidity, based on 
risk profiles and time-to-event risk, would be a very interesting next step for the complex field of 
longitudinal multimorbidity research.   
To date, extensive research has been conducted to examine and delineate the life course 
epidemiology of individual chronic diseases (Bijker et al., 2016; Oliveira et al., 2016; Ben-
Shlomo et al., 2016; Pavela and Latham, 2015; Viner et al., 2015; Duijts et al., 2014; Kelishadi et 
al., 2014; Power et al., 2013; Godfrey et al., 2010; White et al., 2009; Batty et al., 2007; Lynch 
and Smith, 2005; Barker, 2004).  However, further research is required to move beyond the focus 
on individual chronic disease epidemiology across the life course.  This will help to determine 
how and why individuals accumulate multiple diseases over a lifetime, using both social and 
biological pathways (Ben-Shlomo et al., 2016).  This information can encourage PHC providers 
to proactively offset the risk of their patients developing multimorbidity based on their 
influential role in society (Mercer et al., 2014; McWhinney and Freeman, 2009; Starfield et al., 
2005).  Ideally, this information will also support the need for more comprehensive health 
promotion across the life course.  These resources must be made available to individuals 
regardless of life circumstances, such as early childhood disease or socioeconomic disadvantage.  
Finally, this information will enable the collaborative work of primary health care and public 
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health systems in the prevention of individual chronic diseases and multiple chronic diseases as 
populations continue to age over time.   
 
6.2.3 Predicting Time Until Subsequent Chronic Disease  
In the multilevel, recurrent event survival analysis, the relevant patient-level predictors of 
time until subsequent chronic disease included patient age, patient sex, patient residential 
location, median household income and the total number of chronic diseases diagnosed.  The 
provider- and practice-level predictors of time until subsequent chronic disease were provider 
age, patient sex, EMR software type and practice location.  Among the patient-level independent 
variables, patient sex and total number of chronic diseases were found to be significantly related 
to the time until subsequent chronic disease diagnosis, controlling for all other variables in the 
final model.  Female patients were found to experience a 19% decrease in the rate until the next 
chronic disease diagnosis, as compared to male patients and controlling for all other variables in 
the model.  Similarly, as the number of chronic diseases increased by one unit, and with all other 
variables held constant, there was a 33% increase in the rate until the next chronic disease 
diagnosis.  Hsu (2015) and Strauss et al. (2014) also found that patient age and patient sex were 
factors in the trajectory of multimorbidity over time among patients who were 50 years of age 
and older.  More generally, the association between multimorbidity, patient age and patient sex 
has been demonstrated in more descriptive findings (Barnett et al., 2012; Salisbury et al., 2011; 
Harrison et al., 2013; Britt et al., 2008; Uijen et al., 2008; Fortin et al., 2005).   
Among the provider-level independent variables, provider age and provider sex were 
both found to be significantly related to the time until subsequent chronic disease diagnosis, 
controlling for all other variables in the final model.  More specifically, while the increasing age 
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of a PHC provider demonstrated only a 2% decrease in the rate until the next chronic disease 
diagnosis, the patients who received care from a female PHC provider experienced an 8% 
decrease in the rate until their next chronic disease diagnosis.  For practice-level independent 
variables, adult patients who were receiving care from urban-based PHC practices experienced a 
26% decrease in the rate until their subsequent chronic disease diagnosis.  Multiple EMR 
software types were also significantly related to the time until subsequent chronic disease 
diagnosis, as compared to the Accuro EMR software (reference category).   
As described in the Methodology Chapter, provider-level characteristics (including 
provider age and provider sex) may influence diagnostic behaviours and whether a provider 
prefers to use an interventionist or “wait and see” approach (Hajjaj et al., 2010; Forrest et al., 
2006; Tracy et al., 2005; Franks and Bertakis, 2003; Bertakis et al., 2003; McKinlay et al., 2002).  
Likewise, practice-level influences can include characteristics of the practice organization, such 
as geographic location of the practice and availability of health resources (Iverson et al., 2005; 
McKinlay et al., 1996).  Consequently, the patient-, provider- and practice-level domains were 
relevant layers to capture and explore in this time-to-event analysis.   
Finally, within this multilevel survival analysis, the variation in the time until subsequent 
chronic disease diagnosis was assessed at both the level of the PHC provider and the PHC 
practice.  The amount of variation in the outcome contributed at the provider-level was 10.0% 
(95% CI: 8.4 – 11.9), while the amount of variation contributed at the site-level was less than 
1.0% (that is, 0.18%, 95% CI: 0.0 – 2.0).  Although it was important to examine the effect of 
clustering of events (or diagnoses) within PHC practices and within PHC providers, this analysis 
indicated reasonably minimal impact (< 10%) of these clusters.   
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6.3 Strengths and Limitations  
6.3.1 Strengths of Research  
There are three notable strengths of this research.  Firstly, the findings of this work 
provide necessary insight into the prevalence, patterns and progression of multimorbidity among 
adult patients in the Canadian PHC context.  While the multimorbidity literature continues to 
become much more mature and robust, national estimates of multimorbidity in Canada are still 
missing.  While this research represents a small piece of the “multimorbidity puzzle”, it may help 
to guide future multimorbidity research and it will contribute to the international evidence base.   
Secondly, the CPCSSN EMR database represents an important and unique resource for 
researchers who are interested in the combined fields of PHC and multimorbidity.  The 
longitudinal nature of the CPCSSN EMR data allowed for estimates of multimorbidity 
prevalence among adult PHC patients and the examination of the progression of multimorbidity 
over time.  This longitudinal analysis included information that spanned many years (in some 
cases, ten or more years) for a large cohort of patients.  As such, this rich source of longitudinal, 
clinical data provides a PHC-specific picture of how patients progress from living with one 
chronic disease to multiple chronic diseases.  Building on these findings, health care providers 
and health care policy makers could utilize longitudinal data to inform prevention and 
management practices for patients who are most at-risk of developing a subsequent chronic 
disease.  Ideally, these interventions would aim to prevent patient progression into complex 
clinical profiles, and to help a patient maintain or improve upon their current health status.   
Thirdly, the methodology used in this research provided a solution to addressing a 
number of challenges in the EMR database and the study of the complex issue of multimorbidity.  
The challenges encountered in using the EMR database included detecting singular chronic 
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disease diagnoses, as well as clusters of chronic disease diagnoses.  Another challenge was the 
appropriate analyses of the complex longitudinal data.  While the approaches utilized for the 
current research must be compared and contrasted with other approaches, the methodology 
outlined in the work may help to inform future research in similar areas or facing similar 
methodological or data-related challenges.  Finally, this methodology has been published and has 
been made accessible to external researchers to encourage its replication and comparison of the 
eventual findings (Nicholson et al., 2015).   
 
6.3.2 Limitations of Research  
 This research has three important limitations to consider.  Firstly, this research used a 
simplified approach to operationalize the definition of multimorbidity by strictly counting 
chronic disease diagnoses and incident ICD-9 codes within the EMR database.  This approach 
allowed for the identification of the first occurrence of ICD-9 diagnoses throughout the patient’s 
longitudinal electronic record.  However, this approach does not account for the severity of 
disease or symptom burden on the patient, which may be very valuable information when 
examining progression into more complex clinical profiles.  While examining the occurrence of 
combinations and permutations of multiple chronic diseases created an understanding of the 
multidimensional characteristics of multimorbidity, another potentially important dimension 
would be the severity of chronic disease.  For example, although this research was able to detect 
that specific combinations and permutations were most frequent in the sample of adult PHC 
patients, these findings were not stratified by disease severity.  In a similar sense, the 
identification of combinations and permutations did not indicate a causal relationship between 
diseases.  Indeed, this would be an area for extensive further study.   
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Secondly, the use of EMR data may have introduced the potential for misclassification of 
chronic disease occurrence and, therefore, a biased estimate of multimorbidity prevalence.   This 
potential for misclassification is not only specific to EMRs, but to medical records in general.  
For example, if a patient was truly living with one of the twenty chronic diseases included in the 
measurement of multimorbidity, this patient may not have been detected in the EMR database 
because: 1) the patient did not present pathophysiological indications for the PHC provider to 
examine further through laboratory tests or examinations that would confirm a diagnosis; 2) the 
patient did present pathophysiological indications that were diagnosed as one of the twenty 
chronic diseases by the PHC provider, but this diagnosis was not recorded within the patient’s 
EMR; or 3) the patient did present pathophysiological indications that were diagnosed as one of 
the twenty chronic diseases by the PHC provider, but this diagnosis was not recorded in an area 
of the patient’s EMR that was extracted into the CPCSSN EMR database.  Each of these factors 
may have resulted in a patient being misclassified as not living with a chronic disease, when in 
fact this patient was living with one or more chronic diseases.  Alternatively, patient diagnoses 
may have been entered incorrectly into the EMR or with an incorrect date of diagnoses.  A 
related limitation of the EMR data is that potentially modifiable risk factors that were not 
available in the CPCSSN EMR database (e.g., socioeconomic status, lifestyle behaviours or 
levels of self-efficacy to improving lifestyle behaviours) would be meaningful to explore in 
terms of their potential impact on the occurrence or progression of multimorbidity among adult 
PHC patients.  The impact of socioeconomic status on multimorbidity has been identified in 
previous literature (Roberts et al., 2015; Payne et al., 2013; Agborsangaya et al., 2012; Mercer et 
al., 2012; Barnett et al., 2012), and indicates an important area of improvement within the 
CPCSSN EMR database.   
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Finally, the time elapsing between chronic diseases (explored in Objective Two) was 
potentially impacted by the recording behaviours of the providers within an electronic medical 
record.  For example, providers are expected to record the diagnostic codes when a diagnosis 
follows patient visit and presentation of related symptoms.  To adequately examine the time 
elapsing between diagnoses, providers are also expected to record the diagnostic codes at first 
detection or confirmation of a disease within a patient.  While the original intent of Objective 
Two was to report and describe the natural history of multimorbidity over time, the measure of 
“time” could not differentiate between the recording behaviours of the PHC provider and the true 
progression of multimorbidity over time.  For example, the observation that approximately 20% 
of patients received multiple chronic disease diagnoses at the same encounter may have indicated 
an artefact of the EMR data.  However, this is not completely clear as a patient may have been 
truly diagnosed with multiple chronic diseases at a single encounter because: 1) the PHC 
provider may have received awaited results from multiple laboratory tests and/or examinations; 
2) the patient may have been a new patient to the PHC provider and already living with multiple 
chronic diseases, which would then be recorded at a single encounter; or 3) the PHC provider 
may have entered the diagnostic information or associated dates incorrectly.   
 
6.4 Implications 
6.4.1 Clinical and Policy Implications  
The findings from this research could be used in the clinical context to inform training for 
future health care providers, as well as in the policy context to guide intervention efforts.  For 
example, the cluster information could be used to create “multimorbidity-based patient 
vignettes” of either the most common or most uncommon clusters of chronic diseases occurring 
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within subsets of patients.  These could be used for educational purposes by introducing and 
orienting future health care professionals with the realities and complexities of multimorbidity.  
In fact, these vignettes can prime current medical students and health care providers with 
commonly co-occurring issues among PHC patients in Canada.  This information could be used 
to tailor educational modules programs around questions like: “When is the patient most 
susceptible to acquire another chronic disease?” or “How can this progression into a subsequent 
chronic disease be avoided, based on the patient’s preferences and goals?”  These are complex, 
clinical questions to answer in any context.  However, it may be important to start asking these 
questions now within our educational programs.  This approach could be nested within the 
enhanced training environments in which multidisciplinary health care professionals can be 
trained together to provide more integrated and patient-centered health care.   
The implications for the purposes of health policy should be somewhat conservative, due 
to the observed complex nature of this patient group.  However, the time elapsing between 
multiple chronic disease diagnoses information that was derived from Objective Two could be 
used strategically in the design and implementation of chronic disease prevention and 
management programs.  The point of transition from living with one chronic disease to living 
with multimorbidity (defined as two or more chronic diseases) indicates a period of time in 
which the health care team must deliver its most effective care.  This is particularly important to 
avoid a negative evolution into poorer and poorer health by the patient, especially as the patient 
continues to age.  While the exact trajectory of an individual patient cannot be completely 
predicted, the longitudinal data collected over time from millions of adult PHC patients could be 
used to inform more proactive delivery of care.  As stated previously, the time to event findings 
could be carefully used to identify at-risk patients for specific and pragmatic interventions within 
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a PHC setting.  These more adaptive and proactive interventions could be a new focus for health 
policy makers who are looking to alleviate the growing burden of multimorbidity.   
 
6.4.2 Research Implications  
The completion of this work indicates three main areas in which future multimorbidity 
research will be particularly important.  Firstly, measures and definitions of multimorbidity that 
are used in research should be more systematically compared and contrasted between study 
settings.  This would include the replication of the definition and operationalization of 
multimorbidity from the current study in other populations in Canada and abroad.  A more 
consistent methodological approach would allow the international research community to 
establish a more robust understanding of the true burden of multimorbidity among community 
and clinical populations.  Secondly, future research should more clearly define what factors 
make a patient most susceptible to developing multiple chronic diseases.  In other words, the 
sociodemographic and socioeconomic risk factors to becoming a patient with complex chronic 
disease profile should be explored further.  While our research accounted for a number of 
patient-, provider- and practice-level factors that may influence the time until another chronic 
disease diagnosis is received, more substantial and potentially modifiable risk factors (e.g., 
family history, lifestyle habits or patient resiliency) should be examined.  Finally, future research 
should work to understand the impact of these patients with multimorbidity on the health care 
system, and more importantly, where additional resources and supports are needed for both 
patients and their caregivers to improve health-related outcomes.  More specifically, research 
should continue to identify and focus on the most successful approaches to delivering 
individualized, adaptive and patient-centered care for this significant and growing population of 
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patients.  Indeed, this research will be one of the keys to ensuring that those patients living with 
multimorbidity are receiving the highest quality of care from their multidisciplinary health care 
team.  
 
6.5 Future Directions 
 Overall, the results from this doctoral research indicate that the burden of multimorbidity 
among adult PHC in Canada is substantial as approximately 50% of adult PHC patients in our 
sample were living with multimorbidity, defined as two or more chronic diseases.  Moreover, the 
complexity of these patients with multimorbidity was detected.  These results indicate that even 
among a large cohort of adult PHC patients in Canada, patients with multimorbidity were living 
with increasingly unique and increasing complex clinical profiles, indicating the importance of 
an individualized and patient-centered approach to delivering effective and responsive care.  The 
time elapsing between chronic disease diagnoses indicated that there were certain patient profiles 
that resulted in a much quicker accumulation of another chronic disease diagnoses, as well as 
relevant patient-, provider- and practice-level factors influencing this progression.  These 
findings should be carefully assessed in further research in order to confirm whether these 
patterns exist in other patient populations, beyond the pan-Canadian CPCSSN EMR database.  
The results of this research, however, provide empirical evidence that there will not be a singular 
solution to the challenge of multimorbidity.  As such, the international research community must 
continue to work collaboratively together to put the elusive “multimorbidity puzzle” together.   
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Chapter 7 
7 Conclusion 
Broadly, this thesis provided insight into the prevalence, patterns and natural progression 
of multimorbidity among adult PHC patients in Canada.  The prevalence of multimorbidity, 
defined either as “two or more chronic diseases” or “three or more chronic diseases” was found 
to be 53.3% or 33.1% among adult PHC patients in the CPCSSN EMR database, respectively.  
While common combinations and permutations of multiple chronic diseases were explored by 
both patient age and patient sex, the findings from the computational cluster analysis suggested 
that patients with multimorbidity represent increasingly unique clinical profiles.  This has been 
somewhat supported in the growing “associative multimorbidity” literature, but this research is 
distinct as it provides empirical evidence that multimorbidity patients are indeed unique and 
cannot be easily clumped together.  The longitudinal CPCSSN database allowed for the 
exploration of the natural progression of multimorbidity over time.  From this analysis, 
independent predictors of progressing multimorbidity were detected, particularly at the patient-
level.  This requires further exploration, and further delineation of relevant and modifiable risk 
factors.  Most importantly, however, is the voice and perspective of the patients and caregivers 
who are living with these “unique and complex clinical profiles” of multimorbidity.  The 
multidimensional and far-reaching impact that multimorbidity has on patient’s life cannot be 
underestimated or underexplored.  As such, the conduct of both large-scale, quantitative 
analyses, as presented here in this thesis, and small-scale, qualitative analyses should be 
encouraged and facilitated into the future.  This multidisciplinary combination of research will 
provide the complete picture and understanding of multimorbidity – something for which we are 
continuing to strive towards.  
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Appendices 
Appendix A. Multilevel structure of the CPCSSN data and relevant CPCSSN data elements 
 
Group Data Element Detailed Data Elements 
Network_ID NetworkName 
Practice_ID LocationType, LocationFSA, Province, EMRName, StartDate 
Provider_ID BirthYear, Sex 
Patient_ID 
BirthYear, Sex, OptedOut, PatientStatus_orig, PatientStatus_calc, Occupation, 
HighestEducation, HousingStatus, Language, Ethnicity, DeceasedYear, ResidenceFSA, 
DateCreated 
Encounter_ID 
EncounterDate, Reason_orig, Reason_calc, EncounterType, DiagnosisText_orig, 
DiagnosisText_calc, DiagnosisCodeType_orig, DiagnosisCodeType_calc, 
DiagnosisCode_orig, DiagnosisCode_calc, DateCreated 
Billing_ID 
ServiceDate, ServiceCode, DiagnosisText_orig, DiagnosisText_calc, 
DiagnosisCodeType_orig, DiagnosisCodeType_calc, DiagnosisCode_orig, 
DiagnosisCode_calc, DateCreated 
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Appendix B. CPCSSN Letter of Permission for secondary data source access  
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Appendix C. Ethics approval notice from research ethics board (#104705) 
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Appendix D. Data dictionary of original and created CPCSSN data elements  
Data Element Description 
Cycle_ID Name of the cycle 
Network_ID Unique identifier for each network 
NetworkName Name of CPCSSN network 
Site_ID Unique identifier for each site 
Site_LocationType Type of site practice 
Site_LocationFSA First three digits of the postal code of the site location 
Site_Province Unique two-character province name of the site location 
Site_EMRName Name of the EMR used by the participating site 
Site_EMRStartDate Date the site implemented the EMR 
Provider_ID Unique identifier for each provider in the database 
Provider_BirthYear Birth year of provider 
Provider_Sex Sex of provider 
Patient_ID Unique identifier for each patient in the database 
Patient_BirthYear Birth year of patient 
Patient_Sex Sex of patient 
Patient_OptedOut If the patient has opted out in any extraction 
PatientStatus_orig Status of patient (original) 
PatientStatus_calc CPCSSN re-coding of patient status into consistent text (data cleaning) 
Patient_Occupation Occupation of patient 
Patient_HighestEducation Highest education achieved by patient 
Patient_HousingStatus Housing status of patient 
Patient_Language Primary language of patient 
Patient_Ethnicity Ethnicity of patient 
Patient_DeceasedYear Deceased year of patient 
Patient_ResidenceFSA First three digits of the patient residential postal code 
Patient_DateCreated EMR date stamp of when the original record was created 
Encounter_ID Unique identifier for each encounter 
EncounterDate Date the encounter occurred 
EncounterReason_orig Reason for the encounter exactly as it appears in the EMR (original)  
EncounterReason_calc 
CPCSSN re-coding of the reason for the encounter as it appears in the EMR (data 
cleaning) 
EncounterType How or where the encounter occurred 
DiagnosisText_orig Diagnosis text exactly as it appears in the EMR (original)  
EncounterDiagnosisText_calc CPCSSN re-coding of the diagnosis text into consistent text (data cleaning) 
EncounterDiagnosisCodeType_orig 
Diagnosis code type associated with the encounter exactly as it appears in the EMR 
(original)  
EncounterDiagnosisCodeType_calc CPCSSN re-coding of diagnosis code type into consistent text (data cleaning)  
EncounterDiagnosisCode_orig 
Diagnosis code associated with the encounter exactly as it appears in the EMR 
(original) 
EncounterDiagnosisCode_calc CPCSSN re-coding diagnosis code into consistent text (data cleaning)  
Encouner_DateCreated EMR date stamp of when the original record was created 
Billing_ID Unique identifier for each billing entry 
ServiceDate Date the billing was performed/submitted 
Billing_ServiceCode Service code associated with the billing 
BillingDiagnosisText_orig Diagnosis text exactly as it appears in the EMR (original)  
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BillingDiagnosisText_calc CPCSSN re-coding of diagnosis into consistent text (data cleaning) 
BillingDiagnosisCodeType_orig 
Diagnosis code type associated with the billing exactly as it appears in the EMR 
(original)  
BillingDiagnosisCodeType_calc CPCSSN re-coding of diagnosis code type into consistent text (data cleaning) 
BillingDiagnosisCode_orig Diagnosis code associated with the billing exactly as it appears in the EMR (original)  
BillingDiagnosisCode_calc CPCSSN re-coding of diagnosis code into consistent text (data cleaning) 
Billing_DateCreated EMR date stamp of when the original record was created 
Patient_Age Calculated as of September 30, 2013 with the recorded Patient_BirthYear 
Residential_Location Re-coding based on the second character of Patient_ResidenceFSA  
Provider_Age Calculated as of September 30, 2013 with the recorded Provider_BirthYear 
Practice_Location Re-coding based on the second character of Site_LocationFSA  
Chronic_Disease 
Identified in the EMR using list of twenty chronic disease categories and associated 
ICD-9 disease codes 
Time_BetweenDisease Time elapsing (in days) between chronic disease diagnoses  
Total_ChronicDisease 
Total number of “first occurrence” chronic disease diagnoses recorded in the EMR 
using list of twenty chronic disease categories and associated ICD-9 disease codes 
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Appendix E. Example data entries of patient-level socioeconomic characteristics  
Occupation Data Entry Examples 
admin manager engineering machinist (self-employed) RETAIL MANAGER 
Airport attendant Family Caregiver manufacturing manager Retired 
assistant to disabled financial management multiple jobs Revenue Canada 
bank teller FREELANCE WRITER nanny Roofer, full time 
bookkeeper Government analyst Nurse sales coordinator 
Cake decorator hairdresser nutritionist secretarial 
Cashier Home Care Worker Office Work self employed mechanic 
Client Service Officer homemaker Owner/Operator Social work 
consulting business HOUSECLEANER Part-time in sales technician 
delivery driver interior designer Project Co-ordinator truck driver 
Director of Marketing Lawyer Public Health Nurse 
Work, Full-time - 
Bookkeeper 
Employed LIBRARY ASSISTANT Realtor works as chef 
Highest Education Data Entry Examples 
CEGEP Professional Degree Technical College Unfinished studies 
College Secondary Trade School University 
High School    
Housing Status Data Entry Examples 
Common-law spouse Lives alone Separated Widow(er) 
Common-law - x 8 years Married Single With spouse 
Divorced New spouse - 1 year Single - lives with mother With spouse - since 2001 
Ethnicity Data Entry Examples 
ABORIGINAL CAMBODIAN ENGLISH/SCOTTISH JEWISH 
AFRICAN CANADIAN ETHIOPIAN KOREAN 
ASIAN CANTONESE FILIPINO MEXICAN 
AUSTRALIAN CAUCASIAN FIRST NATIONS NATIVE 
BHUTAN CHINESE FRANCOPHONE PAKISTAN 
BLACK/CAUCASIAN CHINESE/ CAUCASIAN FRENCH CANADIAN PHILIPPINO 
BLACK/NATIVE/SPANIS
H/CAUCASIAN 
COLUMBIAN GERMAN PORTUGUESE 
BRAZILIAN CZECH IRISH SRI LANKAN 
BURMESE EAST INDIAN ITALIAN UKRANIAN 
Belgian EL SALVADOR JAPANESE Undetermined 
Language Data Entry Examples 
English Italian Portuguese Undetermined 
French 
Other language not 
specified 
Some English  
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Appendix F. First character of forward sortation area and corresponding province, territory 
or major region 
Alphabetic Character Province, Territory or Region 
A Newfoundland and Labrador 
B Nova Scotia 
C Prince Edward Island 
E New Brunswick 
G Québec East 
H Montréal 
J Québec West 
K Eastern Ontario 
L Central Ontario 
M Toronto 
N Southwestern Ontario 
P Northern Ontario 
R Manitoba 
S Saskatchewan 
T Alberta 
V British Columbia 
X Northwest Territories and Nunavut 
Y Yukon Territory 
 
 
 
 
 
 
 
 
262 
Appendix G. Complete list of chronic disease categories and corresponding International 
Classification of Disease, 9th Revision (ICD-9) disease codes, for the identification of adult 
primary health care patients with multimorbidity* 
ICD-9 
Code 
ICD-9 Description 
1. Hypertension  
401-405 Hypertensive disease 
401 Essential hypertension 
401 Malignant essential hypertension 
401.1 Benign essential hypertension 
401.9 Unspecified essential hypertension 
405 Secondary hypertension 
405 Malignant secondary hypertension 
405.01 Malignant renovascular hypertension 
405.09 Other malignant secondary hypertension 
405.1 Benign secondary hypertension 
405.11 Benign renovascular hypertension 
405.19 Other benign secondary hypertension 
405.9 Unspecified secondary hypertension 
405.91 Unspecified renovascular hypertension 
405.99 Other unspecified secondary hypertension 
 
2. Obesity 
278 Overweight and obesity 
278 Obesity, unspecified 
278.01 Morbid obesity 
≥30 Body mass index 
 
3. Diabetes – 51 ICD-9 Codes 
250 Diabetes mellitus 
250 Diabetes mellitus without mention of complication 
250 Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled 
250.01 Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled 
250.02 Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled 
250.03 Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled 
250.1 Diabetes with ketoacidosis 
250.1 Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled 
250.11 Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled 
250.12 Diabetes with ketoacidosis, type II or unspecified type, uncontrolled 
250.13 Diabetes with ketoacidosis, type I [juvenile type], uncontrolled 
250.2 Diabetes with hyperosmolarity 
250.2 Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled 
250.21 Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled 
250.22 Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled 
250.23 Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled 
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250.3 Diabetes with other coma 
250.3 Diabetes with other coma, type II or unspecified type, not stated as uncontrolled 
250.31 Diabetes with other coma, type I [juvenile type], not stated as uncontrolled 
250.32 Diabetes with other coma, type II or unspecified type, uncontrolled 
250.33 Diabetes with other coma, type I [juvenile type], uncontrolled 
250.4 Diabetes with renal manifestations 
250.4 Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled 
250.41 Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled 
250.42 Diabetes with renal manifestations, type II or unspecified type, uncontrolled 
250.43 Diabetes with renal manifestations, type I [juvenile type], uncontrolled 
250.5 Diabetes with ophthalmic manifestations 
250.5 Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled 
250.51 Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled 
250.52 Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled 
250.53 Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled 
250.6 Diabetes with neurological manifestations 
250.6 Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled 
250.61 Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled 
250.62 Diabetes with neurological manifestations, type II or unspecified type, uncontrolled 
250.63 Diabetes with neurological manifestations, type I [juvenile type], uncontrolled 
250.7 Diabetes with peripheral circulatory disorders 
250.7 Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled 
250.71 Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled 
250.72 Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled 
250.73 Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled 
250.8 Diabetes with other specified manifestations 
250.8 Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled 
250.81 Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled 
250.82 Diabetes with other specified manifestations, type II or unspecified type, uncontrolled 
250.83 Diabetes with other specified manifestations, type I [juvenile type], uncontrolled 
250.9 Diabetes with unspecified complication 
250.9 Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled 
250.91 Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled 
250.92 Diabetes with unspecified complication, type II or unspecified type, uncontrolled 
250.93 Diabetes with unspecified complication, type I [juvenile type], uncontrolled 
 
4. Chronic Obstructive Pulmonary Disease or Asthma 
491 Chronic bronchitis 
491 Simple chronic bronchitis 
491.1 Mucopurulent chronic bronchitis 
491.2 Obstructive chronic bronchitis 
491.2 Obstructive chronic bronchitis without exacerbation 
491.21 Obstructive chronic bronchitis with (acute) exacerbation 
491.22 Obstructive chronic bronchitis with acute bronchitis 
491.8 Other chronic bronchitis 
491.9 Unspecified chronic bronchitis 
492 Emphysema 
492 Emphysematous bleb 
492.8 Other emphysema 
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493 Asthma 
493 Extrinsic asthma 
493 Extrinsic asthma, unspecified 
493.01 Extrinsic asthma with status asthmaticus 
493.02 Extrinsic asthma with (acute) exacerbation 
493.1 Intrinsic asthma 
493.1 Intrinsic asthma, unspecified 
493.11 Intrinsic asthma with status asthmaticus 
493.12 Intrinsic asthma with (acute) exacerbation 
493.2 Chronic obstructive asthma 
493.2 Chronic obstructive asthma, unspecified 
493.21 Chronic obstructive asthma with status asthmaticus 
493.22 Chronic obstructive asthma with (acute) exacerbation 
493.8 Other forms of asthma 
493.81 Exercise induced bronchospasm 
493.82 Cough variant asthma 
493.9 Asthma unspecified 
493.9 Asthma, unspecified type, unspecified 
493.91 Asthma, unspecified type, with status asthmaticus 
493.92 Asthma, unspecified type, with (acute) exacerbation 
496 Chronic airway obstruction, not elsewhere classified 
 
5. Hyperlipidemia 
272 Disorders of lipoid metabolism 
272 Pure hypercholesterolemia 
272.1 Pure hyperglyceridemia 
272.2 Mixed hyperlipidemia 
272.3 Hyperchylomicronemia 
272.4 Other and unspecified hyperlipidemia 
 
6. Cancer 
140-239 Neoplasms 
140-149 Malignant Neoplasm Of Lip, Oral Cavity and Pharynx 
150-159 Malignant Neoplasm Of Digestive Organs And Peritoneum 
160-165 Malignant Neoplasm Of Respiratory And Intrathoracic Organs 
170-176 Malignant Neoplasm Of Bone, Connective Tissue, Skin and Breast 
179-189 Malignant Neoplasm Of Genitourinary Organs 
190-199 Malignant Neoplasm Of Other And Unspecified Sites 
200-209 Malignant Neoplasm Of Lymphatic And Hematopoietic Tissue 
 
7. Cardiovascular Disease 
412 Old myocardial infarction 
413 Angina pectoris 
413 Angina decubitus 
413.1 Prinzmetal angina 
413.2 Other and unspecified angina pectoris 
440-449 Diseases Of Arteries, Arterioles and Capillaries 
427 Cardiac dysrhythmias 
427.3 Atrial fibrillation and flutter 
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427.31 Atrial fibrillation 
417.32 Atrial flutter 
 
8. Heart Failure 
428 Heart failure 
394 Diseases of mitral valve 
394 Mitral stenosis 
394.1 Rheumatic mitral insufficiency 
394.2 Mitral stenosis with insufficiency 
395 Diseases of aortic valve 
395.1 Rheumatic aortic insufficiency 
395.2 Rheumatic aortic stenosis with insufficiency 
395.9 Other and unspecified rheumatic aortic diseases 
 
9. Anxiety or Depression 
296 Episodic mood disorders 
296.2 Major depressive disorder single episode 
296.2 Major depressive affective disorder, single episode, unspecified 
296.21 Major depressive affective disorder, single episode, mild 
296.22 Major depressive affective disorder, single episode, moderate 
296.23 Major depressive affective disorder, single episode, severe, without mention of psychotic behavior 
296.24 Major depressive affective disorder, single episode, severe, specified as with psychotic behavior 
296.25 Major depressive affective disorder, single episode, in partial or unspecified remission 
296.26 Major depressive affective disorder, single episode, in full remission 
296.3 Major depressive disorder recurrent episode 
296.3 Major depressive affective disorder, recurrent episode, unspecified 
296.31 Major depressive affective disorder, recurrent episode, mild 
296.32 Major depressive affective disorder, recurrent episode, moderate 
296.33 Major depressive affective disorder, recurrent episode, severe, without mention of psychotic behavior 
296.34 Major depressive affective disorder, recurrent episode, severe, specified as with psychotic behavior 
296.35 Major depressive affective disorder, recurrent episode, in partial or unspecified remission 
296.36 Major depressive affective disorder, recurrent episode, in full remission 
300 Anxiety, dissociative and somatoform disorders 
300 Anxiety states 
300 Anxiety state, unspecified 
300.01 Panic disorder without agoraphobia 
300.02 Generalized anxiety disorder 
300.09 Other anxiety states 
 
10. Osteoarthritis or Rheumatoid Arthritis 
714 Rheumatoid arthritis and other inflammatory polyarthropathies 
714 Rheumatoid arthritis 
714.1 Felty's syndrome 
714.2 Other rheumatoid arthritis with visceral or systemic involvement 
714.3 Juvenile chronic polyarthritis 
715 Osteoarthrosis and allied disorders 
715 Osteoarthrosis generalized 
715.1 Osteoarthrosis localized primary 
715.2 Osteoarthrosis localized secondary 
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715.3 Osteoarthrosis localized not specified whether primary or secondary 
715.8 Osteoarthrosis involving or with mention of more than one site but not specified as generalized 
715.9 Osteoarthrosis unspecified whether generalized or localized 
 
11. Stroke or Transient Ischemic Attack 
434 Occlusion of cerebral arteries 
434 Cerebral thrombosis 
434 Cerebral thrombosis without mention of cerebral infarction 
434.01 Cerebral thrombosis with cerebral infarction 
434.1 Cerebral embolism 
434.1 Cerebral embolism without mention of cerebral infarction 
434.11 Cerebral embolism with cerebral infarction 
433.9 Cerebral artery occlusion unspecified 
434.9 Cerebral artery occlusion, unspecified without mention of cerebral infarction 
434.91 Cerebral artery occlusion, unspecified with cerebral infarction 
435 Transient cerebral ischemia 
435 Basilar artery syndrome 
435.1 Vertebral artery syndrome 
435.2 Subclavian steal syndrome 
435.3 Vertebrobasilar artery syndrome 
435.8 Other specified transient cerebral ischemias 
435.9 Unspecified transient cerebral ischemia 
 
12. Thyroid Problem 
240-246 Disorders Of Thyroid Gland 
240 Goiter, simple not otherwise specified 
241 Nontoxic nodular goiter 
242 Thyrotoxicosis 
243 Congenital hypothyroidism 
244 Acquired hypothyroidism 
245 Thyroiditis 
246 Other disorders of the thyroid 
 
13. Kidney Disease or Failure 
585 Chronic kidney disease 
585.1 Chronic kidney disease, Stage I 
585.2 Chronic kidney disease, Stage II (mild) 
585.3 Chronic kidney disease, Stage III (moderate) 
585.4 Chronic kidney disease, Stage IV (severe) 
585.5 Chronic kidney disease, Stage V 
585.6 End stage renal disease 
585.9 Chronic kidney disease, unspecified 
 
14. Osteoporosis 
733 Osteoporosis 
733 Osteoporosis, unspecified 
733.01 Senile osteoporosis 
733.02 Idiopathic osteoporosis 
733.03 Disuse osteoporosis 
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733.09 Other osteoporosis 
 
15. Dementia 
290 Dementias 
290 Senile dementia, uncomplicated 
290.1 Presenile dementia 
290.1 Presenile dementia, uncomplicated 
290.11 Presenile dementia with delirium 
290.12 Presenile dementia with delusional features 
290.13 Presenile dementia with depressive features 
290.2 Senile dementia with delusional or depressive features 
290.2 Senile dementia with delusional features 
290.21 Senile dementia with depressive features 
290.3 Senile dementia with delirium 
290.4 Vascular dementia 
294 Persistent mental disorders due to conditions classified elsewhere 
294.1 Dementia in conditions classified elsewhere 
294.2 Dementia, unspecified 
 
16. Musculoskeletal Problem 
723 Other disorders of cervical region 
723.1 Cervicalgia 
724 Other and unspecified disorders of back 
724.1 Pain in thoracic spine 
724.2 Lumbago 
724.3 Sciatica 
724.4 Thoracic or lumbosacral neuritis or radiculitis, unspecified 
724.5 Backache, unspecified 
725 Polymyalgia rheumatica 
726 Peripheral enthesopathies and allied syndromes 
726 Adhesive capsulitis of shoulder 
726.1 Rotator cuff syndrome of shoulder and allied disorders 
726.2 Other affections of shoulder region, not elsewhere classified 
726.3 Enthesopathy of elbow region 
726.3 Enthesopathy of elbow, unspecified 
726.31 Medial epicondylitis 
726.32 Lateral epicondylitis 
726.33 Olecranon bursitis 
726.39 Other enthesopathy of elbow region 
726.4 Enthesopathy of wrist and carpus 
726.5 Enthesopathy of hip region 
726.6 Enthesopathy of knee 
726.6 Enthesopathy of knee, unspecified 
726.61 Pes anserinus tendinitis or bursitis 
726.62 Tibial collateral ligament bursitis 
726.63 Fibular collateral ligament bursitis 
726.64 Patellar tendinitis 
726.65 Prepatellar bursitis 
726.69 Other enthesopathy of knee 
268 
726.7 Enthesopathy of ankle and tarsus 
726.7 Enthesopathy of ankle and tarsus, unspecified 
726.71 Achilles bursitis or tendinitis 
726.72 Tibialis tendinitis 
726.73 Calcaneal spur 
726.79 Other enthesopathy of ankle and tarsus 
726.9 Unspecified enthesopathy 
726.9 Enthesopathy of unspecified site 
726.91 Exostosis of unspecified site 
727 Other disorders of synovium tendon and bursa 
727 Synovitis and tenosynovitis 
727 Synovitis and tenosynovitis, unspecified 
727.01 Synovitis and tenosynovitis in diseases classified elsewhere 
727.03 Trigger finger (acquired) 
727.04 Radial styloid tenosynovitis 
727.05 Other tenosynovitis of hand and wrist 
727.06 Tenosynovitis of foot and ankle 
727.09 Other synovitis and tenosynovitis 
727.2 Specific bursitides often of occupational origin 
727.3 Other bursitis 
729 Other disorders of soft tissues 
729 Rheumatism, unspecified and fibrositis 
729.1 Myalgia and myositis, unspecified 
729.2 Neuralgia, neuritis and radiculitis, unspecified 
729.4 Fasciitis, unspecified 
729.5 Pain in limb 
 
17. Stomach Problem 
530 Diseases of esophagus 
530.81 Esophageal reflux 
531 Gastric ulcer 
531.4 Chronic or unspecified gastric ulcer with hemorrhage 
531.4 Chronic or unspecified gastric ulcer with hemorrhage, without mention of obstruction 
531.41 Chronic or unspecified gastric ulcer with hemorrhage, with obstruction 
531.5 Chronic or unspecified gastric ulcer with perforation 
531.5 Chronic or unspecified gastric ulcer with perforation, without mention of obstruction 
531.51 Chronic or unspecified gastric ulcer with perforation, with obstruction 
531.6 Chronic or unspecified gastric ulcer with hemorrhage and perforation 
531.6 Chronic or unspecified gastric ulcer with hemorrhage and perforation, without mention of obstruction 
531.61 Chronic or unspecified gastric ulcer with hemorrhage and perforation, with obstruction 
531.7 Chronic gastric ulcer without mention of hemorrhage or perforation 
531.7 Chronic gastric ulcer without mention of hemorrhage or perforation, without mention of obstruction 
531.71 Chronic gastric ulcer without mention of hemorrhage or perforation, with obstruction 
531.9 Gastric ulcer unspecified as acute or chronic without mention of hemorrhage or perforation 
531.9 
Gastric ulcer, unspecified as acute or chronic, without mention of hemorrhage or perforation, without 
mention of obstruction 
531.91 
Gastric ulcer, unspecified as acute or chronic, without mention of hemorrhage or perforation, with 
obstruction 
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18. Colon Problem 
555 Regional enteritis 
555.1 Regional enteritis of large intestine 
555.2 Regional enteritis of small intestine with large intestine 
555.9 Regional enteritis of unspecified site 
556 Ulcerative enterocolitis 
556 Ulcerative (chronic) enterocolitis 
556.4 Pseudopolyposis of colon 
556.5 Left-sided ulcerative (chronic) colitis 
556.6 Universal ulcerative (chronic) colitis 
556.8 Other ulcerative colitis 
556.9 Ulcerative colitis, unspecified 
564 Functional digestive disorders not elsewhere classified 
564.1 Irritable bowel syndrome 
 
19. Liver Disease 
571 Chronic liver disease and cirrhosis 
571 Alcoholic fatty liver 
571.1 Acute alcoholic hepatitis 
571.2 Alcoholic cirrhosis of liver 
571.3 Alcoholic liver damage, unspecified 
571.4 Chronic hepatitis 
571.4 Chronic hepatitis, unspecified 
571.41 Chronic persistent hepatitis 
571.42 Autoimmune hepatitis 
571.49 Other chronic hepatitis 
571.5 Cirrhosis of liver without mention of alcohol 
571.6 Biliary cirrhosis 
571.8 Other chronic nonalcoholic liver disease 
571.9 Unspecified chronic liver disease without mention of alcohol 
 
20. Urinary Problem 
593 Other disorders of kidney and ureter 
593.3 Stricture or kinking of ureter 
593.4 Other ureteric obstruction 
593.5 Hydroureter 
593.7 Vesicoureteral reflux 
593.7 Vesicoureteral reflux unspecified or without reflux nephropathy 
593.71 Vesicoureteral reflux with reflux nephropathy, unilateral 
593.72 Vesicoureteral reflux with reflux nephropathy, bilateral 
593.73 Other vesicoureteral reflux with reflux nephropathy NOS 
593.8 Other specified disorders of kidney and ureter 
593.82 Ureteral fistula 
593.89 Other specified disorders of kidney and ureter 
593.9 Unspecified disorder of kidney and ureter 
595 Cystitis 
595.1 Chronic interstitial cystitis 
595.2 Other chronic cystitis 
595.9 Cystitis, unspecified 
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597 Urethritis not sexually transmitted and urethral syndrome 
597.8 Urethritis, unspecified 
597.81 Urethral syndrome NOS 
597.82 Other urethritis 
600 Hyperplasia of prostate 
601 Inflammatory diseases of prostate 
601.1 Chronic prostatitis 
601.3 Prostatocystitis 
601.8 Other specified inflammatory diseases of prostate 
601.9 Prostatitis, unspecified 
602 Other disorders of prostate 
602 Calculus of prostate 
602.1 Congestion or hemorrhage of prostate 
602.2 Atrophy of prostate 
602.3 Dysplasia of prostate 
602.8 Other specified disorders of prostate 
602.9 Unspecified disorder of prostate 
* Reproduced with permission from co-Principal Investigator of PACE in MM CBPHC Team (Dr. Martin Fortin) 
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Appendix H. Multimorbidity Cluster Analysis Toolkit  
 
 
 
 
Multimorbidity Cluster Analysis Toolkit 
Background  
In examining the burden of multimorbidity, which is the co-occurrence of multiple health issues 
within an individual, previous literature has focused on the descriptive counting of singular 
diseases and the link between non-random clusters of diseases (Garin et al., 2014; Prados-Torres 
et al., 2012).  When examining clusters of diseases, the majority of research has been limited in 
reporting pairs or triplets of chronic disease occurrences.  However, the analysis of cumulative 
interactions and the complete clustering that is occurring within a cohort will help lead to a more 
nuanced understanding of the complexity and uniqueness of individuals living with 
multimorbidity.  
 
A computational cluster analysis can be used to explore and detect the distinct clinical profiles 
that exist within a sample of participants or patients in a research project.  While the 
operationalization of multimorbidity can vary in research projects due to the lack of a gold 
standard measure, research has indicated that at least 12 chronic diseases should be included to 
capture the burden of multimorbidity (Fortin et al., 2012).  As such, detecting all possible 
combinations (that is, unordered clusters) and permutations (that is, ordered clusters) in a dataset 
can become exponentially difficult.  However, there is a need to identify these diverse patients 
and to understand how health outcomes might be impacted based on cluster type.  
 
The Multimorbidity Cluster Analysis Tool (herein referred to as: Tool) and the accompanying 
Multimorbidity Cluster Analysis Toolkit (herein referred to as: Toolkit) have been created to 
allow researchers to identify distinct clusters or clinical profiles that exist within a sample of 
participants or patients living with multimorbidity.  This computational program can be adapted 
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for research projects that utilize varying data sources, diagnostic or disease-reporting systems, 
multimorbidity measurements, sample sizes and research settings.  Its intent is to facilitate a 
consistent approach to identifying subgroups of participants or patients who are living with 
multimorbidity, based on cluster type and cluster sequence.  This information is driven by the 
data and the corresponding results should be assessed carefully.  While this information can be a 
helpful resource for research, clinical care and health policy decisions, the results should be 
interpreted within the appropriate context.  Interpretation of these should incorporate both 
clinical and patient-centered insight.  
 
Development Of This Tool & Toolkit  
The Tool and Toolkit was developed by a research team at Western University from the 
Department of Epidemiology & Biostatistics and the Department of Computer Science.  The 
computational program was developed and prototyped using the electronic medical record 
(EMR) data from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) 
database.  This database is based at Queen’s University and is funded by the Public Health 
Agency of Canada under a contribution agreement with the College of Family Physicians of 
Canada.  The views expressed herein do not necessarily represent the views of the Public Health 
Agency of Canada or the College of Family Physicians of Canada.  
 
The Tool and Toolkit is available for use by any academic researchers who are interested in 
exploring the nuanced characteristics of participants or patients living with multimorbidity.  
When used in research projects, the authors request that appropriate acknowledgement (below) is 
made in any publications or presentations.  
 
Bauer M & Nicholson K.  Multimorbidity Cluster Analysis Tool & Toolkit.  2016.  
 
Who Should Use This Tool & Toolkit?  
Once again, the Tool and Toolkit is available for use by any academic researchers who are 
interested in exploring the nuanced characteristics of participants or patients living with 
multimorbidity.  As noted, the computational program can be adapted to the methodological 
elements of the research project.  These variations include: 1) type of data (e.g., large secondary 
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datasets of electronic information; small primary datasets of self-reported information); 2) type 
of chronic disease information (e.g., ICD-10 Codes; ICD-9 Codes; ICPC-2 Codes; SNOMED CT 
Codes; Read Codes; self-reported diagnoses); 3) multimorbidity measurements (e.g., 
operationalization using 12, 20 or 100 chronic disease diagnoses or chronic disease categories); 
4) sample sizes (e.g., from 2 to approximately 150,000 individual records from participants or 
patients); and 5) research settings (e.g., primary health care; administrative; community-
dwelling).  
 
The computational program will identify all existing, and mutually exclusive, combinations and 
permutations within the dataset.  A description of each concept is included below.  
 
An example of an unordered cluster or combination of multiple chronic diseases would be those 
individuals (participants or patients) who have been diagnosed or have self-reported the same 
three chronic diseases (e.g., obesity, hypertension, cancer), but these diseases did not occur in the 
same sequence between the individuals.  For example, some individuals may have been 
diagnosed with hypertension, then cancer and then obesity.  In comparison, other individuals 
may have been diagnosed with cancer, then obesity and then hypertension.  These individuals 
would still be clustered within the same combination.  
 
 An example of an ordered cluster or permutation of multiple chronic diseases would be those 
individuals (participants or patients) who have been diagnosed or have self-reported the same 
three chronic diseases (e.g., obesity, hypertension, cancer), and these diseases did occur in the 
same sequence between the individuals.  For example, all individuals who may have been 
diagnosed with hypertension, then cancer and then obesity would be clustered within the same 
permutation.  In comparison, those individuals who were diagnosed with cancer, then obesity 
and then hypertension would be clustered within the same permutation.  
 
This computational program will conduct an individual-level categorization to determine the 
frequency and type of mutually exclusive clusters of diseases (that is, combinations and 
permutations) among a sample of individuals with multimorbidity.  This analysis could also be 
tailored to exploring the burden of multimorbidity among a specific subset of participants or 
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patients, such as among a cohort of individuals who are all living with diabetes or depression.  In 
these analyses, the data input file will include only those individuals with the main chronic 
disease of interest, and as such, these results will create output that is more in accordance with 
the concept of co-morbidity.  The concept of multimorbidity ensures that no one chronic disease 
diagnoses takes precedence or focus over any other co-occurring disease within an individual.  
As such, each chronic disease is of equal importance in the conceptualization and analysis of the 
data.  Importantly, however, the results that are created by the computational program do not 
indicate any causal link between the diseases.  
 
What Does This Tool & Toolkit Contain?  
As a companion to the Multimorbidity Cluster Analysis Tool, this Toolkit contains the following 
items: 1) summary of the background, development and use of the Tool; 2) summary of the 
process of creating both the input and output files for the Tool; and 3) frequently asked 
questions.  The Multimorbidity Cluster Analysis Tool (which consists of JAVA code and an 
executable file) has been developed and tested to support up to 150,000 individual records and 
up to 100 disease diagnoses or disease categories.  The basic setup of the input data file was 
designed to allow for reasonable adaptability to methodological differences between research 
projects.  The time that elapses between occurrences of another chronic disease can also be 
explored using this Tool, if the data are available within the research project.  
 
How Should This Tool & Toolkit Be Used?  
The process of using this Tool is outlined below in two multi-part steps.  Step One describes how 
to create the required structure of the input data file and Step Two describes how to run the 
computational program that will create the output data files.  Finally, although the purpose of the 
Multimorbidity Cluster Analysis Tool was developed (and will be explained) with a focus on 
multiple chronic diseases, the same approach could be applied using multiple disease symptoms 
or multiple acute diseases.  
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Step One  
1. Unique Participant/Patient Identifier  
o A unique identifier should be created for each participant or patient within the input data 
file (herein referred to as: ID).  This ID can be maintained from the original study 
database (e.g., 12345, 12346) or can be created as a new unique identifier in the input 
file (e.g., 1, 2, 3).  
o The unique ID for each participant or patient should begin each new line.  This will be 
followed by the individual’s corresponding chronic disease and the time elapsing 
between each occurrence (if applicable).  Only one unique ID should be included on 
each line, and the diagnoses and time variables should be included on the same line and 
correspond directly to each ID.  
o This structure forms the basis of the input data file.  This file can be created in a data 
management program (e.g., SAS, Stata, Excel) and it must then be saved as or exported 
as a “.txt (comma separated values)” file.  
o After the input data file has been saved, it is encouraged that the file is then opened and 
inspected to ensure for appropriate structure and layout (displayed in Figure 1).  
Figure 1: Example Input Data File 
 
2. Chronic Disease Diagnosis/ Disease Category 
o The chronic disease diagnoses or chronic disease category (herein referred to as: 
Disease) that is included in the definition of multimorbidity should be created and 
finalized prior to creating the input data file.  All relevant ICD-10 codes, Read codes or 
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self-reported diseases should be identified to identify those individuals living with 
multimorbidity.  For example, the list of codes or self-reported diseases that constitute 
an occurrence of “diabetes” or “anxiety” should be applied to the dataset.  
o The name of the diagnosis or category can be maintained from the original study, but 
only up to a maximum of ten characters (e.g., anxiety, cancer, Hypertensi).  As such, the 
research team can decide to pre-emptively shorten the name of the diagnosis or category 
before running the computational program.  It is important that the identification and 
naming of each chronic disease is maintained throughout the input data file to ensure 
appropriate interpretation of the output data files, where the same names will be used. 
  
3. Time Between Chronic Diseases  
o If available within the original database, the time elapsing between each date of chronic 
disease (herein referred to as: Time) should be calculated (e.g., in whole days, in whole 
years) and included in the input data file.  The accuracy of these dates should be 
assessed, and biases should be acknowledged if necessary.  
o Typically, the first date of chronic disease occurrence should be used in the calculation 
(to capture the incident chronic disease occurrence) and the resulting time value must be 
rounded to the nearest whole number. 
o The time elapsing between individual chronic disease diagnoses can be calculated in the 
original database by the following equation: [Date of Diagnosis 2] – [Date of Diagnosis 
1].  The same calculation should be used to determine the time elapsing between each 
chronic disease occurrence.  
o It is important to structure the input data file as follows:  
ID, Disease 1, Time 1, Disease 2, Time 2, Disease 3, Time 3, … 
Where Time 1 = Time (whole number) elapsing between Disease 2 and Disease 1 
Time 2 = Time (whole number) elapsing between Disease 3 and Disease 2 
Time 3 = Time (whole number) elapsing between Disease 4 and Disease 3 
 
Step One Summary  
o The input data file should consist of the following information (separated by commas): 
ID, Disease 1, Time 1, Disease 2, Time 2, Disease 3, Time 3, … 
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o The input data can be prepared in a data management program (e.g., SAS, Stata, Excel) 
and should be saved as or exported as a “.txt (comma separated values)” file for use in the 
computational program.   
o This file should be named to be easily identifiable for use in the Multimorbidity Cluster 
Analysis Tool (e.g., mmpatients.txt).  
o Finally, a new folder should be created to hold both the .txt input data file and the 
Multimorbidity Cluster Analysis Tool computational program (which will be accessed 
from the internet in Step Two).  
 
Step Two 
1. Running Computational Program  
o Once the final input data file has been prepared and saved as a .txt file, the 
Multimorbidity Cluster Analysis Tool can now be utilized.  Both the Tool and Toolkit 
are accessible from www.csd.uwo.ca/faculty/bauer/ under the link called 
“Multimorbidity Toolkit” (located to the left on the webpage).  
o To download the program, click on “mm cluster tool”.  When asked to save the 
program, select “Yes”.  The program will download onto the computer system and is 
labelled as “mm cluster tool.jar”.  This .jar program should be saved and moved into the 
same folder as the final input data file that was previously created and saved.  
➢ A JAVA runtime environment is required on the system.  If the “mm cluster tool.jar” 
does not run, a JAVA runtime environment is needed.  A JAVA runtime environment 
can be downloaded online.  To download, select the version that is required for the 
system (e.g., Windows x86) and install this JAVA runtime environment.  
o To run the Multimorbidity Cluster Analysis Tool, double click on the saved “mm cluster 
tool.jar” file.  The program will first prompt for the input data file using an “Open” box.  
Select the appropriate input data file and select “Open”.  
o The program will produce a sequence of display messages, which will inform the user 
of completed steps (e.g., Reading from file; Number of records processed; Number of 
permutations/combinations found; Writing permutations to file; Completed writing 
permutations; Writing combinations to file; Completed writing combinations; 
Processing completed).  Select “OK” for each step, as program waits for user response.  
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o Each output data file name indicates if it holds the permutations (mmperms.txt) or 
combinations (mmcombs.txt) and whether it holds detailed results (mmpermsDetails.txt 
or mmcombsDetails.txt).  Each output file name also contains the date and time of file 
creation, which will be displayed below.  This means that consecutive runs of the 
program will produce uniquely named files and previous files will not be overwritten.  
 
2. Output Data Files 
o After running through all completed steps, the program will automatically save the 
output data files (as .txt files) in the same folder as the .jar program and input data file.   
o A total of four output files will be created and each are described further below.  
Example output data files are also included below.  
1) The “mmpermsDATETIME.txt” output data file contains all permutations 
(ordered clusters) of diagnoses or categories.  The output is a sort list of 
permutations, which is presented in order from most frequent to least frequent for 
each group of participants or patients with the same number of diseases (e.g., 2 
diseases, 3 diseases, 4 diseases).  These permutations are represented using the 
“>>” character, which indicates an additional disease (in that specific sequence).  
The format of this output file is: Disease Permutation Type, Number of 
Occurrences (Number of Participants/Patients), Total Time (Cumulative from 
First to Last Disease in Days), Mean Time (Days), Standard Deviation Time 
(Days).  This is displayed in Figure 2.  
Figure 2: Output Data File of Permutations  
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2) The “mmcombsDATETIME.txt” output data file contains all combinations 
(unordered clusters) of diagnoses or categories.  The output is a sort list of 
combinations, which is presented in order from most frequent to least frequent for 
each group of participants or patients with the same number of diseases (e.g., 2 
diseases, 3 diseases, 4 diseases).  These combinations are represented using the 
“&” character, which indicates an additional disease (regardless of specific 
sequence).  The format of this output file is: Disease Combination Type, Number 
of Occurrences (Number of Participants/Patients), Total Time (Cumulative from 
First to Last Disease in Days), Mean Time (Days), Standard Deviation Time 
(Days).  This is displayed in Figure 3.  
Figure 3: Output Data File of Combinations  
 
3) The “mmpermsDetailsDATETIME.txt” output data file contains the same 
permutations as the “mmpermsDATETIME.txt” output data file.  This includes 
the Disease Permutation Type, Number of Occurrences (Number of 
Participants/Patients), Total Time (Cumulative from First to Last Disease in 
Days), Mean Time (Days), Standard Deviation Time (Days).  To build from this 
information, the output data file contains further details for each permutation.  
More specifically, the Mean Time (Days) and Standard Deviation Time (Days) is 
presented for each sequence of diseases within a permutation.  The IDs of 
individuals contained within these mutually exclusive clusters are also included in 
this output data file.  This is displayed in Figure 4.  
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Figure 4: Output Data File of Permutation Details 
 
4) The “mmcombsDetailsDATETIME.txt” output data file contains the same 
combinations as the “mmcombsDATETIME.txt” output data file.  This includes 
the Disease Combination Type, Number of Occurrences (Number of 
Participants/Patients), Total Time (Cumulative from First to Last Disease in 
Days), Mean Time (Days), Standard Deviation Time (Days).  To build from this 
information, the output data file contains further details for each combination.  
More specifically, the Mean Time (Days) and Standard Deviation Time (Days) is 
presented for each sequence of diseases within a combination.  The IDs of 
individuals contained within these mutually exclusive clusters are also included in 
this output data file.  This is displayed in Figure 5.  
Figure 5: Output Data File of Permutation Details 
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Step Two Summary  
o The Multimorbidity Cluster Analysis Tool and Toolkit can be accessed from 
www.csd.uwo.ca/faculty/bauer/ under the link called “Multimorbidity Toolkit”.  To run 
the computational program, the “mm cluster tool.jar” and a JAVA runtime environment 
must be downloaded onto the computer.  
o After running through the complete computational program, a total of four output data 
files are created and automatically saved as .txt files within the same folder as the Tool 
and the input data file.  If the program does not run properly, the process of addressing 
any issues in the input data file is outlined in Frequently Asked Questions.  
o These files are named using unique titles based on the date and time of data analysis, 
which means that consecutive runs of the program will produce uniquely named files and 
previous files will not be overwritten.  
o Finally, these four output data files capture both the general and specific information of 
the combinations (that is, unordered clusters) and the permutations (that is, ordered 
clusters) that exist among the participants or patients within the input data file.  These 
output files can be then be imported into data management programs (e.g., Excel) for 
further processing.  
 
Frequently Asked Questions 
 
Question:  Do I have to abbreviate the chronic disease diagnosis/chronic disease category 
names myself?  
Answer:   You may choose to shorten the condition/disease category names yourself or the 
program will automatically shorten the category names to ten characters.   
 
Question:  I cannot find the “mm cluster tool.jar” file on my computer after accessing and 
downloading the Tool online.  Where is it located on my computer?  
Answer: After accessing the Tool online and downloading the file to your computer, the 
file may automatically be placed in the “Downloads” folder or the “Desktop”.  
You can also “Search” for the file on your computer.  Once the file has been 
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located, the file should then be relocated into the same folder that holds the input 
data file.  
 
Question: The data that I will be using to create my input data file does not contain 
information on the date of diagnoses, so I cannot calculate the time between 
diagnoses.  Can I still use this Tool to determine the most frequently occurring 
clusters?    
Answer:   Yes, researchers who do not have data on the time between diagnoses can still use 
this Tool.  In order for the computational program to run properly, however, it is 
important to maintain a column for the time variable between each diagnoses 
(space holder = 0).  For example, it is important to structure the input data file as 
follows:  
ID, Disease 1, Time 1, Disease 2, Time 2, Disease 3, Time 3, … 
Where Time 1, Time 2 and Time 3 = 0  
 
Question: I have prepared the input data file as outlined in this Toolkit and have saved it as a 
common separated text file (.txt file).  After ensuring that the input data file is 
saved in the same folder as the “mm cluster tool.jar” file on my computer and 
selecting this data file for the computational program, I am still receiving an error 
message that the program cannot run.  Why isn’t the program working?  
Answer: There may be a few reasons why the Multimorbidity Cluster Analysis Tool is not 
working properly.  Typically, this is resolved by carefully reviewing your data 
file after exporting the data from the data management program.  Firstly, it is 
important to ensure that you have the correct data structure in your file: 
Participant/Patient ID, Disease Diagnosis/Disease Category, Time Between 
Diseases.  Secondly, it is important to ensure that the Time Between Diseases is 
rounded to the nearest whole number (no decimal points or values below zero).  
Finally, it is important to ensure that there are no extra commas (,) or blank data 
lines in the input data file.  Each of these steps should alleviate errors previously 
encountered, after careful review of the input data file.   
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Question: If I have a follow-up question or comment about the Multimorbidity Cluster 
Analysis Tool and/or Toolkit, where can these be submitted?  
Answer:  Further questions or comments about the Multimorbidity Cluster Analysis Tool 
and/or Toolkit can be directed to: mmclusteranalysis@gmail.com.  
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Appendix I. Identifying “First Occurrence” Chronic Disease Diagnoses 
For each eligible adult patient, the first occurrence of a chronic disease diagnoses (from 
the list of twenty chronic disease categories in Table 4.2) was identified.  This approach 
captured the patient’s first recorded diagnosis for a chronic disease, as well as the corresponding 
diagnosis date.  This represented the first time a patient received documentation of a diagnoses 
within their EMR.  Importantly, the term “incident” was not selected for these chronic disease 
diagnoses, as one cannot definitively state that the diagnostic codes that appear in the patient’s 
EMR are true incident cases of the disease.  For example, a patient may be experiencing 
symptoms of Anxiety or Depression, without receiving a diagnostic code within their EMR.  In 
these cases, while the diagnostic code was not recorded in the patient’s EMR, the patient is very 
much living with this chronic disease.  Alternatively, a patient may have already received a 
diagnosis for Anxiety or Depression from a PHC provider who is not participating in the 
CPCSSN database.  In these cases, the diagnosis for Anxiety or Depression may eventually 
appear within the patient’s EMR, but does not represent the true incidence of this disease (which 
was detected first by the non-participating PHC provider).  Instead, the diagnosis recorded by the 
participating provider would constitute the “first occurrence” of this chronic disease in the 
CPCSSN database.  To detect each patient’s first occurrence of a chronic disease diagnosis, 
patient data were sorted by Patient ID and Encounter Date or Service Date variables (for 
Encounter Diagnosis codes and Billing Diagnosis codes, respectively) and the first 
chronologically diagnosed chronic disease (again, from the list of twenty) was identified.   
The corresponding date on which these chronic disease diagnoses were made was another 
important consideration for Objective Two and its time-to-event analysis.  Within the Billing 
Diagnosis and Encounter Diagnosis tables, date information could be found within two variables: 
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Encounter Date (which represented the actual date of the encounter) and Date Created (which 
represented the date the code was input into the EMR).  A systematic approach was used to 
assign the most appropriate date to each chronic disease diagnosis.  To begin, the Encounter Date 
was selected if available; if this date was missing, the Date Created was used as the alternate date 
source.  Consistency between dates was checked for diagnoses that had both an Encounter Date 
and Date Created.  Consistency between dates was reasonable and did not represent a large 
discrepancy (e.g., the majority of Date Created entries were within one week of the Encounter 
Date), indicating that this was a feasible approach to obtaining the approximate date of each 
chronic disease diagnosis.   
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Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian 
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance 
Network (CPCSSN) electronic medical record (EMR) data 
 Prevalence (95% CI) 
Data Source CCHS CPCSSN CCHS CPCSSN CCHS CPCSSN 
Disease Category 
High Blood 
Pressure 
Hypertension 
Category 
Overweight or 
Obese 
Obesity Category Diabetes Diabetes Category 
Females (Age Category, Years) 
18 –  34 1.9 (1.6 – 2.1) 1.0 (1.0 – 1.2) 33.0 (32.2 – 33.8) 19.7 (19.3 – 20.0) 1.1 (0.9 – 1.3) 0.8 (0.7 – 0.8) 
35 – 44  5.9 (5.4 – 6.5) 2.9 (2.8 – 3.1) 44.9 (43.9 – 46.0) 25.3 (24.9 – 25.8) 3.3 (2.9 – 3.7) 1.2 (1.1 – 1.3) 
45 – 64  24.9 (24.3 – 25.4) 9.4 (9.2 – 9.6) 53.4 (52.8 – 54.1) 26.3 (26.0 – 26.6) 8.8 (8.4 – 9.1) 2.7 (2.6 – 2.8) 
65 – 79 48.3 (47.6 – 49.1) 21.0 (20.6 – 21.4) 55.8 (55.0 – 56.7) 23.4 (23.0 – 23.8) 15.8 (15.2 – 16.4) 6.1 (5.9 – 6.4) 
≥ 80 ** 56.4 (55.1 – 57.6) 28.9 (28.3 – 29.6) 41.0 (39.7 – 42.2) 13.1 (12.7 – 13.6) 15.2 (14.3 – 16.1) 6.9 (6.6 – 7.3) 
Males (Age Category, Years) 
18 –  34 2.8 (2.5 – 3.1) 1.6 (1.5 – 1.7) 46.4 (45.4 – 47.3) 18.8 (18.4 – 19.3) 0.9 (0.7 – 1.1) 0.8 (0.7 – 1.0) 
35 – 44  9.2 (8.6 – 9.9) 4.5 (4.2 – 4.7) 66.7 (65.6 – 67.8) 27.6 (27.0 – 28.1) 3.1 (2.6 – 3.5) 1.8 (1.7 – 2.0) 
45 – 64  28.9 (28.3 – 29.6) 11.6 (11.3 – 11.8) 69.1 (68.4 – 69.7) 31.8 (31.4 – 32.1) 11.2 (10.7 – 11.6) 4.5 (4.4 – 4.7) 
65 – 79 46.3 (45.5 – 47.2) 19.4 (19.0 – 19.9) 65.4 (64.6 – 66.2) 28.2 (27.7 – 28.8) 21.6 (20.9 – 22.4) 9.3 (9.0 – 9.7) 
≥ 80 ** 46.9 (45.2 – 48.6) 23.0 (22.3 – 23.7) 44.8 (43.2 – 46.5) 18.5 (17.8 – 19.1) 18.4 (17.2 – 19.7) 9.5 (9.0 – 10.0) 
Note: All prevalence estimates and 95% CIs calculated by author 
* CI = Confidence interval 
** The oldest age category in the 2013 CCHS was 80 years and older 
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Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian 
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance 
Network (CPCSSN) electronic medical record (EMR) data, Continued 
 Prevalence (95% CI) 
Data Source CCHS CCHS CPCSSN CCHS CPCSSN 
Disease Category 
Chronic Obstructive 
Pulmonary Disease 
Asthma 
Chronic Obstructive 
Pulmonary Disease or 
Asthma Category 
Cancer Cancer Category 
Females (Age Category, Years) 
18 –  34 Not Reported 10.4 (9.9 – 11.0) 3.9 (3.8 – 4.1) 0.3 (0.2 – 0.4) 4.9 (4.7 – 5.1) 
35 – 44  1.6 (1.3 – 1.9) 10.0 (9.4 – 10.7) 3.9 (3.7 – 4.1) 0.8 (0.6 – 1.0) 5.7 (5.5 – 6.0) 
45 – 64  5.0 (4.8 – 5.3) 9.6 (9.2 – 10.0) 3.2 (3.1 – 3.3) 2.5 (2.4 – 2.8) 5.9 (5.8 – 6.1) 
65 – 79 8.5 (8.1 – 9.0) 9.2 (8.8 – 9.7) 2.5 (2.3 – 2.6) 4.8 (4.5 – 5.2) 5.2 (5.0 – 5.4) 
≥ 80 ** 8.0 (7.4 – 8.7) 6.8 (6.2 – 7.4) 2.0 (1.8 – 2.2) 5.4 (4.9 – 6.0) 4.8 (4.5 – 5.1) 
Males (Age Category, Years)  
18 –  34 Not Reported 8.5 (8.0 – 9.0) 4.5 (4.3 – 4.8) 0.2 (0.1 – 0.3) 3.2 (3.0 – 3.4) 
35 – 44  1.3 (1.0 – 1.6) 7.0 (6.5 – 7.7) 3.7 (3.5 – 4.0) 0.3 (0.2 – 0.4) 3.2 (3.0 – 3.4) 
45 – 64  4.6 (4.3 – 4.9) 6.3 (5.9 – 6.6) 2.5 (2.4 – 2.6) 2.4 (2.2 – 2.6) 3.4 (3.2 – 3.5) 
65 – 79 7.3 (6.8 – 7.7) 6.0 (5.6 – 6.4) 1.9 (1.8 – 2.1) 6.1 (5.7 – 6.5) 4.9 (4.7 – 5.2) 
≥ 80 ** 9.1 (8.1 – 10.1) 6.5 (5.7 – 7.4) 2.1 (1.8 – 2.3) 9.6 (8.6 – 10.6) 7.0 (6.6 – 7.4) 
Note: All prevalence estimates and 95% CIs calculated by author 
* CI = Confidence interval 
** The oldest age category in the 2013 CCHS was 80 years and older 
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Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian 
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance 
Network (CPCSSN) electronic medical record (EMR) data, Continued 
 Prevalence (95% CI) 
Data Source CCHS CPCSSN CCHS CCHS CPCSSN 
Disease Category Heart Disease 
Cardiovascular Disease 
Category 
Anxiety Depression 
Anxiety or Depression 
Category 
Females (Age Category, Years) 
18 –  34 0.8 (0.7 – 1.0) 0.6 (0.5 – 0.7) 11.5 (11.0 – 12.1) 33.0 (32.2 – 33.8) 12.1 (11.8 – 12.4) 
35 – 44  1.0 (0.8 – 1.3) 0.7 (0.6 – 0.8) 9.7 (9.1 – 10.4) 32.2 (31.2 – 33.2) 12.1 (11.8 – 12.4) 
45 – 64  4.1 (3.8 – 4.3) 1.0 (0.9 – 1.1) 9.7 (9.3 – 10.1) 33.9 (33.3 – 34.5) 9.6 (9.4 – 9.8) 
65 – 79 11.8 (11.3 – 12.3) 2.1 (1.9 – 2.2) 6.6 (6.2 – 7.0) 33.3 (32.6 – 34.0) 5.2 (5.0 – 5.5) 
≥ 80 ** 23.1 (22.0 – 24.1) 5.5 (5.2 – 5.9) 4.1 (3.7 – 4.7) 31.7 (30.5 – 32.9) 3.6 (3.4 – 3.9) 
Males (Age Category, Years)  
18 –  34 0.8 (0.6 – 0.9) 0.6 (0.5 – 0.7) 6.6 (6.1 – 7.1) 31.9 (31.0 – 32.7) 10.7 (10.3 – 11.0) 
35 – 44  1.6 (1.3 – 1.9) 0.6 (0.5 – 0.7) 6.2 (5.7 – 6.8) 32.4 (31.3 – 33.5) 8.9 (8.5 – 9.2) 
45 – 64  7.7 (7.3 – 8.1) 1.7 (1.6 – 1.8) 5.9 (5.6 – 6.2) 33.3 (32.6 – 33.9) 5.8 (5.6 – 6.0) 
65 – 79 19.1 (18.4 – 19.8) 4.8 (4.5 – 5.0) 3.7 (3.4 – 4.0) 34.0 (33.2 – 34.9) 3.0 (2.8 – 3.2) 
≥ 80 ** 26.0 (24.5 – 27.5) 8.3 (7.9 – 8.8) 2.6 (2.1 – 3.2) 29.9 (28.4 – 31.4) 2.1 (1.9 – 2.4) 
Note: All prevalence estimates and 95% CIs calculated by author 
* CI = Confidence interval 
** The oldest age category in the 2013 CCHS was 80 years and older 
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Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian 
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance 
Network (CPCSSN) electronic medical record (EMR) data, Continued 
 Prevalence (95% CI) 
Data Source CCHS CPCSSN CCHS CPCSSN CCHS CPCSSN 
Disease Category Arthritis 
Osteoarthritis or 
Rheumatoid Arthritis 
Category 
Stroke 
Stroke or Transient 
Ischemic Attack 
Category 
Back Problems 
Musculoskeletal 
Problem Category 
Females (Age Category, Years)  
18 –  34 3.1 (2.8 – 3.4) 0.4 (0.4 – 0.5) 2.0 (1.8 – 2.3) 0.01 (0.0 – 0.02) 14.1 (13.5 – 14.7) 7.1 (6.8 – 7.3) 
35 – 44  8.7 (8.1 – 9.3) 0.8 (0.7 – 0.9) 2.2 (1.9 – 2.5) 0.02 (0.01 – 0.05) 18.2 (17.4 – 19.1) 9.5 (9.2 – 9.8) 
45 – 64  30.4 (29.8 – 31.0) 2.7 (2.6 – 2.8) 3.5 (3.3 – 3.8) 0.05 (0.04 – 0.07) 25.4 (24.8 – 26.0) 10.7 (10.5 – 11.0) 
65 – 79 50.0 (48.9 – 50.5) 4.9 (4.7 – 5.1) 3.6 (3.4 – 3.9) 0.2 (0.1 – 0.2) 26.6 (25.9 – 27.3) 6.5 (6.2 – 6.7) 
≥ 80 ** 57.2 (55.9 – 58.4) 5.7 (5.4 – 6.0) 3.6 (3.2 – 4.1) 0.5 (0.4 – 0.6) 28.3 (27.2 – 29.5) 5.2 (4.9 – 5.5) 
Males (Age Category, Years) 
18 –  34 2.4 (2.1 – 2.7) 0.5 (0.4 – 0.6) 1.7 (1.5 – 2.0) 0.01 (0.01 – 0.04) 10.5 (9.9 – 11.1) 9.9 (9.6 – 10.3) 
35 – 44  7.1 (6.5 – 7.7) 0.9 (0.8 – 1.0) 2.2 (1.9 – 2.5) 0.01 (0.00 – 0.03) 19.0 (18.1 – 20.0) 12.5 (12.1 – 12.9) 
45 – 64  21.1 (20.5 – 21.7( 2.2 (2.1 – 2.3) 2.9 (2.6 – 3.2) 0.1 (0.1 – 0.2) 25.8 (25.2 – 26.4) 10.8 (10.6 – 11.1) 
65 – 79 34.1 (33.2 – 34.9) 3.5 (3.2 – 3.7) 2.9 (2.6 – 3.2) 0.1 (0.1 – 0.2) 25.6 (24.8 – 26.4) 5.6 (5.3 – 5.8) 
≥ 80 ** 42.1 (40.4 – 43.7) 4.1 (3.8 – 4.4) 3.2 (2.6 – 3.8) 0.5 (0.4 – 0.7) 24.3 (22.9 – 25.8) 4.5 (4.1 – 4.9) 
Note: All prevalence estimates and 95% CIs calculated by author 
* CI = Confidence interval 
** The oldest age category in the 2013 CCHS was 80 years and older 
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Appendix J: Comparative prevalence estimates for selected self-reported chronic disease diagnoses from the 2013 Canadian 
Community Health Survey (CCHS) and the chronic disease categories from the Canadian Primary Care Sentinel Surveillance 
Network (CPCSSN) electronic medical record (EMR) data, Continued 
 Prevalence (95% CI) 
Data Source CCHS CPCSSN CCHS CPCSSN 
Disease Category  Stomach Problems Stomach Problem Category Bowel Problems Colon Problem Category 
Females (Age Category, Years)  
18 –  34 1.1 (0.9 – 1.3) 0.7 (0.6 – 0.8) 0.2 (0.1 – 0.3) 1.8 (1.7 – 1.9) 
35 – 44  3.0 (2.7 – 3.4) 0.7 (0.7 – 0.8) 0.4 (0.2 – 0.5) 1.3 (1.2 – 1.5) 
45 – 64  9.0 (8.7 – 9.4) 0.8 (0.8 – 0.9) 1.3 (1.1 – 1.4) 1.1 (1.0 – 1.2) 
65 – 79 16.4 (15.8 – 17.0) 0.9 (0.8 – 1.0) 2.5 (2.3 – 2.8) 0.8 (0.7 – 0.9) 
≥ 80 ** 20.6 (19.6 – 21.7) 0.7 (0.6 – 0.8) 5.2 (4.7 – 5.8) 0.6 (0.5 – 0.7) 
Males (Age Category, Years) 
18 –  34 0.5 (0.4 – 0.7) 1.1 (1.0 – 1.2) 0.1 (0.1 – 0.2) 1.1 (1.0 – 1.3) 
35 – 44  1.2 (1.0 – 1.5) 1.2 (1.1 – 1.4) 0.4 (0.3 – 0.6) 1.0 (0.9 – 1.1) 
45 – 64  4.9 (4.6 – 5.2) 1.0 (0.9 – 1.1) 1.5 (1.3 – 1.7) 0.7 (0.6 – 0.8) 
65 – 79 15.3 (14.7 – 16.0) 0.8 (0.7 – 0.9) 4.0 (3.6 – 4.3) 0.6 (0.5 – 0.7) 
≥ 80 ** 22.0 (20.6 – 23.5) 0.6 (0.5 – 0.8) 6.1 (5.4 – 7.0) 0.7 (0.6 – 0.9) 
Note: All prevalence estimates and 95% CIs calculated by author 
* CI = Confidence interval 
** The oldest age category in the 2013 CCHS was 80 years and older 
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Appendix K: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, 
among female patients of all ages with multimorbidity (n = 113,209) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female 
Patients, All Ages 
2 
(n = 41,890) 
Anxiety or Depression & Obesity 3,991 3.5 
Musculoskeletal Problem & Obesity 3,837 3.4 
Hypertension & Obesity 3,491 3.1 
Cancer & Obesity 2,791 2.5 
Anxiety or Depression & Musculoskeletal Problem 2,291 2.0 
3 
(n = 29,597) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 1,621 1.4 
Hypertension & Musculoskeletal Problem & Obesity 1,019 0.9 
Diabetes & Hypertension & Obesity 869 0.8 
Anxiety or Depression & Cancer & Obesity 854 0.8 
Anxiety or Depression & Hypertension & Obesity 816 0.7 
4 
(n = 19,043) 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 454 0.4 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 428 0.4 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 346 0.3 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 329 0.3 
Diabetes & Hyperlipidemia & Hypertension & Obesity 308 0.3 
≥ 5 
(n = 22,679) 
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity 155 0.1 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 149 0.1 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
138 0.1 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 138 0.1 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
115 0.1 
* Combinations listed in alphabetical order  
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Appendix L: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
female patients aged 18 – 34 years with multimorbidity (n = 11,507) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female Patients, 
18 – 34 Years 
2 
(n = 7,143) 
Anxiety or Depression & Obesity 1,197 10.4 
Musculoskeletal Problem & Obesity 817 7.1 
Anxiety or Depression & Musculoskeletal Problem 608 5.3 
Cancer & Obesity 581 5.0 
Anxiety or Depression & Cancer 332 2.9 
3 
(n = 2,914) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 373 3.2 
Anxiety or Depression & Cancer & Obesity 205 1.8 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Obesity 131 1.1 
Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal Problem & Obesity 104 0.9 
Cancer & Musculoskeletal Problem & Obesity 100 0.9 
4 
(n = 1,026) 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 68 0.6 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity 
58 0.5 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Urinary Problem 37 0.3 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Thyroid Problem 28 0.2 
Anxiety or Depression & Colon Problem & Musculoskeletal Problem & Obesity 28 0.2 
≥ 5 
 (n = 424) 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Thyroid Problem 10 0.1 
Anxiety or Depression & Cancer & Chronic Obstructive Pulmonary Disease or Asthma & 
Musculoskeletal Problem & Obesity 
10 0.1 
Anxiety or Depression & Cancer & Colon Problem & Musculoskeletal Problem & Obesity 9 0.1 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Urinary Problem 9 0.1 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Colon Problem & 
Musculoskeletal Problem & Obesity 
8 0.1 
* Combinations listed in alphabetical order  
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Appendix M: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, 
among female patients aged 35 – 44 years with multimorbidity (n = 14,756) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female Patients, 
35 – 44 Years 
2 
(n = 7,696) 
Anxiety or Depression & Obesity 1,140 7.7 
Musculoskeletal Problem & Obesity 1,034 7.0 
Cancer & Obesity 654 4.4 
Anxiety or Depression & Musculoskeletal Problem 634 4.3 
Hypertension & Obesity 338 2.3 
3 
(n = 4,145) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 483 3.3 
Anxiety or Depression & Cancer & Obesity 234 1.6 
Cancer & Musculoskeletal Problem & Obesity 170 1.2 
Anxiety or Depression & Cancer & Musculoskeletal Problem 156 1.1 
Anxiety or Depression & Obesity & Thyroid Problem 130 0.9 
4 
(n = 1,834) 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 110 0.7 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity 
86 0.6 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 76 0.5 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Thyroid Problem 56 0.4 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Urinary Problem 54 0.4 
≥ 5 
 (n = 1,081) 
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity 24 0.2 
Anxiety or Depression & Cancer & Chronic Obstructive Pulmonary Disease or Asthma & 
Musculoskeletal Problem & Obesity 
24 0.2 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Hypertension & 
Musculoskeletal Problem & Obesity 
22 0.1 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity & Thyroid Problem 22 0.1 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity & Thyroid Problem 
13 0.1 
* Combinations listed in alphabetical order  
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Appendix N: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
female patients aged 45 – 64 years with multimorbidity (n = 44,712) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female Patients, 
45 – 64 Years 
2 
(n = 17,048) 
Musculoskeletal Problem & Obesity 1,693 3.8 
Hypertension & Obesity 1,595 3.6 
Anxiety or Depression & Obesity 1,439 3.2 
Cancer & Obesity 1,181 2.6 
Anxiety or Depression & Musculoskeletal Problem 935 2.1 
3 
(n = 12,480) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 680 1.5 
Hypertension & Musculoskeletal Problem & Obesity 551 1.2 
Cancer & Musculoskeletal Problem & Obesity 426 1.0 
Anxiety or Depression & Hypertension & Obesity 425 1.0 
Hyperlipidemia & Hypertension & Obesity 360 0.8 
4 
(n = 7,693) 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 238 0.5 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 222 0.5 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 187 0.4 
Anxiety or Depression & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
139 0.3 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 130 0.3 
≥ 5 
 (n = 7,491) 
Anxiety or Depression & Cancer & Hypertension & Musculoskeletal Problem & Obesity 86 0.2 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 81 0.2 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 76 0.2 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
64 0.1 
Anxiety or Depression & Diabetes & Hypertension & Musculoskeletal Problem & Obesity 58 0.1 
* Combinations listed in alphabetical order  
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Appendix O: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, 
among female patients aged 65 – 84 years with multimorbidity (n = 33,264) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female Patients, 
65 – 84 Years 
2 
(n = 7,820) 
Hypertension & Obesity 1,181 3.6 
Diabetes & Obesity 446 1.3 
Cancer & Obesity 343 1.0 
Hyperlipidemia & Hypertension 323 1.0 
Musculoskeletal Problem & Obesity 275 0.8 
3 
(n = 8,016) 
Diabetes & Hypertension & Obesity 427 1.3 
Hyperlipidemia & Hypertension & Obesity 386 1.2 
Hypertension & Musculoskeletal Problem & Obesity 292 0.9 
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 269 0.8 
Cancer & Hypertension & Obesity 252 0.8 
4 
(n = 6,811) 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 158 0.5 
Diabetes & Hyperlipidemia & Hypertension & Obesity 153 0.5 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 141 0.4 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity 131 0.4 
Diabetes & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 110 0.3 
≥ 5 
 (n = 10,617) 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
69 0.2 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 66 0.2 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
63 0.2 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Thyroid Problem 56 0.2 
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
50 0.2 
* Combinations listed in alphabetical order  
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Appendix P: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
female patients aged 85 years and older with multimorbidity (n = 8,970) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Female Patients, 
≥ 85 Years 
2 
(n = 2,183) 
Hypertension & Obesity 212 2.4 
Dementia & Hypertension 151 1.7 
Cardiovascular Disease & Hypertension 126 1.4 
Diabetes & Hypertension 99 1.1 
Cancer & Hypertension 98 1.1 
3 
(n = 2,042) 
Diabetes & Hypertension & Obesity 59 0.7 
Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 54 0.6 
Cancer & Hypertension & Obesity 53 0.6 
Hypertension & Musculoskeletal Problem & Obesity 46 0.5 
Cardiovascular Disease & Hypertension & Obesity 46 0.5 
4 
(n = 1,679) 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 33 0.4 
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Osteoarthritis or 
Rheumatoid Arthritis 
21 0.2 
Anxiety or Depression & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 20 0.2 
Cardiovascular Disease & Diabetes & Hypertension & Obesity 17 0.2 
Diabetes & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis 16 0.2 
≥ 5 
 (n = 3,066) 
Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
14 0.2 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
14 0.2 
Cancer & Cardiovascular Disease & Hypertension & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
12 0.1 
Dementia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
11 0.1 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis & 
Thyroid Problem 
10 0.1 
* Combinations listed in alphabetical order 
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Appendix Q: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, 
among male patients of all ages with multimorbidity (n = 82,622) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male 
Patients, All Ages 
2 
(n = 32,080) 
Hypertension & Obesity 3,866 4.7 
Musculoskeletal Problem & Obesity 3,580 4.3 
Anxiety or Depression & Obesity 2,431 2.9 
Hyperlipidemia & Obesity 2,109 2.6 
Diabetes & Obesity 1,966 2.4 
3 
(n = 22,010) 
Hyperlipidemia & Hypertension & Obesity 1,389 1.7 
Diabetes & Hypertension & Obesity 1,226 1.5 
Hypertension & Musculoskeletal Problem & Obesity 1,061 1.3 
Anxiety or Depression & Musculoskeletal Problem & Obesity 823 1.0 
Hyperlipidemia & Musculoskeletal Problem & Obesity 755 0.9 
4 
(n = 13,823) 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 551 0.7 
Diabetes & Hyperlipidemia & Hypertension & Obesity 539 0.7 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity 376 0.5 
Cancer & Hyperlipidemia & Hypertension & Obesity 283 0.3 
Cancer & Hypertension & Musculoskeletal Problem & Obesity 244 0.3 
≥ 5 
 (n = 14,709) 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 254 0.3 
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 138 0.2 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 127 0.2 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
97 0.1 
Cancer & Diabetes & Hyperlipidemia & Hypertension & Obesity 93 0.1 
* Combinations listed in alphabetical order  
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Appendix R: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
male patients aged 18 – 34 years with multimorbidity (n = 5,959) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
18 – 34 Years 
2 
(n = 4,204) 
Anxiety or Depression & Obesity 713 12.0 
Musculoskeletal Problem & Obesity 648 10.9 
Anxiety or Depression & Musculoskeletal Problem 422 7.1 
Chronic Obstructive Pulmonary Disease or Asthma & Obesity 260 4.4 
Cancer & Obesity 227 3.8 
3 
(n = 1,331) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 171 2.9 
Cancer & Musculoskeletal Problem & Obesity 67 1.1 
Anxiety or Depression & Cancer & Obesity 60 1.0 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem 
53 0.9 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Obesity 52 0.9 
4 
(n = 327) 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 18 0.3 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Musculoskeletal 
Problem & Obesity 
18 0.3 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 13 0.2 
Diabetes & Hyperlipidemia & Hypertension & Obesity 10 0.2 
Anxiety or Depression & Colon Problem & Musculoskeletal Problem & Obesity 10 0.2 
≥ 5 
 (n = 97) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Combinations listed in alphabetical order  
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Appendix S: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
male patients aged 35 – 44 years with multimorbidity (n = 9,098) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
35 – 44 Years 
2 
(n = 5,439) 
Musculoskeletal Problem & Obesity 932 10.2 
Anxiety or Depression & Obesity 653 7.2 
Hypertension & Obesity 479 5.3 
Anxiety or Depression & Musculoskeletal Problem 369 4.1 
Hyperlipidemia & Obesity 340 3.7 
3 
(n = 2,357) 
Anxiety or Depression & Musculoskeletal Problem & Obesity 241 2.6 
Hypertension & Musculoskeletal Problem & Obesity 127 1.4 
Cancer & Musculoskeletal Problem & Obesity 122 1.3 
Hyperlipidemia & Hypertension & Obesity 104 1.1 
Hyperlipidemia & Musculoskeletal Problem & Obesity 99 1.1 
4 
(n = 873) 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 31 0.3 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 30 0.3 
Anxiety or Depression & Cancer & Musculoskeletal Problem & Obesity 28 0.3 
Diabetes & Hyperlipidemia & Hypertension & Obesity 24 0.3 
Chronic Obstructive Pulmonary Disease or Asthma & Hypertension & Musculoskeletal Problem & 
Obesity 
22 0.2 
≥ 5 
 (n = 429) 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 13 0.1 
Anxiety or Depression & Chronic Obstructive Pulmonary Disease or Asthma & Hypertension & 
Musculoskeletal Problem & Obesity 
10 0.1 
Chronic Obstructive Pulmonary Disease or Asthma & Diabetes & Hypertension & Musculoskeletal 
Problem & Obesity 
7 0.1 
Anxiety or Depression & Diabetes & Hypertension & Musculoskeletal Problem & Obesity 7 0.1 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 6 0.1 
* Combinations listed in alphabetical order  
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Appendix T: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
male patients aged 45 – 64 years with multimorbidity (n = 34,856) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
45 – 64 Years 
2 
(n = 14,268) 
Hypertension & Obesity 1,999 5.7 
Musculoskeletal Problem & Obesity 1,725 4.9 
Hyperlipidemia & Obesity 1,310 3.8 
Diabetes & Obesity 937 2.7 
Anxiety or Depression & Obesity 919 2.6 
3 
(n = 10,148) 
Hyperlipidemia & Hypertension & Obesity 785 2.3 
Hypertension & Musculoskeletal Problem & Obesity 605 1.7 
Diabetes & Hypertension & Obesity 559 1.6 
Hyperlipidemia & Musculoskeletal Problem & Obesity 532 1.5 
Anxiety or Depression & Musculoskeletal Problem & Obesity 378 1.1 
4 
(n = 5,834) 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 347 1.0 
Diabetes & Hyperlipidemia & Hypertension & Obesity 277 0.8 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity 188 0.5 
Anxiety or Depression & Hypertension & Musculoskeletal Problem & Obesity 145 0.4 
Anxiety or Depression & Hyperlipidemia & Hypertension & Obesity 137 0.4 
≥ 5 
 (n = 4,606) 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 148 0.4 
Anxiety or Depression & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 75 0.2 
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 62 0.2 
Cardiovascular Disease & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 45 0.1 
Anxiety or Depression & Diabetes & Hyperlipidemia & Hypertension & Obesity 44 0.1 
* Combinations listed in alphabetical order  
 
 
301 
Appendix U: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
male patients aged 65 – 84 years with multimorbidity (n = 27,430) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
65 – 84 Years 
2 
(n = 6,914) 
Hypertension & Obesity 1,092 4.0 
Diabetes & Obesity 678 2.5 
Cancer & Obesity 377 1.4 
Hyperlipidemia & Obesity 361 1.3 
Cardiovascular Disease & Obesity 267 1.0 
3 
(n = 6,981) 
Diabetes & Hypertension & Obesity 536 2.0 
Hyperlipidemia & Hypertension & Obesity 468 1.7 
Cancer & Hypertension & Obesity 262 1.0 
Hypertension & Musculoskeletal Problem & Obesity 258 0.9 
Cardiovascular Disease & Hypertension & Obesity 237 0.9 
4 
(n = 5,768) 
Diabetes & Hyperlipidemia & Hypertension & Obesity 221 0.8 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 159 0.6 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity 158 0.6 
Cancer & Hyperlipidemia & Hypertension & Obesity 146 0.5 
Cardiovascular Disease & Diabetes & Hypertension & Obesity 143 0.5 
≥ 5 
 (n = 7,767) 
Diabetes & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 95 0.3 
Cancer & Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity 68 0.2 
Hyperlipidemia & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or 
Rheumatoid Arthritis 
61 0.2 
Cancer & Diabetes & Hyperlipidemia & Hypertension & Obesity 54 0.2 
Diabetes & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
53 0.2 
* Combinations listed in alphabetical order  
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Appendix V: Most frequently occurring combinations of multimorbidity, stratified by total number of chronic diseases, among 
male patients aged 85 years and older with multimorbidity (n = 5,279) 
Total Number of 
Chronic Diseases 
Combinations* 
Total Number 
of Patients 
% of Male Patients, 
≥ 85 Years 
2 
(n = 1,255) 
Hypertension & Obesity 124 2.3 
Cancer & Hypertension 71 1.3 
Cardiovascular Disease & Hypertension 63 1.2 
Diabetes & Obesity 62 1.2 
Diabetes & Hypertension 58 1.1 
3 
(n = 1,193) 
Diabetes & Hypertension & Obesity 53 1.0 
Cardiovascular Disease & Hypertension & Obesity 38 0.7 
Cancer & Hypertension & Obesity 29 0.5 
Hypertension & Musculoskeletal Problem & Obesity 28 0.5 
Cancer & Cardiovascular Disease & Hypertension 25 0.5 
4 
(n = 1,021) 
Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid Arthritis 23 0.4 
Cancer & Cardiovascular Disease & Hypertension & Obesity 23 0.4 
Cardiovascular Disease & Diabetes & Hypertension & Obesity 18 0.3 
Cancer & Diabetes & Hypertension & Obesity 17 0.3 
Cancer & Hypertension & Musculoskeletal Problem & Obesity 12 0.2 
≥ 5 
 (n = 1,810) 
Cancer & Cardiovascular Disease & Hypertension & Musculoskeletal Problem & Obesity 8 0.2 
Cancer & Hypertension & Musculoskeletal Problem & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
7 0.1 
Cancer & Hypertension & Musculoskeletal Problem & Osteoarthritis or Rheumatoid Arthritis & 
Urinary Problem 
7 0.1 
Cancer & Hypertension & Obesity & Osteoarthritis or Rheumatoid Arthritis & Urinary Problem 7 0.1 
Cardiovascular Disease & Dementia & Hypertension & Obesity & Osteoarthritis or Rheumatoid 
Arthritis 
6 0.1 
* Combinations listed in alphabetical order 
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Appendix W: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, 
among female patients of all ages with multimorbidity (n = 113,209) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female 
Patients, All Ages 
2 
(n = 41,890) 
Obesity >> Musculoskeletal Problem 2,455 2.2 
Obesity >> Anxiety or Depression 2,286 2.0 
Obesity >> Cancer 1,942 1.7 
Obesity >> Hypertension 1,869 1.7 
Anxiety or Depression >> Obesity 1,705 1.5 
3 
(n = 29,597) 
Obesity >> Anxiety or Depression >> Musculoskeletal Problem 389 0.3 
Obesity >> Musculoskeletal Problem >> Anxiety or Depression 311 0.3 
Hypertension >> Obesity >> Musculoskeletal Problem 275 0.2 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 274 0.2 
Obesity >> Hypertension >> Musculoskeletal Problem 252 0.2 
4 
(n = 19,043) 
Obesity >> Hypertension >> Anxiety or Depression >> Musculoskeletal Problem 39 0.0 
Obesity >> Anxiety or Depression >> Cancer >> Musculoskeletal Problem 37 0.0 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 36 0.0 
Obesity >> Hypertension >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis 36 0.0 
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia 35 0.0 
≥ 5 
 (n = 22,679) 
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem >> Anxiety or 
Depression 
7 0.0 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem >> Osteoarthritis or 
Rheumatoid Arthritis 
6 0.0 
Hypertension >> Diabetes >> Obesity >> Hyperlipidemia >> Cancer 6 0.0 
Obesity >> Hypertension >> Hyperlipidemia >> Cancer >> Musculoskeletal Problem 6 0.0 
Hypertension >> Obesity >> Diabetes >> Musculoskeletal Problem >> Cancer 5 0.0 
* Permutations listed in sequential order 
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Appendix X: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
female patients aged 18 – 34 years with multimorbidity (n = 11,507) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female Patients, 
18 – 34 Years 
2 
(n = 7,143) 
Obesity >> Anxiety or Depression 667 5.8 
Anxiety or Depression >> Obesity 530 4.6 
Obesity >> Musculoskeletal Problem 507 4.4 
Obesity >> Cancer 400 3.5 
Anxiety or Depression >> Musculoskeletal Problem 351 3.1 
3 
(n = 2,914) 
Obesity >> Musculoskeletal Problem >> Anxiety or Depression 92 0.8 
Obesity >> Anxiety or Depression >> Musculoskeletal Problem 76 0.7 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 57 0.5 
Obesity >> Cancer >> Anxiety or Depression 54 0.5 
Obesity >> Anxiety or Depression >> Cancer 53 0.5 
4 
(n = 1,026) 
Obesity >> Anxiety or Depression >> Cancer >> Musculoskeletal Problem 8 0.1 
Obesity >> Cancer >> Anxiety or Depression >> Musculoskeletal Problem 7 0.1 
Chronic Obstructive Pulmonary Disease or Asthma >> Obesity >> Anxiety or Depression >> 
Musculoskeletal Problem 
7 0.1 
Thyroid Problem >> Anxiety or Depression >> Obesity >> Musculoskeletal Problem 6 0.1 
Obesity >> Chronic Obstructive Pulmonary Disease or Asthma >> Musculoskeletal Problem >> 
Anxiety or Depression 
6 0.1 
≥ 5 
 (n = 424) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Appendix Y: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
female patients aged 35 – 44 years with multimorbidity (n = 14,756) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female Patients, 
35 – 44 Years 
2 
(n = 7,696) 
Obesity >> Anxiety or Depression 665 4.5 
Obesity >> Musculoskeletal Problem 653 4.4 
Anxiety or Depression >> Obesity 475 3.2 
Obesity >> Cancer 429 2.9 
Musculoskeletal Problem >> Obesity 381 2.6 
3 
(n = 4,145) 
Obesity >> Anxiety or Depression >> Musculoskeletal Problem 132 0.9 
Obesity >> Musculoskeletal Problem >> Anxiety or Depression 88 0.6 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 75 0.5 
Obesity >> Anxiety or Depression >> Cancer 72 0.5 
Anxiety or Depression >> Musculoskeletal Problem >> Obesity 69 0.5 
4 
(n = 1,834) 
Anxiety or Depression >> Musculoskeletal Problem >> Obesity >> Cancer 11 0.1 
Obesity >> Anxiety or Depression >> Cancer >> Musculoskeletal Problem 10 0.1 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem >> Cancer 10 0.1 
Obesity >> Chronic Obstructive Pulmonary Disease or Asthma >> Anxiety or Depression >> 
Musculoskeletal Problem 
9 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression 8 0.1 
≥ 5 
 (n = 1,081) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Appendix Z: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, among 
female patients aged 45 – 64 years with multimorbidity (n = 44,712) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female Patients, 
45 – 64 Years 
2 
(n = 17,048) 
Obesity >> Musculoskeletal Problem 1,096 2.5 
Obesity >> Hypertension 905 2.0 
Obesity >> Cancer 844 1.9 
Obesity >> Anxiety or Depression 819 1.8 
Hypertension >> Obesity 690 1.5 
3 
(n = 12,480) 
Obesity >> Anxiety or Depression >> Musculoskeletal Problem 156 0.3 
Hypertension >> Obesity >> Musculoskeletal Problem 151 0.3 
Obesity >> Hypertension >> Musculoskeletal Problem 137 0.3 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 125 0.3 
Hypertension >> Obesity >> Hyperlipidemia 114 0.3 
4 
(n = 7,693) 
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia 20 0.0 
Hypertension >> Obesity >> Musculoskeletal Problem >> Anxiety or Depression 20 0.0 
Obesity >> Hypertension >> Anxiety or Depression >> Musculoskeletal Problem 20 0.0 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 18 0.0 
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem 17 0.0 
≥ 5 
 (n = 7,491) 
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem >> Anxiety or 
Depression 
5 0.0 
Results Supressed (<5 Patients) 
  
  
  
  
* Permutations listed in sequential order 
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Appendix AA: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, 
among female patients aged 65 – 84 years with multimorbidity (n = 33,264) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female Patients, 
65 – 84 Years 
2 
(n = 7,820) 
Hypertension >> Obesity 604 1.8 
Obesity >> Hypertension 577 1.7 
Obesity >> Diabetes 257 0.8 
Obesity >> Cancer 249 0.7 
Hypertension >> Hyperlipidemia 224 0.7 
3 
(n = 8,016) 
Hypertension >> Obesity >> Hyperlipidemia 110 0.3 
Obesity >> Hypertension >> Hyperlipidemia 94 0.3 
Obesity >> Diabetes >> Hypertension 91 0.3 
Diabetes >> Obesity >> Hypertension 90 0.3 
Hypertension >> Obesity >> Musculoskeletal Problem 86 0.3 
4 
(n = 6,811) 
Obesity >> Hypertension >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis 18 0.1 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 17 0.1 
Obesity >> Hypertension >> Cancer >> Musculoskeletal Problem 16 0.0 
Hypertension >> Obesity >> Musculoskeletal Problem >> Hyperlipidemia 15 0.0 
Hypertension >> Diabetes >> Obesity >> Osteoarthritis or Rheumatoid Arthritis 15 0.0 
≥ 5 
 (n = 10,617) 
Obesity >> Hypertension >> Thyroid Problem >> Musculoskeletal Problem >> Hyperlipidemia 5 0.0 
Results Supressed (<5 Patients) 
  
  
  
  
* Permutations listed in sequential order 
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Appendix AB: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, 
among female patients aged 85 years and older with multimorbidity (n = 8,970) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Female 
Patients, ≥ 85 
Years 
2 
(n = 2,183) 
Hypertension >> Obesity 119 1.3 
Hypertension >> Dementia 108 1.2 
Obesity >> Hypertension 93 1.0 
Hypertension >> Cardiovascular Disease 74 0.8 
Hypertension >> Cancer 72 0.8 
3 
(n = 2,042) 
Hypertension >> Obesity >> Cancer 22 0.2 
Hypertension >> Obesity >> Osteoarthritis or Rheumatoid Arthritis 20 0.2 
Obesity >> Hypertension >> Cancer 16 0.2 
Hypertension >> Obesity >> Dementia 15 0.2 
Hypertension >> Obesity >> Musculoskeletal Problem 15 0.2 
4 
(n = 1,679) 
Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoarthritis or Rheumatoid Arthritis 6 0.1 
Hypertension >> Obesity >> Musculoskeletal Problem >> Osteoporosis 5 0.1 
Results Supressed (<5 Patients) 
  
  
  
≥ 5 
 (n = 3,066) 
  
  
  
  
  
* Permutations listed in sequential order 
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Appendix AC: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, 
among male patients of all ages with multimorbidity (n = 82,622) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male 
Patients, All Ages 
2 
(n = 32,080) 
Obesity >> Hypertension 2,201 2.7 
Obesity >> Musculoskeletal Problem 2,138 2.6 
Hypertension >> Obesity 1,665 2.0 
Obesity >> Hyperlipidemia 1,530 1.9 
Obesity >> Anxiety or Depression 1,467 1.8 
3 
(n = 22,010) 
Obesity >> Hypertension >> Hyperlipidemia 382 0.5 
Hypertension >> Obesity >> Hyperlipidemia 336 0.4 
Obesity >> Hypertension >> Musculoskeletal Problem 286 0.3 
Obesity >> Hyperlipidemia >> Hypertension 271 0.3 
Obesity >> Hyperlipidemia >> Musculoskeletal Problem 237 0.3 
4 
(n = 13,823) 
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem 64 0.1 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 51 0.1 
Obesity >> Hyperlipidemia >> Hypertension >> Musculoskeletal Problem 42 0.1 
Obesity >> Hypertension >> Diabetes >> Hyperlipidemia 36 0.0 
Obesity >> Diabetes >> Hypertension >> Musculoskeletal Problem 35 0.0 
≥ 5 
 (n = 14,709) 
Obesity >> Diabetes >> Hyperlipidemia >> Hypertension >> Musculoskeletal Problem 8 0.0 
Diabetes >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem >> Obesity 8 0.0 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem >> Diabetes 6 0.0 
Hypertension >> Hyperlipidemia >> Cancer >> Obesity >> Musculoskeletal Problem 6 0.0 
Musculoskeletal Problem >> Hypertension >> Hyperlipidemia >> Obesity >> Urinary Problem 6 0.0 
* Permutations listed in sequential order 
310 
Appendix AD: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, 
among male patients aged 18 – 34 years with multimorbidity (n = 5,959) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients, 
18 – 34 Years 
2 
(n = 4,204) 
Obesity >> Anxiety or Depression 437 7.3 
Obesity >> Musculoskeletal Problem 356 6.0 
Musculoskeletal Problem >> Obesity 292 4.9 
Anxiety or Depression >> Obesity 276 4.6 
Musculoskeletal Problem >> Anxiety or Depression 213 3.6 
3 
(n = 1,331) 
Obesity >> Anxiety or Depression >> Musculoskeletal Problem 54 0.9 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 34 0.6 
Musculoskeletal Problem >> Anxiety or Depression >> Obesity 24 0.4 
Obesity >> Anxiety or Depression >> Cancer 23 0.4 
Musculoskeletal Problem >> Obesity >> Anxiety or Depression 20 0.3 
4 
(n = 327) 
Results Supressed (<5 Patients) 
  
  
  
  
  
≥ 5 
 (n = 97) 
  
  
  
  
  
* Permutations listed in sequential order 
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Appendix AE: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, 
among male patients aged 35 – 44 years with multimorbidity (n = 9,098) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients, 
35 – 44 Years 
2 
(n = 5,439) 
Obesity >> Musculoskeletal Problem 532 5.8 
Musculoskeletal Problem >> Obesity 400 4.4 
Obesity >> Anxiety or Depression 379 4.2 
Obesity >> Hypertension 288 3.2 
Anxiety or Depression >> Obesity 274 3.0 
3 
(n = 2,357) 
Obesity >> Anxiety or Depression >> Musculoskeletal Problem 55 0.6 
Obesity >> Musculoskeletal Problem >> Anxiety or Depression 47 0.5 
Anxiety or Depression >> Obesity >> Musculoskeletal Problem 41 0.5 
Musculoskeletal Problem >> Obesity >> Anxiety or Depression 37 0.4 
Musculoskeletal Problem >> Anxiety or Depression >> Obesity 36 0.4 
4 
(n = 873) 
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem 5 0.1 
Results Supressed (<5 Patients) 
  
  
  
  
≥ 5 
 (n = 429) 
  
  
  
  
  
* Permutations listed in sequential order 
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Appendix AF: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, 
among male patients aged 45 – 64 years with multimorbidity (n = 34,856) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients, 
45 – 64 Years 
2 
(n = 14,268) 
Obesity >> Hypertension 1,167 3.3 
Obesity >> Musculoskeletal Problem 1,066 3.1 
Obesity >> Hyperlipidemia 963 2.8 
Hypertension >> Obesity 832 2.4 
Musculoskeletal Problem >> Obesity 659 1.9 
3 
(n = 10,148) 
Obesity >> Hypertension >> Hyperlipidemia 214 0.6 
Hypertension >> Obesity >> Hyperlipidemia 185 0.5 
Obesity >> Hypertension >> Musculoskeletal Problem 174 0.5 
Obesity >> Hyperlipidemia >> Musculoskeletal Problem 172 0.5 
Obesity >> Hyperlipidemia >> Hypertension 156 0.4 
4 
(n = 5,834) 
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem 33 0.1 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 27 0.1 
Obesity >> Hypertension >> Musculoskeletal Problem >> Hyperlipidemia 25 0.1 
Obesity >> Hyperlipidemia >> Hypertension >> Musculoskeletal Problem 23 0.1 
Obesity >> Diabetes >> Hyperlipidemia >> Hypertension 22 0.1 
≥ 5 
 (n = 4,606) 
Obesity >> Diabetes >> Hyperlipidemia >> Hypertension >> Musculoskeletal Problem 5 0.0 
Obesity >> Hyperlipidemia >> Diabetes >> Hypertension >> Musculoskeletal Problem 5 0.0 
Results Supressed (<5 Patients) 
  
  
  
* Permutations listed in sequential order 
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Appendix AG: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, 
among male patients aged 65 – 84 years with multimorbidity (n = 27,430) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients, 
65 – 84 Years 
2 
(n = 6,914) 
Obesity >> Hypertension 584 2.1 
Hypertension >> Obesity 508 1.9 
Obesity >> Diabetes 364 1.3 
Diabetes >> Obesity 314 1.1 
Obesity >> Cancer 288 1.0 
3 
(n = 6,981) 
Obesity >> Hypertension >> Hyperlipidemia 134 0.5 
Hypertension >> Obesity >> Hyperlipidemia 118 0.4 
Obesity >> Diabetes >> Hypertension 113 0.4 
Diabetes >> Hypertension >> Obesity 96 0.3 
Diabetes >> Obesity >> Hypertension 95 0.3 
4 
(n = 5,768) 
Obesity >> Hypertension >> Hyperlipidemia >> Musculoskeletal Problem 24 0.1 
Hypertension >> Obesity >> Hyperlipidemia >> Musculoskeletal Problem 19 0.1 
Obesity >> Hypertension >> Cancer >> Musculoskeletal Problem 19 0.1 
Obesity >> Diabetes >> Hypertension >> Musculoskeletal Problem 19 0.1 
Obesity >> Hypertension >> Hyperlipidemia >> Cancer 18 0.1 
≥ 5 
 (n = 7,767) 
Results Supressed (<5 Patients) 
  
  
  
  
  
* Permutations listed in sequential order 
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Appendix AH: Most frequently occurring permutations of multimorbidity, stratified by total number of chronic diseases, 
among male patients aged 85 years and older with multimorbidity (n = 5,279) 
Total Number of 
Chronic Diseases 
Permutations* 
Total Number 
of Patients 
% of Male Patients,  
≥ 85 Years 
2 
(n = 1,255) 
Hypertension >> Obesity 68 1.3 
Obesity >> Hypertension 56 1.1 
Hypertension >> Cancer 52 1.0 
Hypertension >> Cardiovascular Disease 41 0.8 
Obesity >> Diabetes 38 0.7 
3 
(n = 1,193) 
Diabetes >> Obesity >> Hypertension 14 0.3 
Hypertension >> Obesity >> Musculoskeletal Problem 13 0.2 
Hypertension >> Obesity >> Dementia 11 0.2 
Hypertension >> Obesity >> Cancer 11 0.2 
Hypertension >> Diabetes >> Obesity 11 0.2 
4 
(n = 1,021) 
Results Supressed (<5 Patients) 
  
  
  
  
  
≥ 5 
 (n = 1,810) 
  
  
  
  
  
* Permutations listed in sequential order 
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses), 
stratified by patient age category (years), patient sex and total number of chronic diseases 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
T1  T2 
(n = 286,998) 
178.0 
442.6 
(612.2) 
158.0 
453.5 
(654.8) 
63.0 
383.5 
(646.6) 
10.6 
266.5 
(577.5) 
5.2 
224.4 
(527.7) 
87.0 
424.1 
(654.9) 
63.0 
403.9 
(647.8) 
21.7 
345.3 
(630.9) 
5.5 
256.1 
(581.0) 
7.5 
232.8 
(540.2) 
T2  T3 
(n = 195,838) 
372.5 
587.5 
(756.1) 
374.0 
616.9 
(802.6) 
297.6  
554.9  
(804.8) 
192.7 
464.1 
(838.6) 
168.0 
406.2 
(763.5) 
340.7 
577.1 
(792.2) 
327.1 
583.2 
(821.6) 
268.0 
542.2 
(819.7) 
194.2 
468.6 
(842.4) 
173.0 
396.1 
(723.6) 
T3  T4 
(n = 121,864) 
337.6 
488.1 
(507.3) 
348.0 
517.4 
(579.2) 
283.7 
466.9 
(560.8) 
219.8 
398.4 
(532.6) 
203.9 
378.6 
(485.2) 
334.0 
517.1 
(567.8) 
304.2 
498.5 
(599.3) 
285.0 
476.6 
(587.4) 
224.0 
416.4 
(586.1) 
208.0 
373.0 
(490.3) 
T4  T5 
(n = 70,256) 
282.4 
427.3 
(465.2) 
346.0 
501.5 
(532.6) 
285.2 
449.9 
(503.6) 
243.9 
395.9 
(455.3) 
224.0 
386.5 
(475.0) 
290.1 
426.4 
(454.5) 
295.6 
483.1 
(535.6) 
300.1 
461.7 
(512.4) 
264.0 
420.0 
(484.5) 
239.0 
385.0 
(445.2) 
T5  T6 
(n = 37,390) 
332.0 
482.4 
(496.7) 
280.0 
424.9 
(462.3) 
259.7 
402.2 
(445.1) 
252.0 
402.3 
(446.2) 
276.8 
431.0 
(505.0) 
276.8 
431.0 
(505.0) 
291.9 
446.0 
(469.4) 
301.0 
455.6 
(494.3) 
269.0 
416.4 
(453.8) 
242.2 
389.6 
(444.8) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red 
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses), 
stratified by patient age category (years), patient sex and total number of chronic diseases, Continued 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
Hypertension  T2 67.8 
343.3 
(549.9) 
40.5 
313.6 
(527.3) 
3.0 
242.1 
(527.0) 
1.2 
191.0 
(482.0) 
1.0 
171.9 
(462.7) 
8.2 
328.3 
(624.9) 
1.1 
273.0 
(567.0) 
1.0 
234.0 
(523.0) 
1.0 
181.8 
(479.3) 
3.2 
192.5 
(484.5) 
Obesity  T2 27.2 
203.0 
(346.4) 
5.7 
235.9 
(429.7) 
1.0 
209.6 
(436.0) 
1.0 
161.9 
(382.8) 
4.0 
92.2 
(165.9) 
1.0 
311.8 
(648.1) 
1.0 
259.2 
(545.5) 
1.0 
249.9 
(524.0) 
1.0 
113.9 
(253.8) 
1.0 
109.3 
(188.5) 
Diabetes  T2 6.6 
301.8 
(595.5) 
25.7 
342.9 
(640.4) 
2.0 
204.7 
(482.8) 
1.0 
187.6 
(520.0) 
1.0 
166.2 
(472.8) 
1.0 
181.4 
(455.3) 
2.0 
235.1 
(515.3) 
1.0 
201.1 
(493.4) 
1.0 
153.0 
(429.4) 
2.0 
184.7 
(487.7) 
Chronic Obstructive Pulmonary 
Disease or Asthma  T2 
70.0 
322.3 
(523.3) 
109.4 
391.2 
(600.6) 
45.6 
358.4 
(663.2) 
19.9 
277.0 
(580.0) 
21.0 
279.9 
(594.7) 
8.4 
275.9 
(502.0) 
22.0 
344.0 
(579.4) 
14.5 
348.4 
(669.0) 
20.0 
324.8 
(705.7) 
6.6 
191.2 
(428.0) 
Hyperlipidemia  T2 194.3 
486.9 
(727.9) 
109.6 
414.9 
(587.1) 
69.5 
363.3 
(626.8) 
21.0 
228.9 
(464.1) 
1.0 
145.0 
(398.1) 
47.0 
297.6 
(517.6) 
38.4 
312.4 
(529.8) 
31.2 
307.9 
(572.3) 
13.5 
229.0 
(495.9) 
4.5 
162.4 
(341.5) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red for each patient category
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses), 
stratified by patient age category (years), patient sex and total number of chronic diseases, Continued 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
Cancer  T2 237.5 
460.9 
(603.0) 
231.8 
504.8 
(669.2) 
139.1 
456.0 
(684.2) 
35.0 
341.7 
(669.8) 
7.3 
243.0 
(525.4) 
99.8 
439.3 
(664.9) 
80.3 
431.7 
(656.9) 
58.4 
400.0 
(650.3) 
15.4 
319.6 
(652.4) 
19.2 
283.7 
(637.5) 
Cardiovascular Disease  T2 307.9 
528.3 
(655.8) 
225.0 
513.8 
(692.7) 
114.0 
470.2 
(709.4) 
17.4 
323.7 
(618.2) 
12.2 
265.4 
(593.8) 
65.0 
461.2 
(714.2) 
62.0 
391.3 
(564.9) 
29.6 
420.9 
(711.4) 
10.5 
323.7 
(693.9) 
4.2 
233.9 
(548.3) 
Heart Failure  T2 14.0 
165.6 
(301.1) 
28.0 
381.6 
(467.2) 
176.6 
440.1 
(872.5) 
9.1 
248.4 
(562.9) 
29.0 
240.9 
(481.1) 
141.9 
561.3 
(1,010.2) 
60.3 
117.1 
(189.0) 
17.0 
372.0 
(725.2) 
16.6 
273.1 
(534.9) 
21.7 
209.2 
(456.5) 
Anxiety or Depression  T2 149.8 
435.7 
(614.8) 
132.3 
430.7 
(638.1) 
68.0 
392.2 
(634.5) 
26.5 
319.1 
(644.7) 
19.4 
288.8 
(648.0) 
80.2 
413.4 
(634.6) 
56.6 
407.9 
(663.8) 
24.5 
341.3 
(614.7) 
10.6 
344.7 
(679.3) 
49.7 
329.9 
(596.7) 
Osteoarthritis or Rheumatoid 
Arthritis  T2 
140.0 
428.8 
(587.2) 
216.3 
495.2 
(658.5) 
136.5 
494.7 
(738.7) 
39.9 
388.4 
(710.2) 
31.5 
358.9 
(667.9) 
137.8 
523.9 
(755.7) 
94.0 
489.1 
(725.5) 
70.5 
477.7 
(744.4) 
29.7 
418.6 
(784.2) 
17.4 
368.9 
(734.5) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red for each patient category
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses), 
stratified by patient age category (years), patient sex and total number of chronic diseases, Continued 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
Stroke or Transient Ischemic 
Attack  T2 
Results 
Supressed  
1.00 
103.6 
(190.0) 
74.0 
595.8 
(868.9) 
46.9 
507.6 
(829.9) 
7.6 
392.5 
(711.2) 
996.5 
1,177.0 
(1,390.7) 
Results 
Supressed 
7.0 
289.5 
(498.9) 
8.4 
235.8 
(456.2) 
3.0 
199.7 
(575.0) 
Thyroid Problem  T2 91.9 
364.9 
(554.8) 
63.0 
349.4 
(569.2) 
31.6 
319.0 
(577.2) 
7.6 
232.8 
(525.5) 
10.1 
215.9 
(536.9) 
39.0 
286.1 
(575.1) 
29.6 
263.7 
(552.6) 
10.5 
303.4 
(608.3) 
4.0 
241.6 
(476.8) 
8.6 
274.4 
(610.0) 
Kidney Disease or Failure  T2 48.8 
162.5 
(263.9) 
124.5 
361.1 
(520.1) 
26.7 
139.8 
(217.5) 
183.3 
712.9 
(1,052.0) 
95.7 
566.5 
(910.8) 
7.6 
58.7 
(98.2) 
52.8 
89.6 
(103.6) 
124.8 
547.8 
(830.8) 
50.0 
466.4 
(867.5) 
1.0 
92.9 
(248.2) 
Osteoporosis  T2 199.0 
650.8 
(859.7) 
110.5 
383.7 
(599.2) 
71.3 
369.1 
(604.4) 
14.5 
247.9 
(455.0) 
1.0 
168.6 
(378.4) 
28.0 
95.6 
(152.8) 
3.0 
182.8 
(314.1) 
92.3 
326.5 
(474.9) 
25.3 
197.0 
(346.3) 
64.0 
269.6 
(354.5) 
Dementia  T2 451.0  
505.1 
(526.0) 
130.2 
355.7 
(733.7) 
166.3 
500.7 
(773.9) 
6.6 
297.0 
(661.2) 
5.3 
216.2 
(476.4) 
555.7 
666.6 
(707.7) 
554.7 
705.6 
(658.8) 
188.0 
507.4 
(700.4) 
25.2 
326.3 
(590.0) 
6.0 
202.4 
(475.3) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red for each patient category 
** Results were supressed when < 5 patients were included in the category  
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Appendix AI: Time (in days) until subsequent chronic disease diagnosis (including zero days elapsing between diagnoses), 
stratified by patient age category (years), patient sex and total number of chronic diseases, Continued 
 Female Male 
 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 18 – 34  35 – 44  45 – 64  65 – 84  ≥ 85 
Musculoskeletal Problem  T2 245.4 
524.7 
(664.9) 
257.6 
553.1 
(718.5) 
159.6 
483.4 
(711.0) 
61.1 
360.8 
(651.2) 
52.0 
311.4 
(591.4) 
191.0 
528.2 
(726.9) 
196.0 
508.6 
(710.8) 
113.3 
471.0 
(720.2) 
38.6 
368.0 
(670.3) 
62.5 
330.3 
(638.0) 
Stomach Problem  T2 197.4 
385.2 
(485.4) 
137.4 
444.4 
(653.0) 
118.8 
397.9 
(614.1) 
75.8 
296.2 
(548.0) 
54.3 
178.0 
(294.8) 
141.1 
451.1 
(639.2) 
132.0 
438.8 
(656.6) 
99.0 
416.1 
(673.3) 
56.5 
343.3 
(651.7) 
39.2 
243.0 
(454.7) 
Colon Problem  T2 252.0 
477.5 
(609.3) 
137.9 
421.9 
(658.8) 
98.0 
390.6 
(610.8) 
60.0 
359.8 
(668.1) 
67.0 
224.5 
(402.9) 
161.0 
432.3 
(610.8) 
36.9 
332.1 
(499.0) 
53.0 
368.3 
(610.5) 
81.7 
346.7 
(585.7) 
85.6 
324.4 
(557.7) 
Liver Disease  T2 320.6 
437.6 
(414.0) 
0.0 
70.2 
(102.9) 
34.0 
248.0 
(473.5) 
0.0 
262.2 
(524.5) 
367.7 
367.7 
(519.4) 
643.5 
734.4 
(619.2) 
564.6 
731.4 
(935.9) 
101.8 
384.1 
(581.4) 
34.0 
321.1 
(663.4) 
0.00 
9.8 
(17.1) 
Urinary Problem  T2 342.4 
569.5 
(650.8) 
385.4 
647.3 
(763.4) 
276.2 
589.2 
(784.9) 
154.0 
471.4 
(774.4) 
46.2 
287.8 
(591.4) 
268.6 
565.7 
(734.1) 
185.5 
513.2 
(724.6) 
130.0 
480.7 
(725.0) 
26.5 
338.4 
(665.3) 
35.5 
264.9 
(565.9) 
* Each cell contains median time, mean time and standard deviation, all measured in days; longest time between diagnoses highlighted in green and shortest time 
between diagnoses highlighted in red for each patient category 
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Appendix AJ: Results of multilevel, single event survival analyses among adult patients with one or more chronic diseases 
 Hazard Ratio (95% CI)  
Independent Variable 
 ≥ 1 Chronic Diseases 
(n = 238,237) 
 ≥ 2 Chronic Diseases 
(n = 159,365) 
≥ 3 Chronic Diseases 
(n = 96,945) 
≥ 4 Chronic Diseases 
(n = 54,753) 
≥ 5 Chronic Diseases 
(n = 28,675) 
Patient-Level 
Age 1.00 (1.00 – 1.00) *** 1.00 (1.00 – 1.00) *** 1.00 (1.00 – 1.00) ** 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
Sex (Female) 0.81 (0.78 – 0.85) *** 0.83 (0.78 – 0.87) *** 0.78 (0.72 – 0.85) *** 0.74 (0.66 – 0.83) *** 0.80 (0.66 – 0.95) ** 
Residential Location (Urban) 0.99 (0.97 – 1.01) 0.98 (0.96 – 1.01) 0.98 (0.95 – 1.01) 0.96 (0.92 – 1.00) 0.95 (0.89 – 1.02) 
Median Household Income 1.00 (1.00 – 1.00) ** 1.00 (1.00 – 1.00) ** 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
Total Number of Chronic 
Diseases 
1.33 (1.33 – 1.34) *** 1.29 (1.29 – 1.30) *** 1.23 (1.22 – 1.24) *** 1.19 (1.17 – 1.20) *** 1.16 (1.14 – 1.18) *** 
Provider-Level 
Age 0.98 (0.98 – 0.99) *** 0.99 (0.98 – 0.99) *** 0.99 (0.98 – 0.99) *** 0.98 (0.98 – 0.99) *** 0.98 (0.98 – 0.99) *** 
Female 0.92 (0.85 – 0.99) ** 0.97 (0.88 – 1.05) 0.97 (0.88 – 1.08) 0.95 (0.84 – 1.06) 0.94 (0.83 – 1.06) 
Practice-Level 
EMR Type      
Accuro Reference Reference Reference Reference Reference 
Bell 1.43 (1.21 – 1.69) *** 1.27 (1.04 – 1.55) ** 1.15 (0.90 – 1.48) 1.04 (0.76 – 1.43) 0.99 (0.68 – 1.44) 
DaVinci 0.85 (0.72 – 1.03)  0.77 (0.71 – 1.04) 0.72 (0.61 – 1.05) 0.67 (0.54 – 1.01) 0.72 (0.58 – 1.04) 
Jonoke 0.91 (0.80 – 1.10) 0.82 (0.73 – 1.01) 0.82 (0.77 – 1.02) 0.74 (0.63 – 1.05) 0.79 (0.67 – 1.02) 
Med Access 0.87 (0.74 – 1.01) 0.80 (0.67 – 0.96) ** 0.76 (0.62 – 0.93) ** 0.70 (0.56 – 0.88) ** 0.74 (0.58 – 0.94) ** 
Nightingale 0.95 (0.85 – 1.05) 0.86 (0.77 – 0.97) ** 0.84 (0.73 – 0.96) ** 0.79 (0.68 – 0.91) ** 0.81 (0.69 – 0.95) ** 
Oscar 1.56 (1.35 – 1.80) *** 1.47 (1.24 – 1.74) *** 1.34 (1.10 – 1.63) ** 1.29 (1.01 – 1.63) ** 1.35 (1.00 – 1.82) ** 
Practice Solutions 0.43 (0.37 – 0.50) *** 0.41 (0.35 – 0.49) *** 0.43 (0.36 – 0.53) *** 0.44 (0.36 – 0.55) *** 0.51 (0.40 – 0.63) *** 
Wolf 0.73 (0.64 – 0.84) *** 0.68 (0.58 – 0.80) *** 0.63 (0.53 – 0.75) *** 0.59 (0.48 – 0.72) *** 0.62 (0.50 – 0.76) *** 
Xwave 1.91 (0.82 – 4.46) 1.79 (0.62 – 5.16) 1.56 (0.40 – 6.12) 0.66 (0.08 – 5.60) 0.67 (0.08 – 5.65) 
Practice Location (Urban) 0.74 (0.67 – 0.83) *** 0.75 (0.66 – 0.85) *** 0.71 (0.61 – 0.82) *** 0.69 (0.58 – 0.82) *** 0.72 (0.60 – 0.88) ** 
Interaction Term 
Patient Age & Patient Sex 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.01) 1.00 (1.00 – 1.00) 
% Variance (95% CI) Contributed by Each Level 
Within Provider 9.10 (6.82 – 12.14) 11.66 (8.45 – 16.08) 14.48 (12.00 – 17.47) 16.98 (13.84 – 20.84) 16.41 (13.01 – 20.69) 
Within Site 0.18 (0.00 – 2.13) 0.20 (0.00 – 3.63) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
* CI = Confidence interval; ** p-value < 0.05; *** p-value < 0.001
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